WorldWideScience

Sample records for benign prostatic hyperplasia

  1. Benign prostate hyperplasia (BPH) - resources

    Science.gov (United States)

    Resources - benign prostatic hyperplasia (BPH); Prostate enlargement resources; BPH resources ... The following organizations provide information on benign prostatic hyperplasia ( prostate enlargement ... Urology Care Foundation -- www. ...

  2. BENIGN PROSTATIC HYPERPLASIA: UPDATED REVIEW

    OpenAIRE

    Praveen.R

    2013-01-01

    Benign Prostatic Hyperplasia (BPH) is one of the commonest medical conditions affecting the geriatric male population. The enlargement of prostate can lead to various clinical symptoms like difficulty in voiding, urinary retention etc. The symptoms are varied depending on the size of enlargement. The International Prostatic Symptom Score (IPSS) is the gold standard and first step in understanding and diagnosing the disease clinically, but in the recent past there are various other newer tools...

  3. Benign Prostatic Hyperstatic Hyperplasia (BPH) (Beyond the Basics)

    Science.gov (United States)

    ... names for benign prostatic hyperplasia include benign prostatic hypertrophy, an enlarged prostate, and BPH. BPH occurs only ... prostatic hyperplasia" .) Alpha blockers — These medications relax the muscle of the prostate and bladder neck, which allows ...

  4. Nocturia and benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Laketić Darko

    2008-01-01

    Full Text Available Background/Aim. Nocturia often occurs in patients with benign prostate hyperplasia (BPH. The aim of the study was to investigate the frequency of nocturia in patients with BPH. Nocturia and other factors associated with it were also investigated. Methods. Forty patients with the confirmed diagnosis of BPH were studied. Transurethral and transvesical prostatectomy were performed in all the patients. Symptoms were evaluated with the International Prostate Symptom Score before, as well as three and six months after the surgery. All the results were compared with the control group. Results. There was no statistically significant difference between the patients before and after the surgery regarding nocturia. There was, however, a statistically significant difference between the operated patients and the control group regarding nocturia, as well as a statistically significant correlation between noctruia and the age of the patients in both the investigated and the control group. A correlation also existed between nocturia and the prostatic size. Conclusion. There was no statistically significant improvement in symptoms of nocturia after the surgery. It is necessary to be very careful in decision making in patients with nonabsolute indiction for surgery and isolated bothersome symptom of nocturia. Age of a patient should also be considered in the evaluation of favorable result of the surgery because of a significant correlation between noctura and the age of a patient.

  5. [Benign prostatic hyperplasia: background and diagnosis].

    Science.gov (United States)

    Gratzke, C; Schlenker, B; Weidlich, P; Seitz, M; Reich, O; Stief, C G

    2007-08-16

    Lower UrinaryTracts Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) represent an increasing prevalent condition in ageing men. Patients often seek primarily consultation at their general practitioner. Aetiology and natural history of LUTS due to BPH have not been completely clarified. The development of symptomatic LUTS is age-dependent and determined to varying degrees by the presence of Benign Prostatic Hyperplasia (BPH), Benign Prostatic Enlargement (BPE) as well as Bladder Outlet Obstruction (BOO). A causal relationship does not always exist. Basis for a specific medical or surgical treatment in the individual patient with LUTS due to BPH is an exact diagnosis by the practising urologist. PMID:17912862

  6. Pharmacological treatment of the benign prostatic hyperplasia

    International Nuclear Information System (INIS)

    Benign prostatic hyperplasia is a common disease in over 50 years-old men consisting in uncontrolled and benign growth of prostatic gland that leads to lower urinary tract symptoms. The etiology of benign prostatic hyperplasia is multifactoral involving the increased conversion of testosterone in dihydrotestosterone by the prostatic 5α-reductase action, which brought about events that encourage the prostate growth (static component) and the increase of the bladder and prostate smooth muscle tone (dynamic component) regulated by the aα1 -adrenoceptors (ADR). The pharmacological treatment of the benign prostatic hyperplasia includes the prostatic 5aα-reductase inhibitors, the aα1-adrenoreceptor blockers, their combined therapy and the phytotherapy. This paper was aimed at presenting the most relevant aspects of the pharmacology of drugs used for treating the benign prostatic hyperplasia, and providing elements to analyze their efficacy, safety and tolerability. To this end, a review was made of the different drugs for the treatment of this pathology and they were grouped according to their mechanism of action. Natural products were included as lipid extracts from Serenoa repens and Pygeum africanum as well as D-004, a lipid extract from Roystonea regia fruits, with proved beneficial effects on the main etiological factors of benign prostatic hyperplasia. D-004 is a prostatic 5a-reductase inhibitor, an aα1-adrenoceptor antagonist, aα 5-lipooxygenase inhibitor and has antioxidant action, all of which reveals a multifactoral mechanism. The results achieved till now indicate that D-004 is a safe and well-tolerated product

  7. Urodynamic implications of benign prostatic hyperplasia

    DEFF Research Database (Denmark)

    Jensen, K M; Andersen, J T

    1990-01-01

    By the age of 60, about 70% of men have developed benign prostatic hyperplasia (BPH), and 85%-95% of these have symptomatic dysfunction of the lower urinary tract, 10%-20% undergoing prostatectomy. Although transurethral resection of the prostate is generally considered to be a safe and effective...

  8. Natural history of benign prostate hyperplasia

    Institute of Scientific and Technical Information of China (English)

    WU Shi-liang; LI Ning-chen; XIAO Yun-xiang; JIN Jie; QIU Shao-peng; YE Zhang-qun; KONG Chui-ze; SUN Guang; NA Yan-qun

    2006-01-01

    Background Benign prostate hyperplasia is one of the most common diseases affecting the health of the aging males. Watchful waiting is an acceptable management strategy for benign prostate hyperplasia in which the patient is monitored by the physician but receives no active intervention. The epidemiological data on this are lacking in China. Our study was designed to evaluate the changes of signs and symptoms of patients with benign prostate hyperplasia during management by watchful waiting in China.Methods One hundred and forty-five patients with benign prostate hyperplasia aged > 50 years were enrolled in management by watchful waiting. All the patients were visited every 6 months and were given an International Prostate Symptom Score and Quality of Life questionnaire to complete. They also had uroflowmetry and were assessed using ultrasonography to get the volume of prostate, transition zone and amount of residual urine. The Student's t test, the Chi-square test, and variance analysis were used in the statistical analysis.Results All patients were visited after 6 months, the mean volume of transitional zone was found to haveincreased by 1.6 ml (P<0.01), International Prostate Symptom Score was increased by 0.8 (P<0.01) and Quality of Life was increased by 0.2 (P<0.01), and there was no statistical change in other data. Among these patients,17.9% (26/145) visited again after 12 months when the data failed to show a statistically significant difference among the three groups (0, 6, and 12 months).Conclusions After one year's follow-up, the progression of benign prostate hyperplasia was slow and the clinical data did not undergo much change.

  9. Benign prostatic hyperplasia: symptoms and objective interpretation

    DEFF Research Database (Denmark)

    Andersen, J T

    1991-01-01

    Considerable new knowledge about benign prostatic hyperplasia has been gained over the past two decades, particularly with regard to its natural history, hydrodynamic changes in the lower urinary tract, and the symptomatic and urodynamic results of treatment. A survey of the literature has been...

  10. Laser Applications for Benign Prostate Hyperplasia

    Directory of Open Access Journals (Sweden)

    Akyüz O.

    2012-02-01

    Full Text Available Transurethral prostate resection is still accepted as golden standard treatment modality for the management of benign prostate hyperplasia (BPH. Laser represents the most promising option among the minimal invasive alternatives. Laser with different wavelengths can provide coagulation, enucleation or vaporization on the target tissues. The significant advantages of laser applications are lesser complication rates of mainly retrograde ejaculation and erectile dysfunction, shorter hospitalization and catheterization times, and applicability in patients on anticoagulant treatment. However, further randomized multicenter trials are certainly required for laser to become a candidate for golden standard treatment for BPH.

  11. Testosterone and benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Thomas R Jarvis

    2015-04-01

    Full Text Available The use of testosterone to treat the symptoms of late-onset hypogonadal men has increased recently due to patient and physician awareness. However, concerns regarding the effect of testosterone on the prostate, in particular any possible effect on the risk of prostate cancer have prompted further research in this regard. Surprisingly, numerous retrospective or small, randomized trials have pointed to a possible improvement in male lower urinary tract symptoms (LUTS in patients treated with testosterone. The exact mechanism of this improvement is still debated but may have a close relationship to metabolic syndrome. For the clinician, the results of these studies are promising but do not constitute high levels of evidence. A thorough clinical examination (including history, examination and laboratory testing of testosterone should be undertaken before considering the diagnosis of late-onset hypogonadism or instigating treatment for it. Warnings still remain on the testosterone supplement product labels regarding the risk of urinary retention and worsening LUTS, and these should be explained to patients.

  12. OTC tamsulosin for benign prostatic hyperplasia.

    Science.gov (United States)

    2010-10-01

    Earlier this year, tamsulosin, an alpha blocker previously only available on prescription, became available for sale by pharmacists as a treatment for functional symptoms of benign prostatic hyperplasia (BPH) in men aged 45-75 years (Flomax Relief MR - Boehringer Ingelheim). A television advert for the over-the-counter (OTC) product claims that it is a "simple and effective" treatment that can relieve symptoms within 1 week, allowing the user to "take control of your annoying pee problems".¹ Here we review the evidence on tamsulosin and assess whether its availability as an OTC product confers worthwhile advantages. PMID:20926447

  13. Giant Benign Prostatic Hyperplasia in a Pakistani Patient *

    OpenAIRE

    Zafaruddin Khan; Muzamil Tahir; H. Shahzad Ashraf; FazaluRehman Khan Niazi; Munazza Khan; Sadaf Mustafa; Naseruddin Höti

    2014-01-01

    “Giant hyperplasia” of the prostate is a rare pathology of the prostate gland. We report one such case, in which a successful retropubic prostatectomy was performed on an elderly male patient in Pakistan. The weight of the resected prostate was 700 g, which is the eighth largest prostate with benign prostatic hyperplasia reported.

  14. Treating benign prostatic hyperplasia with botulinum neurotoxin.

    Science.gov (United States)

    Brisinda, G; Vanella, S; Marniga, G; Crocco, A; Maria, G

    2011-01-01

    Botulinum toxin (BoNT) has been increasingly used in the interventional treatment of several disorders; the use of this agent has extended to a plethora of conditions including focal dystonia, spasticity, inappropriate contraction in most gastrointestinal sphincters, eye movement disorders, hyperhidrosis, genitourinary disorders and aesthetically undesirable hyperfunctional facial lines. In addition, BoNT is being investigated for the control of pain, and for the management of tension or migraine headaches and myofascial pain syndrome. Benign prostatic hyperplasia (BPH) is a common condition in ageing men; the goal of therapy is to reduce the lower urinary tract symptoms (LUTS) associated with BPH and to improve the quality of life. However, medical treatment, including drugs that relax smooth muscle within the prostate and drugs that shrink the gland are not totally effective or without complications. The standard surgical treatment for BPH is progressively changing to minimally invasive therapies, but none of them has provided clear results. The use of BoNT-A to inhibit the autonomic efferent effects on prostate growth and contraction, and inhibit the abnormal afferent effects on prostate sensation, might be an alternative treatment for BPH. BoNT injections have several advantages over drugs and surgical therapies in the management of intractable or chronic disease; systemic pharmacologic effects are rare, permanent destruction of tissue does not occur, and graded degrees of relaxation may be achieved by varying the dose injected. In this paper, clinical experience over the last years with BoNT in BPH impaired patients will be illustrated.

  15. Transurethral microwave thermotherapy for benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Rubeinstein Jonathan N.

    2003-01-01

    Full Text Available Transurethral resection of the prostate (TURP remains the gold standard for treatment of benign prostatic hyperplasia (BPH. In general, while this procedure is safe, patients require a spinal, epidural, or general anesthesia and often several days of hospital stay; the potential morbidity and mortality limits the use of TURP in high-risk patients. Pharmacotherapy has been recommended as a first-line therapy for all patients with mild to moderate symptoms. Patients are oftentimes enthusiastic if they are offered a one-time method to treat lower urinary tract symptoms secondary to BPH, provided that the method offers reduced risk and allows an efficacy equal to that of medical therapy. One such method is transurethral microwave thermotherapy (TUMT. TUMT involves the insertion of a specially designed urinary catheter with a microwave antenna, which heats the prostate and destroys hyperplastic prostate tissue. TUMT allows the avoidance of general or regional anesthesia, and results in minimal blood loss and fluid absorption. In this review, the authors discussed the current indications and outcome of TUMT, including the history of the procedure, the mechanism of action, the indications for TUMT, the pre-operative considerations, the patient selection, the results in terms of efficacy, by comparing TUMT vs. Sham, TUMT vs. Alpha-blocker and TUMT vs. TURP. Finally, the complications are presented, as well as other uses and future directions of the procedure. The authors concluded that TUMT is a safe and effective minimally invasive alternative to treatment of symptomatic BPH.

  16. Management of benign prostatic hyperplasia with silodosin

    Directory of Open Access Journals (Sweden)

    Tomonori Yamanishi

    2009-08-01

    Full Text Available Tomonori Yamanishi1, Tomoya Mizuno1, Takao Kamai1, Ken-ichiro Yoshida1, Ryuji Sakakibara2, Tomoyuki Uchiyama31Department of Urology, Dokkyo Medical University, Tochigi, Japan; 2Department of Neurology, Sakura Hospital, Toho University, Toho, Japan; 3Department of Neurology, Chiba University, Chiba, JapanAbstract: It has been reported that blockade of α1A-adrenoceptor (AR relieves bladder outlet obstruction, while blockade of α1D-AR is believed to alleviate storage symptoms due to detrusor overactivity. Silodosin, (--1-(3-hydroxypropyl-5-[(2R-2-({2-[2-(2,2,2trifluoroethoxy phenoxy]ethyl}aminopropyl]-2,3-dihydro-1H-indole-7- carboxamide, is a new α1A-AR selective antagonist. Silodosin is highly selective for the α1A-AR subtype, showing an affinity for the α1A-AR that is 583- and 55.5-fold higher than its affinity for the α1B- and α1D-ARs, respectively. In randomized, double-blind, placebo-controlled phase III studies performed in Japan and the United States, silodosin has been shown to be effective for both storage and voiding symptoms associated with benign prostatic hyperplasia. Early effects of silodosin (after 2–6 hours or day 1 on lower urinary tract symptoms have also been reported. In urodynamic studies, detrusor overactivity disappeared in 40% and improved in 35% of patients after administration. In pressure flow studies, the grade of obstruction on the International Continence Society nomogram showed improvement in 56% of patients. The rate of adverse events in the silodosin, tamsulosin and placebo groups was 88.6%, 82.3%, and 71.6%, respectively. The most common adverse event was (mostly mild abnormal ejaculation (28.1%. However, few patients (2.8% discontinued silodosin because of abnormal ejaculation. Orthostatic hypotension showed a similar incidence in the silodosin (2.6% and placebo (1.5% groups. In conclusion, silodosin improves detrusor overactivity and obstruction and thus may be effective for both storage and voiding

  17. Transurethral electrochemical treatment of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    张民; 龚侃; 李宁; 曾荔; 那彦群

    2003-01-01

    Objective To study the mechanism and feasibility of transurethral electrochemical therapy for the treatment of benign prostatic hyperplasia (BPH). Methods Between March 1998 and March 2000, specifically designed devices and catheters for electrochemical therapy were applied to 6 prostate specimens obtained by suprapubic prostatectomy in order to treat BPH patients with urinary retention for whom surgery was contraindicated. Sixteen patients (with a mean age of 77.3 years old) underwent electrical treatment totaling 160-220 coulombs under topical urethral anesthesia for 68-132 min. The catheters remained inside the patient for 7-10 d. Results Irreversible destructive changes occurred within cathodal tissue, while carbonization occurred within anodic tissue. The radius of tissue change was 7-8 mm and 1-2 mm, respectively. In vivo trial: 11 (69%) patients could be weaned off the catheters with satisfactory urination. Three months after therapy, the mean international prostate symptom score (IPSS) was 14.5, mean peak flow rate was 10.5 ml/s, and mean residual urine was 39 ml. No serious complications were observed. Conclusion Transurethral electrochemical treatment is potentially a minimally invasive alternative for treatment of BPH, especially for elderly patients at high risk.

  18. The link between benign prostatic hyperplasia and prostate cancer

    DEFF Research Database (Denmark)

    Ørsted, David Dynnes; Bojesen, Stig E

    2013-01-01

    therapy. Furthermore, risk factors such as prostate inflammation and metabolic disruption have key roles in the development of both diseases. Despite these commonalities, BPH and prostate cancer exhibit important differences in terms of histology and localization. Although large-scale epidemiological......Benign prostatic hyperplasia (BPH) and prostate cancer are among the most common diseases of the prostate gland and represent significant burdens for patients and health-care systems in many countries. The two diseases share traits such as hormone-dependent growth and response to antiandrogen...... studies have shown that men with BPH have an increased risk of prostate cancer and prostate-cancer-related mortality, it remains unclear whether this association reflects a causal link, shared risk factors or pathophysiological mechanisms, or detection bias upon statistical analysis. Establishing BPH...

  19. [Interstitial laser coagulation of benign prostatic hyperplasia].

    Science.gov (United States)

    Muschter, R; Hessel, S; Hofstetter, A; Keiditsch, E; Rothenberger, K H; Schneede, P; Frank, F

    1993-07-01

    We report on the new method of interstitial laser coagulation for the treatment of benign prostatic hyperplasia (BPH). The procedure is based on the interstitial application of Nd:YAG laser irradiation, delivered through a new light guide system. Such light applicators coagulate constant tissue volumes in a homogeneous manner, as proven by in vitro studies in different tissues, including surgically removed prostate adenoma. The extent of the coagulation is determined by laser power and irradiation time. At 5 W, for example, and during a 10-min period, this zone reached a diameter of up to 20 mm. Temperatures generated in the process were over 100 degrees C, as measured by time/space resolution. These results were confirmed by in vivo studies in canine prostates. In the course of 7 weeks, the coagulated areas formed scars with degeneration and fibrosis, accompanied by marked shrinking. Neighbouring organs were not affected. The method was successfully transferred to clinical practice. The application of the light guides to the lateral lobes was performed percutaneously from the perineum under transrectal ultrasound guidance. The median lobe was punctured transurethrally under direct vision. Twenty-seven patients with an average age of 67.7 years were treated between July 1991 and March 1992. At the time of evaluation 15 patients had a follow-up of more than 2 months. They experienced a mean increase of peak flow rate from 6.6 to 15.2 ml/s and a mean decrease of residual volume from 206 to 38 ml. This was accompanied by a marked lessening of symptoms. The average prostate weight decreased from 63 to 44 g. Sexually active patients did not experience retrograde ejaculation.(ABSTRACT TRUNCATED AT 250 WORDS) PMID:7690498

  20. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia

    NARCIS (Netherlands)

    Robert, G.Y.M.; Smit, F.; Hessels, D.; Jannink, S.A.; Karthaus, H.F.M.; Aalders, T.; Jansen, K.; Taille, A. De La; Mulders, P.F.A.; Schalken, J.A.

    2011-01-01

    BACKGROUND: Chronic prostatic inflammation could be a central mechanism in benign prostatic hyperplasia (BPH) progression. Currently, the histological examination of prostate biopsies remains the only way to diagnose prostatic inflammation. Our objective was to find new noninvasive biomarkers for th

  1. Update in minimal invasive therapy in benign prostatic hyperplasia.

    NARCIS (Netherlands)

    Hest, P.J. van; Ancona, F.C.H. d'

    2009-01-01

    Last decade several new treatment modalities for minimal invasive therapy of benign prostatic hyperplasia have been developed, both ablative and non-ablative. In this review the authors describe the different techniques and clinical studies of bipolar transurethral resection of the prostate (TURP),

  2. Epidemiology and management of symptomatic benign prostatic hyperplasia

    NARCIS (Netherlands)

    K.M.C. Verhamme (Katia)

    2004-01-01

    textabstractBenign prostatic hyperplasia (BPH) is the most common non-cancerous form of cell growth in men and usually begins with the formation of microscopic nodules in younger men. As BPH progresses, overgrowth occurs in the central area of the prostate, called the transition zone, which wraps ar

  3. Smoking habits and benign prostatic hyperplasia

    Science.gov (United States)

    Xu, Huan; Fu, Shi; Chen, Yanbo; Chen, Qi; Gu, Meng; Wang, Zhong

    2016-01-01

    Abstract Previous studies have warned against the promoting effects of cigarette smoking on benign prostatic hyperplasia (BPH). In contrast, some have argued that smoking confers a protective effect regarding BPH, while others have observed an aggravated effect. Thus, we performed this meta-analysis to determine whether cigarette use is associated with BPH risk. To identify articles from observational studies of relevance, a search was performed concurrent to March 21, 2016, on PubMed, Web of Science, Cochrane, EBSCO, and EMBASE databases. Random-effect model, according to the heterogeneity, was calculated to reveal the relative risks (RRs) and corresponding 95% confidence intervals (CIs). Eight articles were included in this meta-analysis, representing data for 44,100 subjects, of which 5221 (11.8%) had BPH as defined according to the criteria. Seven reports are concerned with analysis between nonsmokers and ex-smokers, in which no significant difference was observed (RR = 0.99, 95% CI 0.94–1.05). Another meta-analysis of 7 studies indicated an observable trend, but without significant difference between groups of nonsmokers and current smokers (RR = 1.17, 95% CI 0.98–1.41). Between groups of heavy (6 articles; RR = 1.02, 95% CI 0.84–1.24) and light smokers (5 articles; RR = 0.90, 95% CI 0.71–1.15), again no significant difference appears. Finally, we combined individuals as never-smokers and ever-smokers and still found no significant difference between the 2 groups of patients (RR = 1.03, 95% CI 0.92–1.15). Sensitivity analysis was displayed and confirmed the stability of the present results. Combined evidence from observational studies shows no significant association between cigarette smoking and BPH risk, either for ex-smokers or for current smokers. The trend of elevated BPH risk from smoking was observed only in current smokers compared with nonsmokers, while marginal significance was observed in comparing ever-smokers with

  4. Immunohistochemical Analysis of Omi/HtrA2 Expression in Prostate Cancer and Benign Prostatic Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    HU Xiaoyong; CHEN Xiaochun; PING Hao; CHEN Zhaohui; ZENG Fuqing; LU Gongcheng

    2005-01-01

    To study the expression and significance of the serine protease Omi/HtrA2 in prostate cancer and benign prostatic hyperplasia. The expression of Omi/HtrA2 was assayed by means of immunohistochemical technique in 41 prostate cancer (Cap), 20 benign prostatic hyperplasia (BPH) and 10 normal prostate (NP) specimens. Omi/HtrA2 expression was positive in 30 (73.17%) prostate cancer specimens, and the positive rate of Omi/HtrA2 was lower in well differentiated than in poorly and moderately differentiated groups (P<0.05). By contrast, the cells in normal prostate and benign prostatic hyperplasia groups showed no or weak expression of Omi/HtrA2.Prostate cancer cells in vivo may need Omi/HtrA2 expression for apoptosis, and that Omi/HtrA2expression might be involved in prostate cancer development.

  5. Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia.

    Science.gov (United States)

    Aaron, LaTayia; Franco, Omar E; Hayward, Simon W

    2016-08-01

    Prostate development follows a common pattern between species and depends on the actions of androgens to induce and support ductal branching morphogenesis of buds emerging from the urogenital sinus. The human prostate has a compact zonal anatomy immediately surrounding the urethra and below the urinary bladder. Rodents have a lobular prostate with lobes radiating away from the urethra. The human prostate is the site of benign hyperplasia, prostate cancer, and prostatitis. The rodent prostate has little naturally occurring disease. Rodents can be used to model aspects of human benign hyperplasia, but care should be taken in data interpretation and extrapolation to the human condition. PMID:27476121

  6. Management of Benign Prostatic Hyperplasia in Older Adults.

    Science.gov (United States)

    Woodard, Todd J; Manigault, Kendra R; McBurrows, Niesha N; Wray, Tiffany L; Woodard, Laresa M

    2016-01-01

    Benign prostatic hyperplasia (BPH), also known as benign prostatic hypertrophy, is a nonmalignant adenomatous overgrowth of the periurethral prostate gland commonly seen in aging men. Historically, it has been assumed that the pathophysiology of lower urinary tract symptoms in men is the result of bladder outlet obstruction associated with prostate enlargement. Symptoms such as urinary hesitancy, incomplete bladder emptying, dribbling or prolonged urination, nocturia, urinary urgency, and/or urge incontinence are common. Understanding the differential diagnosis and ordering appropriate laboratory tests are essential in accurately identifying a BPH diagnosis. Management can be broken down into medical or pharmacological and surgical therapies. This article aims to provide an overview of BPH and its management in older adults. PMID:27535076

  7. Suppression of benign prostate hyperplasia by Kaempferia parviflora rhizome

    OpenAIRE

    Kazuya Murata; Hirotaka Hayashi; Shinichi Matsumura; Hideaki Matsuda

    2013-01-01

    Background: Kaempferia parviflora rhizome is used as a folk medicine in Thailand for the treatment of various symptoms. In the present study, the inhibitory activities of extract from K. parviflora rhizome against 5α-reductase (5αR) were subjected. Furthermore, the effects of the extract from K. parviflorar hizome in benign prostate hyperplasia (BPH) were studied using the model mice. Materials and Methods: Preparations of extracts from the rhizomes of K. parviflora, Curcuma zedoaria and Zing...

  8. Recent advances in treatment for Benign Prostatic Hyperplasia

    OpenAIRE

    van Rij, Simon; Gilling, Peter

    2015-01-01

    Clinical benign prostatic hyperplasia (BPH), often identified as a worsening ability of a male to pass urine, is a significant problem for men in our society. In 2015, the use of personalised medicine is tailoring treatment to individual patient needs and to genetic characteristics. Technological advances in surgical treatment are changing the way BPH is treated and are resulting in less morbidity. The future of BPH treatments is exciting, and a number of novel techniques are currently under ...

  9. Serenoa repens extract in the treatment of benign prostatic hyperplasia

    OpenAIRE

    Geavlete, Petrisor; Multescu, Razvan; Geavlete, Bogdan

    2011-01-01

    We are experiencing a revival of interest in phytotherapeutic agents, both in Europe and North America, especially as a consequence of patients’ dissatisfaction with the adverse effects of the medical alternatives. One of the most frequently prescribed and studied such agents is Serenoa repens extract, derived from the berry of the dwarf palm tree. We aimed to review the most important published data regarding this type of treatment for benign prostatic hyperplasia. A review of the existing a...

  10. Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects

    OpenAIRE

    Marina Zamuner; Ciro Eduardo Falcone; Arnaldo Amstalden Neto; Tomás Bernardo Costa Moretti; Luis Alberto Magna; Fernandes Denardi; Leonardo Oliveira Reis

    2014-01-01

    Background. Benign prostatic hyperplasia (BPH) pharmacological treatment may promote a decrease in prostate vascularization and bladder neck relaxation with theoretical improvement in prostate biopsy morbidity, though never explored in the literature. Methods. Among 242 consecutive unselected patients who underwent prostate biopsy, after excluding those with history of prostate biopsy/surgery or using medications not for BPH, we studied 190 patients. On the 15th day after procedure patients w...

  11. Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results from the Prostate Cancer Prevention Trial

    OpenAIRE

    Schenk, Jeannette M.; Kristal, Alan R.; Arnold, Kathryn B.; Tangen, Catherine M.; Neuhouser, Marian L; Lin, Daniel W; White, Emily; Thompson, Ian M

    2011-01-01

    This study examined the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer risk in 5,068 placebo-arm participants enrolled in the Prostate Cancer Prevention Trial (1993–2003). These data include 1,225 men whose cancer was detected during the 7-year trial—556 detected for cause (following abnormal prostate-specific antigen or digital rectal examination) and 669 detected not for cause (without indication), as well as 3,843 men who had biopsy-proven absence of...

  12. Benign prostatic hyperplasia (BPH) management in the primary care setting.

    Science.gov (United States)

    Kapoor, Anil

    2012-10-01

    Benign prostate hyperplasia (BPH) occurs in up to 50% of men by age 50, and the incidence increases with age. This common clinical problem is diagnosed by history, including the International Prostate Symptom Score (IPSS) questionnaire, and physical examination by digital rectal examination (DRE). Initial management for BPH includes lifestyle modification, and smooth muscle relaxant alpha blocker therapy. Alpha blockers usually take effect quickly within 3-5 days, and have minimal side effects. Current commonly used alpha blockers include the selective alpha blockers tamsulosin (Flomax), alfusosin (Xatral), and silodosin (Rapaflo). For patients with larger prostates, the 5-alpha reductase inhibitor class (finasteride (Proscar) and dutasteride (Avodart)) work effectively to shrink prostate stroma resulting in improved voiding. The 5-ARI class of drugs, in addition to reducing prostate size, also reduce the need for future BPH-related surgery, and reduce the risk of future urinary retention. Drugs from the phosphodiesterase-5 (PDE-5) inhibitor class may now be considered for treating BPH. Once daily 5 mg tadalafil has been shown to improve BPH-related symptoms and is currently approved to treat patients with BPH. Referral to a urologist can be considered for patients with a rising prostate-specific antigen (PSA), especially while on 5-ARI, failure of urinary symptom control despite maximal medical therapy, suspicion of prostate cancer, hematuria, recurrent urinary infections, urinary retention, or renal failure. Currently the primary care physician is armed with multiple treatment options to effectively treat men with symptomatic BPH. PMID:23089343

  13. Comparison of telomerase activity in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Soleiman Mahjoub

    2006-11-01

    Full Text Available BACKGROUND: Telomerase is a reverse transcriptase enzyme that synthesizes telomeric DNA on chromosome ends. The enzyme is important for the immortalization of cancer cells because it maintains the telomeres. METHODS: Telomerase activity (TA was measured by fluorescence-based telomeric repeat amplification protocol (FTRAP assay in prostate carcinoma and benign prostatic hyperplasia (BPH. RESULTS: TA was present in 91.4% of 70 prostate cancers, 68.8% of 16 prostatic intraepithelial neoplasia (PIN, 43.3% of 30 BPH*, 21.4% of 14 atrophy and 20% of 15 normal samples adjacent to tumor. There was not any significant correlation between TA, histopathological tumor stage or gleason score. In contrast to high TA in the BPH* tissue from the cancer-bearing gland, only 6.3% of 32 BPH specimens from patients only diagnosed with BPH were telomerase activity-positive. CONCLUSIONS: These results indicate that TA is present in most prostate cancers. The high rate of TA in tissue adjacent to tumor may be attributed either to early molecular alteration of cancer that was histologically unapparent, or to the presence of occult cancer cells. Our findings suggest that the re-expression of telomerase activity could be one step in the transformation of BPH to PIN. KEY WORDS: Telomerase activity, prostate cancer, prostatic intraepithelial neoplasia, benign prostatic hyperplasia.

  14. An insidious risk factor for cardiovascular disease: benign prostatic hyperplasia.

    Science.gov (United States)

    Karatas, Omer Faruk; Bayrak, Omer; Cimentepe, Ersin; Unal, Dogan

    2010-10-29

    Patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTSs) have a considerably higher prevalence of cardiovascular disease (CVD) than the general population in old age. Many hypotheses have been created to explain traditional clinical risk factors of CVD, including age, male gender, cigarette smoking, inheritance, high blood pressure (BP), obesity, elevated fasting plasma glucose, diabetes mellitus, dyslipidemia, decreased physical activity and metabolic syndrome; or nontraditional risk factors such as oxidative stress, inflammation, vascular calcification, malnutrition, homocysteine and genetic variation. Although these risk factors are important in CVD pathophysiology and clinical presentation, there is still no single theory sufficient to provide an adequate explanation for all the properties of CVD. We speculate that by causing nocturia-induced sleep disturbances, BP variability, increased sympathetic activity, non-dipping BP variations; BPH may be an insidious risk factor for CVD. Benign prostate hyperplasia may be related to increased BP, coronary ischemic hearth disease or other cardiovascular pathologic conditions. This attention on BPH may produce a new approach to the diagnosis and treatment of CVD. Although the underlying mechanisms are still exactly unclear, further prospective randomized controlled studies are needed to identify if patients with BPH/LUTS is higher risk for CVD. PMID:19359054

  15. Benign prostatic hyperplasia: An overview of existing treatment

    Directory of Open Access Journals (Sweden)

    Neelima Dhingra

    2011-01-01

    Full Text Available Benign prostatic hyperplasia (BPH is the most common condition in aging men, associated with lower urinary tract symptoms (LUTS. A better understanding of the prostate physiology, function, and pathogenesis has led to the development of promising agents, useful in the management of LUTS in men. The specific approach used to treat BPH depends upon number of factors like age, prostrate size, weight, prostate-specific antigen level, and severity of the symptoms. 5α-reductase inhibitors decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume, increased peak urinary flow rate, improvement of symptoms, decreased risk of acute urinary retention, and need for surgical intervention. α1 -adrenergic receptor (α1 -AR antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Clinical efficacy of either 5α-reductase inhibitor or α1 -AR antagonist has been further improved by using combination therapy; however, long-term outcomes are still awaited. Many more potential new therapies are under development that may improve the treatment of BPH. This article gives a brief account of rationale and efficacy of different treatment options presently available in the management of BPH.

  16. Benign prostatic hyperplasia: age-related tissue-remodeling.

    Science.gov (United States)

    Untergasser, Gerold; Madersbacher, Stephan; Berger, Peter

    2005-03-01

    Aging and androgens are the two established risk factors for the development of benign prostatic hyperplasia (BPH) and benign prostatic enlargement (BPE), which can lead to lower urinary tract symptoms (LUTS) in elderly men. BPH, consisting of a nodular overgrowth of the epithelium and fibromuscular tissue within transition zone and periurethral areas, is first detectable around the fourth decade of life and affects nearly all men by the ninth decade. The pathogenesis of BPH is still largely unresolved, but multiple partially overlapping and complementary theories have been proposed, all of which seem to be operative at least to some extent. In addition to nerve-, endocrine- and immune system, local para- and luminocrine pleiotrope mechanisms/factors are implicated in the prostatic tissue-remodeling process. Prostate tissue-remodeling in the transition zone is characterized by: (i) hypertrophic basal cells, (ii) altered secretions of luminal cells leading to calcification, clogged ducts and inflammation, (iii) lymphocytic infiltration with production of proinflammatory cytokines, (iv) increased radical oxygen species (ROS) production that damages epithelial and stromal cells, (v) increased basic fibroblast (bFGF) and transforming growth factor beta (TGF-beta 1) production leading to stromal proliferation, transdifferentiation and extracellular matrix production, (vi) altered autonomous innervation that decreases relaxation and leads to a high adrenergic tonus, (vii) and altered neuroendocine cell function and release of neuroendocrine peptides (NEP). This review summarizes the multifactorial nature of prostate tissue remodeling in elderly men with symptomatic BPH with a particular focus on changes of cell-cell interactions and cell functions in the human aging prostate.

  17. The histology of prostate tissue following prostatic artery embolization for the treatment of benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    George Camara-Lopes

    2013-04-01

    Full Text Available Objective Prostatic artery embolization (PAE for the treatment of patients with symptomatic benign prostatic hyperplasia (BPH is believed to be a safe procedure with a low risk of adverse side effects. Artery embolization is a viable treatment option in patients who are refractory to the classic noninvasive treatments. Knowledge of the histological characteristics of prostate tissue following the procedure is still limited. In this study, we describe the microscopic aspects of the prostate following PAE for BPH. Materials and Methods Two patients underwent transurethral resections of the prostate (TURP after PAE. Embolizations were performed under local anesthesia with an initial pelvic angiography to evaluate the iliac vessels and the prostate arteries using a 2.8 French microcatheter. The prostate was embolized with 300-500µm Microspheres (Embosphere®, using complete blood stasis as the end point. The prostate tissues were analyzed histologically to characterize the effects of the embolization. Results The embolic material within the prostate tissue was easily identified as homogeneous, bright eosin-red spheroids filling the vessel lumens. Ischemic necrosis surrounded or not by chronic inflammatory reactions containing macrophages were considered as a result of the artery embolization. Also, some aspects related to the healing process were observed being fibrotic nodules surrounded by glands with squamous metaplasia of the epithelial lining the most important. In the remaining sections, due to the precocious surgical intervention, the classic findings of BPH were still present with the glandular and stromal hyperplasia associated with nonspecific chronic prostatitis. Conclusions This is the first description of prostate histology in BPH patients treated by PAE, a new procedure that is being used increasingly as a therapeutic intervention. The recognition of the changes caused by this new modality of treatment has become a very important

  18. Prostatic Artery Embolization for Enlarged Prostates Due to Benign Prostatic Hyperplasia. How I Do It

    Energy Technology Data Exchange (ETDEWEB)

    Carnevale, Francisco C., E-mail: fcarnevale@uol.com.br [University of Sao Paulo Medical School, Interventional Radiology Unit (Brazil); Antunes, Alberto A., E-mail: antunesuro@uol.com.br [University of Sao Paulo Medical School, Division of Urology (Brazil)

    2013-12-15

    Prostatic artery embolization (PAE) has emerged as an alternative to surgical treatments for benign prostatic hyperplasia (BPH). Patient selection and refined technique are essential for good results. Urodynamic evaluation and magnetic resonance imaging are very important and technical limitations are related to elderly patients with tortuous and atherosclerotic vessels, anatomical variations, difficulty visualizing and catheterizing small diameter arteries feeding the prostate, and the potential risk of bladder and rectum ischemia. The use of small-diameter hydrophilic microcatheters is mandatory. Patients can be treated safely by PAE with low rates of side effects, reducing prostate volume with clinical symptoms and quality of life improvement without urinary incontinence, ejaculatory disorders, or erectile dysfunction. A multidisciplinary approach with urologists and interventional radiologists is essential to achieve better results.

  19. Current clinical management strategies for benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    ZHANG Xiang-hua

    2008-01-01

    @@ This article summarizes the major new findings on clinical management for benign prostatic hyperplasia (BPH) that were presented at the annual meeting of the American Urological Association (AUA) in May 2008.The management of symptomatic BPH has been changed significantly over the last decade in response to the availability of new treatment options.Prior to the 1980s,open prostatectomy was the only widely accepted intervention for BPH.Since then,the advent of new medical therapies for BPH and the introduction of a range of minimally invasive therapies have provided for men with lower urinary tract symptoms (LUTS) secondary to BPH.1 In this year's AUA meeting,several new findings were reported in the filed of BPH which involved epidemiology,clinical progression,drug therapy and new technologies in surgical therapy of BPH.

  20. Economic issues and the management of benign prostatic hyperplasia.

    Science.gov (United States)

    Holtgrewe, H L

    1995-09-01

    Enormous financial resources are expended worldwide on the treatment of the urologic complications and symptoms induced by benign prostatic hyperplasia (BPH). Even for its surgical management, where the best data exist, current international accounting of these expenditures remains very poorly documented. On February 8, 1994, the Department of Health and Human Services of the US government released clinical guidelines for the diagnosis and management of BPH. Imaging of the upper urinary tract as a routine diagnostic procedure is not recommended in these guidelines unless a comorbidity indicating its need exists. Diagnostic cystoscopy to assist in the decision of the need to treat is not recommended. Adherence to these two principles along with adherence to the strategies of management presented in the guidelines and discussed herein has the potential of achieving profound financial savings without impairing quality of care worldwide.

  1. The role of combination medical therapy in benign prostatic hyperplasia.

    Science.gov (United States)

    Greco, K A; McVary, K T

    2008-12-01

    To review key trials of monotherapy and combination therapy of alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs), 5alpha-reductase inhibitors (5alphaRIs) and anti-muscarinic agents in the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and Cochrane databases (1976-2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, alpha(1)-adrenergic receptor antagonists, 5alpha-reductase inhibitors, anti-muscarinics, anticholinergics, combination therapy, alfuzosin, doxazosin, tamsulosin, terazosin, dutasteride, finasteride, tolterodine, flavoxate, propiverine, oxybutynin, erectile dysfunction, sildenafil, vardenafil and tadalafil. Data from the Medical Therapy of Prostatic Symptoms (MTOPS) study indicated a role for long-term use of alpha(1)-ARAs and 5alphaRIs in combination. In the MTOPS study, combination therapy with the alpha(1)-ARA doxazosin and the 5alphaRI finasteride was significantly more effective than either component alone in reducing symptoms (P=0.006 vs doxazosin monotherapy; Pfinasteride monotherapy) and in lowering the rate of clinical progression (Pdutasteride resulted in a significantly greater decrease in International Prostate Symptom Score (IPSS) when compared with either monotherapy. Several recent trials have studied the efficacy of combining alpha(1)-ARAs and anti-muscarinic agents in the treatment of BPH. These studies have found this combination to result in statistically significant benefits in quality of life scores, patient satisfaction, urinary frequency, storage symptoms and IPSS scores. Studies have not shown an increased risk of urinary retention associated with the use of anti-muscarinics in a highly select cohort of men with BPH. The available data suggest that combination therapy can be beneficial

  2. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia

    NARCIS (Netherlands)

    Mochtar, CA; Kiemeney, LALM; van Riemsdijk, MM; Barnett, GS; Laguna, MP; Debruyne, FMJ; de la Rosette, JJMCH

    2003-01-01

    Objectives: To assess the ability of serum prostate specific antigen (PSA) to estimate prostate volume (PV) to aid in the management of patients with benign prostatic hyperplasia (BPH). Methods: From 1989 to 2002, data were collected from 2264 patients complaining of lower urinary tract symptoms (LU

  3. Suppression of benign prostate hyperplasia by Kaempferia parviflora rhizome

    Directory of Open Access Journals (Sweden)

    Kazuya Murata

    2013-01-01

    Full Text Available Background: Kaempferia parviflora rhizome is used as a folk medicine in Thailand for the treatment of various symptoms. In the present study, the inhibitory activities of extract from K. parviflora rhizome against 5a-reductase (5aR were subjected. Furthermore, the effects of the extract from K. parviflorar hizome in benign prostate hyperplasia (BPH were studied using the model mice. Materials and Methods: Preparations of extracts from the rhizomes of K. parviflora, Curcuma zedoaria and Zingiber officinale, and methoxyflavones isolated from K. parviflora was used for 5aR inhibition assay. The effects of K. parviflora extract on growth suppression for the prostates and seminal vesicles were performed based on the Hershberger′s method. The K. parviflora extract was administered to castrated mice for 14 days. Results: K. parviflora extract showed more potent inhibitory activity on 5aR than C. zedoaria and Z. officinale extracts. The active principles were identified as 3,5,7,3′,4′-pentamethoxyflavone and 5,7,3′,4′-tetramethoxyflavone by activity guided fractionation. Furthermore, K. parviflora extract suppressed the weights of prostates and seminal vesicles in BPH model rats by daily administration for 14 days. Conclusion: These results indicate that K. parviflora extract can be a promising agent for the treatment of BPH.

  4. Role of laser therapy in benign prostate hyperplasia (BPH)

    Science.gov (United States)

    de Riese, Werner T.; Sharpe, Brent A.; Aronoff, David B.; Mittemeyer, Bernhard T.

    2001-05-01

    Benign prostatic hyperplasia (BPH) is a common disease in males older than 50 years of age. 75-80% of this population is considered to have some degree of BPH causing clinical symptoms and requiring urological treatment. Transurethral resection of the prostate (TUR-P) is currently the standard surgical treatment modality for BPH. In an attempt to minimize the need for hospitalization and the associated perioperative and postoperative morbidity, alternatives have been sought. Various types of laser techniques such as interstitial laser coagulation and side-firing technology have been proposed. Numerous studies have shown that laser procedures safely and effectively reduce the volume of the prostate. Intra- and postoperative bleeding are nearly unknown complications for laser procedures, whereas this is the most relevant complication for the TUR-P. Due to significant tissue edema after laser treatment, patients commonly show delayed time to void adequately and, therefore, catheter drainage is often necessary for 3 to 21 days. Retrograde ejaculation is reported to occur less (0- 10%) compared to TUR-P (greater than 60%). Urinary tract infections are very common after interstitial laser coagulation. Although not many long-term clinical data are available, various studies have shown that BPH patients improve in symptom score, flow rate and post-void residual up to 3 years after laser treatment. This paper presents a concise review of efficacy, advantages and disadvantages of the most frequently used laser techniques as well as the long-term clinical data compared to TUR-P.

  5. Protective Effect of Naringin on Testosterone Induced Benign Prostatic Hyperplasia in Rats

    OpenAIRE

    Naresh KN; Aparna B; Dr. Veeresh B

    2013-01-01

    Major components of plants being flavonoids containing polyphenolic derivatives which possesantioxidant property have shown to improve uncontrolled growth of the prostate gland and urinary tractsymptoms, which are associated with benign prostatic hyperplasia. Our study investigated whetherNaringin prevents testosterone induced prostatic hyperplasia in rats by virtue of its antioxidant property.In vitro studies were carried out to assess the protective effect of prostate tumor cell lines. BPH ...

  6. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.

    OpenAIRE

    Mantzoros, C S; Tzonou, A.; Signorello, L B; Stampfer, M.; Trichopoulos, D; Adami, H. O.

    1997-01-01

    Blood samples were collected from 52 incident cases of histologically confirmed prostate cancer, an equal number of cases of benign prostatic hyperplasia (BPH) and an equal number of apparently healthy control subjects. The three groups were matched for age and town of residence in the greater Athens area. Steroid hormones, sex hormone-binding globulin, and insulin-like growth factor 1 (IGF-1) were measured in duplicate by radioimmunoassay in a specialized US centre. Statistical analyses were...

  7. Outcome of Transurethral Plasmakinetic Vaporization for Benign Prostatic Hyperplasia

    Directory of Open Access Journals (Sweden)

    Magdy El-Tabey

    2015-04-01

    Full Text Available Purpose To assess the outcome of transurethral plasmakinetic vaporization (PKVP in the management of benign prostatic hyperplasia (BPH. Patients and methods From August 2010 to May 2012, 60 patients with obstructive LUTS due to BPH were included in the study. All patients were evaluated by International Prostate Symptom Score (IPSS, general examination, digital rectal examination, PSA, routine laboratory examinations, pelvi-abdominal ultrasound, trans-rectal ultrasound, and uroflowmetry. Patients with Qmax of 8 and a prostate volume of >40 mL underwent transurethral PKVP. Results Mean age of the patients was 66.8±4.5 years. The mean times of the operation, post-operative bladder irrigation, and post-operative catheterization were 63.8±13.9 minutes, 15.2±5.7 hours, and 23.9±5.2 hours, respectively. At 3 months of follow-up, there were significant reductions in the mean IPSS from 23.4±3.5 to 9.2±3.7 (P=0.4, mean PSA from 3.03±2.2 ng/mL to 1.2±1.04 ng/mL (P value=0.02, mean post voiding residual urine from 149.8±59.5 mL to 46.9±24.1 mL (P value <0.01, and mean prostate volume from 72.8±10.3 mL to 22.7±6.1 mL (P value <0.01. Also, there was a statistically significant increase in the mean Q max. from 8.7±2.4 mL/s to 19.5±3.5 mL/s (P value <0.01. Conclusion PKVP is an effective and safe treatment option in the management of symptomatic BPH.

  8. Evaluation for Madigan's prostatectomy in patients with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    Li-Min LIAO; Bing-Yi SHI; Chun-Quan LIANG; Werner SCH(..)AFER

    2001-01-01

    To comparatively evaluate the efficacy and post-operative complications of the Madigan's prostatectomy (MPC) and suprapubic prostatectomy (SPPC). Methods: A total of 43 patients with benign prostatic hyperplasia were divided into two groups: 21 underwent MPC and 22, SPPC. In all the patients, the international prostate symptom score (IPSS) and urinary pressure-flow studies were assessed before and 6 months after operation. The International Continence Society (ICS) nomogram, Abrams-Griffiths (AG) number and linear passive urethral resistance relation analysis (L-PURR) were used to diagnose and grade bladder outlet obstruction (BOO). The IPSS and the urodynamic parameters before and after operation, as well as the advantages and post-operative complications were recorded and compared. Results: Patients of both the MPC and SPPC groups had a significant improvement in IPSS and urodynamic parameters. Obstruction was relieved in 81.0% of MPC and 86.4 % of SPPC patients. MPC has the advantages of the absence of postoperative hematuria and post-catheter stricture, a shorter period of hospitalization, and lower incidence of retrograde ejaculation and erectile dysfunction. Conclusion: Both MPC and SPPC can effectively relieve BOO. MPC has certain advantages and a lower incidence of complications as compared with SPPC.

  9. Combination pharmacological therapies for the management of benign prostatic hyperplasia.

    Science.gov (United States)

    Cohen, Seth A; Parsons, J Kellogg

    2012-04-01

    Benign prostatic hyperplasia (BPH) is a highly prevalent condition of older men caused by unregulated growth of the prostate gland. Clinical trials of medical therapy for BPH have consistently demonstrated that combined therapy with an α(1)-adrenergic receptor (AR) antagonist and a 5α-reductase inhibitor is superior to either agent alone. The addition of anticholinergic therapy to a treatment regimen could effectively improve symptoms in men with persistent storage lower urinary tract symptoms (LUTS) who have not seen a benefit with an α(1)-AR antagonist or 5α-reductase inhibitor. Among α(1)-AR antagonists, doxazosin, terazosin, tamsulosin, and alfuzosin, although with slight differences in adverse event profiles, are equivalent in effectiveness and efficacy. No data in the form of direct comparator trials exist to suggest a difference in clinical efficacy of finasteride and dutasteride, the two 5α-reductase inhibitors currently available. Current American Urological Association guidelines do not recommend phytotherapy or dietary supplements in any combination for the medical management of BPH. The current literature supports the safety and efficacy of the combination of an α(1)-AR antagonist and a 5α-reductase inhibitor in the treatment of symptomatic BPH and, in select patients, the use of an α(1)-AR antagonist and anticholinergic medication in the treatment of LUTS suggestive of BPH. PMID:22428659

  10. TRANSURETHRAL RESECTION VERSUS TRANSVESICAL APPROACH FOR BENIGN PROSTATIC HYPERPLASIA

    Directory of Open Access Journals (Sweden)

    Karbhari

    2015-01-01

    Full Text Available BACKGROUND: Benign Prostatic Hyperplasia (BPH is a common disease in elderly people. Different surgical treatment options were available in which transvesical and transurethral resection of prostate are commonly employed for BPH in our set up. AIM : To compare the immediate complications, hospital stay, days of immobilization, duration of indwelling catheter, mortality and morbidity. MATERIALS AND METHODS: A comparative study was conducted between August 2012 to August 2014, which involved patients underwent TURP and transvesical prostatectomy. Patients having associated complications and post - op morbidities were compared. RESULTS: Commonest affected age group was 50 - 90 yrs. (M ean age 69.6 yrs. . 14 patients developed immediate significant postoperative complications in both, the procedures. 11patients developed significant delayed post - operative complications in transvesical procedure. In TURP no delayed complications. In transvesical procedure average postop erative hospital stay was 16.08 days. In TURP it was 6.24 days. Compared to transvesical procedure days of immobilization (6.48 days and indwelling catheterization (6.12 days is significantly lower in TURP 3.12 days and 2.60 days respectively. Morbidities were more in transvesical prostatectomy and none in TURP. There was no mortality in this study. CONCLUSION: TURP has definite advantage over the transvesical suprapubic prostectomy, because of shorter period of hospitalization, postoperative complications are less frequent, shorter duration and less severe. It has got lowest mortality and morbidity rates.

  11. Fibronectin Pattern in Benign Hyperplasia and Cancer of the Prostate

    Directory of Open Access Journals (Sweden)

    Miroslava M. Janković

    2008-01-01

    Full Text Available Fibronectin (FN is a multifunctional glycoprotein involved in cell-matrix interactions. It exhibits a complex pattern of forms differing in respect to aminoacid and oligosaccharide composition. In this study we examined glycobiochemical and functional properties of the FN in benign prostatic hyperplasia (BPH and prostatic cancer (PCa, attempting to resolve disease-related differences. Two BPH sera pools and three PCa sera pools were used as the FN source. The affinity-purified molecule was characterized by SDS-PAGE, immuno- and lectin blot, lectin-affinity chromatography and adhesion assay. BPH FN existed as intact molecule, giving the main immunoreactive band at 220 kDa. In contrast, PCa FN comprised three main immunoreactive fragments of 140, 110 and 90 kDa. As for glycosylation the ratio of altogether lectin-reactive PCa FN was different from that of BPH FN manifested as a decrease of Con A- and an increase of LCA-reactive moieties. Fibroblasts adhered to both FN preparations in a concentration dependent manner, but with a significantly lower efficiency to PCa FN. The results obtained showing distinct structural characteristics of PCa FN compared to BPH FN could be important for modulation of its ligand and recognition properties expressed as gain or loss of functions or as specific markers of its origin.

  12. Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH)

    OpenAIRE

    Cambio, Angelo J; Evans, Christopher P.

    2007-01-01

    Background Benign prostatic hyperplasia (BPH) is a common disease of the aging male population. BPH treatment includes a variety of pharmacological and surgical interventions. The goal of this paper is to review the natural history of BPH, outcomes of pharmacological management, effects on quality of life (QoL), future pharmacotherapies, and associated patient-focused perspectives. Materials and methods Medline searches for the keywords benign prostatic hyperplasia, BPH, alpha blockers, 5 alp...

  13. Evolution of the use of the holmium laser for the treatment of benign prostatic hyperplasia

    Science.gov (United States)

    Gilling, Peter J.; Cass, Carol B.; Cresswell, Michael D.; Kennett, Katie M.; Mackey, Michael; Fraundorfer, Mark R.; Kabalin, John N.

    1997-05-01

    The holmium laser is becoming an important tool in the urologists' armamentarium. In this manuscript the evolution of laser resection of the prostate using the holmium wavelength is described. This technique represents a significant advance in the surgical management of benign prostatic hyperplasia and allows even very large prostates to be safely and efficiently managed transurethrally.

  14. Various treatment options for benign prostatic hyperplasia: A current update.

    Science.gov (United States)

    Shrivastava, Alankar; Gupta, Vipin B

    2012-01-01

    In benign prostatic hyperplasia (BPH) there will be a sudden impact on overall quality of life of patient. This disease occurs normally at the age of 40 or above and also is associated with sexual dysfunction. Thus, there is a need of update on current medications of this disease. The presented review provides information on medications available for BPH. Phytotherapies with some improvements in BPH are also included. Relevant articles were identified through a search of the English-language literature indexed on MEDLINE, PUBMED, Sciencedirect and the proceedings of scientific meetings. The search terms were BPH, medications for BPH, drugs for BPH, combination therapies for BPH, Phytotherapies for BPH, Ayurveda and BPH, BPH treatments in Ayurveda. Medications including watchful waitings, Alpha one adrenoreceptor blockers, 5-alpha reductase inhibitors, combination therapies including tamsulosin-dutasteride, doxazosin-finasteride, terazosin-finasteride, tolterodine-tamsulosin and rofecoxib-finasteride were found. Herbal remedies such as Cernilton, Saxifraga stolonifera, Zi-Shen Pill (ZSP), Orbignya speciosa, Phellodendron amurense, Ganoderma lucidum, Serenoa Repens, pumpkin extract and Lepidium meyenii (Red Maca) have some improvements on BPH are included. Other than these discussions on Ayurvedic medications, TURP and minimally invasive therapies (MITs) are also included. Recent advancements in terms of newly synthesized molecules are also discussed. Specific alpha one adrenoreceptor blockers such as tamsulosin and alfuzosin will remain preferred choice of urologists for symptom relief. Medications with combination therapies are still needs more investigation to establish as preference in initial stage for fast symptom relief reduced prostate growth and obviously reduce need for BPH-related surgery. Due to lack of proper evidence Phytotherapies are not gaining much advantage. MITs and TURP are expensive and are rarely supported by healthcare systems. PMID:22923974

  15. Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

    NARCIS (Netherlands)

    V. Tzortzis; S. Gravas; J.J.M.C.H. de la Rosette

    2009-01-01

    Although transurethral resection of the prostate (TURP) is considered to be the reference standard for minimally invasive surgical treatment (MIST) of lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO), it is associated with a noteworthy rate of complication. Transurethral

  16. AUA SYMPTOM SCORE - A SIMPLE TOOL FOR ASSESSMENT OF BENIGN PROSTATIC HYPERPLASIA IN A RURAL SETTING

    OpenAIRE

    SP Patel; VK Srivastava

    2013-01-01

    Background: Benign Prostatic Hyperplasia (BPH) is one of the most common disease in ageing men and can be associated with Lower Urinary Tract Symptoms (LUTS) that affect quality of life by interfering with normal daily activities. The American Urological Association Symptoms Index (AUA-SI) is recommended as symptom scoring instrument to be used in initial assessment of each patient presenting with symptoms of prostatism. Objective: To assess the severity of symptoms in Benign Prostatic Hy...

  17. Estimated costs of treatment of benign prostate hyperplasia in Brazil

    Directory of Open Access Journals (Sweden)

    Haylton J. Suaid

    2003-06-01

    Full Text Available INTRODUCTION: The treatment of benign prostate hyperplasia (BPH presents 2 options: medical or surgical, and there are doubts about what is the best treatment since 80% of patients who undergo surgery become asymptomatic and 10 to 40% of those under medical regimen undergo surgery within a 5 years period. It is difficult to assess the actual costs of treating BPH in Brazil due to several factors, among them regional particularities and the scarcity of current statistical data. PATIENTS AND METHODS: Recently, in the Ribeirão Preto area, São Paulo, Brazil, the IPSS (International Prostatic Symptoms Score and quality of life were verified in 934 volunteers. It was determined the percentage of individuals with ages ranging from 40 to 79 years with moderate symptoms (score 8-19 and with severe symptoms (score 20-35, values for which are indicated medical and surgical treatment, respectively, according to the Brazilian Society of Urology consensus on BPH. Data on Brazilian population in that age range were obtained from the Brazilian Institute of Geography and Statistics referent to the year of 2000. It was determined the number of patients, according to the criteria above, subjected to either one of the treatments mentioned. Surgical costs of prostate transurethral resection were researched according to Unified Health System - SUS tables (US$ 173 and of Brazilian Medical Society - AMB with a mean cost in 3 hospitals of US$ 933. Drug costs were calculated by the annual mean price (US$ 355 of 4 alpha-blockers (tamsulosin, alfuzosin, doxazosin and terazosin. RESULTS: The estimated population for medical treatment was 5,397,321 individuals, with a cost corresponding to US$ 1,916,489,055.00. The estimated population for surgical treatment was 2,040,299 men, what would represent a cost of US$ 353,291,204.00 based on the SUS table and of US$ 1,904,279,066.00 based on AMB with hospital expenses included. CONCLUSION: All theses facts induce us to predict

  18. Radiological and clinical observation on benign prostatic hyperplasia

    International Nuclear Information System (INIS)

    A radiological and clinical observation was made on 77 cases of benign prostatic hyperplasia admitted to the department of Urology, Cho-Sun University Hospital during the period from January 1972 to December 1979 and following results were obtained. 1. Incidence of PBH was 8.1% to 953 total inpatients, 11.3% to 679 male inpatients, and 34.5% to male inpatients of 50 years more. 2. Majority of cases was found in 7th and 8th decades (80.5%) with mean age of 69.4 years old. 3. A gradual tendency of annual increase of the cases was observed and the mean interval elapsed from initial symptoms to visit was 29.9 months. Common symptoms were dysuria in 72 cases (93.5%), hematuria in 53 cases (68.8%), frequency in 51 cases (66.2%) and 12 cases (15.6%) were acute urinary retention. 4. I. V. P. findings of BPH were elevation of the bladder base in 71 cases (92.2%), trabeculation of the bladder wall in 58 cases (75.3%), hypertrophy of the bladder in 24 cases (31.2%) and the complications-hydronephrosis and hydroureter 16 cases (20.8%), bladder diverticula 9 cases (11.7%) and bladder stone were 5 cases (6.5%). 5. Cystourethrographic findings of the posterior urethra with 33 cases of PBH were smooth, gentle sloping in 28 cases 84.8%), widening in sagittal plane in 23 cases (69.7%), elongation and narrowing of the urethra in 26 cases (78.8%)

  19. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk.

    NARCIS (Netherlands)

    Anderson, J.; Roehrborn, C.G.; Schalken, J.A.; Embrechts, M.

    2001-01-01

    BACKGROUND: Benign prostatic hyperplasia (BPH) is often associated with enlargement of the prostate gland, lower urinary tract symptoms, decreased urinary flow and a reduced quality of life. Furthermore, if the symptoms associated with BPH are left untreated, serious complications, such as acute uri

  20. Correlation between benign prostate hyperplasia and the related indicators of atherosclerosis

    Institute of Scientific and Technical Information of China (English)

    张瑞华

    2012-01-01

    Objective To investigate the correlation between benign prostate hyperplasia (BPH) and atherosclerotic related indicators. Methods Totally 125 patients were divided into two groups based on prostate volume(PV):50 cases without BPH(PV≤30 ml) and 75 cases with BPH (PV>30ml)

  1. THE CLINICAL SIGNIFICANCE OF PERCENT FREE PSA IN DIFFERENTIATING PROSTATE CANCER AND BENIGN PROSTATE HYPERPLASIA

    Institute of Scientific and Technical Information of China (English)

    王子明; 张鹏; 种铁; 赵丽华

    2004-01-01

    Objective To evaluate using prostate specific antigen (PSA) and percent free PSA(fPSA) for the diagnosis of prostate cancer(Pca) and benign prostate hyperplasia(BPH). Methods 315 men with BPH and 55 men with Pca were randomly chosen, serum fPSA and total PSA were determined by ELISA and then we compared the sensitivity and specificity of PSA and percent fPSA for the diagnosis of Pca. Results While using PSA and percent fPSA for the diagnosis of prostate cancer, the sensitivity was similar (89.8% vs. 94.5%, P>0.05), but the specificity was significanty different (52.7% vs. 89.8%, P<0.005). Conclusions Using percent fPSA might decrease false-positive and avoid 37.1% negative biopsies as compared with PSA, it is very valuable for the diagnosis of Pca.

  2. Comparison of Urinary Symptoms in Patients with Benign Prostatic Hyperplasia after Prostatectomy for Prostates weighted more and less than 50 Grams

    OpenAIRE

    Reza Bidaki; Masoud Radman; Hamid Mirhoseini; Omid Rezahosseini; Ali Panahi; Mohammad Jamali-Paghale

    2014-01-01

    Nowadays prostatic hyperplasia is the most common benign neoplasm in aging male [1]. Different treatment options like medical and surgical interventions are available. But the suitable technique according prostate weight is not recognized. The main purpose of this study was to compare urinary symptoms after open prostatectomy in the benign prostatic hyperplasia patients with prostatic weight more and less than 50 grams.

  3. Risk factors for prostatic inflammation extent and infection in benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    Fa-Xian Yi; Qiang Wei; Hong Li; Xiang Li; Ming Shi; Qiang Dong; Yu-Ru Yang

    2006-01-01

    Aim: To investigate the risk factors for prostatic inflammation extent and infection in patients with benign prostatic hyperplasia (BPH) so as to manage prostatic inflammation more efficiently. Methods: Sixty patients with BPH undergoing TURP between September 2005 and December 2005 in West China Hospital of Sichuan University were studied. Prostate fluid (PF) was collected for the measurement of secretory IgA (SIgA) and complement 3 (C3).Prostate tissue were collected for testing bacterial 16S rDNA by real-time PCR, examining SIgA in the tissue and examining the inflammation. The possible clinical and immune risk factors for prostatic inflammation or infection were analyzed by using the logistic regression method. Results: Abnormal white blood cell count in urinalysis, prostatic infection and a high concentration of C3 in PF are the risk factors for prostatic inflammation extent (P = 0.025, 0.034 and 0.035, respectively and odds ratio [OR] = 18.269, 8.284 and 1.508, respectively). Risk factors for prostatic infection include the C3 concentration and the concentration of S IgA in PF (P = 0.003 and 0.013, respectively, and OR= 1.645 and 0.993, respectively). Conclusion: The present study suggests that prostatic inflammation is associated with urinary tract infection, prostatic infection and the activated complement and that prostatic infection is associated with the activated complement and downregulated mucosal immunity in prostates of the patients with BPH. It is also suggested that individual immune regulation should be considered in the treatment of prostatic inflammation and infection of patients with BPH.

  4. Convective Water Vapor Energy for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.

    Science.gov (United States)

    DeLay, Kenneth Jackson; McVary, Kevin T

    2016-08-01

    Benign prostatic hyperplasia (BPH) refers to proliferation of smooth muscle and epithelial cells within the transition zone of the prostate. Half of men over 40 develop histologic BPH. About half of men with BPH develop an enlarged prostate gland, called benign prostatic enlargement; among these, about half develop some degree of bladder outlet obstruction. Bladder outlet obstruction and changes in smooth muscle tone and resistance may result in lower urinary tract symptoms, including storage disturbances (such as daytime urinary urgency, frequency, and nocturia) and voiding disturbances (such as urinary hesitancy, weak urinary stream, straining to void, and prolonged voiding). PMID:27476129

  5. Analysis of risk factors for benign prostatic hyperplasia and metabolic syndrome in the elderly undergoing health examination

    Institute of Scientific and Technical Information of China (English)

    王蕾蕾

    2013-01-01

    Objective To investigate the prevalences of benign prostatic hyperplasia (BPH) and metabolic syndrome (MS) and to analyze the risk factors for benign prostatic hyperplasia and metabolic syndrome in the elderly.Methods A total of 490 elderly men undergoing health examination in our hospital from January 2010 to

  6. Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, and International Prostate Symptom Score in Patients with Benign Prostatic Hyperplasia

    OpenAIRE

    Kim, Jong Min; Song, Phil Hyun; Kim, Hyun Tae; Moon, Ki Hak

    2011-01-01

    Purpose We examined the correlation between body mass index (BMI) as a marker of obesity and prostate-specific antigen (PSA), prostate volume (PV), and International Prostate Symptom Score (IPSS) in patients with benign prostatic hyperplasia (BPH). Materials and Methods From January 2008 to December 2008, we examined 258 patients diagnosed with BPH. Patients taking 5α-reductase inhibitors or those diagnosed with prostate cancer were excluded from this study. BPH was defined as PV≥25 ml and IP...

  7. Computed Tomography of the Prostate Gland in Healthy Intact Dogs and Dogs with Benign Prostatic Hyperplasia.

    Science.gov (United States)

    Pasikowska, J; Hebel, M; Niżański, W; Nowak, M

    2015-10-01

    To date, there is only scarce data on the evaluation of the prostate gland in dogs using computed tomography (CT). The aims of our study were to describe CT features of BPH in dogs and to determine the size of the prostate gland in healthy male dogs and dogs with benign prostatic hyperplasia (BPH) through CT. Additionally, we aimed to compare and establish the most useful parameters for CT measurements of the prostate in patients with BPH. The study population consisted of 20 healthy intact male dogs and 20 male intact dogs with confirmed BPH. Pre- and post-contrast CT studies were evaluated. The most common CT features in dogs with recognized BPH were symmetrical prostatomegaly and heterogeneity of the prostatic parenchyma. The mean prostatic density (D) was 56HU (±4.39) in pre-contrast CT images and 84HU (±8) in post-contrast images in dogs with BPH. The mean prostatic length (L) was 43.87 mm (±11), the mean width (W) amounted to 48.95 mm (±8.76) and the mean height (H) reached 44.9 mm (±9.48) in clinically affected patients. The mean ratios were: rL - 2,12 (±0.5); rW - 2.39 (±0.53) and rH - 2.16 (±0.39) in the BPH group. The prostate should be considered to be enlarged when rL exceeds 3.05; rW exceeds 3.38 and rH exceeds 2.94. Our findings indicated that CT is a useful tool in diagnosing prostate disorders, including BPH. The heterogeneity, density and ratios of prostatic length, width and height can be useful parameters in the diagnosis of BPH.

  8. Evaluation of benign prostatic hyperplasia treatments : How can we improve the outcome measures and success criteria?

    NARCIS (Netherlands)

    Mensink, H

    1997-01-01

    Treatment evaluation in benign prostatic hyperplasia (BPH) is complicated by a number of interdependent factors. The evaluation of the individual patient is influenced by the risk:benefit ratio and health related quality of life and this, in turn, is interrelated with the evaluation of therapeutic o

  9. Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

    NARCIS (Netherlands)

    M. Michel; J. de la Rosette

    2009-01-01

    Context: Medical treatment is the primary option for most patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH; LUTS/BPH), but individual patients may have distinct treatment goals. Objective: To describe the specific effects of available treatment option

  10. Clinical effects of statins on benign prostatic hyperplasia complicating metabolic syndrome in elderly patients

    Institute of Scientific and Technical Information of China (English)

    曾小芳

    2014-01-01

    Objective To evaluate the effect of simvastatin and atorvastatin on clinical progression of benign prostatic hyperplasia(BPH)in elderly patients with metabolic syndrome(MS).Methods A total of 135 patients with BPH and MS aged 60 years and over were divided into three groups:simvastatin group(n=45,40 mg/d),atorvasta-

  11. The correlation between metabolic syndrome and benign prostatic hyperplasia and drug efficacy evaluation

    Institute of Scientific and Technical Information of China (English)

    李欣

    2014-01-01

    Objective To explore the correlation between metabolic syndrome(MS)and benign prostatic hyperplasia(BPH)and the drug treatment of BPH.Methods 300cases of BPH patients treated between May 2011 to June2012 in our hospital and Tonghai County hospitals of traditonal Chinese medicine were included.The patients were divided into observing group(n=100)and control

  12. Efficacy observation on benign prostatic hyperplasia treated with acupuncture and moxibustion

    Institute of Scientific and Technical Information of China (English)

    徐泽杰

    2014-01-01

    Objective To compare the difference in the clinical efficacy on benign prostatic hyperplasia(BPH)between the acupuncture-moxibustion therapy and the medication of Qianliekang tablets.Methods One hundred and twenty eight patients were randomized into an acupuncturemoxibustion group and a Qianliekang,64 cases in each.In the acupuncture-moxibustion group,acupuncture was

  13. Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia

    NARCIS (Netherlands)

    Hansen, BJ; Meyhoff, HH; Nordling, J; Mensink, HJA; Mogensen, P; Larsen, EH; Leenarts, JAF; Oosten, JK; vanSoest, FF; Dijkman, GA; Hoekstra, JW; vanBaasbank, NJW; Bijleveld, RT; Braam, PFCM; Schlatmann, TJM; Felderhof, J; Kapper, BJ; Dik, P; Schou, J; Poulsen, AL; Christoffersen, J; Geerdsen, JP; Hvidt, [No Value; Dahl, C; Luke, M; Lendorph, A; Jacobsen, B; Bilde, T; Mortensen, S; Walter, S

    1996-01-01

    In order to establish accurately the exact effect of any drug therapy for symptomatic benign prostatic hyperplasia (BPH) it is important to define the effect of placebo treatment. This effect was assessed by thoroughly analyzing the placebo arm, which included 101 patients, from a randomized, double

  14. Efficacy of Kanchanara Guggulu and Matra Basti of Dhanyaka Gokshura Ghrita in Mootraghata (benign prostatic hyperplasia)

    OpenAIRE

    Patel, Joyal Kumar K.; Dudhamal, Tukaram S.; Gupta, Sanjay Kumar; Mahanta, Vyasadeva

    2015-01-01

    Background: Benign prostatic hyperplasia (BPH), a senile disorder affects male of and above 40 years characterized by retention, incomplete voiding, dribbling, hesitancy, and incontinence of urine. This condition is comparable with Mootraghata in Ayurveda. Surgical intervention has been accepted as standard management, but has acute cystitis, acute epididymitis, erectile dysfunction, retrograde ejaculation, etc. as complications. Conservative treatment with modern medicine is also associated ...

  15. Nonablative minimally invasive thermal therapies in the treatment of symptomatic benign prostatic hyperplasia.

    NARCIS (Netherlands)

    Ancona, F.C.H. d'

    2008-01-01

    PURPOSE OF REVIEW: As all new treatment modalities nonablative thermal therapy for minimal invasive treatment of benign prostatic hyperplasia should be critically analyzed. This review discusses the literature to identify the merits of these so-called minimally invasive treatments and the place they

  16. Is there a relationship between androgenic alopecia and benign prostatic hyperplasia?

    OpenAIRE

    Ladan Dastgheib; Mehdi Shirazi; Iman Moezzi; Saber Dehghan; Maryam-Sadat Sadati

    2015-01-01

    Androgenic alopecia as a physiologic process and benign prostatic hyperplasia (BPH) as a pathologic process in the older population are androgen-dependent processes influenced by 5-alpha reductase enzyme which converts testosterone to dihydrotestosterone. This cross sectional study was done to evaluate the relationship between androgenic alopecia and BPH. 150 men older than 50 years old, who presented to the free prostate screening clinic, were included. They were asked about urinary symptoms...

  17. Transurethral enucleation of large benign prostatic hyperplasia in sodium chloride solution

    OpenAIRE

    I. N. Shvarev; Andreev, S. S.; V. V. Savich

    2016-01-01

    Background. Transurethral resection is a generally recognized treatment for small to medium-sized benign prostatic hyperplasia (BPH). Numerous original tools are proposed for surgery of large BPH. These include laser (holmium laser enucleation of the prostate) and transurethral (transurethral enucleation with bipolar (TUEB)) enucleation in 0.9 % NaCl solution, which are accompanied by removal of the maximum adenoma tissue volume, short-term recovery, and a substantially fewer early and late c...

  18. DIAGNOSIS AND MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA IN A PIED TAMARIN (SAGUINUS BICOLOR).

    Science.gov (United States)

    Barbon, Alberto Rodriguez; Ordóñez, Israel Alamilla; Haworth, Peter; Glendewar, Gale; Routh, Andrew; Pocknell, Ann

    2016-06-01

    An intact male pied tamarin (Saguinus bicolor) presented with a hunched posture while moving, dysuria, pollakiuria, and hematuria. After diagnostic imaging assessment and prostate biopsy, benign prostatic hyperplasia was diagnosed. Treatments with delmadinone acetate and osaterone caused clinical signs and hematuria to resolve temporarily for a variable period of time. Because of frequent recurrence, elective surgical castration was performed, leading to resolution of the clinical signs. PMID:27468035

  19. Inflammatory mediators in the development and progression of benign prostatic hyperplasia.

    Science.gov (United States)

    De Nunzio, Cosimo; Presicce, Fabrizio; Tubaro, Andrea

    2016-09-30

    Benign prostatic hyperplasia (BPH) is the most common urological disease in elderly men. Epidemiological data suggest a causal link between this condition and prostatic inflammation. The prostate is an immune-competent organ characterized by the presence of a complex immune system. Several stimuli, including infectious agents, urinary reflux, metabolic syndrome, the ageing process, and autoimmune response, have been described as triggers for the dysregulation of the prostatic immune system via different molecular pathways involving the development of inflammatory infiltrates. From a pathophysiological standpoint, subsequent tissue damage and chronic tissue healing could result in the development of BPH nodules. PMID:27686153

  20. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia

    OpenAIRE

    Hong, Heeok; Kim, Chun-Soo; Maeng, Sungho

    2009-01-01

    This study was to investigate the role of complementary and alternative medicine in the prevention and treatment of benign prostatic hyperplasia. For this purpose, a randomized, double-blind, placebo-controlled trial was performed over 12 months on 47 benign prostatic hyperplasia patients with average age of 53.3 years and international prostate symptom score over 8. Subjects received either sweet potato starch (group A, placebo, 320 mg/day), pumpkin seed oil (group B, 320 mg/day), saw palmet...

  1. Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays

    Science.gov (United States)

    Prakash, Kulkarni; Pirozzi, Gregorio; Elashoff, Michael; Munger, William; Waga, Iwao; Dhir, Rajiv; Kakehi, Yoshiyuki; Getzenberg, Robert H.

    2002-05-01

    Benign prostatic hyperplasia (BPH) is a disease of unknown etiology that significantly affects the quality of life in aging men. Histologic BPH may present itself either as symptomatic or asymptomatic in nature. To elucidate the molecular differences underlying BPH, gene expression profiles from the prostate transition zone tissue have been analyzed by using microarrays. A set of 511 differentially expressed genes distinguished symptomatic and asymptomatic BPH. This genetic signature separates BPH from normal tissue but does not seem to change with age. These data could provide novel approaches for alleviating symptoms and hyperplasia in BPH.

  2. Protective Effect of Naringin on Testosterone Induced Benign Prostatic Hyperplasia in Rats

    Directory of Open Access Journals (Sweden)

    Naresh KN

    2013-06-01

    Full Text Available Major components of plants being flavonoids containing polyphenolic derivatives which possesantioxidant property have shown to improve uncontrolled growth of the prostate gland and urinary tractsymptoms, which are associated with benign prostatic hyperplasia. Our study investigated whetherNaringin prevents testosterone induced prostatic hyperplasia in rats by virtue of its antioxidant property.In vitro studies were carried out to assess the protective effect of prostate tumor cell lines. BPH wasinduced in experimental groups by intramuscular injection of Testosterone Enanthate on day 1, 7 and 14.Naringin was administered daily by oral gavage for a period of 21 days. On 22nd day, rats weresacrificed, prostate tissue weighed and histopathological studies were carried out. Prostate zinc,oxidative parameters were measured. Treatment with Naringin showed significant inhibition of prostateenlargement and restored the histoarchitecture when compared with positive control group. Inconclusion, the present study showed that Naringin reduced the elevated levels of both prostate weightand prostate weight to body weight ratio, markers of testosterone induced prostatic hyperplasia in rats.

  3. Holmium laser for treatment of benign prostatic hyperplasia: old wine in a new bottle?

    Science.gov (United States)

    Nelius, Thomas; de Riese, Werner T. W.

    2003-06-01

    Urinary tract symptoms related to benign prostatic hyperplasia affect 70% of men older than 70 years. Complications are common problems and a significant cause of morbidity in this population, placing a considerable burden on health services. In the early 1990s laser treatment of benign prostatic hyperplasia became widely used after the introduction of the side-firing neodym: YAG laser. However, because of technical limitations and inferior results compared to classical transurethral resection of the prostate many Urologists became desinterested in this device. With the introduction of the holmium: YAG laser a new laser generation became available for use in Urology. Beside several other applications the holmium: YAG laser can be used for incision, ablation, resection, and more recently enucleation of the prostate. In this paper we reviewed the current literature regarding the holmium: YAG laser resection and enucleation of the prostate compared to transurethral resection of the prostate and open prostatectomy. The holmium: YAG laser technique is an effective and durable surgical alternative to standard transurethral resection of the prostate. Interestingly, enucleation of the prostate with this device seems to be a safe and effective procedure for large prostatic adenomas, it may become an attractive alternative to open prostatectomy.

  4. Correlation of transrectal ultrasonographic findings of the prostate with the occurrence of detrusor instability in patients with benign prostatic hyperplasia.

    Science.gov (United States)

    Tong, Y C; Lin, Y M; Yang, W H; Tzai, T S; Lin, J S

    1995-01-01

    Forty patients with benign prostatic hyperplasia were evaluated with urodynamics and transrectal ultrasonography. Seventeen patients were found to have detrusor instability while the remaining 23 did not. No significant differences were noted during ultrasonography in the estimated prostatic volume, the presumed circle area ratio and the incidence of finding prostatic calcification between these two groups. However, the incidence of detecting intravesical protrusion of the prostate is significantly higher in patients with instability than in patients with stable bladder (53 vs. 13%, p prostate and alter the stability status of the urinary bladder.

  5. [Changes in prostatic circulation in response to laser therapy and magnetic therapy in patients with benign prostatic hyperplasia].

    Science.gov (United States)

    2005-01-01

    The results of preoperative preparation were analysed in 59 patients with prostatic benign hyperplasia (PBH) subjected to TUR. Treatment outcomes were assessed by transrectal ultrasound (color Doppler mapping) in two groups of patients. Group 1 received combined therapy including transrectal laser radiation of the prostate, group 2--transrectal magnetotherapy. The analysis showed that laser radiation reduced insignificantly the size of the prostate and adenomatous node, improved microcirculation and circulation in the prostate. This resulted in relief of inflammation and reduction of the number of postoperative inflammatory complications. Transrectal magnetotherapy has a positive effect on vascularization and hemodynamics of the prostate, local immunity, contamination of the tissues with pathogenic flora. PMID:16419474

  6. Benign Prostatic Hyperplasia: Health Seeking Behaviour of patients at a tertiary care hospital.

    Directory of Open Access Journals (Sweden)

    Aman Deep

    2010-03-01

    Full Text Available BackgroundBenign Prostatic Hyperplasia is a widely prevalent conditionaffecting elderly men throughout the world. With increasinglife expectancy, there has been a rise in the percentage ofelderly men and so for this disease across the globe. There islack of information about health seeking behaviour of patientswith Benign Prostatic Hyperplasia. Therefore the study wasdesigned with the objectives of assessing health-seekingbehaviour and the effect of literacy on it among adult andolder subjects suffering from Benign Prostatic Hyperplasiaattending a tertiary care hospital.MethodA series of 81 patients suffering from Benign ProstaticHyperplasia above the age of 50 years, attending surgical OutPatient Department of a tertiary care hospital in Delhi, wereassessed for their health seeking behaviour using a pre-testedand a modified questionnaire designed for assessing healthseeking behaviour.ResultsPositive health seeking behaviour of patients was observed in44%, who reported to a doctor within a month of noticingtheir problem. A greater proportion of the literates was awareabout the symptoms suggestive of enlarged prostate andconsulted a qualified health care practitioner as their firstaction. More literates approached the higher level of healthcare facility on being referred and had maximum faith inallopathic system of medicine. Also, lesser number of literateshad performed pooja (Hindi word for worship or othertraditional rituals for relief of their problems.ConclusionWe concluded that majority of subjects suffering fromBenign Prostatic Hypertrophy were not aware of theirdisease and their health-seeking behaviour was poor andcould be related to literacy. Our data highlights the needfor public awareness program targeting the younger malepopulation so that early detection and treatment can beoffered.

  7. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis

    Energy Technology Data Exchange (ETDEWEB)

    Ren, J. [Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi' an (China); Huan, Y. [Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi' an (China)], E-mail: huanyi3000@163.com; Wang, H. [Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi' an (China); Chang, Y.-J.; Zhao, H.-T.; Ge, Y.-L.; Liu, Y.; Yang, Y. [Department of Radiology, Xijing Hospital, Fourth Military Medical University, Xi' an (China)

    2008-02-15

    Aim: To investigate the diagnostic and differential diagnostic values of dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) in prostatic diseases, and to investigate the correlation between the parameters of SI-T curves and angiogenesis. Materials and methods: Twenty-one patients with proven prostatic carcinoma (Pca) and 29 patients with proven benign prostatic hyperplasia (BPH) were examined using DCE MRI. Diagnostic characteristics for differentiation were examined using threshold values for maximum peak time, enhancement degree, and enhancement rate. Then, the signal intensity-time curves (SI-T curves) were analysed, and the correlations between the parameters of SI-T curves and the expression levels of vascular endothelial growth factor (VEGF) and microvascular density (MVD) were investigated. All patients underwent prostatectomy. DCE MRI and histological findings were correlated. Results: Pca showed stronger enhancement with an earlier peak time, higher enhancement, and enhancement rate (p < 0.05). Regarding the type of SI-T curves, in the BPH group six were type A, 10 were type B, and 13 were type C, whereas in the Pca group, 14 were type A, six were type B, and only one was type C (Chi-square test, {chi}{sup 2} = 13.57, P < 0.005). The VEGF and MVD expression levels of Pca were higher than those of BPH. Peak time was negatively correlated with the expression levels of VEGF and MVD, whereas the enhancement degree and enhancement rate showed positive correlations (Pearson correlation, p < 0.05). Conclusion: Based on T2-weighted imaging, DCE MRI curves can help to differentiate benign from malignant prostate tissue. In the present study the type C curve was rarely seen with malignant disease, but these results need confirmation.

  8. Photoselective vaporization of the prostate in the treatment of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    FU Wei-jun; HONG Bao-fa; YANG Yong; CAI Wei; GAO Jiang-ping; WANG Chun-yang; WANG Xiao-xiong

    2005-01-01

    Background The treatment of symptomatic benign prostatic hyperplasia (BPH) remains a challenge for most urologic surgeons. We studied a cumulative cohort of patients with symptomatic benign prostatic hyperplasia (BPH) who underwent photoselective vaporization of the prostate (PVP) and evaluated the efficacy and safety of this procedure.Methods A total of 196 patients with lower urinary tract obstruction symptoms secondary to BPH were treated using laser vaporization of the prostate under sacral canal anesthesia at our institutions. The therapeutic results were assessed using following variables: the safety and efficacy of sacral anesthesia, blood loss, operative time, indwelling catheterization. Preoperative and perioperative parameters were evaluated in the international prostate symptom score (IPSS), quality of life score (QoL), maximal urinary flow rate (Qmax), post-void residual urine volume (PVR) and the change of sexual function. Patients were also assessed for 3-month follow up. Results PVP was performed successfully for all patients. There were 195 patients under sacral anesthesia and 1 patient under epidural anesthesia. Mean operative time was (45.2±18.5) minutes. The mean IPSS decreased from (26.6±3.2) to (5.6±1.4) and the QoL score decreased from (5.7±0.4) to (1.6±0.5), respectively (P<0.05), while mean Qmax increased from (6.7±2.5) ml/s preoperatively to (19.6±2.4) ml/s, PVR decreased from 158.4 to 25.8 ml, respectively (P<0.05). Average catheterization time was (1.8±0.9) days. There was no significant blood loss or fluid absorption during the period of PVP. Complications consisted of transient dysuria in 3 patients (1.5%), delayed gross hematuria in 5 patients (2.5%), respectively. Significant improvement in clinical outcomes were noted as early as 3 months after PVP treatment.Conclusions PVP is considered as a high satisfaction rate by patient and a minimal postoperative complication. Hence, PVP is a novel, safe, effective and minimal invasive

  9. Inflammatory Responses in a Benign Prostatic Hyperplasia Epithelial Cell Line (BPH-1) Infected with Trichomonas vaginalis.

    Science.gov (United States)

    Kim, Sang-Su; Kim, Jung-Hyun; Han, Ik-Hwan; Ahn, Myoung-Hee; Ryu, Jae-Sook

    2016-04-01

    Trichomonas vaginalis causes the most prevalent sexually transmitted infection worldwide. Trichomonads have been detected in prostatic tissues from prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. Chronic prostatic inflammation is known as a risk factor for prostate enlargement, benign prostatic hyperplasia symptoms, and acute urinary retention. Our aim was to investigate whether T. vaginalis could induce inflammatory responses in cells of a benign prostatic hyperplasia epithelial cell line (BPH-1). When BPH-1 cells were infected with T. vaginalis, the protein and mRNA of inflammatory cytokines, such as CXCL8, CCL2, IL-1β, and IL-6, were increased. The activities of TLR4, ROS, MAPK, JAK2/STAT3, and NF-κB were also increased, whereas inhibitors of ROS, MAPK, PI3K, NF-κB, and anti-TLR4 antibody decreased the production of the 4 cytokines although the extent of inhibition differed. However, a JAK2 inhibitor inhibited only IL-6 production. Culture supernatants of the BPH-1 cells that had been incubated with live T. vaginalis (trichomonad-conditioned medium, TCM) contained the 4 cytokines and induced the migration of human monocytes (THP-1 cells) and mast cells (HMC-1 cells). TCM conditioned by BPH-1 cells pretreated with NF-κB inhibitor showed decreased levels of cytokines and induced less migration. Therefore, it is suggested that these cytokines are involved in migration of inflammatory cells. These results suggest that T. vaginalis infection of BPH patients may cause inflammation, which may induce lower urinary tract symptoms (LUTS). PMID:27180569

  10. Relationship of blood pressure variability and heart rate variability with prostatic volume in patients with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    金江丽

    2014-01-01

    Objective To investigate the relationship of blood pressure variability(BPV)and heart rate variability(HRV)with prostatic volume(PV)in patients with benign prostatic hyperplasia(BPH).Methods A total of133 patients admitted to our department between January2011 and April 2013 were analyzed retrospectively.The patients were divided into BPH group and non-BPH group according to the PV value.The ambulatory blood

  11. Effect of β Radiation on Bcl-2 and Bax Expressions in Benign Prostate Hyperplasia Tissues

    Institute of Scientific and Technical Information of China (English)

    MA Qing-jie; GAO Shi; ZHAO Jie; GU Xin-quan; CAI Shan-yu; ZHAO Guo-qing

    2008-01-01

    The authors chose specimens from nine normal prostate tissues(NP group),15 benign prostate hyperplasia(BPH) prostates(BPH group),and 35 BPH prostates that had been treated with 90Sr/90Y Prostatic Hyperplasia Applicator(exposure group),The expressions of bcl-2 and bax in stroma and epithelia of prostate tissues were demonstrated by means of immunohistochemical staining,and the staining positive rate was semiquantatively determined,so as to observe the expression of bcl-2 and bax genes in the prostate tissues of normal individuals and BPH patients,before and after β radiation,and to evaluate the influence of β radiation on bcl-2 and bax expressions,The expressions of gene bcl-2 in the prostate epithelia of NP and BPH are significantly higher than those in the prostate stroma(P<0.01),However,the expressions of bcl-2 in the prostate epithelia and stroma of the BPH group are obviously higher than those in the NP group(P<0.01),The expression of gene bax in the prostate epithelia of the NP group is higher than that in the BPH group(P<0.05),However,bcl-2 expressions in the prostate epithelia and stroma of the BPH group are significantly higher than the bax expressions(P<0.01),Compared with those of the NP group,the expressions of bcl-2 in the prostate epithelia and stroma of the exposure group decrease remarkably,even as the expressions of the bax notably increase(P<0.01),Thus,the administration of β radiation can remarkably affect bcl-2 and bax gene expressions,to regulate cell apoptosis,in the prostate tissues of BPH.

  12. Pharmacological investigation of an Ayurvedic formulation on testosterone propionate-induced benign prostatic hyperplasia rats

    OpenAIRE

    Soni Hardik; Mehta Hardik; Jani Deepti; Patel Ghanashyam

    2014-01-01

    Objective: This study aimed to investigate the potenital effect of an Ayurvedic herbo-mineral formulation in a rat model of testosterone propionate-induced benign prostatic hyperplasia (BPH). Methods: Male Wistar rats weighing 180-250 g were used. The selected animals were divided into six groups where each group consisted of six animals. Experimentally BPH was developed by subcutaneous administration of testosterone propionate (3 mg/kg) dissolved in corn oil for 28 days. The tested herbo...

  13. Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved

    Directory of Open Access Journals (Sweden)

    Simon van Rij

    2015-12-01

    Full Text Available Clinical benign prostatic hyperplasia (BPH, often identified as a worsening ability of a male to pass urine, is a significant problem for men in our society. In 2015, the use of personalised medicine is tailoring treatment to individual patient needs and to genetic characteristics. Technological advances in surgical treatment are changing the way BPH is treated and are resulting in less morbidity. The future of BPH treatments is exciting, and a number of novel techniques are currently under clinical trial.

  14. Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update

    OpenAIRE

    Aoun F; Marcelis Q; Roumeguère T

    2015-01-01

    Fouad Aoun1, Quentin Marcelis,1,2 Thierry Roumeguère,2 1Department of Urology, Jules Bordet Institute, 2Department of Urology, Erasme Hospital, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium Abstract: Benign prostatic hyperplasia (BPH) represents a spectrum of related lower urinary tract symptoms (LUTS). The cost of currently recommended medications and the discontinuation rate due to side effects are significant drawbacks limiting thei...

  15. Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia

    OpenAIRE

    Choi, Jae Hwi; Hwa, Jung Seog; Kam, Sung Chul; Jeh, Seong Uk; Hyun, Jae Seog

    2014-01-01

    Purpose Previous studies have revealed that tamsulosin is effective in improving lower urinary tract symptoms (LUTS) and erectile functioning but has some inhibitory effects on ejaculation, including decreased ejaculatory volume. However, these inhibitory effects on ejaculation can be beneficial to patients with premature ejaculation (PE). Therefore, this study was conducted to understand the effect of tamsulosin on PE in men with benign prostatic hyperplasia. Materials and Methods Twenty-nin...

  16. [Prostatilen effects on voiding disorders in patients with benign prostatic hyperplasia].

    Science.gov (United States)

    Al'-Shukri, S Kh; Gorbachev, A G; Borovets, S Iu; Belousov, V Ia; Kuz'min, I V

    2005-01-01

    The authors review the experience with prostatilen treatment gained in the urological clinic of the St-Petersburg State Medical University and analyze treatment outcomes for 96 patients with benign prostatic hyperplasia (BPH) aged from 51 to 89 years. Prostatilen proved its efficacy in relieving manifestations of infravesical obstruction in BPH, therefore, prostatilen administration in the treatment of patients with initial or moderate subjective and objective symptoms is justified. Dimexide suppositoria containing 30 mg of prostatilen are preferable.

  17. Two micron continuous wave laser vaporesection for the treatment of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    Wei-Jun Fu; Bao-Fa Hong; Yong Yang; Jiang-Ping Gao; Lei Zhang; Wei Cai; Yao-Fu Chen; Xiao-Xiong Wang

    2008-01-01

    @@ Dear Editor. I'm Wei-Jun Fu, from Department of Urology, Chi-nese People's Liberation Army General Hospital, Military Postgraduate Medical College, Beijing, China. We write to you to present an observation on the safety and clini-cal effects of RevoLix 70 W 2 micron continuous wave laser vaporesection for the treatment of obstructive be-nign prostatic hyperplasia (BPH).

  18. Accumulation of [{sup 11}C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer

    Energy Technology Data Exchange (ETDEWEB)

    Kato, Takashi; Tsukamoto, Eriko; Takei, Toshiki; Shiga, Tohru; Nakada, Kunihiro; Tamaki, Nagara [Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 6, Kita-ku, Sapporo 060-8638 (Japan); Kuge, Yuji; Katoh, Chietsugu [Department of Tracer Kinetics, Hokkaido University Graduate School of Medicine, Sapporo (Japan); Shinohara, Nobuo [Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo (Japan)

    2002-11-01

    Carbon-11 acetate positron emission tomography (PET) has been reported to be of clinical value for the diagnosis of prostate cancer. However, no detailed analysis has yet been carried out on the physiological accumulation of [{sup 11}C]acetate in the prostate. The purpose of this study was to elucidate the physiological accumulation of [{sup 11}C]acetate in the prostate using dynamic PET. The study included 30 subjects without prostate cancer [21 with normal prostate and nine with benign prostatic hyperplasia (BPH)] and six patients with prostate cancer. A dynamic PET study was performed for 20 min after intravenous administration of 555 MBq of [{sup 11}C]acetate. The standardised uptake value (SUV) at 16-20 min post tracer administration and the early-to-late-activity ratio of the SUV (E/L ratio), which was determined by dividing the SUV{sub 6-10} {sub min} by the SUV {sub 16-20min}, were calculated to evaluate the accumulation of [ {sup 11}C]acetate. The prostate was clearly visualised and distinguished from adjacent organs in PET images in most of the cases. The SUV of the prostate (2.6 {+-}0.8) was significantly higher than that of the rectum (1.7 {+-}0.4) or bone marrow (1.3 {+-}0.3) (P <0.0001 in each case). The SUV of the normal prostate of subjects aged <50 years (3.4 {+-}0.7) was significantly higher than both the SUV for the normal prostate of subjects aged {>=}50 years (2.3 {+-}0.7) and that of subjects with BPH (2.1 {+-}0.6) (P <0.01 in each case). The primary prostate cancer in six cases was visualised by [ {sup 11}C]acetate PET. However, the difference in the SUV between subjects aged {>=}50 with normal prostate or with BPH and the patients with prostate cancer (1.9 {+-}0.6) was not statistically significant. There was also no significant difference in the E/L ratio between subjects aged {>=}50 with normal prostate (0.98 {+-}0.04) or BPH (0.96 {+-}0.08) and patients with prostate cancer (1.02 {+-}0.12). In conclusion, a normal prostate exhibits age

  19. Comparison of MR imaging and urodynamic findings in benign prostatic hyperplasia

    Energy Technology Data Exchange (ETDEWEB)

    Alam, A.M.; Ishida, Jun; Igawa, Mikio [Shimane Medical Univ., Izumo (Japan); Sugimura, Kazuro; Okizuka, Hiromi

    2000-04-01

    In benign prostatic hyperplasia (BPH), it is uncertain whether the size of the prostate is related to the degree of urodynamically demonstrated bladder outlet obstruction. We compared MR imaging findings and urodynamic data in patients with surgically confirmed BPH. We prospectively studied 43 benign prostatic hyperplasia (BPH) patients in whom transurethral resection of the prostate (TURP) was planned. We obtained T1- and T2-weighted images in the transverse and sagittal planes with a 1.5 Tesla superconducting unit. The predicted volume of the inner gland and the peripheral zone were obtained on T2-weighted transverse images. Prostatic protrusion into the urinary bladder (IB protrusion) and the inner gland ratio (IG ratio: inner gland volume/total prostatic volume) were determined. IB protrusion and inner IG ratio were significantly greater in patients with severe stenosis than in those without. A surgical capsule (SC) was seen in 20 of 25 patients (80%) with severe stenosis and 8 of 18 (44%) of those without it. The accuracy of IB protrusion + IG ratio, IB protrusion + surgical capsule, and IB protrusion + IG ratio + surgical capsule was 89%, and that of IG ratio + surgical capsule was 86%. The inner gland ratio, protrusion into the bladder, and presence of surgical capsule were the most important factors in bladder outlet obstruction. The probability of outlet stenosis increases in patients with more than two of these criteria. (author)

  20. Detection of benign prostatic hyperplasia nodules in T2W MR images using fuzzy decision forest

    Science.gov (United States)

    Lay, Nathan; Freeman, Sabrina; Turkbey, Baris; Summers, Ronald M.

    2016-03-01

    Prostate cancer is the second leading cause of cancer-related death in men MRI has proven useful for detecting prostate cancer, and CAD may further improve detection. One source of false positives in prostate computer-aided diagnosis (CAD) is the presence of benign prostatic hyperplasia (BPH) nodules. These nodules have a distinct appearance with a pseudo-capsule on T2 weighted MR images but can also resemble cancerous lesions in other sequences such as the ADC or high B-value images. Describing their appearance with hand-crafted heuristics (features) that also exclude the appearance of cancerous lesions is challenging. This work develops a method based on fuzzy decision forests to automatically learn discriminative features for the purpose of BPH nodule detection in T2 weighted images for the purpose of improving prostate CAD systems.

  1. Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review

    DEFF Research Database (Denmark)

    Andersen, J T

    1995-01-01

    During recent years, pharmacological treatment of symptomatic benign prostatic hyperplasia (BPH) has become the primary treatment choice for an increasing number of patients. The 2 principal drug classes employed are alpha 1-blockers and 5 alpha-reductase inhibitors. Current information from...... of patients who will respond well to alpha 1-blockers have yet to be identified, and data concerning the long term effects of these drugs are not yet available. 5 alpha-Reductase inhibitors have a slow onset of effect, but treatment leads to improvement in symptoms, reduction of the size of the prostate gland...

  2. Bilateral spontaneous urinary extravasation shown by computed tomography urography in a patient with benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Haopeng Pang, MD, PhD

    2015-12-01

    Full Text Available Spontaneous extravasation of urine (SUE is a rare urologic manifestation. Predisposing conditions of SUE include ureteric calculus, retrograde pyelography, pregnancy, abdominal aorta aneurysm, tumors, or enlargement of the prostate gland. Usually, SUE is a self-limiting condition that mandates differentiaton from other catastrophic conditions of pelviureteric ruptures. Most reported cases of SUE based on urograms are unilateral in presentation. Herein, we report a case of bilateral SUE evident on computed tomography urography in a patient with benign prostatic hyperplasia. We also review the literature briefly.

  3. Interstitial laser coagulation of benign prostatic hyperplasia: a minimally invasive treatment alternative

    Science.gov (United States)

    Ordonez, Robert F.; Mittemeyer, Bernhard T.; Aronoff, David R.; de Riese, Werner T. W.

    2003-06-01

    The use of minimally invasive treatments for benign prostatic hyperplasia (BPH) have been introduced into the medical community. Over the last decade several minimally invasive treatment techniques have been approved for use. In particular, interstitial laser coagulation (ILC) has shown pomise as an alternative to the current gold standard, transurethral resection of prostate (TURP). Studies show ILC to have equal efficacy as TURP while causing less side effects. Future technical advances as well as increased physician experience with ILC could lead to the replacement of TURP as the gold standard in trestment of BPH.

  4. Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update

    Directory of Open Access Journals (Sweden)

    Aoun F

    2015-08-01

    Full Text Available Fouad Aoun1, Quentin Marcelis,1,2 Thierry Roumeguère,2 1Department of Urology, Jules Bordet Institute, 2Department of Urology, Erasme Hospital, University Clinics of Brussels, Université Libre de Bruxelles, Brussels, Belgium Abstract: Benign prostatic hyperplasia (BPH represents a spectrum of related lower urinary tract symptoms (LUTS. The cost of currently recommended medications and the discontinuation rate due to side effects are significant drawbacks limiting their long-term use in clinical practice. Interventional procedures, considered as the definitive treatment for BPH, carry a significant risk of treatment-related complications in frail patients. These issues have contributed to the emergence of new approaches as alternative options to standard therapies. This paper reviews the recent literature regarding the experimental treatments under investigation and presents the currently available experimental devices and techniques used under local anesthesia for the treatment of LUTS/BPH in the vast majority of cases. Devices for delivery of thermal treatment (microwaves, radiofrequency, high-intensity focused ultrasound, and the Rezum system, mechanical devices (prostatic stent and urethral lift, fractionation of prostatic tissue (histotripsy and aquablation, prostate artery embolization, and intraprostatic drugs are discussed. Evidence for the safety, tolerability, and efficacy of these “minimally invasive procedures” is analyzed. Keywords: lower urinary tract symptoms (LUTS, benign prostatic hyperplasia (BPH, minimally invasive therapies, new approaches, experimental therapy

  5. Sexual outcome of patients undergoing thulium laser enucleation of the prostate for benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Luca Carmignani

    2015-01-01

    Full Text Available Treatment of patients with lower urinary tract symptoms (LUTS secondary to benign prostatic hyperplasia (BPH may affect the quality of sexual function and ejaculation. The effect of new surgical procedures, which are currently available to treat BPH, on erection and ejaculation, has been poorly studied. This study aimed to assess the effect of thulium laser enucleation of the prostate (ThuLEP on sexual function and retrograde ejaculation in patients with LUTS secondary to BPH. We performed a prospective study in 110 consecutive patients who had undergone ThuLEP to analyze changes in sexual function and urinary symptoms. To evaluate changes in erection and ejaculation, and the effect of urinary symptoms on the quality of life (QoL, five validated questionnaires were used: the ICIQ-MLUTSsex, MSHQ-EjD, International Index of Erectile Function 5, International Prognostic Scoring System (IPSS questionnaire, and QoL index of the intraclass correlation coefficients. Patients also underwent IPSS and flowmetry to assess the outcome of flow. Patients were evaluated before surgery and 3-6 months after ThuLEP, whereas those with previous abdominal surgery were excluded. The patients′ mean age was 67.83 years. Postoperative urinary symptoms improved after surgery. No significant differences in erectile function before and after surgery were observed. As compared with other techniques described in the literature, the percentage of patients with conserved ejaculation increased by 52.7% after ThuLEP. ThuLEP positively affects urinary symptoms and their effect on the QoL of patients as assessed by questionnaire scores. While endoscopic management of BPH (e.g. transurethral resection of the prostate causes retrograde ejaculation in most patients, those who undergo ThuLEP have conserved ejaculation and erectile function.

  6. Radiological Findings of Prostatic Arterial Anatomy for Prostatic Arterial Embolization: Preliminary Study in 55 Chinese Patients with Benign Prostatic Hyperplasia.

    Directory of Open Access Journals (Sweden)

    Guodong Zhang

    Full Text Available To describe the prostatic arterial supply using Cone-beam computed tomography (CT and digital subtraction angiography (DSA before prostatic arterial embolization (PAE for benign prostatic hyperplasia (BPH.In a retrospective study from January 2012 to January 2014, 55 male patients (110 hemipelves with BPH who underwent PAE were evaluated by Cone-beam CT in addition to pelvic DSA during embolization planning. Each hemipelvis was evaluated regarding the number of prostatic arteries (PA and their origins, diameters, territorial perfusion, and anastomoses with adjacent arteries.A total of 114 PAs were identified in 110 hemipelves. There was one PA in 96.4% of the hemipelves (n=106, and two independent PAs in the other 3.6% (n=4. The PA was found to originate from the anterior trunk of the internal iliac artery in 39.5% of cases (n=45 , from the superior vesical artery in 32.6% (n=37, and from the internal pudendal artery in 27.9% of cases (n=32. Extra-prostatic anastomoses between PA and adjacent arteries were found in 39.1% of hemipelves (n=43. Intra-prostatic anastomoses between PAs and contra-lateral prostatic branches were found in 61.8% of hemipelves (n=68. In 67.3% of our study population (n=37, the prostate was dominantly supplied via a unilateral PA.The prostatic vascularization is complex with frequent anatomic variations. Knowledge of the vascular anatomy of the prostate may provide indications for planning PAE and avoiding nontarget embolization.

  7. Immunohistochemical Study Of Bcl-2 Protein And Estrogen Receptor-Alpha Expression In Benign Prostatic Hyperplasia And Prostatic Carcinoma

    OpenAIRE

    Ahmed H. Abel-Rahman- Ghada A. Abdel-Aziz*- Ali Emad S** Abdel

    2004-01-01

    The human prostate, a male sexual accessory tissue involved in seminal fluid production, has a remarkably high incidence of hyperplastic and neoplastic disease. The present study was carried out on one hundred and twenty (120) specimens divided into two groups; group 1: Included forty cases of benign prostatic hyperplasia (BPH) and group 2: Included sixty cases of prostatic adenocarcinoma (PC) (22 were low grade; GS: 2-6 and 38 were high grade; GS: 7-10),in addition to twenty cases of histolo...

  8. COMPARATIVE ANALYSIS OF THE BACTERIAL POPULATION OF THE PROSTATE IN ITS CANCER AND BENIGN HYPERPLASIA

    Directory of Open Access Journals (Sweden)

    M. I. Kogan

    2011-01-01

    Full Text Available A bacteriological study of prostate biopsy specimens was conducted in patients with prostate benign hyperplasia (PBH and in those with prostate cancer (PC. It revealed a wide range of aerobic (Corynebacterium sp., Enterococcus sp., E. coli, S. haemolyticus, S. hominis and nonclostridial anaerobic (Bacteroides sp., Bifidobacterium sp., Eubacterium sp., Propionibacterium sp., Рeptococcus niger, Peptostreptococcus sp., Prevotella sp., Veilonella sp., Fusobacterium sp., Capnocytophaga ochracea, Streptococcus parvulus bacteria. Differences were seen in the detection rate of these microorganisms and in the level of tissue infectivity in PBH and PC. The average seeding of the prostate biopsy specimens and the detection rate of different types of bacteria in PBH were greater than those in PC; moreover, some bacteria were undetectable in PC at all.

  9. COMPARATIVE ANALYSIS OF THE BACTERIAL POPULATION OF THE PROSTATE IN ITS CANCER AND BENIGN HYPERPLASIA

    Directory of Open Access Journals (Sweden)

    M. I. Kogan

    2014-08-01

    Full Text Available A bacteriological study of prostate biopsy specimens was conducted in patients with prostate benign hyperplasia (PBH and in those with prostate cancer (PC. It revealed a wide range of aerobic (Corynebacterium sp., Enterococcus sp., E. coli, S. haemolyticus, S. hominis and nonclostridial anaerobic (Bacteroides sp., Bifidobacterium sp., Eubacterium sp., Propionibacterium sp., Рeptococcus niger, Peptostreptococcus sp., Prevotella sp., Veilonella sp., Fusobacterium sp., Capnocytophaga ochracea, Streptococcus parvulus bacteria. Differences were seen in the detection rate of these microorganisms and in the level of tissue infectivity in PBH and PC. The average seeding of the prostate biopsy specimens and the detection rate of different types of bacteria in PBH were greater than those in PC; moreover, some bacteria were undetectable in PC at all.

  10. Nutritional status and nutritional habits of men with benign prostatic hyperplasia or prostate cancer - preliminary investigation

    Directory of Open Access Journals (Sweden)

    Zuzanna Goluch-Koniuszy

    2013-09-01

    Full Text Available Introduction. The ageing in men, the most frequent pathologic lesions affecting the prostatic gland in this period are benign prostatic hyperplasia (BPH and prostate cancer (PC, the course of which may be infl uenced by the improper nutritional status of patients and their nutritional habits. The aim of this study was, therefore, to evaluate the nutritional status and eating habits of men diagnosed and treated for one of the above diseases. Material and metods. The nutritional status of 30 male patients with clinically confi rmed and treated disease of the prostatic gland, including 15 men (aged 51-75 years with BPH and 15 men (aged 51-73 years with PC, was evaluated based on their BMI, WC, WHR, and WHtR parameters. In turn, the energy and nutritive value of 90 daily food rations (DFRs was evaluated. Finally, calculations were made for the Key’s index of diet atherogenicity, resultant Glycemic Index (GI and Glycemic Load (GL. Results. Higher values of the BMI, WC, WHR and WHtR parameters were noted in the men with PC, they were also characterized by a higher incidence of peripheral subcutaneous obesity and visceral obesity. The DFRs of the men were characterized by a low energy value and by a low intake of available carbohydrates, dietary fi ber, K, Ca, Mg, vitamins D and C, and fl uids at a simultaneously high intake of total and animal protein, cholesterol, Na, P, Fe, Cu as well as vitamins B2 and PP. The contribution of energy derived from the basic nutrients diverged from the recommended values. In addition, the DFRs were characterized by high values of Key’s index and 24-h GL. Differences in meeting the RDA for selected nutrients between the analysed groups of men were statistically signifi cant. Conclusions. The improper nutritional status of the men may result from their incorrect nutritional habits which fail to improve their health status, and even predispose them to the development of some diet-dependent diseases. In view of that

  11. Predictors of urinary retention in benign prostate hyperplasia

    Directory of Open Access Journals (Sweden)

    Chandrashekhar C. Mahakalkar

    2016-02-01

    Conclusions: Out of the four factors considered to be the independent risk factors, all of them have positive correlation with the symptom of acute urinary retention. None of these four factors i.e. age in years, symptom severity, prostate Volume on DRE and USG grade could establish significant correlation. [Int J Res Med Sci 2016; 4(2.000: 486-490

  12. Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 2, Insights into the Technical Rationale

    Energy Technology Data Exchange (ETDEWEB)

    Sun, Fei, E-mail: feisun@ccmijesususon.com; Crisóstomo, Verónica, E-mail: crisosto@ccmijesususon.com; Báez-Díaz, Claudia, E-mail: cbaez@ccmijesususon.com; Sánchez, Francisco M., E-mail: msanchez@ccmijesususon.com [Jesús Usón Minimally Invasive Surgery Centre (Spain)

    2016-02-15

    Rationale of prostatic artery embolization (PAE) in the treatment of symptomatic benign prostatic hyperplasia is conventionally believed to include two parts: shrinkage of the enlarged prostate gland as a result of PAE-induced ischemic infarction and potential effects to relax the increased prostatic smooth muscle tone by reducing the number and density of α{sub 1}-adrenergic receptor in the prostate stroma. This review describes new insights into the likely mechanisms behind PAE, such as ischemia-induced apoptosis, apoptosis enhanced by blockage of androgens circulation to the embolized prostate, secondary denervation following PAE, and potential effect of nitric oxide pathway immediately after embolization. Studies on therapeutic mechanisms in PAE may shed light on potentially new treatment strategies and development of novel techniques.

  13. Morphogenetic aspects of biomineralization on the background of benign prostatic hyperplasia.

    Science.gov (United States)

    Moskalenko, R; Romanyuk, A; Danilchenko, S; Stanislavov, O; Piddubniy, A; Zakorko, I-М; Tkach, G

    2013-01-01

    Despite the considerable spread of pathological prostate inclusions their nature and significance in the development of gland pathology are not established exactly. The work includes histological research of 628 surgical biopsies of benign prostatic hyperplasia, the sections were stained with hematoxylin and eosin or Congo red, von Kossa methods. Mineral constituent of prostatoliths (5 cases) was studied by infrared spectroscopy (IRS); scanning electron microscopy with X-ray microanalysis (REMMA/EDX), transmission electron microscopy and electron diffraction (TEM/ED). The average age of the operated patients was 69,5±0,42 years old. In 88,22±1,67% of cases nodular prostatic hyperplasia was combined with diffuse or focal inflammation, engorgements of prostate gland secretion were observed in 81,76±2,97%. In the lumen of the prostate gland corpora amylacea were detected in 64,72±1,13% of cases, in 27,6±3,48% - concreations. There was a significant strong correlation between inflammation and calculi - r = 0.93 (pprostate secretions, but it's not a dystrophic calcification of the corpora amylacea. Mineral component of prostatic concrements is carbonate bioapatite with a minor inclusion of other chemical elements.

  14. Interstitial laser coagulation therapy for benign prostatic hyperplasia

    Science.gov (United States)

    McNicholas, Thomas A.; Alsudani, Mohammed

    1996-05-01

    Alternatives to the side-firing laser method include controlled destruction of prostatic adenoma by an atraumatic saline cooled laser fiber introduced endoscopically into the prostate under visual and transrectal ultrasound (TRUS) control. Laser light produces intense heating and interstitial laser coagulation (ILC) occurs with characteristic TRUS changes which are used to control the volume of tissue destruction. The prostatic urethral lining is preserved which may reduce laser side effects). Thirty-six men with symptomatic BPH were treated by ILC between April 1994 and September 1995. All were discharged home on the first post-operative day and reviewed periodically to 12 months post-treatment with measurement of IPSS, flow rate (FR), residual volume, complications, potency and TRUS. Seventeen men (47%) voided immediately, 15 (42%) performed intermittent self-catheterization (ISC) for 3.5 days (2 - 5). Four men (11%) required catheterization for 1/52. Thirty-five men tolerated the treatment well, requiring only mild oral analgesia. One man developed dysuria and required early transurethral resection revealing a large volume of coagulative necrosis. Improvement in symptoms and flow rate developed from 1 - 30 days later. There were no significant complications. Hyperechoic and cystic zones developed at the ILC site which persisted to 12 months. This clinical study indicates the feasibility and safety of intense heating by ILC with visible and ultrasound control to coagulate the adenoma while preserving the urethra. Changes are easily seen on TRUS, symptomatic improvement is good and there have been minimal urethral symptoms or complications.

  15. Nanostructured systems containing babassu (Orbignya speciosa oil as a potential alternative therapy for benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    de Sousa VP

    2013-08-01

    Full Text Available Valeria Pereira de Sousa,1 Joanne Crean,2 Vinícius Raphael de Almeida Borges,1 Carlos Rangel Rodrigues,1 Lidia Tajber,2 Fabio Boylan,2 Lucio Mendes Cabral1 1Department of Pharmaceutics, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; 2School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland Abstract: The oil of babassu tree nuts (Orbignya speciosa is a potential alternative for treatment and prophylaxis of benign prostatic hyperplasia. Improved results can be obtained by drug vectorization to the hyperplastic tissue. The main objective of this work was the preparation and characterization of poly(lactic-co-glycolic acid (PLGA nanoparticle and clay nanosystems containing babassu oil (BBS. BBS was extracted from the kernels of babassu tree nuts and characterized by gas chromatography-mass spectrometry as well as 1H and 13C nuclear magnetic resonance. BBS-clay nanosystems were obtained by adding polyvinylpyrrolidone, Viscogel B8®, and BBS at a 2:1:1 mass ratio and characterized by X-ray diffraction, thermogravimetric analysis, infrared spectroscopy, and laser diffraction. The PLGA-BBS nanoparticles were prepared by the precipitation-solvent evaporation method. Mean diameter, polydispersity, zeta potential, and scanning electron microscopic images of the nanosystems were analyzed. Thermogravimetric analysis showed successful formation of the nanocomposite. PLGA nanoparticles containing BBS were obtained, with a suitable size that was confirmed by scanning electron microscopy. Both nanostructured systems showed active incorporation yields exceeding 90%. The two systems obtained represent a new and potentially efficient therapy for benign prostatic hyperplasia. Keywords: babassu oil, nanocomposite, poly(lactic-co-glycolic acid, nanoparticles, benign prostatic hyperplasia, treatment, nanotechnology

  16. Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia.

    Science.gov (United States)

    Song, Lingmin; Shen, Wenhao; Zhang, Heng; Wang, Qiwu; Wang, Yongquan; Zhou, Zhansong

    2016-07-01

    This study aimed to identify the differential expression levels of androgen receptor (AR), estrogen receptors (ERα, ERβ), and progesterone receptor (PGR) between normal prostate and benign prostatic hyperplasia (BPH). The combination of immunohistochemistry, quantitative real-time reverse transcription polymerase chain reaction, and Western blotting assay was used to identify the distribution and differential expression of these receptors at the immunoactive biomarker, transcriptional, and protein levels between 5 normal human prostate tissues and 40 BPH tissues. The results were then validated in a rat model of BPH induced by testosterone propionate and estradiol benzoate. In both human and rat prostate tissues, AR was localized mainly to epithelial and stromal cell nuclei; ERα was distributed mainly to stromal cells, but not exclusively; ERβ was interspersed in the basal layer of epithelium, but sporadically in epithelial and stromal cells; PGR was expressed abundantly in cytoplasm of epithelial and stromal cells. There were decreased expression of ERα and increased expression of PGR, but no difference in the expression of ERβ in the BPH compared to the normal prostate of both human and rat. Increased expression of AR in the BPH compared to the normal prostate of human was observed, however, the expression of AR in the rat prostate tissue was decreased. This study identified the activation of AR and PGR and repression of ERα in BPH, which indicate a promoting role of AR and PGR and an inhibitory role of ERα in the pathogenesis of BPH. PMID:27483178

  17. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.

    Science.gov (United States)

    Barry, M J; Cockett, A T; Holtgrewe, H L; McConnell, J D; Sihelnik, S A; Winfield, H N

    1993-08-01

    In previous studies the severity of symptoms of prostatism in men with benign prostatic hyperplasia have not correlated well with prostate size, degree of bladder trabeculation, uroflowmetry or post-void residual volume. As part of a prospective cohort study of benign prostatic hyperplasia treatment effectiveness in 4 university-based urology practices, we correlated symptom severity and these commonly used measures of disease severity. Symptom severity was quantified using the American Urological Association symptom index. Analyses were based on 198 outpatients completing a standardized evaluation (84 of these men have completed 6 months of followup after treatment with prostatectomy, balloon dilation, terazosin or watchful waiting). At baseline, symptom severity was not correlated with uroflowmetry, post-void residual, prostate size and degree of bladder trabeculation. However, symptom severity was much more strongly related to overall health status than the other measures. Reduction in symptoms with treatment did correlate with improvements in uroflowmetry. This poor baseline correlation with symptoms may reflect unreliability in measurement of the physiological/anatomical variables. Alternatively, these parameters may be measuring different pathophysiological phenomena.

  18. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.

    Directory of Open Access Journals (Sweden)

    Elizabeth Singer

    Full Text Available Histological staining of reactive stroma has been shown to be a predictor of biochemical recurrence in prostate cancer, however, molecular markers of the stromal response to prostate cancer have not yet been fully delineated. The objective of this study was to determine whether or not the stromal biomarkers detected with a thioredoxin-targeted nanodevice could be used to distinguish the stroma associated with benign prostatic hyperplasia from that associated with PCA. In this regard, we recently demonstrated that a thioredoxin-targeted nanodevice selectively binds to reactive stroma in frozen prostate tumor tissue sections. To accomplish this, random frozen prostate tissue sections from each of 35 patients who underwent resection were incubated with the nanodevice and graded for fluorescent intensity. An adjacent section from each case was stained with Hematoxylin & Eosin to confirm the diagnosis. Select cases were stained with Masson's Trichrome or immunohistochemically using antibodies to thioredoxin reductase 1, thioredoxin reductase 2 or peroxiredoxin 1. Our results demonstrate that the graded intensity of nanodevice binding to the stroma associated with PCA was significantly higher (p = 0.0127 than that of benign prostatic hyperplasia using the t-test. Immunohistochemical staining of adjacent sections in representative cases showed that none of the two commonly studied thioredoxin interacting protein partners mirrored the fluorescence pattern seen with the nanodevice. However, thioredoxin reductase 2 protein was clearly shown to be a biomarker of prostate cancer-associated reactive stroma whose presence distinguishes the stroma associated with benign prostatic hyperplasia from that associated with prostate cancer. We conclude that the signal detected by the nanodevice, in contrast to individual targets detected with antibodies used in this study, originates from multiple thioredoxin interacting protein partners that distinguish the M2

  19. Possible mechanism of benign prostatic hyperplasia induced by androgen-estrogen ratios in castrated rats

    Directory of Open Access Journals (Sweden)

    Xiang-Yun Liu

    2010-01-01

    Full Text Available Objectives : To explore the role of androgen-estrogen balance in benign prostatic hyperplasia (BPH induced by varying doses of estradiol/testosterone propionate (E 2 /TP in castrated rats. Materials and Methods : A total of 222 rats were divided into 37 groups at random, including 35 groups of different E 2 /TP, one control, and one castrated group. All 37 groups except the control group were castrated, for eliminating endogenesis of testosterone in rats. The treated groups were administered testosterone propionate (TP; at the dosages of 0.15, 0.74, 3.7, 18.5, and 92.6 mg/kg, combined with estradiol (E 2 ; at the dosage of 0, 0.4, 2, 10, 50, 250, and 1250 μg/kg diluted in vegetable oil for 30 days, respectively, whereas the control groups received only vegetable oil. All prostate specimens were removed under anesthesia, then fixed and embedded in paraffin, for measuring the organ quotient, volume, area of prostate glandular cavity, and the height of prostate epithelia. Results : When the dosages of TP were 0.15, 3.7, 18.5, and 92.6 mg/kg, the degree of prostatic hyperplasia had no obvious dose-effect relationship with E 2 . When TP was 0.74 mg/kg, with the increase of the dosage of E 2 , the volume and quotient of prostate were increasing. However, when the dosage of E 2 exceeded 50 μg/kg, E 2 /TP was 5/74, the prostatic volume did not increase obviously. Conclusion : The proper levels of E2/TP play an important role in the pathogenesis of BPH. In rats, the balance point of E 2 /TP is 5/74.

  20. Effects of Melandrium firmum methanolic extract on testosterone-induced benign prostatic hyperplasia in Wistar rats

    Institute of Scientific and Technical Information of China (English)

    Mee-Young Lee; In-Sik Shin; Chang-Seob Seo; Nam-Hun Lee; Hye-Kyung Ha; Jong-Keun Son; Hyeun-Kyoo Shin

    2012-01-01

    Benign prostatic hyperplasia (BPH) is an age-related disease of unknown aetiology characterized by prostatic enlargement coincident with distinct alterations in tissue histomorphology.Instead of therapeutic agents that can cause severe side effects,plant extracts are frequently used to treat BPH.In this study,we investigated whether the Melandrium firmum methanolic extract (M FM E) improves BPH,using the testosterone propionate (TP)-induced BPH rat model.Castration was performed via the scrotal route under sodium pentobarbital anaesthesia.BPH in castrated rats was generated via daily subcutaneous injections of TP (3 mg kg-1) dissolved in corn oil,for 4 weeks.MFME was administered daily by oral gavage at a dose of 200 mg kg-1 for 4 weeks,along with the TP injections.The control group received injections of corn oil subcutaneously.At the scheduled termination of the experiment,all rats were killed and their prostates weighed; the relative prostate weight (prostate/body weight ratio) was calculated,and histomorphological changes in the prostate were examined.Additionally,we measured the levels of testosterone and dihydrotestosterone (DHT) in the serum and the prostate.Experimentally induced BPH led to marked decreases in the relative prostate weight and the DHT levels in the serum and the prostate.Histologically,BPH was evident in the ventral lobe of the prostate,and MFME treatment suppressed the severity of the lesions.These results indicate that MFME effectively inhibits the development of BPH induced by testosterone in a rat model.Further studies will be needed to identify the compound(s) responsibility for inducing the protective effect against BPH and determine its mechanism of action.

  1. Antiproliferative and Antioxidant Effects of Withania coagulans Extract on Benign Prostatic Hyperplasia in Rats

    Science.gov (United States)

    Sarbishegi, Maryam; Khani, Mohaddeseh; Salimi, Saeedeh; Valizadeh, Mohharam; Sargolzaei Aval, Fereydoon

    2016-01-01

    Background: Benign prostate hyperplasia (BPH) is a common urological disorder in elderly men. Phytotherapy is frequently used to alleviate the symptoms of this condition. Objectives: The present study investigated the effect of Withania coagulans extract (WCE), which is known to have antioxidant, anti-inflammatory, antihyperglycemic, and anti-cancer properties, on testosterone-induced BPH in rats. Materials and Methods: Forty Wistar rats were divided into five groups (each n = 8): the control group, the untreated BPH group, and three WCE-treated groups (WCE250, 500, and 1000). BPH was induced with 3 mg/kg subcutaneous injections of testosterone propionate for four weeks. WCE was concomitantly administrated by oral gavage. At the end of the induction schedule, the animals were sacrificed and their prostate glands were dissected, weighed, and fixed for histological examination (H&E and proliferating cell nuclear antigen [PCNA] staining). Half of each sample was prepared for measurement of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels in the prostate. Results: The present study revealed that BPH caused elevation of MDA levels, suppression of TAC levels, and increased PCNA expression in the prostate gland. Interestingly, in a dose-dependent manner, WCE caused decreased MDA levels and increased TAC levels in the prostate gland, compared to the untreated BPH group. Histopathological examinations showed a reduction in PCNA expression in the prostate epithelium of the WCE animals. Conclusions: W. coagulans inhibits the development of BPH can be useful for the treatment of this condition. PMID:26981498

  2. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

    Science.gov (United States)

    Nicholson, Tristan M; Ricke, William A

    2011-01-01

    Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) are common clinical problems in urology. While the precise molecular etiology remains unclear, sex steroids have been implicated in the development and maintenance of BPH. Sufficient data exists linking androgens and androgen receptor pathways to BPH and use of androgen reducing compounds, such as 5α-reductase inhibitors which block the conversion of testosterone into dihydrotestosterone, are a component of the standard of care for men with LUTS attributed to an enlarged prostate. However, BPH is a multifactorial disease and not all men respond well to currently available treatments, suggesting factors other than androgens are involved. Testosterone, the primary circulating androgen in men, can also be metabolized via CYP19/aromatase into the potent estrogen, estradiol-17β. The prostate is an estrogen target tissue and estrogens directly and indirectly affect growth and differentiation of prostate. The precise role of endogenous and exogenous estrogens in directly affecting prostate growth and differentiation in the context of BPH is an understudied area. Estrogens and selective estrogen receptor modulators (SERMs) have been shown to promote or inhibit prostate proliferation signifying potential roles in BPH. Recent research has demonstrated that estrogen receptor signaling pathways may be important in the development and maintenance of BPH and LUTS; however, new models are needed to genetically dissect estrogen regulated molecular mechanisms involved in BPH. More work is needed to identify estrogens and associated signaling pathways in BPH in order to target BPH with dietary and therapeutic SERMs.

  3. Ischemia in pelvic organs as an independent pathogenic factor in the development of benign prostatic hyperplasia and urinary bladder dysfunction.

    Science.gov (United States)

    Kirpatovskii, V I; Mudraya, I S; Mkrtchyan, K G; Revenko, S V; Efremov, G D; Nadtochii, O N; Kabanova, I V

    2015-04-01

    Blood supply to the pelvic organs of outbred male rats was diminished by graduated constriction of the distal part of the inferior vena cava. Deficiency of intramural blood supply in prostate and urinary bladder was revealed by bioimpedance harmonic analysis according to the magnitude of first cardiac peak in the bioimpedance spectrogram. In 1-1.5 months, the histological examination revealed the glandular-stromal form of progressive benign prostatic hyperplasia in all ischemic rats. The development of hyperplasia was not accompanied by the changes in testosterone, dihydrotestosterone, or estradiol in blood and prostatic tissue. Assessment of vesical functional status by recording the intravesical pressure during infusion cystometry revealed an increase in the amplitude of spontaneous fluctuations of detrusor tone and intravesical pressure during bladder filling, which can be considered as indicator of detrusor hyperactivity. The data conclude that chronic ischemia of pelvic organs is an individual pathogenic factor in the development of benign prostatic hyperplasia and associated urinary disorders. PMID:25896589

  4. Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications

    Energy Technology Data Exchange (ETDEWEB)

    Sun, Fei, E-mail: feisun@ccmijesususon.com; Crisóstomo, Verónica, E-mail: crisosto@ccmijesususon.com; Báez-Díaz, Claudia, E-mail: cbaez@ccmijesususon.com; Sánchez, Francisco M., E-mail: msanchez@ccmijesususon.com [Jesús Usón Minimally Invasive Surgery Centre (Spain)

    2016-01-15

    Pathological features of benign prostatic hyperplasia (BPH) dictate various responses to prostatic artery embolization (PAE). Typically, BPH originates in the transition zone and periurethral region, where should be considered the primary target area in PAE procedures. Given that histological heterogeneity of components in hyperplasia nodules, epithelial or stromal, identifying the more responsive nodules to PAE will have clinical implications. Since some lower urinary tract symptoms (LUTS) in patients with BPH are usually related to bladder outlet obstruction-induced changes in bladder function rather than to outflow obstruction directly, proper selection of candidate patients prior to PAE is of great clinical importance. BPH is a typical chronic progressive condition, suggesting PAE could aim not only to relieve LUTS but also to delay or prevent the clinical progression. Awareness of the pathological background of BPH is essential for interventional radiologists to improve clinical outcomes and develop new treatment strategies in clinical practice of PAE.

  5. miRNA Regulation Network Analysis in Qianliening Capsule Treatment of Benign Prostatic Hyperplasia

    Directory of Open Access Journals (Sweden)

    Liya Liu

    2015-01-01

    Full Text Available Objective. The objective of this study was to evaluate the molecular mechanism by which Qianliening capsule (QC treats benign prostatic hyperplasia (BPH. Methods. Benign prostatic hyperplasia epithelial cell line BPH-1 was treated with 0, 1.25, 2.5, and 5 mg/mL QC for 48 h, respectively. Evaluation of cell viability and observation of morphologic changes of BPH-1 cell gene expression and miRNA expression profiles were analyzed. Real-time quantitative PCR was used to confirm changes in miRNA and gene expression. GO and KEGG pathway-based approaches were used to investigate biological functions and signaling pathways affected by differentially expressed mRNAs. Results. QC inhibited BPH-1 cell proliferation. Differential expression of 19 upregulated and 2 downregulated miRNAs was observed in QC-treated BPH-1 cells compared to untreated control cells. 107 upregulated and 71 downregulated genes were identified between the two groups. Significantly enriched signaling pathways based on deregulated mRNAs were mainly involved in regulation of cell proliferation, apoptosis, and so on. Additionally, miRNA-mRNA network analysis integrated these miRNAs and genes by outlining interactions of miRNA and related genes. Conclusion. The study was the first report of differentially expressed miRNA and mRNA in QC-treated BPH-1 cells.

  6. Urolift: a New Face of Minimally Invasive Surgical Technique for Benign Prostatic Hyperplasia?

    Science.gov (United States)

    Tsui, Johnson F; Dixon, Christopher M

    2016-09-01

    The management of clinical benign prostatic hyperplasia (BPH) remains a common problem in daily urologic practice. Recently, a new minimally invasive procedure for BPH, the Urolift System, has been introduced. This article reviews the current literature discussing the technique, efficacy, adverse events, limitations, and possible concerns. The existing data which includes a 3-month, sham-controlled multicenter trial with a subsequent 3-year follow-up indicates significant improvements in the outcome measures in particular urinary symptoms. The adverse event profile and reoperation rates are acceptable. A particular benefit includes the lack of negative effects on erectile or ejaculatory function. The procedure can be performed with minimal anesthesia, but is limited to lateral lobe enlargement as it is unsuitable for median lobe or central zone obstruction. Another potential drawback is the placement of permanent implants into the prostatic urethra. The adoption of this procedure will ultimately be determined by multiple factors including ease of use, patient satisfaction, durability, and reimbursement. PMID:27432380

  7. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Yoshida M

    2011-06-01

    Full Text Available Masaki Yoshida1, Junzo Kudoh2, Yukio Homma3, Kazuki Kawabe41Department of Medical Informatics, 2Department of Urology, Japan Labor Health and Welfare Organization, Kumamoto Rosai Hospital, Kumamoto, Japan; 3Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; 4Tokyo Teishin Hospital, Tokyo, JapanAbstract: Lower urinary tract symptoms (LUTS associated with benign prostatic hyperplasia (BPH are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS associated with BPH. Mainstays in the treatment of male LUTS and clinical BPH are the α1-adrenergic receptor antagonists. Silodosin is a new α1-adrenergic receptor antagonist that is selective for the α1A-adrenergic receptor. By antagonizing α1A-adrenergic receptors in the prostate and urethra, silodosin causes smooth muscle relaxation in the lower urinary tract. Since silodosin has greater affinity for the α1A-adrenergic receptor than for the α1B-adrenergic receptor, it minimizes the propensity for blood pressure-related adverse effects caused by α1B-adrenergic receptor blockade. In the clinical studies, patients receiving silodosin at a total daily dose of 8 mg exhibited significant improvements in the International Prostate Symptom Score and maximum urinary flow rate compared with those receiving placebo. Silodosin showed early onset of efficacy for both voiding and storage symptoms. Furthermore, long-term safety of silodosin was also demonstrated. Retrograde or abnormal ejaculation was the most commonly reported adverse effect. The incidence of orthostatic hypotension was low. In conclusion, silodosin, a novel selective α1A-adrenergic receptor antagonist, was effective in general and without obtrusive side effects. This review provides clear evidence in support of the clinical usefulness of silodosin in the treatment of LUTS associated with BPH.Keywords: α1A-adrenoceptor antagonist, silodosin, selective, benign prostatic

  8. The medical management of lower urinary tract symptoms and benign prostatic hyperplasia.

    Science.gov (United States)

    Holtgrewe, H L

    1998-11-01

    Prostatism is a widely used term assigned to the symptom complex of older men with voiding dysfunction. The cause of the syndrome has routinely been ascribed to an enlarged prostate. More recent thinking recognizes that many men with such symptoms do not, in fact, have prostate enlargement or benign prostatic hyperplasia (BPH) and that such symptoms are not a surrogate for BPH. Such recognition is essential if cost effective medical management of lower urinary tract symptoms (LUTS) is to be achieved. Prostate volume has emerged as a key factor in the selection of medical therapy of LUTS and BPH not only regarding symptom relief but also to the newer concept of the prevention of disease progression and the avoidance of future adverse events in those men with true BPH. In the United States, medical management is now first line therapy for LUTS. The proper selection of therapy based on the patient's individual pathophysiologic characteristics is now made possible by many new recent studies within the medical literature.

  9. Transurethral photodynamic therapy in benign prostatic hyperplasia : a canine pilot study using benzoporphyrin derivative

    Science.gov (United States)

    Shetty, Sugandh D.; Peabody, James O.; Beck, Elsa R.; Cerny, Joseph C.; Amin, Mahul B.; Richter, Anna M.

    1999-06-01

    Photodynamic therapy (PDT) principles were evaluated in management of benign prostatic hyperplasia (BPH) in a canine model. Five dogs were injected with benzoporphyrin derivative (BPD) and samples of prostate, bladder, urethra and rectum were taken at 1, 2, 3 and 4 hours and analyzed for BPD. Next, 16 dogs were treated with 100 Joules at 690 nm light form argon dye laser 1 hour after administration of BPD at 0.5 mg/kg using cylindrical diffuser tip fiber passed transurethrally. The prostates were harvested weekly up to 4 weeks and the size of the lesion was measured and the prostates were examined. Prostate had the highest BPD levels. Hemorrhagic lesion of 2.5 cm in diameter was noted at 1 week after PDT. At 3 and 4 weeks there were changes of glandular atrophy in the periurethral region. Minimally invasive technique of transurethral PDT causes glandular and stromal changes in the periurethral zone and has potential in the treatment of BPH.

  10. [Up-to-date on the treatment of benign prostatic hyperplasia. Which adenoma to treat and how to do it?].

    Science.gov (United States)

    Lahlaidi, K; Ariane, M M; Fontaine, E

    2014-03-01

    Benign prostatic hyperplasia is a state of the nature rather than a disease. It affects mainly men over 50 years and represents a public health problem. A literature review on the therapeutic management of benign prostatic hyperplasia was carried out from a selection of publications with the highest level of evidence. Medical treatment is based on herbal medicine, alpha-blockers and 5-alpha-reductase inhibitors. Surgical treatment is used in case of complications or failure of medical management. Surgical options are numerous. Transurethral prostate resection and prostate adenomectomy are the most usual procedures. Due to their significant morbidity, other less invasive procedures have recently been developed. The choice of treatment will depend on prostate volume and anatomy and patient's comorbidities.

  11. Current trends in management of men with lower urinary tract symptoms and benign prostatic hyperplasia.

    Science.gov (United States)

    Holtgrewe, H L

    1998-04-01

    Management of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) has been central to urology for decades. The urologic community has increasingly come to realize that many men with LUTS do not have prostate enlargement and do not need their prostates debulked surgically. Of all the factors that have emerged to alter the trends associated with management of LUTS and BPH, none has had more impact than the advent of medical therapy. The selective, long-acting, alpha1-blocking agents terazosin, doxazosin, and tamsulosin have become most popular because of their specificity in the urinary tract, reduced side effects, and simplicity of dosage. In addition, finasteride, a 5-alpha-reductase inhibitor, was found to be effective in men with prostates of > or = 40 g. Furthermore, the larger the prostate at baseline, the greater the efficacy of finasteride on symptom relief and flow rate improvement. In addition to medical therapy, an array of device therapies has emerged in the management of LUTS and BPH. Laser prostatectomy is the oldest of the device therapies and includes transurethral vaporization of the prostate (VLAP), transurethral evaporation of the prostate (TUEP), and transurethral interstitial laser prostatectomy (TILP). Studies report beneficial outcomes approaching those achieved with transurethral resection of the prostate (TURP) with less morbidity and a shorter hospital stay. Common diseases contribute the most to national healthcare expenditures. The management of LUTS and BPH are such disorders and result in the expenditure of vast healthcare resources worldwide. The surgical strategies have an established record of outcomes documenting their potential for symptom relief and the avoidance of future complications. Medical and device therapies, although currently promising and attractive, therefore must prove comparable durability.

  12. KAI1/CD82 gene expression in benign prostatic hyperplasia and late-stage prostate cancer in Chinese

    Institute of Scientific and Technical Information of China (English)

    Wei-LieHU; Ying-QiuLI; Hui-XuHE; Qing-RongLI; YeTIAN; Ri-QuanLAI; HuaMEI

    2000-01-01

    Aim: To evaluate KAI1/CD82 expression in Chinese patients with benign prostatic hyperplasia (BPH) and latestage carcinoma of prostate (CAP). Methods: Thirty Chinese patients with benign prostatic hyperplasia and 34 with CaP (adenocarcinoma clinical stage C and D) were analyzed by means of immunohistochemical methods. Results: The KAI1/CD82 expression in BPH tissue was all positive, which was uniformly located on the glandular cell membrane at the cell-to-cell borders, but KAI1/CD82 expression in metastasis CaP tissues was either significantly lower than that of BPH or negative, and the immunostaining pattern was not continuous. In late-stage CaP KAI1/CD82 expression was correlated inversely to the pathological grade ( P 0.05). Conclusion: The authors believe that decreased and negative KAI1/CD82 expression in late-stage CAP may be related to tumor pro-gression and metastasis, and appears to be a prognostic marker.

  13. Is there a relationship between androgenic alopecia and benign prostatic hyperplasia?

    Science.gov (United States)

    Dastgheib, Ladan; Shirazi, Mehdi; Moezzi, Iman; Dehghan, Saber; Sadati, Maryam-Sadat

    2015-01-01

    Androgenic alopecia as a physiologic process and benign prostatic hyperplasia (BPH) as a pathologic process in the older population are androgen-dependent processes influenced by 5-alpha reductase enzyme which converts testosterone to dihydrotestosterone. This cross sectional study was done to evaluate the relationship between androgenic alopecia and BPH. 150 men older than 50 years old, who presented to the free prostate screening clinic, were included. They were asked about urinary symptoms. PSA level, prostate volume with sonography and alopecia grading using Hamilton-Norwood classification (grade I to VII) were evaluated. Analysis was done by SPSS statistical method. 59.6% of men had mild alopecia (grade I, II, III), 34.1% had moderate alopecia (grade IV, V) and 6.3% had severe alopecia (grade VI, VII).The mean PSA level was 1.37 ± 1.48 ng/ml. The minimum PSA level was 0.1 ng/ml, and the maximum level was 6.8 ng/ml. The mean prostate volume was 37.85 ± 21.85cc. The minimum prostate size was 10 ml, and the maximum volume was 173 ml. The mean international prostate symptom score (IPSS) was 7.6 ± 6.11 with the minimum score 0 and the maximum score 27. However, no relationship between these parameters and androgenic alopecia was detected. This study showed that there is no relationship between androgenic alopecia, PSA level, IPSS, and prostate volume. Occurrence of alopecia in younger age and a positive family history correlated with a higher grade of alopecia. PMID:25597602

  14. Is there a relationship between androgenic alopecia and benign prostatic hyperplasia?

    Directory of Open Access Journals (Sweden)

    Ladan Dastgheib

    2015-01-01

    Full Text Available Androgenic alopecia as a physiologic process and benign prostatic hyperplasia (BPH as a pathologic process in the older population are androgen-dependent processes influenced by 5-alpha reductase enzyme which converts testosterone to dihydrotestosterone. This cross sectional study was done to evaluate the relationship between androgenic alopecia and BPH. 150 men older than 50 years old, who presented to the free prostate screening clinic, were included. They were asked about urinary symptoms. PSA level, prostate volume with sonography and alopecia grading using Hamilton-Norwood classification (grade I to VII were evaluated. Analysis was done by SPSS statistical method. 59.6% of men had mild alopecia (grade I, II, III, 34.1% had moderate alopecia (grade IV, V and 6.3% had severe alopecia (grade VI, VII.The mean PSA level was 1.37 ± 1.48 ng/ml. The minimum PSA level was 0.1 ng/ml, and the maximum level was 6.8 ng/ml. The mean prostate volume was 37.85 ± 21.85cc. The minimum prostate size was 10 ml, and the maximum volume was 173 ml. The mean international prostate symptom score (IPSS was 7.6 ± 6.11 with the minimum score 0 and the maximum score 27. However, no relationship between these parameters and androgenic alopecia was detected. This study showed that there is no relationship between androgenic alopecia, PSA level, IPSS, and prostate volume. Occurrence of alopecia in younger age and a positive family history correlated with a higher grade of alopecia.

  15. Effect of Pulsed Electromagnetic Field Therapy on Prostate Volume and Vascularity in the Treatment of Benign Prostatic Hyperplasia: A Pilot Study in a Canine Model

    OpenAIRE

    Leoci, Raffaella; Aiudi, Giulio; Silvestre, Fabio; Lissner, Elaine; Lacalandra, Giovanni Michele

    2014-01-01

    BACKGROUND Benign prostatic hyperplasia (BPH) is a result of urogenital aging. Recent studies suggest that an age-related impairment of the blood supply to the lower urinary tract plays a role in the development of BPH and thus may be a contributing factor in the pathogenesis of BPH. The canine prostate is a model for understanding abnormal growth of the human prostate gland. We studied the efficacy of pulsed electromagnetic field therapy (PEMF) in dogs to modify prostate blood flow and evalu...

  16. Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes.

    Science.gov (United States)

    Norström, Melissa M; Rådestad, Emelie; Sundberg, Berit; Mattsson, Jonas; Henningsohn, Lars; Levitsky, Victor; Uhlin, Michael

    2016-04-26

    Benign prostatic hyperplasia (BPH) is a common chronic non-malignant condition whose prevalence substantially increases with age. Immune cell infiltration and pro-inflammatory mediators have been implicated in the pathogenesis. Here, we characterized 21 extracellular markers on prostate-infiltrating lymphocytes (PILs) and analyzed expression of 26 soluble proteins in prostate tissue obtained from BPH patients (n = 31). These data were correlated with clinical parameters and compared with peripheral blood mononuclear cells (PBMCs) (n = 10). Increased frequencies of T cells expressing co-inhibitory receptors LAG-3, PD-1, TIM-3 or CTLA-4, and co-stimulatory receptors CD28, OX40 or 4-1BB were observed in BPH tissue compared to PBMCs. These findings are consistent with chronic activation and possible functional exhaustion of PILs that may be further augmented by several identified pro-inflammatory factors, such as IL-8 and MCP-1, promoting inflammation and chemotaxis of immune cells to the prostate. Prostate size and plasma prostate-specific antigen levels positively correlated with IL-8 and MCP-1 concentrations, and frequencies of T cells expressing CTLA-4 and TIM-3. It remains to be established whether the link between inflammation and BPH progression supported by our findings reflects a progressive failure of the immune system leading to decreased immune surveillance and development of prostate cancer. PMID:26993768

  17. Anti-Proliferation Effects of Garlic (Allium sativum L.) on the Progression of Benign Prostatic Hyperplasia.

    Science.gov (United States)

    Chung, Kyung-Sook; Shin, Su-Jin; Lee, Na Young; Cheon, Se-Yun; Park, Wansu; Sun, Seung-Ho; An, Hyo-Jin

    2016-07-01

    Benign prostatic hyperplasia (BPH) is a urologic disease that affects most of men over the age 50. But until now there is no such perfect cure without side effects. Because of diverse adverse effects, it is desirable to develop effective and long term-safety-herbal medicines to inhibit the progress of BPH. In spite of garlic's large use and a wide spectrum of studies, including anti-hyperlipidemic, cardio-protective, and anti-inflammatory activities, there was none to prove efficacy for BPH. In this study, we evaluated the efficacy of garlic to prove its suppressing effects on BPH. Garlic administration decreased relative prostate weight ratio, suppressed mRNA expression level of AR, DHT serum levels, and the growth of prostatic tissue in BPH-induced rats. Moreover, garlic administration decreased the levels of inflammatory proteins, iNOS, and COX-2 in prostatic tissue. Further investigation showed that garlic induced accumulation of death-inducing signal complex and activation of AMPK and decreased the levels of anti-apoptotic proteins, such as Bcl-2, Bcl-xL, and survivin. These results suggest that garlic may have suppressing effects on BPH and it has great potential to be developed as treatment for BPH. Copyright © 2016 John Wiley & Sons, Ltd. PMID:27191676

  18. Protective potential of epigallocatechin-3-gallate against benign prostatic hyperplasia in metabolic syndrome rats.

    Science.gov (United States)

    Chen, Jinglou; Song, Hongping

    2016-07-01

    Epigallocatechin-3-gallate (EGCG) is a major catechin in green tea with functions of antioxidant, anti-proliferative, anti-inflammatory and attenuating metabolic syndrome. In this study, rat model of benign prostatic hyperplasia (BPH) accompanied with metabolic syndrome was induced by fed on high-fat diet for 12 weeks combined with testosterone injection (10mg/kg/d) from 9th to 12th weeks. EGCG was orally given from 9th to 12th weeks. Finally, the levels of glucose, total cholesterol, triglyceride, prostate weight, insulin-like growth factors (IGFs), inflammatory cytokines, antioxidant enzymes, and prostatic expression of IGF binding protein-3 (IGFBP-3) and peroxisome proliferator activated receptors (PPARs) were evaluated. It was found that EGCG significantly decreased the levels of glucose, total cholesterol, triglyceride, IGFs, and inflammatory cytokines, normalized the activities of antioxidant enzymes, as well as increased the prostatic expression of IGFBP-3 and PPARs. These results indicated that EGCG was able to exert anti-BPH activities in metabolic syndrome rats. PMID:27348728

  19. Involvement of Fibroblast Growth Factor Receptor Genes in Benign Prostate Hyperplasia in a Korean Population

    Directory of Open Access Journals (Sweden)

    Hae Jeong Park

    2013-01-01

    Full Text Available Fibroblast growth factors (FGFs and their receptors (FGFRs have been implicated in prostate growth and are overexpressed in benign prostatic hyperplasia (BPH. In this study, we investigated whether single nucleotide polymorphisms (SNPs of the FGFR genes (FGFR1 and FGFR2 were associated with BPH and its clinical phenotypes in a population of Korean men. We genotyped four SNPs in the exons of FGFR1 and FGFR2 (rs13317 in FGFR1; rs755793, rs1047100, and rs3135831 in FGFR2 using direct sequencing in 218 BPH patients and 213 control subjects. No SNPs of FGFR1 or FGFR2 genes were associated with BPH. However, analysis according to clinical phenotypes showed that rs1047100 of FGFR2 was associated with prostate volume in BPH in the dominant model (GA/AA versus GG, P = 0.010. In addition, a significant association was observed between rs13317 of FGFR1 and international prostate symptom score (IPSS in the additive (TC versus CC versus TT, P = 0.0022 and dominant models (TC/CC versus TT, P = 0.005. Allele frequency analysis also showed significant association between rs13317 and IPSS (P = 0.005. These results suggested that FGFR genes could be related to progression of BPH.

  20. Sonablate-500TM Transrectal High-intensity Focused Ultrasound (HIFU) for Benign Prostatic Hyperplasia Patients

    Institute of Scientific and Technical Information of China (English)

    L(U) Jun; HU Weilie; WANG Wei; ZHANG Yuanfeng; CHEN Zhaoyang; YE Zhangqun

    2007-01-01

    To evaluate the safety and efficacy of transrectal high-intensity focused ultrasound (HIFU) in the treatment of benign prostatic hyperplasia (BPH), serial studies were conducted in 150 BPH pa- tients before and 30 min, 1, 2, 6 and 12 month(s) after Sonablate-500TM HIFU treatment. A sili- con-coated indwelling 16F latex catheter was placed during the determination of the therapy zone. Preoperative and postoperative evaluations were made by using the international prostate symptom score (IPSS), quality of life (QOL), uroflowmetric findings and transrectal ultrasound, and incidence of complications. The cystourethrography was done in 23 patients within 1 year postoperatively. The results showed that after HIFU treatment, IPSS and QOL scores were significantly decreased at 1, 2, 6 and 12 month(s) (P<0.01). Maximum urine flow rate (6.0 to 17.2 mL/s, P<0.01), PVR (75.0 to 30.3,P<0.01) and prostatic volume (65.0 to 38.1 mL, P<0.05) were significantly improved 12 months after the operation. Recurrent urinary retention (n=2) and urethrorectal fistula (n=1) occurred at the 15th postoperative day. The duration of the HIFU prostate ablation was 25-90 rain. The mean time for an indwelling catheter was 3-19 days. These data demonstrate that treatment of BPH with Sonab- late-500TM HIFU is safe and effective.

  1. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia.

    Science.gov (United States)

    Kasturi, Sanjay; Russell, Shane; McVary, Kevin T

    2006-07-01

    Increasing evidence recently has pointed toward a relationship between lower urinary tract symptoms (LUTS) and the presence of metabolic syndrome. This relationship has been supported by recent epidemiologic findings. Possible pathophysiologic links also have been proposed to explain the relationship between these two syndromes. The increasing prevalence of obesity in the United States makes this an increasingly relevant problem. Animal studies support a link between autonomic nervous system (ANS) overactivity and the development of urinary symptoms, low bladder compliance, compensatory prostatic hyperplasia, and blockage of the same using alpha-blockade. There appears to be a significant link between ANS overactivity as part of the metabolic syndrome and LUTS secondary to benign prostatic hyperplasia (BPH). However, it is unlikely that ANS overactivity could be responsible for the development of LUTS. Rather, ANS overactivity plays a key role in increasing the severity of LUTS above an intrinsic basal intensity that is determined by the genitourinary anatomic/pathophysiologic characteristics of each BPH patient. This paper defines metabolic syndrome as a collection of abnormalities, including being overweight (visceral abdominal fat distribution), dyslipidemia, hypertension, impaired glucose metabolism, elevated C-reactive protein (chronic inflammation), and autonomic-sympathetic overactivity, with insulin resistance as the hypothesized underlying pathogenic mechanisms.

  2. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue

    Institute of Scientific and Technical Information of China (English)

    Zong-Lin Wu; Ya Yuan; He Geng; Shu-Jie Xia

    2012-01-01

    This study was designed to investigate the association between immune inflammation and androgen receptor (AR) expression in benign prostatic hyperplasia (BPH).We retrospectively analyzed 105 prostatectomy specimens.An immune inflammation score for each specimen was defined by combining three immunohistochemical markers (CD4,CD8 and CD20).The immunohistochemical markers were CD4 and CD8 for T lymphocytes,CD20 for B lymphocytes and AR antibody for the AR in BPH samples.Rates of CD4,CD8,CD20 and AR expression in BPH were 20 (19.0%),21 (20.0%),101 (96.2%) and 48 (45.7%),respectively.Total prostate volume (TPV) was higher in the immune inflammation group than in the non-immune inflammation group (62.7 ml vs.49.2 ml,t=2.482,P<0.05).Patients in the immune inflammation group had a higher serum prostate-specific antigen (PSA) than those in the non-inflammation group (7.5 ng ml-1 vs.5.4 ng ml-1,t=2.771,P<0.05).Specifically,the immune inflammation group showed a higher rate of AR expression than the non-inflammation group (56.1% vs.28.2%,x2=7.665,P<0.05).Our study revealed a strong association between immune inflammation and TPV,serum PSA and AR expression in BPH tissue.Prostate hyperplasia caused by an immune inflammatory process may contribute to BPH progression over time.Therefore,the inflammatory response involved in BPH may be a prime therapeutic target.

  3. Association of Clinical Benign Prostate Hyperplasia with Prostate Cancer Incidence and Mortality Revisited: A Nationwide Cohort Study of 3 009 258 Men

    DEFF Research Database (Denmark)

    Ørsted, David Dynnes; Bojesen, Stig E; Nielsen, Sune F;

    2011-01-01

    BACKGROUND: Although benign prostate hyperplasia (BPH) and prostate cancer (PCa) share features such as hormone-dependent growth and response to treatment with antiandrogen therapy, BPH is generally not considered a premalignant lesion. OBJECTIVE: To determine whether clinical BPH is associated...

  4. Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia

    NARCIS (Netherlands)

    Eckhardt, MD; van Venrooij, GEPM; Boon, TA

    2001-01-01

    Objectives. To estimate the differences in symptoms, prostate volume, and urodynamic variables of symptom-free elderly volunteers, volunteers with lower urinary tract symptoms (LUTS), and urologic patients with LUTS suggestive of benign prostatic hyperplasia. Methods. The study included 14 male volu

  5. Benign prostatic hyperplasia presenting with renal failure--what is the role for transurethral resection of the prostate (TURP)?

    LENUS (Irish Health Repository)

    Thomas, A Z

    2009-02-01

    The aim of the study was to determine the role of transurethralresection of prostate (TURP) in normalising renal function in men presenting with obstructive renal failure secondary to benign prostatic hyperplasia. We reviewed the cases of 14 men who presented in the last 5 years with renal impairment associated with symptoms of bladder outflow obstruction and radiological evidence of obstructive uropathy. The mean serum creatinine at presentation was 632 ng\\/mL (range 1299 - 225). The mean age at presentation was 68.2 years (range 50 - 83 years). Duration of symptoms prior to presentation ranged between 1 - 118 months (mean 21.5 months). Following catheter insertion, all patients underwent TURP. Six of the 14 patients required dialysis prior to surgery. Histology of the resected prostate confirmed benign prostatic hypertrophy and\\/or hyperplasia in all cases. Patients with carcinoma of the prostate were excluded from the study. Following TURP, 2 of the 14 men (14%) failed to void spontaneously following removal of catheter - one patient performs clean self intermittent catheterization (CSIC), the other man has an in-dwelling catheter in situ. One patient died 7 months following TURP due to a myocardial infarction. However, 8 patients, (57%) remained dialysis dependent following TURP. Two of these patients have since undergone successful renal transplantation. Of the remaining 6 patients, only 3 have normal renal function with the other 3 experiencing moderately elevated serum creatinine (range 236 - 344 ng\\/mL). In patients presenting with renal failure due to bladder outflow obstruction, TURP restores normal voiding pattern in many cases. However renal failure due to bladder outflow obstruction tends to be more refractory and only 3 of 14 patients experienced return to normal renal function post treatment.

  6. Androgen receptor CAG polymorphism and the risk of benign prostatic hyperplasia in a Brazilian population

    Directory of Open Access Journals (Sweden)

    Vanderlei Biolchi

    2012-06-01

    Full Text Available Benign prostatic hyperplasia (BPH is a very frequent age-related proliferative abnormality in men. Polymorphic CAG repeat in the androgen receptor (AR can alter transactivation of androgen-responsive genes and potentially influence BPH risk. We investigated the association between CAG repeat length and risk of BPH in a case-control study of a Brazilian population. We evaluated 214 patients; 126 with BPH and 88 healthy controls. DNA was extracted from peripheral leucocytes and the AR gene was analyzed using fragment analysis. Hazard ratio (HR and 95% confidence interval were estimated using logistic regression models. Mean CAG length was not different between patients with BPH and controls. The CAG repeat length was examined as a categorical variable (CAG 21 and CAG 22 and did not differ between the control vs. the BPH group. We found no evidence for an association between AR CAG repeat length in BPH risk in a population-based sample of Brazilians.

  7. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates.

    Science.gov (United States)

    Egan, Kathryn Brigham

    2016-08-01

    This article assesses the reported prevalence and incidence rates for benign prostatic hyperplasia and lower urinary tract symptoms (BPH/LUTS) by age, symptom severity, and race/ethnicity. BPH/LUTS prevalence and incidence rates increase with increasing age and vary by symptom severity. The BPH/LUTS relationship is complex due to several factors. This contributes to the range of reported estimates and difficulties in drawing epidemiologic comparisons. Cultural, psychosocial, economic, and/or disease awareness and diagnosis factors may influence medical care access, symptom reporting and help-seeking behaviors among men with BPH/LUTS. However, these factors and their epidemiologic association with BPH/LUTS have not been thoroughly investigated. PMID:27476122

  8. A study of molecular signals deregulating mismatch repair genes in prostate cancer compared to benign prostatic hyperplasia.

    Directory of Open Access Journals (Sweden)

    Sanmitra Basu

    Full Text Available Prostate cancer is one of the leading causes of mortality among aging males. There is an unmet requirement of clinically useful biomarkers for early detection of prostate cancer to reduce the liabilities of overtreatment and accompanying morbidity. The present population-based study investigates the factors disrupting expression of multiple functionally related genes of DNA mismatch repair pathway in prostate cancer patients to identify molecular attributes distinguishing adenocarcinoma from benign hyperplasia of prostate. Gene expression was compared between tissue samples from prostate cancer and benign prostatic hyperplasia using real-time-PCR, western blot and immunohistochemistry. Assessment of genotypes of seven single-nucleotide-polymorphisms of three MMR genes was conducted using PCR-coupled RFLP and sequencing. Promoter methylation was interrogated by methylation-specific-PCR and bisulfite-sequencing. Interaction between microRNAs and MMR genes was verified by 3'UTR-based dual luciferase assays. Concurrent reduction of three MMR genes namely hMLH1, hMSH6 and hMSH2 (34-85%, P<0.05 was observed in prostate cancer tissues. hMSH6 polymorphism rs1800932(Pro92Pro conferred a borderline protection in cancer patients (OR = 0.33, 95% CI = 0.15-0.75. Relative transcript level of hMLH1 was inversely related (r = -0.59, P<0.05 with methylation quotient of its promoter which showed a significantly higher methylation density (P = 0.008, Z = -2.649 in cancer patients. hsa-miR-155, hsa-miR-141 and hsa-miR-21 gene expressions were significantly elevated (66-85%, P<0.05 in tumor specimens and negatively correlated (r = -0.602 to -0.527, P<0.05 with that of MMR genes. hsa-miR-155 & hsa-miR-141 and hsa-miR-155 & hsa-miR-21 were demonstrated to bind to their putative seed sequences in hMLH1 and hMSH6 3'UTRs respectively. Relatively higher expression of DNA methyl-transferases (DNMT1 and DNMT3b and HIF-1α genes (34-50%, P<0.05 were also detected in tumor

  9. Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial

    OpenAIRE

    Lee, Hye-Yoon; Nam, Jong-Kil; Lee, Sang-Don; Lee, Dong-Hoon; Han, Ji-Yeon; Yun, Young-Ju; Lee, Ji-Hye; Park, Hye-lim; Park, Seong-Ha; Kwon, Jung-Nam

    2015-01-01

    Introduction This study aims to explore the feasibility of using moxibustion as a supplementary intervention and to assess the sample size for verifying the effectiveness and safety of integrative treatment involving moxibustion compared with conventional treatment for patients with benign prostatic hyperplasia accompanying moderate to severe lower urinary tract symptoms. Methods and analysis A total of 60 patients diagnosed with benign prostatic hyperplasia by a urologist based on prostate s...

  10. New surgical treatment options in patients with benign prostate hyperplasia (BPH)

    Science.gov (United States)

    de Riese, Werner T. W.; Nelius, Thomas; Aronoff, David R.; Mittemeyer, Bernhard T.

    2003-06-01

    Benign prostatic hyperplasia (BPH) is a common disease in males older than 50 years of age. 75-80% of this population is considered to have some degree of BPH causing clinical symptoms and requiring urological treatment. Transurethral resection of the prostate (TUR-P) is currently the standard surgical treatment modality for BPH. In an attempt to minimize the need for hospitalization and the associated perioperative and postoperative morbidity, alternatives have been sought. Various types of Laser techniques such as interstitial Laser cogaulation and side-firing technology have been proposed. Numerous studies have shown that Laser procedures safely and effectively reduce the volume of the prostate. Intra- and postoperative bleeding are nearly unknown complications for Laser procedures, whereas this is the most relevant complication for the TUR-P. Due to significant tissue edema after Laser treatment, patients commonly show delayed time to void adequately, and therefore, catheter drainage is often necessary for 3 to 21 days. Retrograde ejaculation is reported to occur less (0 - 10%) compared to TUR-P (> 60%). Urinary tract infections are very common after interstitial laser coagulation. Although not many long-term clinical data are available, various studies have shown that BPH patients improve in symptom score, flow rate and post-void residual up to 3 years after Laser treatment. This paper presents a concise review of efficacy, advantages and disadvantages of the most frequently used Laser techniques as well as the long-term clinical data compared to TUR-P.

  11. Relationship between serum sex hormones levels and degree of benign prostate hyperplasia in Chinese aging men

    Institute of Scientific and Technical Information of China (English)

    Qin-Song Zeng; Zheng Li; Bo Wang; Ying-Hao Sun; Chuan-Liang Xu; Zhi-Yong Liu; Hui-Qing Wang; Bo Yang; Wei-Dong Xu; Tai-Le Jin; Cheng-Yao Wu; Gang Huang

    2012-01-01

    Benign prostatic hyperplasia (BPH) is one of the most common medical conditions in middle aged and older men.This study investigated the relationship between serum levels of sex hormones and measures of BPH in the aging male population of China.Prostate symptoms were assessed as part of a free health screening program for men ≥40 years of age.The examination included digital rectal examination,determination of serum prostate-specific antigen levels,International Prostate Symptom Scorn (IPSS) and transrectal ultrasonography.Serum levels of total testosterone (TT),sex hormone binding globulin (SHBG),free testosterone (FT),luteinizing hormone (LH),follicle-stimulating hormone (FSH),prolactin (PRL) and estradiol (E2) were evaluated.The men also completed a health and demographics questionnaire and received a detailed physical examination.The final study population consisted of 949 men with a mean age of 58.9 years.Pearson correlation analysis indicated that there were significant correlations between age and levels of all sex hormones except TT,and between age and prostate volume (PV; r=-0.243; P<0.01) or IPSS (r=0.263; P<0.01 ).Additional significant correlations were found between IPSS and serum levels of LH (r=0.112; P<0.01 ) and FSH (r=0.074; P<0.05),but there were no significant correlations between sex hormone levels and PV.Multivariate linear regression analysis showed significant correlations between age and body mass index (BMI) with PV (P<0.0001).In addition,there was a significant correlation between age and PV with IPSS (P<0.0001).Serum sex hormone levels did not correlate with PV or IPSS.The effects of endocrine changes on measures of BPH in aging men require further investigation in longitudinal and multicenter studies that include patients with all severities of BPH.

  12. AUA SYMPTOM SCORE - A SIMPLE TOOL FOR ASSESSMENT OF BENIGN PROSTATIC HYPERPLASIA IN A RURAL SETTING

    Directory of Open Access Journals (Sweden)

    SP Patel

    2013-08-01

    Full Text Available Background: Benign Prostatic Hyperplasia (BPH is one of the most common disease in ageing men and can be associated with Lower Urinary Tract Symptoms (LUTS that affect quality of life by interfering with normal daily activities. The American Urological Association Symptoms Index (AUA-SI is recommended as symptom scoring instrument to be used in initial assessment of each patient presenting with symptoms of prostatism. Objective: To assess the severity of symptoms in Benign Prostatic Hyperplasia subjects by using AUA symptom score in rural population of Lucknow, U.P. Materials and Methods: It is a rural community based cross-sectional study (2008-2009 conducted in the field practice area of Rural Health Training Centre (RHTC of Community Medicine department, CSM Medical University UP, Lucknow. The study covered three villages by doing house to house survey. All males of 45 years and above were contacted and information regarding bio-social characteristics taken by using pre-tested questionnaire. Information regarding LUTS was gathered using AUA symptom score questionnaire. Data was analyzed using chi square test. Results:The prevalence of BPH amongst males aged 45 years and above in the rural area studied was 11.8%. The prevalence of BPH was maximum (62.5% in the age group of 75 years and above. About 60% BPH patient aged > 75 years was found to have AUA symptom score of moderate grade (8to19, whereas only 25% BPH aged 45-54 years were having same grade of AUA symptom score. In the present study, out of 66 patients only 23 (34.8% had moderate AUA symptom score and 43 had mild (1-7 AUA symptom score. No one had severe symptom score. Conclusions: Only 34.8% BPH cases were found to have moderate symptoms and awareness of prostate swelling seems to be much poor even after consultation. For proper management of subjects with moderate to severe symptoms, public health awareness campaigns and annual surgical camp must bearrange in rural area.

  13. Comparison the Efficacy of Four Different Alpha Blockers in the Treatment of Benign Prostatic Hyperplasia

    Directory of Open Access Journals (Sweden)

    Fatih Fırat

    2011-05-01

    Full Text Available Aim: Benign prostatic hyperplasia (BPH also known as nodular hyperplasia, benign enlargement of the prostate refers to the increase in size of the prostate in middle aged and elderly men. Although four different types of specific alpha blocker have been used in the treatment of BPH it remains controversial that which alpha adrenergic blocker is effective than others. The aim of this study is to compare the efficacy of 4 different alpha blockers agents on the treatment of BPH. Material and Methods: Between June 2005 and December 2008 a total of 135 consecutive patients with diagnosed of BPH were evaluated in our clinic. Patients were randomized into four groups according to alpha blocker types as fallows: group I, doxazosin 4 mg; group II, tamsulosin 0.4 mg; group III, terazosin 5 mg; and group IV, alfuzosin 10 mg. All patients were followed up with International Prostatic Symptom Score (IPSS, maximal urinary flow rates (Qmax and adverse effects were determined at baseline and again at least 3 months as efficacy parameters. Results: The mean age of the patients were 59.8±5.4 years, 58.9±6.4 years, 58.7±5.1 years, and 59.2±5.5 years in group I, group II, group III, and group IV, respectively (p>0.05. After 3 months treatment with alpha blockers the improvements in IPSS were found as 2.73, 3.73, 3.55 and 4.44 in group I, group II, group III, and group IV, respectively. Maximum urine flow rates increased as 2.81 ml/sec, 3.24 ml/sec, 3.88 ml/sec and 4.49 ml/sec in group I, group II, group III, and group IV, respectively. However, among 4 alpha blockers statistically significant difference was found only between doxazosin and alfuzosin groups according to uroflowmetry and IPSS results. According to these results, when compared adverse effect, the significant difference was observed only in tamsulosine group. Conclusions: As a result we can say that except retrograde ejaculation in tamsulosine group, adverse effects are not different between the

  14. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia

    Science.gov (United States)

    Hong, Heeok; Kim, Chun-Soo

    2009-01-01

    This study was to investigate the role of complementary and alternative medicine in the prevention and treatment of benign prostatic hyperplasia. For this purpose, a randomized, double-blind, placebo-controlled trial was performed over 12 months on 47 benign prostatic hyperplasia patients with average age of 53.3 years and international prostate symptom score over 8. Subjects received either sweet potato starch (group A, placebo, 320 mg/day), pumpkin seed oil (group B, 320 mg/day), saw palmetto oil (group C, 320 mg/day) or pumpkin seed oil plus saw palmetto oil (group D, each 320 mg/day). International prostate symptom score, quality of life, serum prostate specific antigen, prostate volume and maximal urinary flow rate were measured. In groups B, C and D, the international prostate symptom score were reduced by 3 months. Quality of life score was improved after 6 months in group D, while those of groups B and C were improved after 3 months, compared to the baseline value. Serum prostate specific antigen was reduced only in group D after 3 months, but no difference was observed in prostate volume in all treatment groups. Maximal urinary flow rate were gradually improved in groups B and C, with statistical significance after 6 months in group B and after 12 months in group C. None of the parameters were significantly improved by combined treatment with pumpkin seed oil and saw palmetto oil. From these results, it is suggested that administrations of pumpkin seed oil and saw palmetto oil are clinically safe and may be effective as complementary and alternative medicine treatments for benign prostatic hyperplasia. PMID:20098586

  15. Effects of pumpkin seed oil and saw palmetto oil in Korean men with symptomatic benign prostatic hyperplasia.

    Science.gov (United States)

    Hong, Heeok; Kim, Chun-Soo; Maeng, Sungho

    2009-01-01

    This study was to investigate the role of complementary and alternative medicine in the prevention and treatment of benign prostatic hyperplasia. For this purpose, a randomized, double-blind, placebo-controlled trial was performed over 12 months on 47 benign prostatic hyperplasia patients with average age of 53.3 years and international prostate symptom score over 8. Subjects received either sweet potato starch (group A, placebo, 320 mg/day), pumpkin seed oil (group B, 320 mg/day), saw palmetto oil (group C, 320 mg/day) or pumpkin seed oil plus saw palmetto oil (group D, each 320 mg/day). International prostate symptom score, quality of life, serum prostate specific antigen, prostate volume and maximal urinary flow rate were measured. In groups B, C and D, the international prostate symptom score were reduced by 3 months. Quality of life score was improved after 6 months in group D, while those of groups B and C were improved after 3 months, compared to the baseline value. Serum prostate specific antigen was reduced only in group D after 3 months, but no difference was observed in prostate volume in all treatment groups. Maximal urinary flow rate were gradually improved in groups B and C, with statistical significance after 6 months in group B and after 12 months in group C. None of the parameters were significantly improved by combined treatment with pumpkin seed oil and saw palmetto oil. From these results, it is suggested that administrations of pumpkin seed oil and saw palmetto oil are clinically safe and may be effective as complementary and alternative medicine treatments for benign prostatic hyperplasia. PMID:20098586

  16. Thulium laser enucleation of the prostate is a safe and a highly effective modality for the treatment of benign prostatic hyperplasia - Our experience of 236 patients

    OpenAIRE

    Ketan P Vartak; Prashant H Salvi

    2016-01-01

    Context: Thulium LASER is fast emerging as a safe and effective modality for benign prostatic hyperplasia (BPH). Still, compared to holmium laser transurethral enucleation of the prostate (HoLEP) the number of institutes all over the world using Thulium LASER are limited. This is our effort to bring the statistical facts about the safety and effectivity of Thulium LASER. Aims: To study the efficacy of thulium laser enucleation of the prostate (ThuLEP). Settings and Design: All patients ...

  17. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial

    Directory of Open Access Journals (Sweden)

    Satabdi Pande

    2014-01-01

    Full Text Available Objectives: Benign prostatic hyperplasia (BPH is the most common cause of lower urinary tract symptoms in elderly men. Selective alfa 1 -adrenergic antagonists are now first-line drugs in the medical management of BPH. We conducted a single-blind, parallel group, randomized, controlled trial to compare the effectiveness and safety of the new alfa 1 -blocker silodosin versus the established drug tamsulosin in symptomatic BPH. Materials and Methods: Ambulatory male BPH patients, aged above 50 years, were recruited on the basis of International Prostate Symptom Score (IPSS. Subjects were randomized in 1:1 ratio to receive either tamsulosin 0.4 mg controlled release or silodosin 8 mg once daily after dinner for 12-week. Primary outcome measure was reduction in IPSS. Proportion of subjects who achieved IPSS <8, change in prostate size as assessed by ultrasonography and changes in peak urine flow rate and allied uroflowmetry parameters, were secondary effectiveness variables. Treatment emergent adverse events were recorded. Results: Data of 53 subjects - 26 on silodosin and 27 on tamsulosin were analyzed. Final IPSS at 12-week was significantly less than baseline for both groups. However, groups remained comparable in terms of IPSS at all visits. There was a significant impact on sexual function (assessed by IPSS sexual function score in silodosin arm compared with tamsulosin. Prostate size and uroflowmetry parameters did not change. Both treatments were well-tolerated. Retrograde ejaculation was encountered only with silodosin and postural hypotension only with tamsulosin. Conclusions: Silodosin is comparable to tamsulosin in the treatment of BPH in Indian men. However, retrograde ejaculation may be troublesome for sexually active patients.

  18. The natural history of benign prostatic hyperplasia: what have we learned in the last decade?

    Science.gov (United States)

    Kirby, R S

    2000-11-01

    Benign prostatic hyperplasia (BPH) frequently has a significant detrimental impact on a patient's quality of life. If the disease is left untreated, it may progress in severity, leading to recurrent bladder infections, bladder calculi, and acute urinary retention (AUR), necessitating surgical treatment. The Forth Valley, Scotland, study reported that 14% of men aged 40 to 50 years have BPH. This increases to 43% of men >60 years old. BPH has been shown to be nearly as prevalent as hypertension and diabetes among patients seeking treatment for erectile dysfunction. The effects of BPH on quality of life include lack of sleep, anxiety, reduced mobility, interference with leisure activities and usual daily activities, and a compromised sense of well-being. Three symptoms are associated with an increased risk of AUR in men with BPH: a reduction in the force of the urinary stream, a sensation of incomplete bladder emptying, and an enlarged prostate gland on digital rectal examination. Age is a strong independent risk factor for the development of AUR. Transurethral resection of the prostate was more effective than watchful waiting in preventing AUR, as shown in the Veteran's Affairs Cooperative Study. Data from the Olmsted County study revealed that urinary flow decreases and prostate size increases with advanced age. This study also showed that lower urinary tract symptoms have a negative impact on parameters of physical and mental aspects of health. More recently, studies have shown that medical treatment with 5alpha-reductase inhibitors and possibly also alpha-blockers may alter the natural history and progression of BPH. PMID:11074195

  19. Transurethral enucleation of large benign prostatic hyperplasia in sodium chloride solution

    Directory of Open Access Journals (Sweden)

    I. N. Shvarev

    2016-01-01

    Full Text Available Background. Transurethral resection is a generally recognized treatment for small to medium-sized benign prostatic hyperplasia (BPH. Numerous original tools are proposed for surgery of large BPH. These include laser (holmium laser enucleation of the prostate and transurethral (transurethral enucleation with bipolar (TUEB enucleation in 0.9 % NaCl solution, which are accompanied by removal of the maximum adenoma tissue volume, short-term recovery, and a substantially fewer early and late complications.Objective: to evaluate the safety and efficiency of TUEB in patients with large BPH.Subjects and methods. TUEB was carried out in 58 patients with large BPH. Their mean age was 64 years. The gland size was ≥ 102 сm3. The residual urine volume in all the patients was more than 100 ml. One year later, the results of treatment were analyzed using the International Prostate Symptom Score (IPSS, Quality of Life (QoL Questionnaire, as well as from residual urine volume and remaining prostate tissue.Results. The mean time of surgery and enucleation was 90 and 55 min, respectively. The mean volume of removed adenoma tissue was 99 ml. By the end of month 2 following TUEB, there was a progressive reduction in the total IPSS and QoL scores from 35 to 7 and from 5 to 1, respectively, which preserved this trend by the end of a 1-year follow-up. study. The residual urine amount was less than 30 ml. The mean volume of the prostate tissue left was 8.5 сm3 and less than 11.0 сm3. The ultrasound anatomy of the prostatic urethra (transformation of thin-walled spherical TUR defect that is characteristic slit-like one resembles the inverted letter Y eventually formed by the end of the 1-year follow-up. Stricture of the urethra and contracture of the bladder neck were noted in none of the cases. Conclusion. TUEB is an alternative to open surgery in patients with the enlarged prostate. The use of isotonic NaCl solution as washing fluid allows one to plan

  20. Efficacy and safety of the doxazosin gastrointestinal therapeutic system for the treatment of benign prostate hyperplasia.

    Science.gov (United States)

    Sun, Guang-Huan; Tsui, Ke-Hung; Wu, Tony T; Chang, Chao-Hsiang; Cheng, Chen-Li; Schou, Manjula

    2010-10-01

    This study was carried out to obtain information on the efficacy and safety of the controlled release formulation of the doxazosin Gastrointestinal Therapeutic System (GITS) in Taiwanese subjects with benign prostatic hyperplasia (BPH). Studies of doxazosin in Asian populations for this indication have lacked data particularly from Taiwan. This was an 8-week, post-marketing, open-label, non-comparative study. Eighty male subjects (mean age=64 years) with BPH received doxazosin GITS 4 mg once daily. At week 4, subjects who achieved an increase in maximum urinary flow rate (Qmax) of ≥3mL/s and a ≥30% reduction in the total International Prostate Symptom Score (IPSS) continued on doxazosin GITS 4 mg for the remaining 4 weeks; all other subjects were up-titrated to 8 mg once daily. Change from baseline at weeks 4 and 8 (primary endpoint) in IPSS and Qmax was evaluated using two-sided paired t tests for the intent-to-treat population. Safety was assessed throughout the study. A total of 53 (66.3%) subjects completed the study. Baseline Qmax and IPSS were 10.7+3.4 mL/s and 20.6+5.4, respectively. At week 8, a significant increase from baseline in Qmax of 3.3+4.6 mL/s (95% confidence interval = 2.2-4.4, pinformation for clinicians on the use of doxazosin GITS for the treatment of BPH, particularly in Taiwanese patients. PMID:20950778

  1. Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia

    Science.gov (United States)

    Minutoli, Letteria; Rinaldi, Mariagrazia; Marini, Herbert; Irrera, Natasha; Crea, Giovanni; Lorenzini, Cesare; Puzzolo, Domenico; Valenti, Andrea; Pisani, Antonina; Adamo, Elena B.; Altavilla, Domenica; Squadrito, Francesco; Micali, Antonio

    2016-01-01

    Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can result in bothersome lower urinary tract symptoms. The molecular mechanisms and networks underlying the development and the progression of the disease are still far from being fully understood. BPH results from smooth muscle cell and epithelial cell proliferation, primarily within the transition zone of the prostate. Apoptosis and inflammation play important roles in the control of cell growth and in the maintenance of tissue homeostasis. Disturbances in molecular mechanisms of apoptosis machinery have been linked to BPH. Increased levels of the glycoprotein Dickkopf-related protein 3 in BPH cause an inhibition of the apoptosis machinery through a reduction in B cell lymphoma (Bcl)-2 associated X protein (Bax) expression. Inhibitors of apoptosis proteins influence cell death by direct inhibition of caspases and modulation of the transcription factor nuclear factor-κB. Current pharmacotherapy targets either the static component of BPH, including finasteride and dutasteride, or the dynamic component of BPH, including α-adrenoceptor antagonists such as tamsulosin and alfuzosin. Both these classes of drugs significantly interfere with the apoptosis machinery. Furthermore, phytotherapic supplements and new drugs may also modulate several molecular steps of apoptosis. PMID:27529214

  2. LILRA3 Is Associated with Benign Prostatic Hyperplasia Risk in a Chinese Population

    Directory of Open Access Journals (Sweden)

    Jielin Sun

    2013-04-01

    Full Text Available A recent prostate cancer (PCa genome-wide association study (GWAS identified rs103294, a single nucleotide polymorphism (SNP located on LILRA3, a key component in the regulation of inflammatory inhibition, to be significantly associated with PCa risk in a Chinese population. Because inflammation may be a common etiological risk factor between PCa and benign prostatic hyperplasia (BPH, the current study was conducted to investigate the association of rs103294 with BPH risk. rs103294 was genotyped in a Chinese population of 426 BPH cases and 1,008 controls from Xinhua Hospital in Shanghai, China. Association between rs103294, BPH risk and clinicopathological traits were tested with adjustment for age. rs103294 was significantly associated with BPH risk with a p-value of 0.0067. Individuals with risk allele “C” had increased risk for BPH (OR = 1.34, 95% CI: 1.09–1.66. Stratified analysis revealed a stronger association risk for younger patients who are below 72 years old (OR = 1.51, 95% CI: 1.06–2.16. Our study represents the first effort to demonstrate that LILRA3 gene is significantly associated with BPH risk in a Chinese population. Our results support a common role of inflammation in the development of PCa and BPH. Additional studies are needed to further evaluate our results.

  3. Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia

    Directory of Open Access Journals (Sweden)

    Letteria Minutoli

    2016-08-01

    Full Text Available Benign prostatic hyperplasia (BPH is a chronic condition common in older men that can result in bothersome lower urinary tract symptoms. The molecular mechanisms and networks underlying the development and the progression of the disease are still far from being fully understood. BPH results from smooth muscle cell and epithelial cell proliferation, primarily within the transition zone of the prostate. Apoptosis and inflammation play important roles in the control of cell growth and in the maintenance of tissue homeostasis. Disturbances in molecular mechanisms of apoptosis machinery have been linked to BPH. Increased levels of the glycoprotein Dickkopf-related protein 3 in BPH cause an inhibition of the apoptosis machinery through a reduction in B cell lymphoma (Bcl-2 associated X protein (Bax expression. Inhibitors of apoptosis proteins influence cell death by direct inhibition of caspases and modulation of the transcription factor nuclear factor-κB. Current pharmacotherapy targets either the static component of BPH, including finasteride and dutasteride, or the dynamic component of BPH, including α-adrenoceptor antagonists such as tamsulosin and alfuzosin. Both these classes of drugs significantly interfere with the apoptosis machinery. Furthermore, phytotherapic supplements and new drugs may also modulate several molecular steps of apoptosis.

  4. Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia.

    Science.gov (United States)

    Minutoli, Letteria; Rinaldi, Mariagrazia; Marini, Herbert; Irrera, Natasha; Crea, Giovanni; Lorenzini, Cesare; Puzzolo, Domenico; Valenti, Andrea; Pisani, Antonina; Adamo, Elena B; Altavilla, Domenica; Squadrito, Francesco; Micali, Antonio

    2016-01-01

    Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can result in bothersome lower urinary tract symptoms. The molecular mechanisms and networks underlying the development and the progression of the disease are still far from being fully understood. BPH results from smooth muscle cell and epithelial cell proliferation, primarily within the transition zone of the prostate. Apoptosis and inflammation play important roles in the control of cell growth and in the maintenance of tissue homeostasis. Disturbances in molecular mechanisms of apoptosis machinery have been linked to BPH. Increased levels of the glycoprotein Dickkopf-related protein 3 in BPH cause an inhibition of the apoptosis machinery through a reduction in B cell lymphoma (Bcl)-2 associated X protein (Bax) expression. Inhibitors of apoptosis proteins influence cell death by direct inhibition of caspases and modulation of the transcription factor nuclear factor-κB. Current pharmacotherapy targets either the static component of BPH, including finasteride and dutasteride, or the dynamic component of BPH, including α-adrenoceptor antagonists such as tamsulosin and alfuzosin. Both these classes of drugs significantly interfere with the apoptosis machinery. Furthermore, phytotherapic supplements and new drugs may also modulate several molecular steps of apoptosis. PMID:27529214

  5. Does bladder outlet obstruction affect distance between the ureteric orifices in patients with benign prostate hyperplasia?

    Directory of Open Access Journals (Sweden)

    Cüneyt Özden

    2009-01-01

    Full Text Available Objectives: Many morphological changes occur in the bladder due to bladder outlet obstruction (BOO in pa-tients with benign prostate hyperplasia (BPH. In the present study we evaluated the relationship between in-terureteric distance (IUD of the orifices and BOO in BPH patients.Materials and methods: Thirty-seven consecutive pa-tients with lower urinary tract symptoms at the urology polyclinic included in the study. Patients divided into 2 groups according to maximal flow rate (Qmax. The first group constituted of 18 patients with Qmax 15ml/s. The IUD measurement was performed with Doppler ultrasonography.Results: There was no significant difference between the groups regarding mean age and prostate volume. Mean IUD in the first group was 32.7±5.4 mm and mean IUD in the second group was 31.5±5.1 mm. There was no statistically significant difference between the groups regarding the IUD.Conclusions: Data obtained from the study revealed that measurement of IUD with Doppler ultrasonography not significantly related to BOO.

  6. Gokshuradi Vati and Dhanyaka-Gokshura Ghrita Matra Basti in the management of Benign Prostatic Hyperplasia

    Science.gov (United States)

    Bhalodia, Shreyas G.; Bhuyan, Chaturbhuj; Gupta, Sanjay Kumar; Dudhamal, Tukaram S.

    2012-01-01

    Benign Prostatic Hyperplasia (BPH) is a burning senile problem of elderly men and no definitive conservative cure is available. The present available surgical and minimal invasive methods have their own limitations. Hence, to find out a suitable Ayurvedic approach, an effort has been made towards the management of BPH, In this study, 32 selected patients of Mootraghata at par to BPH were divided into three groups randomly and treated accordingly. In group A, Gokshuradi compound (GC) Vati (GV) 500 mg was given three times a day with luke-warm water after food; while in group B, Dhanyaka-Gokshura Ghrita (DGG) as Matra Basti (MB) of 60 ml, once in a day, just after lunch and combined therapy of both formulations in group C was administered. Out of 32 patients, total 30 patients (10 in each group) were completed the treatment course of 21 days. In results, 54.09% improvement was seen in group C, 45.67% in group A and 47.99% in group B. The size of prostate gland was found reduced highly significant in group C. Hence, it is concluded that combined therapy of GV and DGG MB is beneficial without developing any adverse drug reactions and can be prescribed safely for Mootraghata (BPH). PMID:23723674

  7. Transurethral dividing vaporesection for the treatment of large volume benign prostatic hyperplasia using 2 micron continuous wave laser

    Institute of Scientific and Technical Information of China (English)

    SUN Dong-chong; YANG Yong; WEI Zhi-tao; HONG Bao-fa; ZHANG Xu

    2010-01-01

    Background The safety and efficiency of transurethral laser resection of the prostate to treat benign prostatic hyperplasia have been verified. However, this method does still not manage large volume prostates efficiently. To tackle this problem, we have designed a method of "transurethral dividing vaporesection of prostate" using a 2 micron continuous wave laser. The aim of this study was to evaluate the safety and efficiency of this method in the management of large prostates (>80 ml).Methods In this study, 45 cases of benign prostatic hyperplasia with a median prostatic volume of (123.7±26.7) ml (range, 80.2-159.8 ml) were treated by the same surgeon under epidural anesthesia. During the surgery, superapubic catheters were needed, and saline solution was used for irrigation. First, the prostate was divided longitudinally into several parts from the bladder neck to the prostatic apex, and then gradually incised transversely chip by chip. Intraoperative blood transfusion rate, postoperative complications, maximum urinary flow rate, International Prostate Symptom Score and quality of life scores were recorded for statistical analysis using SPSS 16.0 software.Results Intraoperatively, no transurethral resection syndrome was observed, and no blood transfusions were needed.The resected prostatic chips were easily flushed out of the bladder through the resectoscope sheath without the use of a morcellator. Median vaporesection time was (95.0±13.2) minutes (range, 75-120 minutes), and the median retrieved and removed prostatic tissue were (25.2±5.1) g (range, 15.5-34.7 g) and (75.4±16.4) g (range, 43.8-106.1 g), respectively. Median catheter time and hospital stay were (3.3±0.9) days (range, 3-5 days) and (4.8±1.8) days (range, 3-9 days), respectively. After a follow-up of 6 to 12 months, two patients had stress urinary incontinence and three had anterior urethral strictures. Satisfactory improvement was seen in maximum urinary flow rate, International Prostate

  8. Possible factors influencing high serum Prostate-specific Antigen (PSA in Indonesian patients with Benign Prostatic Hyperplasia (BPH

    Directory of Open Access Journals (Sweden)

    Djoko Rahardjo

    2001-03-01

    Full Text Available Benign prostatic hyperplasia (BPH cases in Indonesia frequently associated with high serum prostate specific antigen (PSA. To explore possible factors that could increase serum PSA level, we performed a retrospective, cross-sectional study on 805 consecutive patients in Sumber Waras and Dr. Cipto Mangunkusumo Hospitals from 1994 to 1997. Clinical manifestations were evaluated and prostate biopsies were performed if indicated. Complete histopathological data were only available in 82 BPH patients with no urinary retention from 1998-1999 and a thin section of paraffin blocks of BPH patients which still could be found from 1994-1999 was analyzed using flow cytometer to obtain the S-phase fraction as a parameter of proliferative activity, From 805 patients, 461 (57% presented with urinary retention and need to be catheteized. Catheteization significantly increased PSA level if compared to noncatheterized patients (16.3 vs. 6,8 ng/mL, p= 0,000. Another data of 82 uncatheteized patients from 1998-1999 has revealed that 79 patients (96.3% had chronic prostatitis and 19 (23.2% showed the presence of prostatic-intraepithelial neoplasia (PIN with an increase of PSA level (5.4 ng/mL. The S-phase fraction of BPH without PIN cases was significantly higher in cases with PSA > 4 ng/ml than patients with PSA ≤ 4 ng/ml (I3.1% vs. 8.9%, p=0,008. As conclusion, the high serum PSA level was mostly due to urethral catheteization and increased prostate volume. There was a tendency of increasing PSA in subclinical inflammation and PIN. Cases with high PSA also showed high proliferative activities which is suggestive of mitogenic activity. (Med J Indones 2001; 10:22-8Keywords: BPH, high PSA, PIN, proliferative activity, s-phase fraction

  9. A 63 element 1.75 dimensional ultrasound phased array for the treatment of benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Smith Nadine

    2005-06-01

    Full Text Available Abstract Background Prostate cancer and benign prostatic hyperplasia are very common diseases in older American men, thus having a reliable treatment modality for both diseases is of great importance. The currently used treating options, mainly surgical ones, have numerous complications, which include the many side effects that accompany such procedures, besides the invasive nature of such techniques. Focused ultrasound is a relatively new treating modality that is showing promising results in treating prostate cancer and benign prostatic hyperplasia. Thus this technique is gaining more attention in the past decade as a non-invasive method to treat both diseases. Methods In this paper, the design, construction and evaluation of a 1.75 dimensional ultrasound phased array to be used for treating prostate cancer and benign prostatic hyperplasia is presented. With this array, the position of the focus can be controlled by changing the electrical power and phase to the individual elements for electronically focusing and steering in a three dimensional volume. The array was designed with a maximum steering angle of ± 13.5° in the transverse direction and a maximum depth of penetration of 11 cm, which allows the treatment of large prostates. The transducer piezoelectric ceramic, matching layers and cable impedance have been designed for maximum power transfer to tissue. Results To verify the capability of the transducer for focusing and steering, exposimetry was performed and the results correlated well with the calculated field. Ex vivo experiments using bovine tissue were performed with various lesion sizes and indicated the capability of the transducer to ablate tissue using short sonications. Conclusion A 1.75 dimensional array, that overcame the drawbacks associated with one-dimensional arrays, has been designed, built and successfully tested. Design issues, such as cable and ceramic capacitances, were taken into account when designing this

  10. The fish-hook configuration of the distal ureter indicates bladder outlet obstruction due to benign prostatic hyperplasia

    OpenAIRE

    Mamoulakis, Charalampos; Herrmann, Thomas R.W.; Höfner, Klaus; Oelke, Matthias

    2010-01-01

    Purpose The aim of this retrospective study was to evaluate in a historical series of patients whether morphological changes of the urinary tract imaged on intravenous urography (IVU) are associated with clinical or urodynamic data. Methods During a 1-year period, every man 45 years or older with lower urinary tract symptoms suggestive of benign prostatic hyperplasia was systematically evaluated with multi-channel computer-urodynamic investigation and IVU. Men with urinary retention, known bl...

  11. Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo-controlled randomized study

    DEFF Research Database (Denmark)

    Tørring, Niels; Jensen, Klaus Møller-Ernst; Lund, L;

    2002-01-01

    To analyse the expression of the epidermal growth factor (EGF) system in prostate tissue and secretions obtained from patients with benign prostatic hyperplasia (BPH) treated with or without finasteride (which primarily targets the androgen-sensitive secretory epithelial cells in the prostate...

  12. Immunohistochemical Study Of Bcl-2 Protein And Estrogen Receptor-Alpha Expression In Benign Prostatic Hyperplasia And Prostatic Carcinoma

    Directory of Open Access Journals (Sweden)

    Ahmed H. Abel-Rahman- Ghada A. Abdel-Aziz*- Ali Emad S** Abdel

    2004-12-01

    Full Text Available The human prostate, a male sexual accessory tissue involved in seminal fluid production, has a remarkably high incidence of hyperplastic and neoplastic disease. The present study was carried out on one hundred and twenty (120 specimens divided into two groups; group 1: Included forty cases of benign prostatic hyperplasia (BPH and group 2: Included sixty cases of prostatic adenocarcinoma (PC (22 were low grade; GS: 2-6 and 38 were high grade; GS: 7-10,in addition to twenty cases of histologically normal prostates taken as controls. Immunohistochemical technique was applied to detect Bcl-2 as well as ER positivity in all specimens. Group 1 showed the following profile: ER (+ in all cases (100%, Bcl-2 (- in 95%, ER (+ / Bcl-2 (+ in 95%, ER (- / Bcl-2 (+ in 0%, ER (+ / Bcl-2 (- in 5% and ER (- / Bcl-2 (- in 0% of cases while group 2 showed the following profile: ER (+ in 30%, Bcl-2 (+ in 21.7%, ER (+ / Bcl-2 (+ in 15%, ER (- / Bcl-2 (+ in 6.7%, ER (+ / Bcl-2 (- in 15% and ER (- / Bcl-2 (- in 70% of cases. The mean epithelial ER -immunolabeling was, however, significantly increased in group 2 than in group 1 (P < 0.05 which, in turn, being higher than the normal cases (P<0.05 . Among group 2 , the mean ER was significantly more in high grade than in low grade tumors (P < 0.05, however, the mean ER immunolabeling revealed no significant correlation with T-stage (P = 0.219 or with the clinical stage (P = 0.391. In contrast, the Bcl-2 immunostaining was statistically higher in group 1 than in group 2 (P < 0.05 and showed a significant correlation with T stage (P < 0.05 although the study displayed no significant correlation between Bcl-2 immunopositivity and either Gleason score (P = 0.125 or the histologic grade (P = 0.146. In addition, combined ER (+/ Bcl 2 (+ immunoreactivity demonstrated the aggressive subgroup of PC cases more accurately than either ER (+ or Bcl-2 (+ alone. Finally, multivariate analysis showed that the Bcl-2, proved to be an

  13. Current status of 5α-reductase inhibitors in the treatment of benign hyperplasia of prostate

    Directory of Open Access Journals (Sweden)

    Kumar Vijay

    2008-04-01

    Full Text Available Benign prostatic hyperplasia (BPH is a common problem in aging men, which is associated with lower urinary tract symptoms. This condition is dependent on the presence of androgens for its progression, and medical therapy is the first-line treatment for BPH patients with moderate-to-severe symptoms and includes the use of either alpha 1-adrenergic blockers or 5α-reductase inhibitors. Adrenergic blocking drugs reduce the dynamic component while the 5α-reductase inhibitors reduce the static component of bladder outlet obstruction in BPH. By inhibiting the generation of active form of testosterone, viz., dihydrotestosterone, the 5α-reductase inhibitors not only reduce the symptoms of BPH but also decrease the need for surgery and further progression of BPH. Besides, prolonged use of combination of 5α-reductase inhibitors and alpha 1-adrenergic blockers has been found to be more beneficial than either of the two drugs given alone. This review gives a brief account of rationale and efficacy of treatment by 5α-reductase inhibitors in the management of BPH.

  14. Benign Prostatic Hyperplasia – An economic assessment of fixed combination therapy based on a literature review

    Directory of Open Access Journals (Sweden)

    Roberto Messina

    2015-09-01

    Full Text Available FederAnziani Senior Italia and SIU – Italian Society of Urology – have decided to work together to draft a document focussing on Benign Prostatic Hyperplasia (BPH, and to stress the importance of adherence with pharmacological treatment in this setting, from both a scientific and a patient standpoint. Starting from a literature search, the two associations analysed to what extent an increase in treatment adherence amongst these patients influences hospital savings and to what extent therapy persistence levels are affected by monotherapy rather than free drug combinations. These estimates were performed only on patients taking medicinal products belonging to the 5 α-reductase inhibitors (5ARI class that, although not indispensable, are the compounds that bring the greatest benefits, especially in the elderly and for which we know that every additional 30 days of therapy reduced the likelihood of acute urinary retention (AUR and surgery by 14% and 11% respectively *. The results show that the use of fixed combination therapy would involve an increase in persistence due to the lower rate of patients abandoning treatment over time. Each 30 day-increment of 5ARI therapy, i.e. for an expenditure of 10.6 million euros extra per year for 5ARI medication, savings of approximately 24.3 million euros in hospital costs could be achieved.

  15. Benign Prostatic Hyperplasia - An economic assessment of fixed combination therapy based on a literature review.

    Science.gov (United States)

    Messina, Roberto; Mirone, Vincenzo

    2015-09-01

    FederAnziani Senior Italia and SIU - Italian Society of Urology - have decided to work together to draft a document focussing on Benign Prostatic Hyperplasia (BPH), and to stress the importance of adherence with pharmacological treatment in this setting, from both a scientific and a patient standpoint. Starting from a literature search, the two associations analysed to what extent an increase in treatment adherence amongst these patients influences hospital savings and to what extent therapy persistence levels are affected by monotherapy rather than free drug combinations. These estimates were performed only on patients taking medicinal products belonging to the 5 α-reductase inhibitors (5ARI) class that, although not indispensable, are the compounds that bring the greatest benefits, especially in the elderly and for which we know that every additional 30 days of therapy reduced the likelihood of acute urinary retention (AUR) and surgery by 14% and 11% respectively *. The results show that the use of fixed combination therapy would involve an increase in persistence due to the lower rate of patients abandoning treatment over time. Each 30 day-increment of 5ARI therapy, i.e. for an expenditure of 10.6 million euros extra per year for 5ARI medication, savings of approximately 24.3 million euros in hospital costs could be achieved. PMID:26428637

  16. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta analysis

    Institute of Scientific and Technical Information of China (English)

    REN Rui-min; KOU Min; LAN Xiao-xu

    2010-01-01

    Background Pharmacological therapy has been considered as the first-line treatment for patients with uncomplicated benign prostatic hyperplasia (BPH). The aim of this study was to evaluate the efficacy and safety of tamsulosin compared with a placebo for treating BPH. Methods The randomized placebo-controlled trials (RCT) of tamsulosin for the treatment of BPH from all over the world were searched. PubMed, Ovid, ScienceDirect, EBSCO, CBM, and CNKI were searched, as well as a manual search of four Chinese journals: Chinese Journal of Andrology, National Journal of Andrology, Chinese Journal of Urology, and Journal of Clinical Urology was also performed. Two reviewers independently screened the studies for eligibility, evaluated the quality and extracted the data from the eligible studies, with confirmation by cross-checking. Divergences of opinions were settled by discussion. Meta-analysis was processed by Rev Man 5.0 software, fail-safe number was performed by SAS8.0 software. Results Seven RCTs involving 2455 men met the inclusion criteria. The basic characteristics of patients were comparable in all the studies. Comparing three common criteria: international prostate symptom score (IPSS)/Boyarsky symptom score, maximum flow rate (MFR), quality of life (QOL), tamsulosin was better than placebo at improving IPSS and MFR, with no significant difference in the QOL. Adverse events of tamsulosin also showed no significant difference from the placebo group (Z=1.62, P=0.10, OR=1.22, 95% CI 0.96-1.54).Conclusions Tamsulosin is better than placebo at improving IPSS and MFR. Adverse events of tamsuloisn show no significant difference compared with placebo. More high quality trials with larger samples and longer follow-up are proposed.

  17. Regulation of Prostate Development and Benign Prostatic Hyperplasia by Autocrine Cholinergic Signaling via Maintaining the Epithelial Progenitor Cells in Proliferating Status

    Directory of Open Access Journals (Sweden)

    Naitao Wang

    2016-05-01

    Full Text Available Regulation of prostate epithelial progenitor cells is important in prostate development and prostate diseases. Our previous study demonstrated a function of autocrine cholinergic signaling (ACS in promoting prostate cancer growth and castration resistance. However, whether or not such ACS also plays a role in prostate development is unknown. Here, we report that ACS promoted the proliferation and inhibited the differentiation of prostate epithelial progenitor cells in organotypic cultures. These results were confirmed by ex vivo lineage tracing assays and in vivo renal capsule recombination assays. Moreover, we found that M3 cholinergic receptor (CHRM3 was upregulated in a large subset of benign prostatic hyperplasia (BPH tissues compared with normal tissues. Activation of CHRM3 also promoted the proliferation of BPH cells. Together, our findings identify a role of ACS in maintaining prostate epithelial progenitor cells in the proliferating state, and blockade of ACS may have clinical implications for the management of BPH.

  18. Withania coagulans Extract Induces Cell Apoptosis and Inhibits COX-2 Expression in a Rat Model of Benign Prostatic Hyperplasia

    Directory of Open Access Journals (Sweden)

    Sarbishegi

    2016-08-01

    Full Text Available Background Phytotherapy is a popular treatment option in cases of benign prostatic hyperplasia (BPH, with many different herbal products being used for the treatment of this condition. Withania coagulans (WC is an herbal medicine that has shown anti-tumoral, anti-inflammatory, and antioxidant effects. Objectives This study examined the effect of Withania coagulans extract (WCE on prostatic cell apoptosis and cyclooxygenase-2 (COX-2 expression in cases of benign prostatic hyperplasia (BPH in rats. Methods Forty Wistar rats were equally divided into five groups: control, sham, BPH, BPH + WCE, and BPH + CLX (celecoxib as a positive control group. The induction of BPH was achieved via the subcutaneous injection of 3 mg/kg of testosterone propionate (TP daily for 28 days. The animals received WCE, celecoxib, or distilled water by oral gavage accompanied by the TP injection. After four weeks, the prostate glands of the rats were weighed to measure the prostatic index (PI. The ventral lobes of the prostates were dissected and processed with paraffin blocks in order to study the number of mast cells. A TUNEL analysis was performed to evaluate the cell apoptosis, while the expression of COX-2 was examined using immunohistochemistry. Results BPH was obvious in the ventral lobe of the prostate, and the administration of WCE markedly decreased the PI and the number of mast cells (P < 0.001 in the BPH rats. Additionally, the WCE treatment induced prostatic cell apoptosis when compared to the BPH group. Furthermore, following the WCE treatment, the expression of COX-2 in the prostatic tissues was significantly decreased when compared to the BPH groups. Conclusions According to the results of this study, WCE was effective in the treatment of BPH in rats. It may therefore have beneficial effects in the treatment of patients with BPH.

  19. DIFFERENTIATION BETWEEN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER IN THE TRANSITIONAL ZONE EVALUATED BY 1H MAGNETIC RESONANCE SPECTROSCOPIC IMAGING

    Institute of Scientific and Technical Information of China (English)

    Sa-ying Li; Min Chen; Rui Wang; Cheng Zhou

    2007-01-01

    To quantitatively evaluate the metabolic changes of benign prostatic hyperplasia (BPH) and prostate cancer in the transitional zone using magnetic resonance spectroscopic imaging ( MRSI), and to analyze the characteristics and differences of the spectra in this zonal area.Methods Eighteen patients with prostate cancer in the transitional zone underwent magnetic resonance imaging( MRI)/MRSI examinations. The ( Choline + Creatine)/Citrate (CC/Ci) ratio and the Choline/Creatine (Cho/Cr) ratio were evaluated in each voxel with cancer or BPH confirmed by pathological results. Discriminant analysis was used to determine the power of the two ratios in differentiation between cancer and BPH.Results The CC/Ci ratio and Cho/Cr ratio for cancer voxels were significantly higher than those in the voxels with BPH in the transitional zone ( CC/Ci: 2.36 ± 1.31 vs. 0.85 ± 0.29, P < 0.01; Cho/Cr: 4.14 ± 1.79 vs. 1.26 ±0.45, P < 0.01 ). As for the discriminant function with the CC/Ci ratio and the Cho/Cr ratio, the specificity, sensitivity, and accuracy were 98.6%, 85.7%, 92.9% respectively for the differentiation between cancer and BPH.Conclusions The prostate cancer is characterized by higher CC/Ci ratio and Cho/Cr ratio compared to BPH in the transitional zone. Both CC/Ci ratio and Cho/Cr ratio have high specificity, sensitivity, and accuracy in their discriminative power between cancer and BPH in this zonal area.

  20. Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia.

    LENUS (Irish Health Repository)

    O'Sullivan, MartinJ

    2012-02-03

    BACKGROUND: This article investigated the effects of transurethral resection of prostate on quality of life (QOL) and urinary symptoms in patients with benign prostatic hyperplasia (BPH). STUDY DESIGN: In a prospective study, 30 patients without significant comorbidities undergoing transurethral resection of prostate for BPH were studied. Patients completed four validated questionnaires: the International Prostate Symptom Score and the associated QOL index because urinary symptoms, the Montgomery and Asberg Depression Rating Scale, the McGill Pain Questionnaire, and the QOL questionnaire Short Form-36. These were completed preoperatively, on the first postoperative day, on discharge from hospital, and at 1 and 3 months postoperatively. RESULTS: The QOL of patients who undergo transurethral resection of prostate for BPH had significantly improved at 3 months after their operation. The International Prostate Symptom Score scores at 1 month (9.3+\\/-4.6) and 3 months (5.4+\\/-5.6) were less than they were preoperatively (19.9+\\/-7.1). The QOL index because urinary symptoms was less at 1 month (2.4+\\/-1.9) and at 3 months postoperatively (1.5+\\/-1.4) in comparison with the preoperative scores (4.5+\\/-1.2). The Montgomery and Asberg Depression Rating Scale scores at 1 month (5.4+\\/-6.8) and 3 months (4.9+\\/-6.5) were less than they were preoperatively (9.2+\\/-8.3). The McGill Pain Questionnaire sensory and pain rating index scores were less at 3 months than they were preoperatively (p=0.02 and p<0.02 respectively). The McGill Pain Questionnaire affective score was less at 1 month than it was preoperatively (p<0.03). The McGill Pain Questionnaire evaluative scores were less than the preoperative score at all times postoperatively. The role physical (p=0.007), bodily pain (p=0.006), social function (p=0.007), and physical component summary (p=0.007) subsections of the Short Form-36 were greater at 3 months postoperatively when compared with the preoperative scores

  1. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

    Directory of Open Access Journals (Sweden)

    Argirović Aleksandar

    2013-01-01

    Full Text Available Background/Aim. It has been observed that a large number of patients with low urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH has been treated with a combination of tamsulosin (TAM + Serenoa repens (SR (TAM + SR. The aim of this study was to compare a combination TAM + SR with TAM and SR alone, to see if there was any difference in efficacy and tolerance of each in patients with LUTS/BPH. Methods. In this prospective study patients had to have prostate volume (PV 3, a maximal flow rate (Qmax of 5-15 mL/s, with post voiding residual volume (PVR < 150 mL and serum prostatic antigen (PSA < 4 ng/mL. TAM (0.4 mg was administered once a day, SR (320 mg daily or SR (320 mg + TAM (0.4 mg daily for a median period of 6 months. Results. A total of 297 patients were recruited, whereas 265 patients were fully available: 87 into the group TAM, 97 into the group SR and 81 into the group TAM + SR. There was no statistically significant difference between the treatment groups in the sense of demographic and other baseline parameters. No difference was found among the 3 treatment groups, neither in the major endpoint of the study in the sense of a change between baseline and final evaluation in total IPSS, obstructive and irritative subscores, improvement of QoLs, increase in Qmax, nor for the second endpoint including diminution of PV, PSA and PVR. During the treatment period 20 (23% of the patients managed with TAM and 17 (21% with TAM + SR had drug-treated with related adverse reactions. No adverse effect was detected in the group SR. Conclusion. Treatment of BPH by both SR and TAM seems to be efficacious alone. None of them had superiority over another and, additionally, a combined therapy (TAM + SR does not provide extra benefits. Furthermore, SR is a well-tolerated agent that can be used alternatively in the treatment of LUTS/BPH.

  2. AB133. Xanthogranulomatous prostatitis with benign prostatic hyperplasia: a case report and review of the literature

    Science.gov (United States)

    Wang, Anxi

    2016-01-01

    Objective To improve the level of diagnosis and treatment of xanthogranulomatous prostatitis. Methods The clinical data of a case of xanthogranulomatous prostatitis were analyzed retrospectively and discussed with relative literature review. Results A 56-year-old man presented with a 1 month history of difficult urination, which was exacerbated for 10 days. The patient was confirmed with xanthogranulomatous prostatitis with chronic suppurative inflammation and abscess by pathologic diagnosis after plasmakinetic resection of the prostate (PKRP). The patient achieved smooth voiding and was discharged after operation for one week. Urination was normal during two months follow up. Conclusions Xanthogranulomatous prostatitis is rare clinical disease, which should be excluded from prostate cancer and can be confirmed by pathobiology. According to the degree of lower urinary tract obstruction, it is treated by medicine or surgical operation. Examination of PSA regularly and long-term follow-up must be performed.

  3. Estrogen receptors in the human male prostatic urethra and prostate in prostatic cancer and benign prostatic hyperplasia

    DEFF Research Database (Denmark)

    Bødker, A; Bruun, J; Balslev, E;

    1999-01-01

    stroma in eight cases and in the glandular epithelium in one. In four cases ERs were seen in the prostatic stroma and in the glandular epithelium. In the prostatic urethra, ERs were found in 19 cases located in the urothelium, lamina propria and/or periurethral glands. In the PC group, ERs were...... demonstrated in the prostatic stroma and/or prostatic urethra in 6 out of 11 cases. In both BPH and PC patients, immunoreactivity was weak and confined to few cells, indicating low ER content in the prostate as well as in the prostatic urethra. Dextran-coated charcoal (DCC) analysis was used for detection...... in the stroma, but in BPH specimens they can also be found in the glandular epithelium. Biochemically, the use of the DCC analysis is of limited value, since ER content in the human prostate and prostatic urethra is at the limit of detection with this method....

  4. Apoptosis and hormonal milieu in ductal system of normal prostate and benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    Shu-Jie XIA; Chun-Xiao XU; Xiao-Da TANG; Wan-Zhong WANG; De-Li DU

    2001-01-01

    Aim: To study theapoptotic rate (AR) and the androgen and estrogen milieu in the proximal and distal ductal sys tems of prostate, in order to help exploring the effects of these factors on prostatic growth and the pathogenesis of be nign prostatic hypertrophy (BPH). Methods: The proximal and distal ends of the ductal system were incised from 20 normal prostate as well as the hypertrophic prostate tissue from 20 patients with BPH. The AR was determined by the DNA end-labeling method and dihydrotestosterone (DHT) and estrodiol (E2), by radioimmunoassay. Results:There was no significant difference in DHT and E2 density between the proximal and distal ends of the ductal systems in normal prostate. E2 appeared to be higher in BPH than in normal prostatic tissues, but the difference was statistically in significant. In normal prostatic tissue, the AR was significantly higher in the distal than in the proximal ends of the ductal system ( P < 0.05), while the AR of the proximal ends was significantly higher ( P < 0.01) than that in the BPH tissue. No significant correlation was noted between the DHT and E2 density and the AR both in the normal prostate and BPH tissues. Conclusion: The paper is the first time describing a difference in AR in different regions of the ductal system of normal prostate, while the hormonal milieu is similar, indicating a functional inhomogeneity of these regions. A low AR in the proximal duct, where BPH originates, and an even lower AR in the BPH tissue, sug gesting the participation of apoptosis in the BPH pathogenesis.

  5. ASSESSMENT OF INDIRECT HEMAGGLUTINATION AND ZYMOGRAPHY PROCEDURES IN EVALUATION OF GELATINASE A IN PATIENTS WITH BENIGN AND MALIGNANT PROSTATE HYPERPLASIA

    Directory of Open Access Journals (Sweden)

    Nastaran Aalizadeh

    2003-09-01

    Full Text Available There are increasing data on novel tumor markers such as gelatinase A, which play a key role in tissue invasion and metastasis. Since prostate cancer is one of the common malignancies, we designed a simple and applicable Indi¬rect Hemagglutination (IHA test for determination of total gelatinase A in se¬rum samples. In this study, we have analyzed the circulating form of gelatinase A (MMP-2 in patients suffering from either benign prostate hyperplasia (n= 54 or prostate cancer (n= 26 and normal individuals as control (n= 26. The gelatinolytic activity was determined by zymography followed by densitomet-ric analysis. PSA was quantified by using a standard ELISA technique. Corre¬lation of densitometric analysis of gelatinase A activity and IHA titer was sig¬nificant at 0.01 level (p< 0.01, r = 0.916. Correlation of PSA and IHA titer was significant at 0.01 level (p< 0.01, r = 0.746. Border line IHA titer in patients with prostate cancer was 512 ± 1 tube titer, in benign prostate hyper¬plasia patients was 128 ± 1 tube titer, and the titer in normal individuals was 8 ± 1 tube titer. These results demonstrate that IHA compared to zymography may be a better and simpler procedure in monitoring and screening patients with prostate cancer.

  6. Multiple factors related to detrusor overactivity in Chinese patients with benign prostate hyperplasia

    Institute of Scientific and Technical Information of China (English)

    LIU Ning; MAN Li-bo; HE Feng; HUANG Guang-lin; WANG Hai; LI Gui-zhong; WANG Jian-wei; L(U) Yan-wei

    2012-01-01

    Background Detrusor overactivity (DO) is a known cause of lower urinary tract symptoms and occurs in 50%-75% of benign prostate hyperplasia (BPH) patients.We sought to investigate the clinical and urodynamic factors that are associated with the presence of DO in Chinese BPH patients.Methods Two hundred and eighty-seven consecutive patients with clinical BPH were retrospectively evaluated in this study.Each patient underwent urodynamic evaluation and completed the International Prostate Symptom Score (IPSS)and Quality of Life (QoL) questionnaire.Patients with neurological symptoms or other diseases likely to affect detrusor functions were strictly excluded.The 184 BPH patients included in the study were divided into groups according to the presence of DO as shown in urodynamic tests.Univariate analysis of factors associated with the presence of DO were performed using Student's t-test and the Mann-Whitney test; multivariate analysis used stepwise Logistic regressions.The relationship between degree of bladder outlet obstruction (BOO) and DO was also investigated using a linear-by-linear association test.Results Of 184 BPH patients,DO was present in 76 (41.3%).On univariate analysis,patients with DO were older (P=0.000),and showed smaller maximal bladder capacity (MBC,P=0.000) and voided volume (P=0.000),higher maximal detrusor pressure (P=0.000) and projected isovolumetric pressure (PIP) (P=0.005),higher Abrams-Griffiths number (P=0.000) and degree of bladder outlet obstruction (P=0.000),higher IPSS (P=0.000) and irritative IPSS subscores (P=0.000).Stepwise Logistic regression analysis showed that PIP (OR=1.012,95% CI1.002-1.023,P=0.019),age (OR=1.030,95% CI 1.005-1.067,P=0.059),and MBC (OR=0.993,95% CI 0.990-0.996,P=0.000)were independent risk factors for DO in BPH patients.Linear-by-linear association tests indicated a positive linear association between DO and severity of BOO,with incidence of DO increasing with BOO grade (P=0.000).Conclusions In

  7. Prostatic Injection of Botulinum A Toxin: An Alternative Treatment for Benign Prostatic Hyperplasia

    Directory of Open Access Journals (Sweden)

    Aliasghar Yarmohamadi

    2009-01-01

    Full Text Available Introduction: We examined the clinical effectiveness of prostate injection of botulinum A toxin in the treatment of BPH. Methods: In this deh1ive study 55 men with BPH who had failed medical treatment and were poor risks for surgery were treated by injection of botulinum A toxin into different parts of the transition zone. Amounts of prostate-specific antigen(PSA prostate symptom scores quality-of-life index prostate volume postvoid residual urine volume and peak urinary flow rates were recorded and compared for all patients before injection and 3 and 6 months after the injection. Results: The mean patient age was 78±2.5 years. The mean symptom score and quality-of-life index significantly improved after 3 months. Maximal urinary flow rate (Qmax showed a significant increase after 3 and 6 months of treatment. Postvoid residual urine volume had a significant decrease after 3 and 6 months (P0.05. Prostate volume decreased from 65±8 ml to 59±6 ml within 1 month and to 49±5 ml within 3 months (P

  8. Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Andrew Thomson

    2005-06-01

    Full Text Available Andrew ThomsonCore Medical Publishing, Knutsford, UKIntroduction: Benign prostatic hyperplasia (BPH is a common condition affecting older men. Bothersome symptoms can progress to serious complications such as acute urinary retention (AUR requiring surgical intervention. Dutasteride, a dual 5-alfa-reductase (5AR inhibitor (5ARI, is a recently introduced therapy for the treatment of BPH. Aims: The objective of this article is to review the evidence for the treatment of BPH with dutasteride. Evidence review: Evidence from large clinical studies shows that men with an enlarged prostate achieve a measurable decrease in prostate volume by up to 26% after 4 years of treatment with dutasteride and urinary symptoms improve after 6 months of treatment. This is achieved by rapid suppression (through inhibition of 5AR of the principal androgen (dihydrotestosterone or DHT responsible for stimulating prostatic growth. Evidence suggests that dutasteride treatment results in a reduction in risk (rather than delay of the most serious complications including episodes of AUR and the need for BPH-related surgery. Early symptom relief has been achieved with the combination of an alfa blocker and dutasteride. There is good evidence that dutasteride is well tolerated; side effects limited to sexual dysfunction (reduced libido, impotence, and gynecomastia are more common compared with placebo but occur with a similar incidence to finasteride, another 5ARI. No pharmacoeconomic evidence from studies with dutasteride has so far been published.Clinical value: In conclusion, dutasteride is a valuable treatment option in men with moderate to severe BPH. Reductions in prostate volume lead to symptom relief and serious complications appear to be reduced.Key words: dutasteride, evidence-based review, benign prostatic hyperplasia (BPH, 5-alfa-reductase inhibitor

  9. Design and evaluation of a 63 element 1.75-dimensional ultrasound phased array for treating benign prostatic hyperplasia

    Science.gov (United States)

    Saleh, Khaldon Y.; Smith, Nadine B.

    2003-10-01

    Focused ultrasound surgery (FUS) is a clinical method for treating benign prostatic hyperplasia (BPH) in which tissue is noninvasively necrosed by elevating the temperature at the focal point above 60°C using short sonications. With 1.75-dimensional (1.75-D) arrays, the power and phase to the individual elements can be controlled electronically for focusing and steering. This research describes the design, construction and evaluation of a 1.75-D ultrasound phased array to be used in the treatment of benign prostatic hyperplasia. The array was designed with a steering angle of +/-13.5 deg in the transverse direction, and can move the focus in three parallel planes in the longitudinal direction with a relatively large focus size. A piezoelectric ceramic (PZT-8) was used as the material of the transducer and two matching layers were built for maximum acoustic power transmission to tissue. To verify the capability of the transducer for focusing and steering, exposimetry was performed and the results correlated well with the calculated fields. In vivo experiments were performed to verify the capability of the transducer to ablate tissue using short sonications. [Work supported by the Whitaker Foundation and the Department of Defense Congressionally Directed Medical Prostate Cancer Research Program.

  10. Effects of Kangquan Recipe(康泉方) on Sex Steroids and Cell Proliferation in Rats with Benign Prostatic Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    黄源鹏; 杜建; 洪振丰; 陈治卿; 吴锦发; 赵锦燕

    2009-01-01

    Objective:To investigate the effects of Kangquan Recipe(康泉方,KQR)on sex steroids and cell proliferation in an experimental benign prostatic hyperplasia(BPH)model in rats.Methods:Seventy-two SD rats were randomly divided into six groups:the normal group,the model group,the finasteride group,and the low-, middle-,and high-dose KQR groups,12 in each group.Except those in the normal group,the rats were injected with testosterone after castration for the establishment of BPH model and then given respectively w...

  11. Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia.

    NARCIS (Netherlands)

    Sedelaar, J.P.M.; Roermund, J.G. van; Leenders, G.L. van; Hulsbergen-van de Kaa, C.A.; Wijkstra, H.; Rosette, J.J.M.H.C. de la

    2001-01-01

    OBJECTIVES: To compare the accuracy of the detection, localization, and staging of prostate cancer using transrectal three-dimensional (3D) grayscale ultrasonography (3D-US) with conventional transrectal two-dimensional grayscale ultrasonography (2D-US). METHODS: Fifty patients with clinical localiz

  12. The value of imaging techniques in the diagnosis of benign prostate hyperplasia and prostate cancer; Wertigkeit der bildgebenden Diagnostik bei benigner Prostatahyperplasie und beim Prostatakarzinom

    Energy Technology Data Exchange (ETDEWEB)

    Doersam, J. [Chirurgisches Zentrum, Abt. Urologie und Poliklinik, Univ. Heidelberg (Germany); Kaelble, T. [Chirurgisches Zentrum, Abt. Urologie und Poliklinik, Univ. Heidelberg (Germany); Riedasch, G. [Chirurgisches Zentrum, Abt. Urologie und Poliklinik, Univ. Heidelberg (Germany); Staehler, G. [Chirurgisches Zentrum, Abt. Urologie und Poliklinik, Univ. Heidelberg (Germany)

    1994-03-01

    Diseases of the prostate are of high socioeconomic importance owing to their high incidence and prevalence rates. Benign prostatic hyperplasia (BPH) can be detected in 80% of males over the age of 80. Clinical symptoms do not correlate with organ enlargement. Only 10% of patients with BPH need surgical treatment. The decision for surgical treatment is made as a result of objective findings and the symptoms reported by the patient. Preoperative evaluation of BPH must include digital rectal examination (DRE), measurement of peak flow rate, sonographic estimation of residual urine, transrectal ultrasound (TRUS), urethrocystography and the assessment of subjective complaints using symptom scores. Prostatic carcinoma is the most common malignancy in men. An abnormal DRE, increased PSA level and/or hypoechogenic lesions in TRUS are indications for prostate biopsy. The sensitivity of TRUS is superior to that of CT and MRI. New MRI techniques are promising with regard to local tumour extent. Whereas CT and MRI are not useful in screening of patients, these methods are valuable diagnostic tools in the follow-up of prostate cancer. (orig.) [Deutsch] Erkrankungen der Prostata haben aufgrund der hohen Inzidenz und Praevalenz eine hohe soziooekonomische Bedeutung. Die benigne Prostatahyperplasie kann histologisch bei 80% der 80jaehrigen Maenner nachgewiesen werden. Die klinische Symptomatik korreliert nicht mit der Organgroesse. Nur ca. 10% der Maenner mit BPH beduerfen einer chirurgischen Therapie. Die Indikation zum operativen Eingriff ergibt sich aus objektiven Befunden und den subjektiven Beschwerden. Die praeoperative Diagnostik besteht aus rektal-digitaler Untersuchung, Uroflowmetrie mit anschliessender sonographischer Bestimmung des Restharnvolumens, transrektaler Sonographie, Urethrozystographie und Evaluation der Beschwerden mittels Symptomscores. Das Prostatakarzinom ist inzwischen der haeufigste Tumor des Mannes. Bei suspektem Befund der rektal-digitalen Untersuchung

  13. Laser-induced interstitial thermotherapy of benign prostatic hyperplasia and prostate cancer

    Science.gov (United States)

    Muschter, Rolf

    1994-12-01

    Urinary outflow obstruction by prostatic enlargement is usually treated by resection or, recently, less invasively by thermal `ablation' of tissue through the urethra. With the latter technique, the amount of tissue that can be removed is limited by the limited penetration depth of suitable radiation sources, e.g. lasers, or conduction of heat. Interstitial thermotherapy was expected to overcome this problem. Our initial in vitro and animal studies with different light guides for interstitial application of Nd:YAG laser radiation showed small carbonized lesions with bare fibers, but large homogeneous coagulation zones with special `ITT' (interstitial thermotherapy) fibers. Further studies using these applicators resulted in a technique to be apt for clinical routine in the treatment of symptomatic prostatic enlargement. The tip of the light guide was repeatedly inserted into the prostate either transurethrally through a cystoscope under direct vision or percutaneously from the perineum under transrectal ultrasound guidance. The number of fiber placements depended on the size and configuration of the gland. Irradiation was performed either for 10 min with 5 or 7 W or in the advanced `turbo'- mode for 5 or 3 min per fiber placement using automatically stepwise reduced power (20 W for 30 s, 15 W for 30 s, 10 W for 30 s, and 7 W for 210 or 90 s). By optical feedback control the laser was switched off automatically in the case of carbonization to avoid fiber damage. From July 15, 1991 to October 1, 1993 239 patients with BPH and 14 patients with advanced prostate cancer, suffering from severe urinary outflow obstruction, were treated by laser induced interstitial thermotherapy. The results and complications of treatment are reported.

  14. Smoking habits and benign prostatic hyperplasia: A systematic review and meta-analysis of observational studies.

    Science.gov (United States)

    Xu, Huan; Fu, Shi; Chen, Yanbo; Chen, Qi; Gu, Meng; Wang, Zhong

    2016-08-01

    Previous studies have warned against the promoting effects of cigarette smoking on benign prostatic hyperplasia (BPH). In contrast, some have argued that smoking confers a protective effect regarding BPH, while others have observed an aggravated effect. Thus, we performed this meta-analysis to determine whether cigarette use is associated with BPH risk.To identify articles from observational studies of relevance, a search was performed concurrent to March 21, 2016, on PubMed, Web of Science, Cochrane, EBSCO, and EMBASE databases. Random-effect model, according to the heterogeneity, was calculated to reveal the relative risks (RRs) and corresponding 95% confidence intervals (CIs).Eight articles were included in this meta-analysis, representing data for 44,100 subjects, of which 5221 (11.8%) had BPH as defined according to the criteria. Seven reports are concerned with analysis between nonsmokers and ex-smokers, in which no significant difference was observed (RR = 0.99, 95% CI 0.94-1.05). Another meta-analysis of 7 studies indicated an observable trend, but without significant difference between groups of nonsmokers and current smokers (RR = 1.17, 95% CI 0.98-1.41). Between groups of heavy (6 articles; RR = 1.02, 95% CI 0.84-1.24) and light smokers (5 articles; RR = 0.90, 95% CI 0.71-1.15), again no significant difference appears. Finally, we combined individuals as never-smokers and ever-smokers and still found no significant difference between the 2 groups of patients (RR = 1.03, 95% CI 0.92-1.15). Sensitivity analysis was displayed and confirmed the stability of the present results.Combined evidence from observational studies shows no significant association between cigarette smoking and BPH risk, either for ex-smokers or for current smokers. The trend of elevated BPH risk from smoking was observed only in current smokers compared with nonsmokers, while marginal significance was observed in comparing ever-smokers with never-smokers in

  15. Smoking habits and benign prostatic hyperplasia: A systematic review and meta-analysis of observational studies.

    Science.gov (United States)

    Xu, Huan; Fu, Shi; Chen, Yanbo; Chen, Qi; Gu, Meng; Wang, Zhong

    2016-08-01

    Previous studies have warned against the promoting effects of cigarette smoking on benign prostatic hyperplasia (BPH). In contrast, some have argued that smoking confers a protective effect regarding BPH, while others have observed an aggravated effect. Thus, we performed this meta-analysis to determine whether cigarette use is associated with BPH risk.To identify articles from observational studies of relevance, a search was performed concurrent to March 21, 2016, on PubMed, Web of Science, Cochrane, EBSCO, and EMBASE databases. Random-effect model, according to the heterogeneity, was calculated to reveal the relative risks (RRs) and corresponding 95% confidence intervals (CIs).Eight articles were included in this meta-analysis, representing data for 44,100 subjects, of which 5221 (11.8%) had BPH as defined according to the criteria. Seven reports are concerned with analysis between nonsmokers and ex-smokers, in which no significant difference was observed (RR = 0.99, 95% CI 0.94-1.05). Another meta-analysis of 7 studies indicated an observable trend, but without significant difference between groups of nonsmokers and current smokers (RR = 1.17, 95% CI 0.98-1.41). Between groups of heavy (6 articles; RR = 1.02, 95% CI 0.84-1.24) and light smokers (5 articles; RR = 0.90, 95% CI 0.71-1.15), again no significant difference appears. Finally, we combined individuals as never-smokers and ever-smokers and still found no significant difference between the 2 groups of patients (RR = 1.03, 95% CI 0.92-1.15). Sensitivity analysis was displayed and confirmed the stability of the present results.Combined evidence from observational studies shows no significant association between cigarette smoking and BPH risk, either for ex-smokers or for current smokers. The trend of elevated BPH risk from smoking was observed only in current smokers compared with nonsmokers, while marginal significance was observed in comparing ever-smokers with never-smokers in

  16. High-Intensity Focused Ultrasound (HIFU) Using Sonablate® Devices for the Treatment of Benign Prostatic Hyperplasia and Localized Prostate Cancer: 18-year experience

    Science.gov (United States)

    Uchida, Toyoaki

    2011-09-01

    From 1993 to 2010, we have treated 156 patients benign prostatic hyperplasia (BPH) and 1,052 patients localized prostate cancer high-intensity focused ultrasound (HIFU). Four different HIFU devices, SonablateR-200, SonablateR-500, SonablateR-500 version 4 and Sonablate® TCM, have been used for this study. Clinical outcome of HIFU for BPH did not show any superior effects to transurethral resection of the prostate, laser surgery or transurethral vapolization of the prostate. However, HIFU appears to be a safe and minimally invasive therapy for patients with localized prostate cancer, especially low- and intermediate-risk patients. The rate of clinical outcome has significantly improved over the years due to technical improvements in the device.

  17. Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study

    Directory of Open Access Journals (Sweden)

    Brabec Marek

    2011-02-01

    Full Text Available Abstract Background Infection plays a role in the pathogenesis of many human malignancies. Whether prostate cancer (PCa - an important health issue in the aging male population in the Western world - belongs to these conditions has been a matter of research since the 1970 s. Persistent serum antibodies are a proof of present or past infection. The aim of this study was to compare serum antibodies against genitourinary infectious agents between PCa patients and controls with benign prostate hyperplasia (BPH. We hypothesized that elevated serum antibody levels or higher seroprevalence in PCa patients would suggest an association of genitourinary infection in patient history and elevated PCa risk. Methods A total of 434 males who had undergone open prostate surgery in a single institution were included in the study: 329 PCa patients and 105 controls with BPH. The subjects' serum samples were analysed by means of enzyme-linked immunosorbent assay, complement fixation test and indirect immunofluorescence for the presence of antibodies against common genitourinary infectious agents: human papillomavirus (HPV 6, 11, 16, 18, 31 and 33, herpes simplex virus (HSV 1 and 2, human cytomegalovirus (CMV, Chlamydia trachomatis, Mycoplasma hominis, Ureaplasma urealyticum, Neisseria gonorrhoeae and Treponema pallidum. Antibody seroprevalence and mean serum antibody levels were compared between cases and controls. Tumour grade and stage were correlated with serological findings. Results PCa patients were more likely to harbour antibodies against Ureaplasma urealyticum (odds ratio (OR 2.06; 95% confidence interval (CI 1.08-4.28. Men with BPH were more often seropositive for HPV 18 and Chlamydia trachomatis (OR 0.23; 95% CI 0.09-0.61 and OR 0.45; 95% CI 0.21-0.99, respectively and had higher mean serum CMV antibody levels than PCa patients (p = 0.0004. Among PCa patients, antibodies against HPV 6 were associated with a higher Gleason score (p = 0.0305. Conclusions

  18. Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules.

    Directory of Open Access Journals (Sweden)

    Tyler M Bauman

    associated with BPH/LUTS, this relationship likely exists in regions of the prostate other than glandular hyperplasia.

  19. Correlation between molecular biomarkers and risk factors for the clinical progression of benign prostatic hyperplasia using tissue microarray immunostaining

    Institute of Scientific and Technical Information of China (English)

    Ma Ding; Yang Bing; Zhou Zhe; Pan Dongliang; Zhang Xianghua

    2014-01-01

    Background The pathogenesis of benign prostatic hyperplasia (BPH) has been widely studied,and several biomarkers are known to play roles in its development.This study aimed to investigate the possible role of cysteine-rich protein 61 (CYR61),vascular endothelial growth factor (VEGF),androgen receptor (AR),interleukin-6 (IL-6),cytochrome c,caspase-3,and proliferating cell nuclear antigen (PCNA) in the clinical progression of BPH.Methods Tissue specimens from 96 BPH cases who underwent transurethral resection of the prostate were processed and transferred to tissue microarrays.Patient age,prostate volume,serum prostate-specific antigen (PSA) level,and International Prostate Symptom Score (IPSS) of all BPH cases were collected before surgery.The expression of CYR61,VEGF,AR,IL-6,cytochrome c,caspase-3,and PCNA was examined by immunostaining in the BPH specimens,and any possible correlation between the different biomarkers and risk factors for BPH clinical progression was analyzed.Results The expression of CYR61,VEGF,AR,IL-6,cytochrome c,caspase-3,and PCNA in the BPH cases was 68.8% (66/96),77.1% (74/96),43.8% (42/96),31.3% (30/96),35.4% (34/96),56.3% (54/96),and 29.2% (28/96),respectively.The expression of both CYR61 and VEGF was positively correlated with patient age,prostate volume,and serum PSA level (P <0.05).Furthermore,cytochrome c and caspase-3 expression were inversely related to prostate volume (P <0.05),and AR expression was positively related to serum PSA level (P <0.05).Conclusion CYR61 and VEGF expression might serve as biomarkers for predicting the clinical progression of BPH due to effects on stromal cell proliferation and angiogenesis.

  20. Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase.

    Science.gov (United States)

    Choi, Hyun-Myung; Jung, Yunu; Park, Jinbong; Kim, Hye-Lin; Youn, Dong-Hyun; Kang, JongWook; Jeong, Mi-Young; Lee, Jong-Hyun; Yang, Woong Mo; Lee, Seok-Geun; Ahn, Kwang Seok; Um, Jae-Young

    2016-01-01

    Cinnamomi cortex (dried bark of Cinnamomum verum) is an important drug in Traditional Korean Medicine used to improve blood circulation and Yang Qi. Benign prostatic hyperplasia (BPH) is a common chronic disease in aging men. This study was conducted to determine the effect of Cinnamomi cortex water extract (CC) on BPH. BPH was induced by a pre-4-week daily injection of testosterone propionate (TP). Six weeks of further injection with (a) vehicle, (b) TP, (c) TP + CC, (d) TP + finasteride (Fi) was carried on. As a result, the prostate weight and prostatic index of the CC treatment group were reduced. Histological changes including epithelial thickness and lumen area were recovered as normal by CC treatment. The protein expressions of prostate specific antigen, estrogen receptor α (ERα), androgen receptor (AR), 5α-reductase (5AR), and steroid receptor coactivator 1 were suppressed by treatment of CC. Immunohistochemical assays supported the western blot results, as the expressions of AR and ERα were down-regulated by CC treatment as well. Further in vitro experiments showed CC was able to inhibit proliferation of RWPE-1 cells by suppressing 5AR and AR. These results all together suggest CC as a potential treatment for BPH. PMID:27549514

  1. CURRENT OPPORTUNITIES FOR COMBINATION TREATMENT OF LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC HYPERPLASIA IN MEN

    Directory of Open Access Journals (Sweden)

    G. R. Kasyan

    2016-01-01

    Full Text Available Lower urinary tract symptoms (LUTS associated with benign prostatic hyperplasia (BPH are widely presented, particularly among elderly men. It was commonly accepted that LUTS are directly or indirectly connected with the prostate. Recent studies have shown that mild andsevere forms of LUTS may have a different etiology, such as, bladder related problems: overactive bladder (OAB/detrusor overactivity or, conversely, an underactive bladder due to compromised contractions of the detrusor. There are three main groups of LUTS: storage symptoms, voiding symptoms and post-micturition symptoms. Patients with LUTS/BPH who are not sufficiently respond to monotherapy with alpha-blockers should receive additional treatment with M‑anticholinergics in accordance with the European urological guidelines. Current studies show that up to 65% of patients with LUTS/BPH with symptoms of urgency and frequency do not have sufficient reduction of symptoms after 3 months of treatment with alphablocker as monotherapy. Until recently, alpha-blockers and M‑anticholinergic medications were prescribed in combination therapy as a two separate pills. Vesomni is a combination of antimuscarinic drug solifenacin 6 mg with α1‑blocker tamsulosin OCAS 0.4 mg in one tablet. It is developed to relieve storage (urgency and frequency and voiding symptoms in men with LUTS/BPH. Solifenacin suppresses the overactivity of the detrusor and reduces storage symptoms. Tamsulosin OCAS relaxes smooth muscle of the prostate, prostatic urethra and bladder neck, and eliminates most voiding symptoms and, to a lesser extent, storage symptoms.

  2. Association of a Common Variant at 10q26 and Benign Prostatic Hyperplasia Aggressiveness in Han Chinese Descent

    Directory of Open Access Journals (Sweden)

    Xin Gu

    2013-01-01

    Full Text Available Recent studies reported that rs2252004 at 10q26 was significantly associated with prostate cancer (PCa risk in a Japanese population and was subsequently confirmed in a Chinese population. We aimed to assess the relationship between this locus and risk/aggressiveness of benign prostatic hyperplasia (BPH. The current study included 426 BPH cases and 1,008 controls from Xinhua Hospital in Shanghai, China. All BPH patients were treated with α-adrenergic blockers and 5α-reductase inhibitors for at least 9 months. Associations between rs2252004 and BPH risk/aggressiveness were tested using logistic regression. Associations between rs2252004 and clinical parameters including International Prostate Symptom Score (IPSS, total prostate volume (TPV, total PSA (tPSA, and free PSA (fPSA were evaluated by linear regression. Allele “A” in rs2252004 was significantly associated with increased risk for aggressiveness of BPH in a Chinese population (OR = 1.42, 95% CI: 1.04–1.96, P=0.03. Patients with the genotype “A/A” (homozygous minor allele had an increase of IPSS and TPV after treatment (P=0.045 and 0.024, resp.. No association was observed between rs2252004, BPH risk, and baseline clinicopathological traits (All P>0.05. Our study is the first to show that rs2252004 at 10q26 was associated with BPH aggressiveness and efficacy of BPH treatment.

  3. Oxidative stress in prostate hyperplasia and carcinogenesis.

    Science.gov (United States)

    Udensi, Udensi K; Tchounwou, Paul B

    2016-01-01

    Prostatic hyperplasia (PH) is a common urologic disease that affects mostly elderly men. PH can be classified as benign prostatic hyperplasia (BPH), or prostate cancer (PCa) based on its severity. Oxidative stress (OS) is known to influence the activities of inflammatory mediators and other cellular processes involved in the initiation, promotion and progression of human neoplasms including prostate cancer. Scientific evidence also suggests that micronutrient supplementation may restore the antioxidant status and hence improve the clinical outcomes for patients with BPH and PCa. This review highlights the recent studies on prostate hyperplasia and carcinogenesis, and examines the role of OS on the molecular pathology of prostate cancer progression and treatment. PMID:27609145

  4. Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients

    Institute of Scientific and Technical Information of China (English)

    Seung Hwan Lee; Cheol Young Oh; Kyung Kgi Park; Mun Su Chung; Se Jeong Yoo; Byung Ha Chung

    2011-01-01

    @@ We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC).In this 12-week prospective observational study,a total of 175 patients aged >,40 years with International Prostate Symptom Scores (IPSS))12 points and prostate volume ≧20ml were prospectively enrolled.The patients were divided into two groups according to BMI orWC.Patients received the doxazosin gastrointestinal therapeutic system (GITS) at a dose of 4 mg once per day for 12 weeks.The changes from baseline in the IPSS,maximal urinary flow rate (Qmax),post-void residual volume,quality of life (QoL) scores and adverse events (AEs) were analysed.Of the 175 enrolled patients,132 completed the study.Sixty-seven patients had BMI >23kg m-2,and 43 had WC>90 cm.Obese patients represented by WC>90 cm or BMI≧23kg m-2 had a significantly greater prostate volume compared with non-obese patients at baseline.Total IPSS was significantly higher in the WC >90 cm group compared to the WC≦90 cm group.Total IPSS was positively correlated with prostate volume (P=0.031) and WC (P=0.045).All groups showed significant improvements in total I PSS and QoL at 12 weeks.However,the improvement of total IPSS was greater in the high-BMI and high-WC groups.The most frequent AE was dizziness (n=13),and it was significantly lower in the obese BPH patients.Obesity was associated with increased prostate volume and lower urinary tract symptoms.Alpha-blockers appear to be efficacious for controlling symptoms,especially in obese men.

  5. Re: Cross-Sectional and Longitudinal Associations of Sexual Function with Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia

    Directory of Open Access Journals (Sweden)

    Fwu C-W

    2015-03-01

    Full Text Available In this study authors examine the cross-sectional associations between baseline characteristics and sexual function and the longitudinal associations between change in lower urinary tract symptoms and change in sexual function among men with benign prostatic hyperplasia. The cross-sectional cohort included 2.916 men who completed Brief Male Sexual Function Inventory (BMSFI at baseline. The longitudinal cohort included 672 men who were randomized to placebo. Increased age, less education, obesity and severe lower urinary tract symptoms were found significantly associated poorer sexual drive, erectile dysfunction, ejaculatory function, sexual problem assessment and overall satisfaction. However, none of these baseline characteristics predicted change in sexual function in the longitudinal cohort. The decline in sexual dysfunction associated with worsening of lower urinary tract symptoms in men assigned to placebo was small.

  6. Influence of bladder outlet obstruction and detrusor contractility on residual urine in patients with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    张鹏; 武治津; 高居忠

    2003-01-01

    Objective To study the relationship between the degree of bladder outlet obstruction (BOO), detrusor contractility and residual urine in patients suffering from benign prostatic hyperplasia (BPH).Methods In 181 patients with BPH, degree of BOO, detrusor contractility, residual urine caculated from cathetering combined with the difference between the filling and the voiding were recorded and analysized statistically using urodynamic technique.Results Residual urine increased when the detusor contractility was weakened (F=12.134, P=0.001). In patients wih severe BOO, there was no significant difference in residual urine (F=2.386, P=0.071).Conclusions Increased residual urine is mainly resulted from decreased detrusor contractility. BOO has no significant influence on residual urine. Some patients with normal or weakened detrusor contractility may have more residual urine

  7. Transurethral resection of the prostate for the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: how much should be resected?

    Directory of Open Access Journals (Sweden)

    Alberto A. Antunes

    2009-12-01

    Full Text Available Objective: To assess the impact of the percent of resected tissue on the improvement of urinary symptoms. Materials and methods: The study included a prospective analysis of 88 men with benign prostatic hyperplasia. Patients were divided in three groups according to the percent of resected tissue: Group 1 50%. Each patient was re-evaluated 3 months after surgery. We assessed the international prostatic symptom score, nocturia and serum prostate specific antigen levels. Results: All patients presented a significant decrease on mean International Prostate System Score (IPSS (23 to 5.9, Quality of Life (QoL (4.9 to 1.0 and nocturia (3.2 to 1.9. Variation in the IPSS was 16.7, 16.6 and 18.4 for patients from Group 1, 2 and 3 respectively (P = 0.504. Although the three groups presented a significant decrease in QoL, patients in Group 3 presented a significantly greater decrease when compared to Group 1. Variation in QoL was 3.1, 3.9 and 4.2 for patients from Group 1, 2 and 3 respectively (p = 0.046. There was no significant difference in nocturia variation according to the percent of resected tissue (p = 0.504. Median pre and postoperative PSA value was 3.7 and 1.9 ng/mL respectively. Patients from Group 1 did not show a significant variation (p = 0.694. Blood transfusions were not required in any group. Conclusions:Resection of less than 30% of prostatic tissue seems to be sufficient to alleviate lower urinary tract symptoms related to benign prostate hyperplasia. However, these patients may not show a significant decrease in serum PSA level.

  8. Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia

    Energy Technology Data Exchange (ETDEWEB)

    Isen, K. [Karaelmas Univ., Zonguldak (Turkey). School of Medicine; Sinik, Z.; Alkibay, T.; Sezer, C.; Soezen, S.; Atilla, S.; Ataoglu, O.; Isik, S.

    2001-02-01

    The purpose of this study was to determine whether magnetic resonance imaging (MRI) or quantitative color-imaged morphometric analysis (MA) of the prostate gland are related to the clinical response to terazosin. Thirty-six male patients with symptomatic benign prostatic hyperplasia (BPH) with a serum prostate-specific antigen level of 4-10 ng/mL underwent MRI with body coil, transrectal prostate unltrasonography and biopsy prior to terazosin therapy. For MRI-determined stromal and non-stromal BPH, the ratio of the signal intensity of the inner gland to the obturator internus muscle was evaluated. Histologic sections were stained with hematoxylin and eosin. The MA of the specimens was performed by Samba 2000. Results of the two techniques were interpreted according to the terazosin therapy results. The mean stromal percentage was 60.5{+-}18.0%. No statistically significant relationship was found between the clinical outcome of terazosin and the MRI findings. The MA results showed a significant relationship between the percentage of stroma and the percent change of the peak urinary flow rate, but not with the percent change of the international prostate symptom score after terazosin therapy (P<0.05). Magnetic resonance imaging alone is not sufficient in predicting the response to terazosin therapy. Morphometric analysis of BPH tissue composition can be used in predicting the clinical outcome of terazosin therapy but it is suitable only in patients for whom prostatic biopsy is necessary in order to rule out prostate cancer. (author)

  9. Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions

    Directory of Open Access Journals (Sweden)

    Giovanni Corona

    2014-01-01

    Full Text Available Metabolic syndrome (MetS is a well-recognized cluster of cardiovascular (CV risk factors including obesity, hypertension, dyslipidemia, and hyperglycaemia, closely associated with an increased risk of forthcoming cardiovascular disease and type 2 diabetes mellitus. Emerging evidence indicates that benign prostate hyperplasia (BPH and its related lower urinary tract symptoms (LUTS represent other clinical conditions frequently observed in subjects with MetS. Several modifiable factors involved in MetS determinism, such as inadequate diet, lack of physical exercise, and smoking and drinking behaviours are emerging as main contributors to the development of BPH. The pathogenetic mechanisms underlying the connection between MetS and BPH have not been completely clarified. MetS and its components, hypogonadism, and prostate inflammation probably play an important role in inducing BPH/LUTS. Although historically considered as a “normal” consequence of the aging process, BPH/LUTS should now be faced proactively, as a preventable disorder of the elderly. Type of diet and level of physical activity are now considered important factors affecting prostate health in the aging male. However, whether physical exercise, weight loss, and modifications of dietary habit can really alter the natural history of BPH/LUTS remains to be determined. Further research is advisable to better clarify these points.

  10. Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systematic review of randomized controlled trials

    Institute of Scientific and Technical Information of China (English)

    Chun Ho Ma; Wai Ling Lin; Sing Leung Lui; Xun-Yuan Cai; Vivian Taam Wong; Eric Ziea; Zhang-Jin Zhang

    2013-01-01

    Chinese herbal medicine is commonly used as a treatment for benign prostatic hyperplasia (BPH),but its efficacy and safety remain to be examined.To compare the efficacy and adverse events of Chinese herbal medicine alone or used adjuvantly with Western medications for BPH.Two independent reviewers searched the major electronic databases for randomized controlled trials comparing Chinese herbal medicine,either in single or adjuvant use with Western medication,with placebo or Western medication.Relevant journals and grey literature were also hand-searched.The outcome measures included changes in urological symptoms,urodynamic measures,prostate volume and adverse events.The frequency of commonly used herbs was also identified.Out of 13 922 identified citations of publications,31 studies were included.Eleven studies with a Jadad score ≥ 3 were selected for meta-analysis.Chinese herbal medicine was superior to Western medication in improving quality of life and reducing prostate volume.The frequency of adverse events in Chinese herbal medicine was similar to that of placebo and less than that of Western medication.The evidence is too weak to support the efficacy of Chinese herbal medicine for BPH due to the poor methodological quality and small number of trials included.The commonly used herbs identified here should provide insights for future clinical practice and research.Larger randomized controlled trials of better quality are needed to truly evaluate the efficacy of Chinese herbal medicine.

  11. The Effect of Seoritae Extract in Men with Mild to Moderate Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

    Directory of Open Access Journals (Sweden)

    Woong Jin Bae

    2016-01-01

    Full Text Available We evaluated the effects of Seoritae extract (SE on mild to moderate lower urinary tract symptoms (LUTS suggestive of benign prostatic hyperplasia (BPH. Seventy-six subjects with mild to moderate LUTS suggestive of BPH were prospectively recruited from the urology outpatient clinic and assigned to either SE (4200 mg or 6 tablets 3 times a day or matching placebo. The primary outcome variable, the International Prostatic Symptom Score (IPSS, was evaluated at baseline and at 4 and 12 weeks. Postvoid residual volume (PVR, maximum urine flow rate (Qmax, and prostate-specific antigen (PSA levels were evaluated. IPSSs decreased significantly from baseline to 12 weeks within the SE group. Significant improvements in IPSS voiding scores at 4 and 12 weeks were also observed in the SE group compared to the placebo group. IPSS storage and quality of life scores were also significantly decreased at 12 weeks in the SE group. There was no change in Qmax or PVR in both groups after 12 weeks. Administration of SE for 12 weeks led to significant improvements in LUTS, and it can be concerned as a reasonable and safe alternative for men with mild to moderate LUTS.

  12. Diagnostic and predictive value of voiding diary data versus prostate volume, maximal free urinary flow rate, and Abrams-Griffiths number in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

    NARCIS (Netherlands)

    van Venrooij, Ger E. P. M.; van Melick, Harm H. E.; Eckhardt, Mardy D.; Boon, Tom A.

    2008-01-01

    OBJECTIVES To investigate the information of voiding data in relation to symptoms and well-being in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) and to compare this information with that of prostate volume (Vprostate), maximal free urinary flow rate (

  13. Inhibitory effect of rape pollen supercritical CO2 fluid extract against testosterone-induced benign prostatic hyperplasia in rats

    Science.gov (United States)

    YANG, BI-CHENG; JIN, LI-LI; YANG, YI-FANG; LI, KUN; PENG, DAN-MING

    2014-01-01

    Benign prostatic hyperplasia (BPH) can lead to lower urinary tract symptoms. Rape pollen is an apicultural product that is composed of nutritionally valuable and biologically active substances. The aim of the present study was to investigate the protective effect of rape pollen supercritical CO2 fluid extract (SFE-CO2) in BPH development using a testosterone-induced BPH rat model. BPH was induced in the experimental groups by daily subcutaneous injections of testosterone for a period of 30 days. Rape pollen SFE-CO2 was administered daily by oral gavage concurrently with the testosterone injections. Animals were sacrificed at the scheduled termination and the prostates were weighed and subjected to histopathological examination. Testosterone, dihydrotestosterone (DHT), 5α-reductase and cyclooxygenase-2 (COX-2) levels were also measured. BPH-induced animals exhibited an increase in prostate weight with increased testosterone, DHT, 5α-reductase and COX-2 expression levels. However, rape pollen SFE-CO2 treatment resulted in significant reductions in the prostate index and testosterone, DHT, 5α-reductase and COX-2 levels compared with those in BPH-induced animals. Histopathological examination also demonstrated that rape pollen SFE-CO2 treatment suppressed testosterone-induced BPH. These observations indicate that rape pollen SFE-CO2 inhibits the development of BPH in rats and these effects are closely associated with reductions in DHT, 5α-reductase and COX-2 levels. Therefore, the results of the present study clearly indicate that rape pollen SFE-CO2 extract may be a useful agent in BPH treatment. PMID:24944593

  14. Clinical evaluation of patients with benign prostatic hyperplasia, treated with the natural product Calprost®: a randomized, controlled study

    Directory of Open Access Journals (Sweden)

    Magnelis Machado-Leiva

    2016-10-01

    Full Text Available Context: Benign Prostatic Hyperplasia (BPH is a common disease that course with Lower Urinary Tract Symptoms (LUTS, mainly in over 50 years-old men. Commonly indicated drugs such as alpha adrenergic-blockers are life-treatment with some adverse reactions. Center for Drug Research and Development produce a microencapsulated lipophilic extract of pumpkin seed oil (Calprost® with anti-androgenic, anti-inflammatory, antioxidant, antiproliferative and diuretic properties. Aims: To evaluate the effect and safety of Calprost® in patients with BPH and LUTS. Methods: A multicenter, randomized, controlled, open exploratory clinical trial was conducted. Two experimental groups, study group (Calprost®, 140 mg daily (n=81, and control group (terazosin, 2 mg daily (n=50 were conformed. All the patients were treated during three months. Efficacy was evaluated through International Prostate Symptoms Score (IPSS, residual bladder volume and prostate volume. Results: Most of the included patients (74.0% were white skin color and their mean age was 66 yrs. Fifteen patients, nine of them from terazosin group, withdraw the trial voluntarily. A significant reduction in the overall IPSS scale was obtained for both groups. Nevertheless, some obstructive (intermittency, straining and irritative (frequency, urgency urinary symptoms decreased more markedly in the Calprost® group being milder. Median residual and prostatic volumes decreased significantly (p=0.048 and p=0.002, respectively only into the Calprost® group. Most of the adverse events were recorded in the terazosin group (79.4%, where postural hypotension prevailed. Conclusions: The natural product Calprost® was probed as a successful treatment of patients with BPH/LUTS, being also well-tolerated.

  15. Evaluation of short term outcomes of patients undergone transurethral resection with plasmakinetic energy for benign prostate hyperplasia

    Directory of Open Access Journals (Sweden)

    Suleyman Baris Kartal

    2013-08-01

    Full Text Available Aim: To evaluate short term outcomes of patients undergone transurethral resection with plasmakinetic energy for benign prostate hyperplasia and to present safety and efficacy of the procedure. Material and Method:86 patients applied to our clinic between March 2011 and February 2012 were enrolled into the study. PSS scores, uroflowmetry, post voiding residual urine, prostate volumes of the patients were recorded. Post operative urethral stricture, bladder neck stricture, incontinance rates were noted. Data assessed after six months were compared to peroperative data. After the operations, the surgeons evaluated their comfort of surgery with visual analog scale from 0 to 10. Results: 24 of 86 patients were hospitalized for acute urinary retention. One patient was hospitalized because of hematuria. Peroperative IPSS was 22.2. at post operative sixth month, mean IPSS was 6.8. VAS scores of surgeons was; to assess visual comfort was 7.41, to assess coagulation was 7.62. Conclusion:After evaluating the data and literature, we believe bipolar plasmakinetik TUR is a safe and comforting method to treat bladder outlet obstruction with goog hemodynamic stability. [Cukurova Med J 2013; 38(4.000: 696-675

  16. The Relationship between Depression, Anxiety, Somatization, Personality and Symptoms of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.

    Science.gov (United States)

    Koh, Jun Sung; Ko, Hyo Jung; Wang, Sheng-Min; Cho, Kang Joon; Kim, Joon Chul; Lee, Soo-Jung; Pae, Chi-Un

    2015-04-01

    This study investigated the relationship of personality, depression, somatization, anxiety with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). The LUTS/BPH patients were evaluated with the International Prostate Symptom Score (IPSS), 44-item Big Five Inventory (BFI), the Patient Health Questionnaire-9 (PHQ-9), the PHQ-15, and 7-item Generalized Anxiety Disorder Scale (GAD-7). The LUTS/BPH symptoms were more severe in patients with depression (p=0.046) and somatization (p=0.024), respectively. Neurotic patients were associated with greater levels of depression, anxiety and somatisation (p=0.0059, p=0.004 and p=0.0095, respectively). Patients with high extraversion showed significantly low depression (p=0.00481) and anxiety (p=0.035) than those with low extraversion. Our exploratory results suggest patients with LUTS/BPH may need careful evaluation of psychiatric problem including depression, anxiety and somatization. Additional studies with adequate power and improved designs are necessary to support the present exploratory findings. PMID:25866530

  17. Expression of leukemia/lymphoma related factor (LRF/Pokemon) in human benign prostate hyperplasia and prostate cancer.

    Science.gov (United States)

    Aggarwal, Himanshu; Aggarwal, Anshu; Hunter, William J; Yohannes, Paulos; Khan, Ansar U; Agrawal, Devendra K

    2011-04-01

    Leukemia/lymphoma related factor (LRF), also known as Pokemon, is a protein that belongs to the POK family of transcriptional repressors. It has an oncogenic role in many different solid tumors. In this study, the expression of LRF was evaluated in benign prostate hyperplastic (BPH) and prostate cancer (PC) tissues. The functional expression of LRF was studied using multiple cellular and molecular methods including RT-PCR, western blotting, immunohistochemistry, and immunofluorescence. Paraffin-embedded human tissues of BPH and PC were used to examine LRF expression. Histological staining of the BPH and PC tissue sections revealed nuclear expression of LRF with minimal expression in the surrounding stroma. The semi-quantitative RT-PCR and western immunoblot analyses demonstrated significantly higher mRNA transcripts and protein expression in PC than BPH. High expression of LRF suggests that it may have a potential role in the pathogenesis of both BPH and prostate cancer. Further studies will help elucidate the mechanisms and signaling pathways that LRF may follow in the pathogenesis of prostate carcinoma. PMID:21251909

  18. Association of GSTM1 and GSTT1 Polymorphism with Lipid Peroxidation in Benign Prostate Hyperplasia and Prostate Cancer: A Pilot Study

    Directory of Open Access Journals (Sweden)

    Vivek Kumar

    2011-01-01

    Full Text Available Association of glutathione S-transferase (GST M1 and T1 deletions with benign prostate hyperplasia (BPH and prostate cancer is well reported. These enzymes metabolize numerous toxins thus protecting from oxidative injury. Oxidative stress has been associated with development of BPH and prostate cancer. The present study was designed to analyze role of GST deletions in development of oxidative stress in these subjects. GSTs are responsible for metabolism of toxins present in tobacco therefore effect of tobacco usage in study groups was also studied. Three groups of subjects: BPH (57 patients, prostate cancer (53 patients and controls (46 subjects were recruited. Genotyping was done using a multiplex polymerase chain reaction (PCR method. Malondialdehyde (MDA levels as marker of oxidative stress were estimated by measuring thiobarbituric acid reactive substance (TBARS in plasma. Based on genotyping, subjects were categorized into: GSTM1+/GSTT1+, GSTM1-/GSTT1+, GSTM1+/GSTT1- and GSTM1-/GSTT1-. Significantly higher plasma MDA levels were noticed in GSTM1-/GSTT1- as compared to GSTM1+/GSTT1+ in all study groups. Double deletion (GSTM1-/GSTT1- is associated with higher oxidative stress which might play a role in the pathogenesis of BPH and prostate cancer. However, other markers of oxidative stress should be analyzed before any firm conclusion.

  19. Clinical Progress on Acupuncture Treatment of Prostatic Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    李丽会; 张淑静; 徐名一; 黄国琪

    2009-01-01

    @@ Prostatic hyperplasia, also termed benign prostatic hyperplasia (BPH), is a commonly encountered disease in middle-aged and old males. This condition is known as "Retention of Urine" and "Urination Syndrome" in Chinese medicine. Now, the literature from 1998 to 2008 on acupuncture treatment of prostatic hyperplasia are abstracted and reviewed, in order to understand the clinical status of acupuncture treatment for this disease.

  20. The experience of Goldwater Tongzhi for treating benign prostatic hyperplasia%金水同治治疗前列腺增生体会

    Institute of Scientific and Technical Information of China (English)

    刘志勇

    2013-01-01

      Benign prostatic hyperplasia, also known as enlarged prostate is a common disease of the older men. Ancient Chinese physicians accumulated a wealth of experience in the treatment of benign prostatic hyperplasia. The author according to lung and kidney homologous Goldwater Aioi traditional Chinese medicine theory, dialectical theory of governance based on the use of the the Goldwater Tongzhi method of treatment of benign prostatic hyperplasia, and achieved satisfactory efficacy.%  前列腺增生又称前列腺肥大,是老年男性的一种常见病。中国古代医家积累了丰富的治疗经验。笔者根据肺肾同源、金水相生的中医理论,在辨证论治的基础上,运用金水同治的方法治疗前列腺增生,取得了满意的疗效。

  1. Efficacy and Safety of 120-W Thulium:Yttrium-Aluminum-Garnet Vapoenucleation of Prostates Compared with Holmium Laser Enucleation of Prostates for Benign Prostatic Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    Kai Hong; Yu-Qing Liu; Jian Lu; Chun-Lei Xiao; Yi Huang; Lu-Lin Ma

    2015-01-01

    Background:This study compared the efficacy and safety between 120-W thulium:yttrium-aluminum-garnet (Tm:YAG) vapoenucleation of prostates (ThuVEP) and holmium laser enucleation of prostates (HoLEP) for patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).Methods:A retrospective analysis of 88 consecutive patients with symptomatic BPH was carried out,who underwent either 120-W ThuVEP or HoLEP nonrandomly.Patient demographics and peri-operative and 12-month follow-up data were analyzed with the International Prostate Symptom Score (IPSS),quality of life (QoL) score,maximum flow rate (Qmax),postvoid residual urine volume (PVR),and rates of peri-operative and late complications.Results:The patients in each group showed no significant difference in preoperative parameters.Compared with the HoLEP group,patients in the 120-W ThuVEP group required significantly shorter time for laser enucleation (58.3 ± 12.8 min vs.70.5 ± 22.3 min,P =0.003),and resulted in a significant superiority in laser efficiency (resected prostate weight/laser enucleation time) for 120-W Tm:YAG lasercompared to holmium:YAG laser (0.69 ± 0.18 vs.0.61 ± 0.19,P =0.048).During 1,6,and 12 months of follow-ups,the procedures did not demonstrate a significant difference in IPSS,QoL score,Qmax,or PVR (P > 0.05).Mean peri-operative decrease of hemoglobin in the HoLEP group was similar to the ThuVEP group (17.1 ± 12.0 g/L vs.15.2 ± 10.1 g/L,P =0.415).Early and late incidences of complications were low and did not differ significantly between the two groups of 120-W ThuVEP and HoLEP patients (P > 0.05).Conclusions:120-W ThuVEP and HoLEP are potent,safe and efficient modalities of minimally invasive surgeries for patients with LUTS due to BPH.Compared with HoLEP,120-W ThuVEP offers advantages of reduction of laser enucleation time and improvement of laser efficiency.

  2. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia - the Markov model based on data from Montenegro

    OpenAIRE

    Dabanović Vera; Kostić Marina; Janković Slobodan

    2016-01-01

    Background/Aim. Benign prostatic hyperplasia (BPH) is one of the most common disease among males aging 50 years and more. The rise of the prevalence of BPH is related to aging, and since duration of life time period has the tendency of rising the prevalence of BPH will rise as costs of BPH treatment will and its influence on health economic budget. Dutasteride is a new drug similar to finasteride, inhibits enzyme testosterone 5-alpha reductase, diminish sym...

  3. The Effect of 5α-reductase Inhibition with Finasteride and Dutasteride on Bone Mineral Density in Older Men with Benign Prostatic Hyperplasia

    OpenAIRE

    Radin Mačukat, Indira; Španjol, Josip; Crnčević Orlić, Željka; Žuvić Butorac, Marta; Marinović, Marin; Fučkar Ćupić, Dora

    2014-01-01

    Testosterone is converted to dihyrotestosterone by two isoenzymes of 5α-reductase. Finasteride and dutasteride are 5α-reductase inhibitors commonly used in the treatment of benign prostatic hyperplasia. We compared indices of bone mineral density in 50 men treated with finasteride, 50 men treated with dutasteride and 50 men as control. Bone mineral density of spine and hip were measured using dual energy X-ray absorptiometry. Bone formation was assessed by measuring serum osteocalcin and bone...

  4. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia

    OpenAIRE

    Zong, Huan-Tao; Peng, Xiao-Xia; Yang, Chen-Chen; Yong ZHANG

    2011-01-01

    5α-reductase inhibitors (5α-RIs), including finasteride and dutasteride, are commonly used medical therapies for benign prostatic hyperplasia (BPH). Many studies reported that preoperative 5α-RI had impact on intraoperative haemorrhage during surgery for BPH, but it was still in controversial. So, we conducted a systematic review of the effects and mechanisms of 5α-RIs on intraoperative bleeding for BPH. MEDLINE, EMBASE, the Cochrane Controlled Trail Register of Controlled Trials and the refe...

  5. Advances in the research of the relation between Livin and benign prostatic hyperplasia%Livin与良性列腺增生关系的研究进展

    Institute of Scientific and Technical Information of China (English)

    李鑫

    2011-01-01

    良性前列腺增生(benign prostatic hyperplasia,BPH)是老年男性的常见病和多发病,随着社会人口老龄化,BPH的发病率将会越来越高.凋亡抑制蛋白Livin通过改变组织细胞凋亡增殖的平衡,而在BPH的发生发展中发挥着重要作用.

  6. Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review

    OpenAIRE

    Haddad, Albert; Jabbour, Michel; Bulbul, Muhammad

    2015-01-01

    Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who hav...

  7. Safety of greenlight photoselective vaporisation of prostate in lower urinary tract symptoms due to benign prostatic hyperplasia in patients using anticoagulants due to cardiovascular comorbidities

    Directory of Open Access Journals (Sweden)

    Basri Cakiroglu

    2015-07-01

    Full Text Available Lasers have been used in the management of benign prostatic hyperplasia for the last two decades. To be comparable, they should reduce or avoid the immediate and long-term complications of transurethral resection of the prostate (TURP or open prostatectomy (OP, especially bleeding and need for blood transfusion. Although Holmium laser treatment of the prostate was compared frequently in terms of cardiovascular safety with TURP or OP, photoselective vaporisation of the prostate (PVP was not largely evaluated. In this article we analyzed the current literature to see if there is convincing data to support the observation of some authors that use of PVP is associated with increased safety in patients on anticoagulants with cardiovascular comorbidities. With this purpose a Medline search between January 2004 to March 2013 was performed using evidence obtained from randomised trials, well-designed controlled studies without randomisation, individual cohort studies, individual case control studies and case reports Results: In the last 10 years, several case-control and cohort studies have demonstrated the efficacy of PVP as well as its safety in patients with cardiovascular comorbidities using anticoagulants. The results confirmed the overall lower perioperative and postoperative morbidity of PVP, whereas the efficacy was comparable to TURP in the short term, despite a higher reoperation rate. Conclusion: Although it is still developing, PVP with KTP or LBO seems to be a promising alternative to both TURP and OP in terms of cardiovascular safety and in patients using anticoagulants.

  8. Drug Treatment Application Value in Benign Prostatic Hyperplasia%药物治疗在良性前列腺增生中的应用价值

    Institute of Scientific and Technical Information of China (English)

    石岩

    2015-01-01

    Elderly patients with benign prostatic hyperplasia drug treatment is a more effective method.Current drug therapy in the clinical treatment of the mechanism and treatment progressed very quickly,using the drug to treat benign prostatic hyperplasia has become a very effective method of treatment,ongoing research work on drug dosage to improve and reduce adverse reactions and other aspects.In this paper,the progress of benign prostatic hyperplasia drug treatment abroad were discussed.%老年良性前列腺增生患者采用药物进行治疗是一种比较有效的方法。目前药物治疗在临床治疗机制与治疗上进展很快,采用药物治疗良性前列腺增生已成为非常有效的治疗方法,目前正在开展药物剂型改进和不良反应降低等方面的研究工作。本文针对国内外药物治疗良性前列腺增生的进展进行初步探讨。

  9. Non-interventional (observational study of application of the tamsulosin (Proflosin® in patients with benign prostatic hyperplasia in routine clinical practice

    Directory of Open Access Journals (Sweden)

    L. G. Spivak

    2015-02-01

    Full Text Available The problem of therapy of benign prostatic hyperplasia has not lost its relevance today due to the high prevalence rate of this pathologyamong the male population. The article provides the results of non-interventional (observational study of application of the tamsulosin(Proflosin® drug or combined therapy with tamsulosin (Proflosin® + Serenoa repens (Prostamol® Uno of patients with benign prostatic hyperplasia in routine clinical practice. 1,000 practicing urology experts from 100 cities and towns of Russia took part in the study as well as 23 492 patients with the established diagnosis of benign prostatic hyperplasia, which were prescribed with tamsulosin (Proflosin® monotherapy or combined therapy with tamsulosin (Proflosin® + Serenoa repens (Prostamol® Uno in conditions of outpatient clinical practice. As a result of the study, improvement of the life standard and subjective symptoms were stated with patients with the absence of significant side effects directly associated with intake of the drug studies.

  10. The exploration of nursing care for patients with benign prostatic hyperplasia treated using 90Sr-90Y

    International Nuclear Information System (INIS)

    An exploration of nursing care for patients with benign prostatic hyperplasia (BPH) treated using 90Sr-90Y through the rectum was carried out . The treatment result and nursing experience in 90 cases were reported in this paper. Before the therapy nurses explained the method and principle of this treatment to the patients for the sake of increasing their confidence and to help them complete the treatment course successfully. During the radiotherapy, nurses practiced strictly radiation protection principles and operating instructions. They assisted the patients to have a healthy life style and good diet . The result of treatment indicated that the total effectiveness rate was 96.7%. The symptoms of lower urinary obstruction were improved evidently and the life quality of the patients elevated. Observation of clinical system confirmed that 90Sr-90Y may be a new treatment method of BPH with benefits of safe irradiation dos, easy operation, non-traumatization, painlessness, and remarkable curative effects. However, it should be stressed that nursing care plays a pivotal role in the treatment result. (authors)

  11. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

    Science.gov (United States)

    Barry, M J; Fowler, F J; O'Leary, M P; Bruskewitz, R C; Holtgrewe, H L; Mebust, W K; Cockett, A T

    1992-11-01

    A symptom index for benign prostatic hyperplasia (BPH) was developed and validated by a multidisciplinary measurement committee of the American Urological Association (AUA). Validation studies were conducted involving a total of 210 BPH patients and 108 control subjects. The final AUA symptom index includes 7 questions covering frequency, nocturia, weak urinary stream, hesitancy, intermittence, incomplete emptying and urgency. On revalidation, the index was internally consistent (Cronbach's alpha = 0.86) and the score generated had excellent test-retest reliability (r = 0.92). Scores were highly correlated with subjects' global ratings of the magnitude of their urinary problem (r = 0.65 to 0.72) and powerfully discriminated between BPH and control subjects (receiver operating characteristic area 0.85). Finally, the index was sensitive to change, with preoperative scores decreasing from a mean of 17.6 to 7.1 by 4 weeks after prostatectomy (p < 0.001). The AUA symptom index is clinically sensible, reliable, valid and responsive. It is practical for use in practice and for inclusion in research protocols.

  12. Plasma Levels of hsa-miR-619-5p and hsa-miR-1184 Differ in Prostatic Benign Hyperplasia and Cancer.

    Science.gov (United States)

    Knyazev, E N; Fomicheva, K A; Mikhailenko, D S; Nyushko, K M; Samatov, T R; Alekseev, B Ya; Shkurnikov, M Yu

    2016-05-01

    Peripheral blood plasma profiles of circulating microRNA expression were analyzed in patients with prostatic cancer and benign hyperplasia. In prostatic cancer, significant increase in hsa-miR-619-5p and hsa-miR-1184 microRNA expression and significant decrease in hsalet-7b-5p and hsa-let-7c-5p microRNA expression were observed. The role of the relationship between the microRNA expression and the activities and functions of host genes with introns encoding these microRNA is discussed. PMID:27265125

  13. 前列腺增生58例临床观察与治疗%The clinical observation and treatment in 58 cases of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    孟昭旭

    2014-01-01

    Objective:To investigate the clinical observation and treatment of benign prostatic hyperplasia.Methods:58 patients with benign prostatic hyperplasia were selected from May 2008 to May 2012.They were treated with transurethral resection of prostate, and we observed and compared the residual urine volume,maximum urine flow,prostate symptom score,prostate volume and other clinical symptoms before and after the treatment.Results:After the treatment,58 patients with benign prostatic hyperplasia had an obviously clinical effect,and the differences in clinical indexes were statistically significant before and after the treatment(P<0.05).Conclusion:Patients with benign prostatic hyperplasia can quickly recoved through the treatment of transurethral transurethral resection of prostate.This therapeutic method is simple,in addation,it has high safety and obviously curative effect,so it is worthy of clinical application and promotion.%目的:探讨前列腺增生的临床观察与治疗。方法:2008年5月-2012年5月收治前列腺增生患者58例,采用经尿道前列腺增生电切术治疗,并对患者的剩余尿量、最大尿流量、前列腺症状评分、前列腺体积等临床症状进行治疗前后的对比观察。结果:58例前列腺增生患者治疗后的临床效果明显,治疗前后的临床指标差异有统计学意义(P<0.05)。结论:经尿道前列腺增生电切术恢复快、安全性高、操作简单、疗效明显,值得临床应用和推广。

  14. Therapeutic effect evaluation of TUPKEP combined with percutaneous cystotomy and nephroscopic EMS minimally invasive therapy for benign prostatic hyperplasia with multiple large bladder calculi

    Institute of Scientific and Technical Information of China (English)

    Zhi-Hu Zhu; Bing-Xun He; Hou-Bin Kang

    2016-01-01

    Objective:To study the therapeutic effect of TUPKEP combined with nephroscopic EMS pneumatic minimally invasive therapy for benign prostatic hyperplasia with multiple large bladder calculi.Methods: Benign prostatic hyperplasia patients with multiple (large) bladder calculi who received surgical treatment in our hospital from May 2012 to October 2015 were selected as the research subjects and randomly divided into TUPKEP group and TURP group, and then perioperative situation, serum PSA levels, liver and kidney function and the degree of inflammation were compared between two groups.Results: During operation, the amount of bleeding and the weight of removed prostate of TUPKEP group were significantly lower than those of TURP group; during postoperative recovery, the time of retention catheterization of TUPKEP group was shorter than that of TURP group; 1 d, 3 d and 7 d after operation, serum PSA levels of both groups were significantly higher than those before operation and serum PSA levels of TUPKEP group were significantly lower than those of TURP group; 3 days after operation, ALT, AST, BUN and Scr levels of TUPKEP group and TURP group were not different, and IL-1β and IL-18 levels in serum as well as mRNA levels of NLPR3, ACS, Caspase-1, IL-1β and IL-18 in peripheral blood mononuclear cells of TUPKEP group were significantly lower than those of TURP group.Conclusion: TUPKEP combined with nephroscopic EMS pneumatic minimally invasive therapy for benign prostatic hyperplasia with multiple large bladder calculi causes less damage, has better resection effect on the hyperplastic gland tissue than TURP, and has equivalent long-term curative effect to TURP.

  15. CLINICAL OBSERVATION ON 60 CASES OF BENIGN HYPERPLASIA OF PROSTATE TREATED BY INJECTION OF "CHUAN-SHEN-TONG" INJECTIO INTO HUIYIN (CV 1)

    Institute of Scientific and Technical Information of China (English)

    WANG Runs-heng; GUO Xiao-chuan

    2005-01-01

    Objective:To observe the therapeutic effect of injection of "Chuan-Shen-Tong" Injectio 川参通注射液 at Huiyin 会阴 CV 1 on benign hyperplasia of prostate. Methods: 60 cases of benign hyperplasia of prostate patients were evenly randomized into treatment group and control group. Those of treatment group were treated with injection of "Chuan-Shen-Tong" Injectio composed of Rhizoma Ligustici Chuanxiong, Radix Salviae Miltiorrhizae, etc. For relieving hyperplasis of prostate, 4 mL/acupoint into Huiyin CV 1 and the other 60 cases of control group were treated by oral administration of Hytrin 1 mg/d in the 1st week and increasing 1 mg/3 d, 4 mg at most. After 28 days' treatment, their therapeutic effects were compared. Results: After treatment, of each 60 cases in treatment and control groups, 11 18.3% and 11 11.7% were controlled in their symptoms, 25 41.7% and 16 26.7% had marked improvement, 18 30.0% and 17 28.3% had improvement, and 6 10.0% and 20 33.3% failed, with the effective rate and the markedly effective rate being 90.0% and 66.7% in the treatment group and 66.7% and 38.3% in the control group respectively. The therapeutic effect of treatment group was significantly superior to that of control group P<0.01 and P<0.05. Conclusion: The therapeutic effect of point-injection of "Chuan-Shen-Tong" for benign hyperplasia of prostate is better than that of oral administration of Hytrin.

  16. A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    Yasukazu Nakanishi; Iwao Fukui; Kazunori Kihara; Hitoshi Masuda; Satoru Kawakami; Mizuaki Sakura; Yasuhisa Fujii; Kazutaka Saito; Fumitaka Koga; Masaya Ito; Junji Yonese

    2012-01-01

    Anthropometric measurements,e.g.,body weight (BW),body mass index (BMI),as well as serum prostate-specific antigen (PSA) and percent-free PSA (%fPSA) have been shown to have positive correlations with total prostate volume (TPV).We developed an equation and nomegram for estimating TPV,incorporating these predictors in men with benign prostatic hyperplasia (BPH).A total of 1852 men,including 1113 at Tokyo Medical and Dental University (TMDU) Hospital as a training set and 739 at Cancer Institute Hospital (CIH) as a validation set,with PSA levels of up to 20 ng ml-1,who underwent extended prostate biopsy and were proved to have BPH,were enrolled in this study.We developed an equation for continuously coded TPV and a logistic regression-based nomngram for estimating a TPV greater than 40 ml.Predictive accuracy and performance characteristics were assessed using an area under the receiver operating characteristics curve (AUC) and calibration plots.The final linear regression model indicated age,PSA,%fPSA and BW as independent predictors of continuously coded TPV.For predictions in the training set,the multiple correlation coefficient was increased from 0.38 for PSA alone to 0.60 in the final model.We developed a novel nomogram incorporating age,PSA,%fPSA and BW for estimating TPV greater than 40 ml.External validation confirmed its predictive accuracy,with AUC value of 0.764.Calibration plots showed good agreement between predicted probability and observed proportion.In conclusion,TPV can be easily estimated using these four independent predictors.

  17. Clinical, Laboratorial, and Urodynamic Findings of Prostatic Artery Embolization for the Treatment of Urinary Retention Related to Benign Prostatic Hyperplasia. A Prospective Single-Center Pilot Study

    Energy Technology Data Exchange (ETDEWEB)

    Antunes, Alberto A. [University of Sao Paulo Medical School, Division of Urology (Brazil); Carnevale, Francisco C., E-mail: fcarnevale@uol.com.br; Motta Leal Filho, Joaquim M. da [University of Sao Paulo Medical School, Interventional Radiology Unit (Brazil); Yoshinaga, Eduardo M. [University of Sao Paulo Medical School, Division of Urology (Brazil); Cerri, Luciana M. O. [University of Sao Paulo Medical School, Ultrasound Unit (Brazil); Baroni, Ronaldo H. [University of Sao Paulo Medical School, Magnetic Resonance Unit (Brazil); Marcelino, Antonio S. Z. [University of Sao Paulo Medical School, Ultrasound Unit (Brazil); Cerri, Giovanni G. [University of Sao Paulo Medical School, Radiology Department (Brazil); Srougi, Miguel [University of Sao Paulo Medical School, Division of Urology (Brazil)

    2013-08-01

    PurposeThis study was designed to describe the clinical, laboratorial, and urodynamic findings of prostatic artery embolization (PAE) in patients with urinary retention due to benign prostatic hyperplasia (BPH).MethodsA prospective study of 11 patients with urinary retention due to BPH was conducted. Patients underwent physical examination, prostate specific antigen (PSA) measurement, transrectal ultrasound, and magnetic resonance imaging. International prostate symptom score (IPSS), quality of life (QoL), and urodynamic testing were used to assess the outcome before and after 1 year.ResultsClinical success was 91 % (10/11 patients) with a mean follow-up of 22.3 months (range, 12-41 months). At the first year follow-up, the mean IPSS score was 2.8 points (p = 0.04), mean QoL was 0.4 points (p = 0.001), mean PSA decreased from 10.1 to 4.3 ng/mL (p = 0.003), maximum urinary flow (Qmax) improved from 4.2 to 10.8 mL/sec (p = 0.009), and detrusor pressure (Pdet) decreased from 85.7 to 51.5 cm H{sub 2}O (p = 0.007). Before PAE, Bladder Outlet Obstruction Index (BOOI) showed values >40 in 100 % of patients. After PAE, 30 % of patients were >40 (obstructed), 40 % were between 20 and 40 (undetermined), and 30 % were <20 (unobstructed). Patients with a BOOI <20 had higher PSA values at 1-day after PAE.ConclusionsClinical and urodynamic parameters improved significantly after PAE in patients with acute urinary retention due to BPH. Total PSA at day 1 after PAE was higher in patients with unobstructed values in pressure flow studies.

  18. Monopolar versus bipolar transurethral resection of prostate for benign prostatic hyperplasia: Operative outcomes and surgeon preferences, a real-world scenario

    Science.gov (United States)

    Madduri, Vijay Kumar Sarma; Bera, Malay Kumar; Pal, Dilip Kumar

    2016-01-01

    Context: Monopolar transurethral resection of prostate (M-TURP) is considered the gold standard for the management of bladder outlet obstruction due to benign prostatic hyperplasia. Its newly introduced modification, bipolar TURP (B-TURP), promises to overcome its most prominent shortcomings, namely bleeding and dilutional hyponatremia. Literature is conflicting regarding merits of B-TURP over M-TURP. Aims: To find a difference, if any, in perioperative outcomes between M-TURP and B-TURP in a real-wold setting. Settings and Design: Prospective nonrandomized study. Subjects and Methods: Operative outcomes of patients undergoing M-TURP and B-TURP from February 2014 to October 2015 were compared. Statistical Analysis Used: Categorical data were compared by Fischer exact test and numerical data were compared by independent samples Mann–Whitney U-test. P <0.05 was considered statistically significant. Results: The mean size of prostate operated by bipolar technology was significantly greater than those operated by monopolar technology (38.12 ± 9.59 cc vs. 66.49 ± 22.95 cc; P < 0.001). The mean fall in postoperative serum sodium concentration was 0.99 ± 0.76 mEq/L for the B-TURP group as compared to 3.60 ± 2.89 mEq/L for the M-TURP group (P < 0.001). The mean drop in postoperative hemoglobin concentration (P = 0.28) was statistically insignificant, even though larger glands were operated by B-TURP. There were three instances of the transurethral resection (TUR) syndrome in the M-TURP group whereas no TUR syndrome occurred in the B-TURP group. Conclusions: In spite of various contrary viewpoints in literature, surgeons prefer to operate on larger prostates using bipolar technology. B-TURP definitely reduces the incidence of bleeding and dilutional hyponatremia, making it a contender to replace M-TURP as the new gold standard. PMID:27453650

  19. Associations between metabolic syndrome and clinical benign prostatic hyperplasia in a northern urban Han Chinese population: A prospective cohort study

    Science.gov (United States)

    Zhao, Si-Cong; Xia, Ming; Tang, Jian-Chun; Yan, Yong

    2016-01-01

    Biologic rationales exist for the associations between metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH). However, epidemiologic studies have yield inconsistent results. The aim of the present study was to prospectively evaluate the associations of MetS with the risk of BPH. The presence of MetS, the number of MetS components, and the individual MetS components were evaluated. After adjusting for potential confounders, MetS was associated with increased risk of BPH (HR: 1.29; 95% CI, 1.08–1.50; p < 0.001). Compared with subjects without any MetS components, the HRs were 0.88 (95% CI, 0.67–1.09; p = 0.86), 1.18 (95% CI, 0.89–1.47; p = 0.29) and 1.37 (95% CI, 1.08–1.66; p = 0.014) for subjects with 1, 2, or ≥3 MetS components, and there was a biologic gradient between the number of MetS components and the risk of BPH (p-trend < 0.001). Central obesity and low high-density lipoprotein cholesterol were the two main divers of the associations between these two conditions, with HRs of 1.93 (95% CI, 1.14–2.72; p = 0.001) for central obesity, and 1.56 (95% CI, 1.08–2.04; p = 0.012) for low HDL-C. Our findings support the notion that MetS may be an important target for BPH prevention and intervention. PMID:27653367

  20. Association of Variants in Genes Related to the Immune Response and Obesity with Benign Prostatic Hyperplasia in CLUE II

    Science.gov (United States)

    Lopez, David S.; Peskoe, Sarah B.; Tsilidis, Konstantinos K.; Hoffman-Bolton, Judy; Helzlsouer, Kathy J.; Isaacs, William B.; Smith, Michael W.; Platz, Elizabeth A.

    2014-01-01

    BACKGROUND Chronic inflammation and obesity may contribute to the genesis or progression of benign prostatic hyperplasia (BPH) and BPH-associated lower urinary tract symptoms (LUTS). The influence of variants in genes related to these states on BPH has not been studied extensively. Thus, we evaluated the association of 17 single nucleotide polymorphisms (SNPs) in immune response genes (IL1B, IL6, IL8, IL10, TNF, CRP, TLR4, RNASEL) and genes involved in obesity, including insulin regulation (LEP, ADIPOQ, PPARG, TCF7L2), with BPH. METHODS BPH cases (N=568) and age-frequency matched controls (N=568) were selected from among adult male CLUE II cohort participants who responded in 2000 to a mailed questionnaire. BPH was defined as BPH surgery, use of BPH medications, or symptomatic BPH (American Urological Association Symptom Index Score ≥15). Controls were men who had not had BPH surgery, did not use BPH medications, and whose symptom score was ≤7. Age-adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression. RESULTS None of the candidate SNPs was statistically significantly associated with BPH. However, we could not rule out possible weak associations for CRP rs1205 (1082C>T), ADIPOQ rs1501299 (276C>A), PPARG rs1801282 (-49C>G), and TCF7L2 rs7903146 (47833T>C). After summing risk alleles, men with ≥4 had an increased BPH risk compared with those with ≤1 (OR, 1.78; 95% CI, 1.10-2.89; Ptrend=0.006). CONCLUSION SNPs in genes related to immune response and obesity, especially in combination, may be associated with BPH. PMID:25224558

  1. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association.

    Science.gov (United States)

    Barry, M J; Fowler, F J; O'Leary, M P; Bruskewitz, R C; Holtgrewe, H L; Mebust, W K

    1995-04-01

    In preparation for an outcomes study of benign prostatic hyperplasia (BPH), two measures of disease-specific health status were developed to supplement a symptom score and overall health status measures. The symptom problem index (SPI) captures how troublesome patients find their urinary symptoms. The BPH impact index (BII) measures how much their urinary problems affect various domains of health. A prospective revalidation of the refined instruments (N = 108 BPH patients and 50 controls) documented that both indices had good internal consistency (Cronbach's alpha = 0.88 and 0.79, respectively) and test-retest (r = 0.88 for both) reliabilities, correlated strongly with symptom scores (r = 0.86 and 0.77), and discriminated between BPH and control subjects (receiver-operating characteristic areas = 0.87 and 0.85, respectively). These indices were nearly as responsive as symptom scores in 50 men actively treated for BPH, and much more responsive than a non-disease-specific General Health Index (GHI), a Mental Health Index (MHI), and an Activity Index (AI). Finally, these measures capture most of the health status significance of BPH symptoms. In linear regression models constructed to predict scores on the GHI, MHI, and AI, symptom scores added little explanatory power to the SPI and, particularly, to the BII. These measures help clarify how BPH affects overall health status and function. Such measures have an important role to play in studies of the outcomes of treatment for BPH, and probably for other conditions that interfere with health status and function.

  2. Transurethral diode (810 nm) laser application for treatment of benign prostatic hyperplasia: a clinical study

    Science.gov (United States)

    Pow-Sang, Mariela; Orihuela, Eduardo; Motamedi, Massoud

    1995-05-01

    The objective of this study was to evaluate the effectiveness and safety of diode laser for the treatment of human BPH. The study included 11 patients with significant BPH that were treated with diode laser 15 watts for 180 seconds (Diomed, Inc., Gallium-Aluminum- Arsenide, 810 nm). Mean age was 69 years (range 59 to 84). Mean prostatic volume was 64.5 cc (range 30 to 96). In all cases the procedure was uncomplicated, the blood loss was minimal (< 100 cc) and all patients were discharged within the first 24 hours. On average, patients voided spontaneously after 4 days (range 1 to 11). There were no postoperative complications. At 6 months follow up the mean AUA-7 symptom score decreased from 24.27 to 8.12, the peak flow rate increased from 7.12 cc/sec, to 13.85 cc/sec, and the post void residual diminished from 58.5 cc to 38 cc. Our study suggests that diode laser therapy may offer a safe and effective alternative for the treatment of BPH.

  3. Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review

    Science.gov (United States)

    Haddad, Albert; Jabbour, Michel; Bulbul, Muhammad

    2015-01-01

    Many men have coexistent erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Phosphodiesterase type 5 (PDE5) inhibitors are effective for treating both of these conditions independently. In this review we summarise the evidence supporting a link between ED and LUTS/BPH, and the results from key clinical studies related to the use of PDE5 inhibitors for treating both conditions. The results from these studies suggest that men who have both ED and LUTS/BPH, and are concerned about their sexual dysfunction, might benefit from single-agent, holistic treatment with a PDE5 inhibitor. PMID:26413339

  4. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer

    OpenAIRE

    Elkahwaji JE

    2012-01-01

    Johny E Elkahwaji1–31Section of Urologic Surgery, 2Section of Medical Oncology and Hematology, 3Genitourinary Oncology Research Laboratory, University of Nebraska Medical Center, Omaha, NE, USAAbstract: Benign prostatic hyperplasia and prostate cancer remain the most prevalent urologic health concerns affecting elderly men in their lifetime. Only 20% of benign prostatic hyperplasia and prostate cancer cases coexist in the same zone of the prostate and require a long time for initiat...

  5. Enlarged prostate

    Science.gov (United States)

    BPH; Benign prostatic hyperplasia (hypertrophy); Prostate - enlarged ... Lepor H. Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Wein AJ, ed. Campbell-Walsh Urology . 10th ...

  6. Blood oxygenation level-dependent magnetic resonance imaging during carbogen breathing: differentiation between prostate cancer and benign prostate hyperplasia and correlation with vessel maturity

    Science.gov (United States)

    Di, Ningning; Mao, Ning; Cheng, Wenna; Pang, Haopeng; Ren, Yan; Wang, Ning; Liu, Xinjiang; Wang, Bin

    2016-01-01

    Objective The aim of this study was to investigate whether the blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) can evaluate tumor maturity and preoperatively differentiate prostate cancer (PCa) from benign prostate hyperplasia (BPH). Patients and methods BOLD MRI based on transverse relaxation time*-weighted echo planar imaging was performed to assess PCa (19) and BPH (22) responses to carbogen (95% O2 and 5% CO2). The average signal values of PCa and BPH before and after carbogen breathing and the relative increased signal values were computed, respectively. The endothelial-cell marker, CD31, and the pericyte marker, α-smooth muscle actin (mature vessels), were detected with immunofluorescence, and were assessed by microvessel density (MVD) and microvessel pericyte density (MPD). The microvessel pericyte coverage index (MPI) was used to evaluate the degree of vascular maturity. The changed signal from BOLD MRI was correlated with MVD, MPD, and MPI. Results After inhaling carbogen, both PCa and BPH showed an increased signal, but a lower slope was found in PCa than that in BPH (PMPI than BPH. The increased signal intensity was positively correlated with MPI in PCa and that in BPH (r=0.616, P=0.011; r=0.658, P=0.002); however, there was no correlation between the increased signal intensity and MPD or MVD in PCa than that in BPH (P>0.05). Conclusion Our results confirmed that the increased signal values induced by BOLD MRI well differentiated PCa from BPH and had a positive correlation with vessel maturity in both of them. BOLD MRI can be utilized as a surrogate marker for the noninvasive assessment of the degree of vessel maturity. PMID:27462169

  7. Clinical Analysis of 28 cases with Benign Prostatic Hyperplasia%前列腺增生28例临床分析

    Institute of Scientific and Technical Information of China (English)

    喻德康

    2007-01-01

    目的 了解尿道前列腺汽化电切术(transurethral electrovaporization of the prostate, TUVP)对良性前列腺增生症(benign prostatic hyperplasia , BPH)的疗效.方法 回顾性分析2003年1月~2005年1月于我院就诊的28例BPH患者资料.28例患者均采用TUVP治疗.结果 ①术后共发生并发症2例.②患者术后6个月最大尿流率、国际前列腺症状评分、以及生活质量评分等指标与术前比较均有明显改善(P<0.05).

  8. Medical and Surgical Treatment Modalities for Lower Urinary Tract Symptoms in the Male Patient Secondary to Benign Prostatic Hyperplasia: A Review.

    Science.gov (United States)

    Macey, Matthew Ryan; Raynor, Mathew C

    2016-09-01

    Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is one of the most common ailments affecting aging men. Symptoms typically associated with BPH include weak stream, hesitancy, urgency, frequency, and nocturia. More serious complications of BPH include urinary retention, gross hematuria, bladder calculi, recurrent urinary tract infection, obstructive uropathy, and renal failure. Evaluation of BPH includes a detailed history, objective assessment of urinary symptoms with validated questionnaires, and measurement of bladder function parameters, including uroflowmetry and postvoid residual. In general, treatment of LUTS associated with BPH is based on the effect of the symptoms on quality of life (QOL) and include medical therapy aimed at reducing outlet obstruction or decreasing the size of the prostate. If medical therapy fails or is contraindicated, various surgical options exist. As the elderly population continues to grow, the management of BPH will become more common and important in maintaining patient's QOL. PMID:27582609

  9. Inhibitory Effect of Yongdamsagan-Tang Water Extract, a Traditional Herbal Formula, on Testosterone-Induced Benign Prostatic Hyperplasia in Rats.

    Science.gov (United States)

    Park, Eunsook; Lee, Mee-Young; Jeon, Woo-Young; Lee, Nari; Seo, Chang-Seob; Shin, Hyeun-Kyoo

    2016-01-01

    Yongdamsagan-tang, a traditional herbal formula, is used widely for the treatment of inflammation and viral diseases. In this study, we investigated whether Yongdamsagan-tang water extract (YSTE) affects testosterone propionate- (TP-) induced benign prostatic hyperplasia (BPH) in a rat model. To induce BPH, rats were injected subcutaneously with 10 mg/kg of TP every day. YSTE was administrated daily by oral gavage at doses of 200 and 500 mg/kg along with the TP injection. After 4 weeks, prostates were collected, weighed, and analyzed. The relative prostrate weight was significantly lower in both YSTE groups (200 and 500 mg/kg/day) compared with the TP-induced BPH group. YSTE administration reduced the expression of proliferation markers PCNA, cyclin D1, and Ki-67 and the histological abnormalities observed in the prostate in TP-induced BPH rats. YSTE attenuated the increase in the TP-induced androgen concentration in the prostate. The YSTE groups also showed decreased lipid peroxidation and increased glutathione reductase activity in the prostate. These findings suggest that YSTE effectively prevented the development of TP-induced BPH in rats through antiproliferative and antioxidative activities and might be useful in the clinical treatment of BPH. PMID:27504137

  10. Inhibitory Effect of Yongdamsagan-Tang Water Extract, a Traditional Herbal Formula, on Testosterone-Induced Benign Prostatic Hyperplasia in Rats

    Science.gov (United States)

    Lee, Mee-Young; Lee, Nari

    2016-01-01

    Yongdamsagan-tang, a traditional herbal formula, is used widely for the treatment of inflammation and viral diseases. In this study, we investigated whether Yongdamsagan-tang water extract (YSTE) affects testosterone propionate- (TP-) induced benign prostatic hyperplasia (BPH) in a rat model. To induce BPH, rats were injected subcutaneously with 10 mg/kg of TP every day. YSTE was administrated daily by oral gavage at doses of 200 and 500 mg/kg along with the TP injection. After 4 weeks, prostates were collected, weighed, and analyzed. The relative prostrate weight was significantly lower in both YSTE groups (200 and 500 mg/kg/day) compared with the TP-induced BPH group. YSTE administration reduced the expression of proliferation markers PCNA, cyclin D1, and Ki-67 and the histological abnormalities observed in the prostate in TP-induced BPH rats. YSTE attenuated the increase in the TP-induced androgen concentration in the prostate. The YSTE groups also showed decreased lipid peroxidation and increased glutathione reductase activity in the prostate. These findings suggest that YSTE effectively prevented the development of TP-induced BPH in rats through antiproliferative and antioxidative activities and might be useful in the clinical treatment of BPH.

  11. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability

    Directory of Open Access Journals (Sweden)

    Barkin J

    2011-10-01

    Full Text Available Jack BarkinHumber River Regional Hospital, Toronto, Canada and Department of Surgery, University of Toronto, Toronto, Ontario, CanadaAbstract: Lower urinary tract symptoms (LUTS caused by benign prostatic hyperplasia (BPH will usually affect older men, of whom 50% over the age 60 years and almost 90% in their nineties will be bothered enough by their symptoms that they request some type of treatment. However, symptomatic bother may also affect men in their forties with a prevalence rate of almost 18%. The International Prostate Symptom Score (IPSS has become the most widely used and best validated questionnaire to allow the patient to quantify the severity of his LUTS/BPH symptoms. This score has become the cornerstone in demonstrating the “rate of symptom response” for the patient who has been exposed to any type BPH management. Question 8 on the IPSS score is what is defined as the “Quality of Life” question or what is also termed the “Bothersome Index.” The score out of 6 as declared by the patient will reflect the degree of concern that the patient is feeling about his symptoms and the reduction of the score after treatment is a statement of their improved quality of life. There are 2 families of accepted medical therapy to treat the symptoms of BPH and potentially prevent the most worrisome long-term sequelae of progression of BPH: urinary retention or the need for surgery. When defining the impact of the main types of medical therapy, the alpha blockers have been termed the “openers” and the 5 alpha-reductase inhibitors are described as the “shrinkers.” Since they each offer a different mechanism of effect, the concept of combination therapy was raised and trialed many times over recent years. The final aspect of any medical therapy is the patient's satisfaction with the treatment and the side effects. In the CombAT (Combination of Avodart and Tamsulosin trial a new assessment was developed and tested called the Patient

  12. Goserelin acetate before transurethral resection of moderately enlarged benign prostatic hyperplasia: Prospective randomised-controlled clinical trial

    Science.gov (United States)

    Abo El-Enen, Mohamed; Tawfik, Ahmed; El-Abd, Ahmed S.; Ragab, Maged; El-Abd, Sherin; Elrashidy, Mohamed; Elmashad, Nehal; Rasheed, Mohamed; El-Abd, Shawky

    2015-01-01

    Objective To evaluate the impact of a luteinising hormone-releasing hormone (LHRH) agonist, goserelin acetate (GA), on surgical blood loss during transurethral resection of the prostate (TURP), as well as its histopathological effect on prostatic microvessel density (MVD). Patients and methods Patients who underwent TURP due to benign prostatic enlargement (60–100 mL) were randomly subdivided into two equal groups according to whether they received preoperative GA administration (3.6 mg; group A) or not (group B). Evaluation parameters were operative time, weight of resected prostatic tissue, perioperative haematocrit (HCT) changes, estimation of intraoperative blood loss, and suburethral and stromal prostatic MVD. Effects of GA on prostate weight and any possible side-effects were also monitored. Results In all, 35 and 33 patients were included in groups A and B, respectively. Operative time and HCT values’ changes were significantly less in group A (P < 0.05). Also, operative blood loss (both total and adjusted per weight of resected tissue) was lower in group A, at a mean (SD) of 178.13 (77.71) mL and 3.74 (1.52) mL/g vs 371.75 (91.09) mL and 8.59 (2.42) mL/g (P < 0.001). The median MVD in both suburethral [8 vs 11 vessels/high-power field (HPF)] and stromal tissues (9 vs 17 vessels/HPF) were significantly lower in group A (P < 0.001). Side-effects were minimal. Conclusion A single dose of GA, a LHRH agonist, before TURP is safe and effective in reducing surgical blood loss. It significantly reduced MVD in both suburethral and stromal nodular prostatic tissues without regional discrepancy. PMID:26966595

  13. Safety and efficacy of a novel Prunus domestica extract (Sitoprin, CR002) on testosterone-induced benign prostatic hyperplasia (BPH) in male Wistar rats.

    Science.gov (United States)

    Swaroop, Anand; Bagchi, Manashi; Kumar, Pawan; Preuss, Harry G; Bagchi, Debasis

    2015-01-01

    The efficacy of a novel Prunus domestica bark extract (Sitoprin, CR002) was investigated on testosterone propionate (TP)-induced benign prostatic hyperplasia (BPH) in male Wistar rats. BPH was induced by daily subcutaneous administration of TP (3.0 mg/kg) over a period of 15 days (interim sacrifice group) and for an additional 21 days (terminal sacrifice group). We evaluated the dose-dependent efficacy (0, 50, 100 and 200 mg/kg body weight/day) of CR002 and a control group against BPH, and compared with a reference standard Prunus africana extract (CR001). Extensive clinical examinations were carried out on days 1, 7, 14, 21, 28 and 35 of treatment period to determine the onset, duration and severity of clinical signs. Clinical pathology, hematology, biochemistry and histopathology were performed on days 15 and 35, prior to necropsy. Animals were fasted overnight prior to blood collection. Prostate glands and tissues were examined. On day 36, histopathology of ventral prostrate of control rats demonstrates single layer of columnar mucin secreting epithelial cells along with a lumen occupied with eosinophilic secretion. In contrast, CR002 and CR001 groups (100 and 200 mg/kg/day) exhibited no hyperplasia and proliferation of epithelial cells. Prostate histopathology of these treated groups was comparable with control rats. The hyperplasia and hypertrophy of prostrate was reduced to single-layered cell indicating the efficacy of CR002 and CR001. Overall, results demonstrate that CR002 exhibits therapeutic efficacy/activity in TP-induced BPH in rats, which is comparable to CR001.

  14. Benign prostatic hyperplasia and new treatment options – a critical appraisal of the UroLift system

    Directory of Open Access Journals (Sweden)

    McNicholas TA

    2016-05-01

    Full Text Available Thomas Anthony McNicholas1–3 1Section of Urology, Royal Society of Medicine, London, UK; 2Urology Department, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; 3Faculty of Health and Human Sciences, University of Hertfordshire, Hatfield, Herts, UK Abstract: The prostatic urethral lift procedure, more commonly known as UroLift, has been designed to improve male lower urinary tract symptoms while avoiding the complications and disadvantages of existing drug and surgical therapies. In particular, UroLift does not damage ejaculatory function or affect orgasmic sensation. It appears an option for men who wish to avoid long-term drug therapy, the side effects of drugs or surgery and who do not need or will not accept traditional surgical treatments. UroLift was introduced following a series of planned studies that led to US Food and Drug Administration approval in September 2013. UroLift has recently been approved by the UK National Institute for Clinical and Health Excellence (September 2015 as effective and safe and cost-effective for use in the UK health system. This review describes the device and the procedure and the evidence base that has led to those approvals. Keywords: UroLift, prostatic urethral lift, LUTS prostatic hyperplasia, minimally invasive, BPH

  15. Transurethral Resection of the Prostate (TURP) Versus Original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a Single Center, Prospective, Urodynamic-Controlled Analysis

    Energy Technology Data Exchange (ETDEWEB)

    Carnevale, Francisco C., E-mail: fcarnevale@uol.com.br [University of Sao Paulo Medical School, Interventional Radiology Unit (Brazil); Iscaife, Alexandre, E-mail: iscaifeboni@yahoo.com.br; Yoshinaga, Eduardo M., E-mail: dumuracca@ig.com.br [University of Sao Paulo Medical School, Division of Urology (Brazil); Moreira, Airton Mota, E-mail: motamoreira@gmail.com [University of Sao Paulo Medical School, Interventional Radiology Unit (Brazil); Antunes, Alberto A., E-mail: antunesuro@uol.com.br; Srougi, Miguel, E-mail: srougi@uol.com.br [University of Sao Paulo Medical School, Division of Urology (Brazil)

    2016-01-15

    PurposeTo compare clinical and urodynamic results of transurethral resection of the prostate (TURP) to original and PErFecTED prostate artery embolization (PAE) methods for benign prostatic hyperplasia.MethodsWe prospectively randomized 30 patients to receive TURP or original PAE (oPAE) and compared them to a cohort of patients treated by PErFecTED PAE, with a minimum of 1-year follow-up. Patients were assessed for urodynamic parameters, prostate volume, international prostate symptom score (IPSS), and quality of life (QoL).ResultsAll groups were comparable for all pre-treatment parameters except bladder contractility and peak urine flow rate (Q{sub max}), both of which were significantly better in the TURP group, and IIEF score, which was significantly higher among PErFecTED PAE patients than TURP patients. All groups experienced significant improvement in IPSS, QoL, prostate volume, and Q{sub max}. TURP and PErFecTED PAE both resulted in significantly lower IPSS than oPAE but were not significantly different from one another. TURP resulted in significantly higher Q{sub max} and significantly smaller prostate volume than either original or PErFecTED PAE but required spinal anesthesia and hospitalization. Two patients in the oPAE group with hypocontractile bladders experienced recurrence of symptoms and were treated with TURP. In the TURP group, urinary incontinence occurred in 4/15 patients (26.7 %), rupture of the prostatic capsule in 1/15 (6.7 %), retrograde ejaculation in all patients (100 %), and one patient was readmitted for temporary bladder irrigation due to hematuria.ConclusionsTURP and PAE are both safe and effective treatments. TURP and PErFecTED PAE yield similar symptom improvement, but TURP is associated with both better urodynamic results and more adverse events.

  16. 手术治疗慢性前列腺炎并前列腺增生症的临床效果观察%Clinical effect of surgical treatment of chronic prostatitis and benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    董向明; 周光辉

    2015-01-01

    OBJECTIVE: To: study the clinical effect of surgical treatment of chronic prostatitis and benign prostatic hyperplasia. Methods: 128 cases of chronic prostatitis and benign prostatic hyperplasia were selected as the research object in our hospital from January 2013 to January. randomly divided into observation group and control group, 64 cases in each group, aged 45~75 years, average age (53+9.6 years), the observation group of chronic prostatitis and prostatic hyperplasia patients for surgery, mainly is for suprapubic bladder and prostate removal surgery, control group prostatic hyperplasia patients with surgical treatment, and to observe the two groups of patients after complications. Results: the observation group of patients with chronic prostatitis and benign prostatic hyperplasia surgery, the effect is poor, the complications are more. Conclusion: Patients with chronic prostatitis in patients with benign prostatic hyperplasia, and between the two presented is is correlation. therefore, in surgery must strictly grasp the operation indication, operation to do a good job in the corresponding prevention and control measures, and thus avoid patients after complication.%目的:研究手术治疗慢性前列腺炎并前列腺增生症的临床效果。方法本研究选择我院自2013年1月~2015年1月收治的128例慢性前列腺炎并前列腺增生症患者作为研究对象。随机分为观察组和对照组,每组64例,年龄45~75岁,平均年龄(53±9.6)岁,其中观察组慢性前列腺炎并前列腺增生症患者进行手术治疗,主要是进行耻骨上膀胱前列腺摘除手术,对照组前列腺增生症患者进行手术治疗,并观察两组患者手术后的并发症发生情况。结果观察组慢性前列腺炎并前列腺增生症患者手术的疗效较差,并发症较多。结论慢性前列腺炎患者对合并前列腺增生,并且二者之间呈现的是正相关联系,因此,在进行手术治疗时就必须

  17. Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan

    Science.gov (United States)

    Masumori, Naoya; Tsukamoto, Taiji; Shibuya, Akihiko; Miyao, Noriomi; Kunishima, Yasuharu; Iwasawa, Akihiko

    2016-01-01

    Purpose Our aim was to prospectively analyze the 3-year outcomes of naftopidil treatment for patients with benign prostatic hyperplasia (BPH), including those who dropped out during follow-up and had retreatment for BPH after termination of the drug within 3 years. Patients and methods Naftopidil, 50 mg/d or 75 mg/d, was given to 117 patients having BPH aged 50 years and older who had international prostate symptom scores (IPSS) ≥8. They were prospectively followed for 3 years with periodic evaluation. If naftopidil was terminated, the reason was determined. For patients with termination, an outcome survey was done to evaluate the status of retreatment for BPH at 3 years. Results Twenty-five patients (21.4%) continued the same medication for 3 years. The total IPSS, quality of life index, BPH problem index, and maximum flow rate were significantly improved during 3 years. Treatment failure defined as symptomatic progression (an increase in the IPSS of ≥4 points compared to the baseline value), development of acute urinary retention, conversion to other α1-blockers, add-on of a 5α-reductase inhibitor, or conversion to surgery was observed in 41 patients (35.0%). In the univariate analysis, age, prostate volume, and serum prostate-specific antigen were predictors of treatment failure. Of the 50 patients who discontinued naftopidil during the follow-up, only 13 (26%) patients reported that they needed retreatment with α1-blockers and/or surgery within 3 years. Conclusion Long-term efficacy of naftopidil was observed, although older age, increased prostate volume, and elevated prostate-specific antigen at baseline were highly likely to result in treatment failure. Even after termination for various reasons, only a small portion of the patients needed retreatment for BPH within 3 years. PMID:27524886

  18. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia.

    Science.gov (United States)

    Zong, Huan-Tao; Peng, Xiao-Xia; Yang, Chen-Chen; Zhang, Yong

    2011-11-01

    5α-reductase inhibitors (5α-RIs), including finasteride and dutasteride, are commonly used medical therapies for benign prostatic hyperplasia (BPH). Many studies reported that preoperative 5α-RI had impact on intraoperative haemorrhage during surgery for BPH, but it was still in controversial. So, we conducted a systematic review of the effects and mechanisms of 5α-RIs on intraoperative bleeding for BPH. MEDLINE, EMBASE, the Cochrane Controlled Trail Register of Controlled Trials and the reference lists of retrieved studies were searched in the analysis. Sixteen publications involving 15 different randomized controlled trials (RCTs) and a total of 1156 patients were used in the analysis, including 10 RCTs for finasteride and five RCTs for dutasteride. We found that preoperative finasteride treatment decreases microvessel density (MVD) in resected prostate specimens. Total blood loss, blood loss per gram of resected prostate tissue and decreases in haemoglobin were all greatly reduced in the finasteride group as compared to controls. Dutasteride appeared to have no effect on bleeding. This meta-analysis shows that preoperative finasteride treatment could decrease intraoperative haemorrhage during surgery for BPH. Preoperative dutasteride had no effect on intraoperative haemorrhage, but further high-quality prospective studies are still needed to confirm this observation. PMID:21892196

  19. Symptomatic benign prostatic hyperplasia: the role of 5-alpha-reductase inhibitors in the prevention of acute urinary retention and surgical therapy

    Directory of Open Access Journals (Sweden)

    Norma Marigliano

    2012-01-01

    Full Text Available Benign prostatic hyperplasia (BPH is a disease that affects over 50% of males aged 50 years or older. In men aged >80 years, the incidence is 90%. BPH occurs in 9-25% of males aged 40 to 79 years. Fifty percent of patients with BPH are symptomatic. The symptoms include reduced urinary flow, nocturia, defective bladder emptying, urinary hesitancy, and dysuria. Disease progression can be associated with acute urinary retention (AUR. Prostatic obstruction includes mechanical and dynamic components, the latter mediated by alpha-muscarinic receptors. Treatment with alpha-1-blockers (alfuzosin, doxazosin, tamsulosin, and terazosin leads to rapid amelioration of symptoms and urinary flow, usually within one or two weeks. The 5-alpha reductase inhibitors (5-ARIs are “disease-modifying drugs.” They control the growth of the prostate by blocking the conversion of testosterone into dihydrotestosterone (DHT. Finasteride is a 5–ARI that is selective for type 2 receptors. Dutasteride is a powerful inhibitor of both 5- alpha reductase isoforms (type 1 and 2 and produces more complete suppression of DHT synthesis than finasteride. Dutasteride also has a much longer half-life than finasteride (five weeks versus five to six hours. The authors review the results of clinical trials involving finasteride and dutasteride, with and without alpha-1-blockers, highlighting the important role of dutasteride in improving acute urinary retention and eliminating the need for surgical therapy.

  20. Effects of stinging nettle root extracts and their steroidal components on the Na+,K(+)-ATPase of the benign prostatic hyperplasia.

    Science.gov (United States)

    Hirano, T; Homma, M; Oka, K

    1994-02-01

    The effects of organic-solvent extracts of Urtica dioica (Urticaceae) on the Na+,K(+)-ATPase of the tissue of benign prostatic hyperplasia (BPH) were investigated. The membrane Na+,K(+)-ATPase fraction was prepared from a patient with BPH by a differential centrifugation of the tissue homogenate. The enzyme activity was inhibited by 10(-4)-10(-5) M of ouabain. The hexane extract, the ether extract, the ethyl acetate extract, and the butanol extract of the roots caused 27.6-81.5% inhibition of the enzyme activity at 0.1 mg/ml. In addition, a column extraction of stinging nettle roots using benzene as an eluent afforded efficient enzyme inhibiting activity. Steroidal components in stinging nettle roots, such as stigmast-4-en-3-one, stigmasterol, and campesterol inhibited the enzyme activity by 23.0-67.0% at concentrations ranging from 10(-3)-10(-6) M. These results suggest that some hydrophobic constituents such as steroids in the stinging nettle roots inhibited the membrane Na+,K(+)-ATPase activity of the prostate, which may subsequently suppress prostate-cell metabolism and growth. PMID:7510891

  1. A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    Huan-Tao Zong; Xiao-Xia Peng; Chen-Chen Yang; Yong Zhang

    2011-01-01

    5α-reductase inhibitors (5α-RIs),including finasteride and dutasteride,are commonly used medical therapies for benign prostatic hyperplasia (BPH).Many studies reported that preoperative 5α-RI had impact on intraoperative haemorrhage during surgery for BPH,but it was still in controversial.So,we conducted a systematic review of the effects and mechanisms of 5α-RIs on intraoperative bleeding for BPH.MEDLINE,EMBASE,the Cochrane Controlled Trail Register of Controlled Trials and the reference lists of retrieved studies were searched in the analysis.Sixteen publications involving 15 different randomized controlled trials (RCTs) and a total of 1156 patients were used in the analysis,including 10 RCTs for finasteride and five RCTs for dutasteride.We found that preoperative finasteride treatment decreases microvessel density (MVD) in resected prostate specimens.Total blood loss,blood loss per gram of resected prostate tissue and decreases in haemoglobin were all greatly reduced in the finasteride group as compared to controls.Dutasteride appeared to have no effect on bleeding.This meta-analysis shows that preoperative finasteride treatment could decrease intraoperative haemorrhage during surgery for BPH.Preoperative dutasteride had no effect on intraoperative haemorrhage,but further high-quality prospective studies are still needed to confirm this observation.

  2. High-energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia: comparative study between 30-and 60-minute single treatments.

    Directory of Open Access Journals (Sweden)

    Yokoyama T

    2004-06-01

    Full Text Available We retrospectively evaluated the subjective and objective treatment results of transurethral microwave thermotherapy (TUMT for benign prostatic hyperplasia (BPH and explored the difference in effectiveness between 30- and 60-min single treatments. From June 1997 through March 2003, 58 men with BPH underwent TUMT using the Targis device. Twenty-seven and 31 patients each received a single treatment of 60 or 30 min, respectively. Evaluations after treatment included a clinical determination of the International Prostate Symptom Score, urodynamic assessments by peak flow rate, and magnetic resonance imaging (MRI. In the 60-min treatment, the symptom score improved significantly, from 17.9 to 9.5 after 2 months. Similarly, there was a significant improvement in peak flow rate, from 6.7 to 11.2 ml/sec after 2 months. In the 30-min treatment, the symptom score also improved significantly, from 18.4 to 13.4 after 2 weeks. Similarly, there was a significant improvement in the peak flow rate, from 6.4 to 11.7 ml/sec after 1 month. MRI imaging showed necrosis of the prostate gland 2 weeks after either treatment. These results demonstrated that both the 60-min and the 30-min treatments were effective for patients with BPH. Moreover, the 30-min treatment led to quicker improvement than the 60-min treatment. Thus, a 30-min TUMT protocol is considered recommendable for this treatment.

  3. Theoretical analysis of transurethral laser-induced thermo-therapy for treatment of benign prostatic hyperplasia. Evaluation of a water-cooled applicator

    Science.gov (United States)

    Sturesson, C.; Andersson-Engels, S.

    1996-03-01

    A mathematical model for predicting the temperature rise in transurethral laser-induced thermo-therapy for benign prostatic hyperplasia was developed. In the model an optical line source emitting light from an Nd:YAG laser isotropically was placed in the urethra. Water cooling of the urethral epithelium was modelled using a two-tube system. The relationship between the difference in outlet and inlet water temperatures and the highest tissue temperature level reached was theoretically investigated. It was found that the water temperature difference was linearly dependent on the steady-state maximum tissue temperature. The theoretical calculations suggest that the water-cooled applicator can be used to measure the maximum tissue temperature. With temperature control, the prostatic tissue temperature can be prevented from exceeding the boiling point of water, excluding tissue carbonization. The model was also used to evaluate the influence of a number of different parameters on the damaged tissue volume. Increasing the urethral lumen radius by a factor of two by means of inserting different sized tubes was found to augment the tissue volume raised to therapeutic temperatures by up to 50%. The calculations showed that cooling of the urethral epithelium can result in an increase in the damaged volume by 80% as compared to not applying any cooling. The temperature of the cooling water was found to influence the tissue temperature only to a small extent.

  4. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].

    Science.gov (United States)

    Utsunomiya, Noriaki; Matsumoto, Keiyu; Tsunemori, Hiroyuki; Muguruma, Koei; Kawakita, Mutsushi; Kamiyama, Yuki; Kanamaru, Sojun; Ito, Noriyuki; Tsukazaki, Hideki; Shirahase, Toshiaki; Takahashi, Takeshi

    2016-07-01

    We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH). Thirty one patients were enrolled in a randomized crossover study. Fourteen patients were initially prescribed naftopidil 75 mg (N) for 8 weeks, followed by tamsulosin 0.2 mg and solifenacin 5 mg (TS) for 8 weeks (group N) ; another 17 were initially prescribed TS, followed by N (group TS). The efficacy variables were the changes in international prostate symptom score (I-PSS), quality of life (QOL) score, overative bladder symptom score (OABSS), and post-void residual (PVR) urine volume. After the study, a questionnaire survey was carried out about the choice of treatment. After treatment with each agent, total I-PSS, storage symptom score, QOL score and OABSS except for the daytime frequency were significantly improved from baseline. PVR was significantly increased after TS treatment. There were no significant differences between the two treatments except for PVR. As a result of the questionnaire survey, 13 patients chose N and 17 chose TS. In conclusion, N monotherapy can be expected to have an equal effect in the treatment of LUTS with OAB secondary to BPH in comparison with TS combination therapy. PMID:27569351

  5. Impact of pharmacotherapy on the incidence of transurethral prostatectomy for benign prostatic hyperplasia and the implications for surgical training.

    LENUS (Irish Health Repository)

    Long, R

    2012-01-31

    Medical therapy has become first line treatment for Benign Prostatic Hypertrophy (BPH) and in many cases TURP may no longer be required. Proof and quantification of this evolution in practice has been somewhat elusive and provided the principle impetus for this study. This is a retrospective study of BPH management in Republic of Ireland from 1995 to 2008. National treatment databases were sourced for numbers undergoing TURP and pharmacotherapy prescribing data was obtained from individual pharmaceutical companies. A total of 28,240 TURP\\'s were performed nationally between 1995 and 2008. TURP\\'s performed annually, decreased by 1,494 (51%), alpha-blocker prescriptions increased from 8,710 to 302,159 units and the number of urology trainees increased by 10 (60%). Clear association between decreases in TURP\\'s and increases in pharmacotherapy for BPH is demonstrated. Implications on training likely exist and will require proper evaluation in order to maintain future standards in this surgical practice.

  6. Impact of pharmacotherapy on the incidence of transurethral prostatectomy for benign prostatic hyperplasia and the implications for surgical training.

    LENUS (Irish Health Repository)

    Long, R

    2010-10-01

    Medical therapy has become first line treatment for Benign Prostatic Hypertrophy (BPH) and in many cases TURP may no longer be required. Proof and quantification of this evolution in practice has been somewhat elusive and provided the principle impetus for this study. This is a retrospective study of BPH management in Republic of Ireland from 1995 to 2008. National treatment databases were sourced for numbers undergoing TURP and pharmacotherapy prescribing data was obtained from individual pharmaceutical companies. A total of 28,240 TURP\\'s were performed nationally between 1995 and 2008. TURP\\'s performed annually, decreased by 1,494 (51%), alpha-blocker prescriptions increased from 8,710 to 302,159 units and the number of urology trainees increased by 10 (60%). Clear association between decreases in TURP\\'s and increases in pharmacotherapy for BPH is demonstrated. Implications on training likely exist and will require proper evaluation in order to maintain future standards in this surgical practice.

  7. Prostatic Stromal Hyperplasia with Atypia

    Directory of Open Access Journals (Sweden)

    Ryan C. Hutchinson

    2013-01-01

    Full Text Available Prostatic stromal hyperplasia with atypia (PSHA is a rare histologic finding diagnosed incidentally on prostate biopsies, transurethral resection specimens, and radical prostatectomy specimens. PSHA has a bizarre histologic appearance and these lesions often raise concern for sarcoma; however, their clinical course is indolent and does not include extraprostatic progression. We discuss a case of PHSA discovered on prostate biopsy performed for an abnormal digital rectal examination and review the literature on this rare pathologic finding.

  8. Prostatic Stromal Hyperplasia with Atypia

    OpenAIRE

    Hutchinson, Ryan C.; Wu, Kevin J.; Cheville, John C.; Thiel, David D

    2013-01-01

    Prostatic stromal hyperplasia with atypia (PSHA) is a rare histologic finding diagnosed incidentally on prostate biopsies, transurethral resection specimens, and radical prostatectomy specimens. PSHA has a bizarre histologic appearance and these lesions often raise concern for sarcoma; however, their clinical course is indolent and does not include extraprostatic progression. We discuss a case of PHSA discovered on prostate biopsy performed for an abnormal digital rectal examination and revie...

  9. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm® system: evaluation of acute ablative capabilities in the human prostate

    Directory of Open Access Journals (Sweden)

    Dixon CM

    2015-01-01

    Full Text Available Christopher M Dixon,1 Edwin Rijo Cedano,2 Lance A Mynderse,3 Thayne R Larson4 1Lenox Hill Hospital, New York, NY, USA; 2Department of Urology, Clinica Canela, La Romana, Dominican Republic; 3Department of Urology, Mayo Clinic, Rochester, MN, USA; 4Institute of Medical Research, Scottsdale, AZ, USA Background: The purpose of this study was to assess the acute ablative characteristics of transurethral convective water vapor (steam using the Rezūm® system in men with benign prostatic hyperplasia through histologic and radiographic studies. Methods: Seven patients were treated with transurethral intraprostatic injections of sterile steam under endoscopic visualization followed by previously scheduled adenectomies. The extirpated adenomas were grossly examined followed by whole mount sectioning and staining with triphenyl-tetrazolium chloride (TTC to evaluate thermal ablation. Histology was performed after hematoxylin and eosin staining on one prostate. After review of results from the first patient cohort, an additional 15 patients with clinical benign prostatic hyperplasia were treated followed by gadolinium-enhanced magnetic resonance imaging (MRI at one week. Results: In the first patient cohort, gross examination of TTC-stained tissue showed thermal ablation in the transition zone. In addition, there was a distinct interface between viable and necrotic prostatic parenchyma. Histopathologic examination revealed TTC staining-outlined necrotic versus viable tissue. Gadolinium-enhanced MRIs in the cohort of 15 patients demonstrated lesion defects in all patients at 1 week post-procedure. Coalesced lesions were noted with a mean (± standard deviation lesion volume of 9.6±8.5 cm3. The largest lesion volume was 35.1 cm3. Ablation using vapor was rapid and remained confined to the transition zone, consistent with the thermodynamic principles of convective thermal energy transfer. Conclusion: Thermal ablation was observed in all specimens. The

  10. The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: A narrative review

    Directory of Open Access Journals (Sweden)

    Rocco Damiano

    2016-07-01

    Full Text Available Objective: Phytotherapeutic compounds are largely used in the treatment of lower urinary tract symptoms (LUTS related to benign prostatic hyperplasia (BPH due to low side-effect profiles and costs, high level of acceptance by patients and a low rate of dropout. Here, we aimed to analyze all available evidence on the role of Cucurbita pepo in the treatment of LUTS-BPH. Material and methods: In May 2016 a systematic search was carried out thorough National Library of Medicine Pubmed, Scopus database and the ISI Web of Knowledge official website in order to identify all published studies on Cucurbita pepo and BPH. The following search strings were used: “Cucurbita pepo” OR “pumpkin seed” AND “prostate”; “Cucurbita pepo” AND “antiandrogen” OR “antiproliferative” OR “anti-inflammatory” OR “antioxidant activities”; “cucurbita pepo” OR “pumpkin seed” AND “LUTS” AND “symptoms improvement” OR “quality of life”. We consider for the present analysis only studies related to LUTS-BPH. Results: Among all 670 screened, 16 were related to LUTSBPH and finally analyzed. Among all, ten of them were performed in “in vitro setting” showing anti-inflammatory and antiandrogen effect, and a reduction in prostate growth and detrusor activity, while six were clinical studies. In all studies an improvement in International Prostatic Symptoms Score (IPSS and uroflowmetry parameters has been reported. In 4 studies, an improvement in quality of life has been reported. Conclusion: On the basis of our narrative review, the use of Cucurbita pepo in the management of patients affected by LUTS-BPH seems to be useful for improving symptoms and quality of life. However, future clinical trials are requested to confirm these promising results.

  11. Analysis of the risk factors for incidental carcinoma of the prostate in patients with benign prostatic hyperplasia Análise dos fatores de risco para o diagnóstico do carcinoma incidental da próstata em pacientes com hiperplasia prostática benigna

    OpenAIRE

    Alberto Azoubel Antunes; Geraldo de Campos Freire; Domingos Aiello Filho; José Cury; Miguel Srougi

    2006-01-01

    PURPOSE: To determine the occurence of incidental carcinoma of the prostate, its characteristics, and the risk factors for this diagnosis in a group of patients surgically treated for benign prostatic hyperplasia. METHODS: The study comprised a retrospective analysis of 218 patients. After surgical treatment, patients with the finding of incidental carcinoma of the prostate were compared to those without this finding. The preoperative variables analyzed were patient age, digital rectal examin...

  12. The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.

    Science.gov (United States)

    Mačukat, Indira Radin; Spanjol, Josip; Orlič, Zeljka Crncevič; Butorac, Marta Zuvič; Marinovič, Marin; Ćupič, Dora Fučkar

    2014-09-01

    Testosterone is converted to dihyrotestosterone by two isoenzymes of 5alpha-reductase. Finasteride and dutasteride are 5alpha-reductase inhibitors commonly used in the treatment of benign prostatic hyperplasia. We compared indices of bone mineral density in 50 men treated with finasteride, 50 men treated with dutasteride and 50 men as control. Bone mineral density of spine and hip were measured using dual energy X-ray absorptiometry. Bone formation was assessed by measuring serum osteocalcin and bone resorptionby measuring serum C-terminal telopeptide of collagen type 1. In addition serum total testosteron and estradiol were determined. The dutasteride group had significantly higher mean bone min- eral density, mean bone mineral content, mean T score, mean Z score at femoral neck and mean total hip Z score than control. Mean total testosterone and estradiol levels were higher in the dutasteride group. There were no significant dif- ferences between the groups in lumbar spine bone density parameters or bone turnover markers. Our results provide evidence that long-term 5alpha-reductase suppression does not adversely affect bone mineral density. Dutasteride therapy could have beneficial effect on bone density. PMID:25507347

  13. Impacts of medical treatments for lower urinary tract symptoms suggestive to benign prostatic hyperplasia on male sexual functions

    Directory of Open Access Journals (Sweden)

    Shih-Tsung Huang

    2016-03-01

    Full Text Available Although alpha blockers with or without 5-alpha reductase inhibitors (5-ARIs have become the standard of treatment for men with moderate to severe lower urinary tract symptoms suggestive to benign prostatic hyperplasia (LUTS/BPH, their negative adverse effects on male sexual functions have become another major issue, which may have a direct impact on patients' quality of life and overall satisfaction. Erectile dysfunction, ejaculation disorders, reduced libido, or anorgasmia have been noted among patients receiving these standards of treatments and these adverse events may be irreversible even after discontinuation of medications. Physicians should inform and discuss with their patients about these potential side effects before prescribing these medications for their LUTS/BPH treatment. Tadalafil is the first phosphodiesterase type 5 inhibitor which has the indications for LUTS/BPH and erectile dysfunction and its efficacy is comparable to alpha-blockers with regards to the reduction of LUTS and improvement of quality of life. Moreover, early clinical studies have showed that the combination use tadalafil with alpha blockers or 5-ARIs may have an additional benefit on symptom relief and maximum urinary flow rate (Qmax improvement. As expected, the improvement on erectile function is significant, especially among patients taking 5-ARIs regularly. Although there are promising data from the combination use of tadalafil with 5-ARIs or tadalafil with alpha-blockers, more large-scale clinical studies are still needed to confirm their long term safety and efficacy profiles.

  14. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer

    Directory of Open Access Journals (Sweden)

    Elkahwaji JE

    2012-12-01

    Full Text Available Johny E Elkahwaji1–31Section of Urologic Surgery, 2Section of Medical Oncology and Hematology, 3Genitourinary Oncology Research Laboratory, University of Nebraska Medical Center, Omaha, NE, USAAbstract: Benign prostatic hyperplasia and prostate cancer remain the most prevalent urologic health concerns affecting elderly men in their lifetime. Only 20% of benign prostatic hyperplasia and prostate cancer cases coexist in the same zone of the prostate and require a long time for initiation and progression. While the pathogenesis of both diseases is not fully understood, benign prostatic hyperplasia and prostate cancer are thought to have a multifactorial etiology, their incidence and prevalence are indeed affected by age and hormones, and they are associated with chronic prostatic inflammation. At least 20% of all human malignancies arise in a tissue microenvironment dominated by chronic or recurrent inflammation. In prostate malignancy, chronic inflammation is an extremely common histopathologic finding; its origin remains a subject of debate and may in fact be multifactorial. Emerging insights suggest that prostate epithelium damage potentially inflicted by multiple environmental factors such as infectious agents, dietary carcinogens, and hormones triggers procarcinogenic inflammatory processes and promotes cell transformation and disease development. Also, the coincidence of chronic inflammation and tumorigenesis in the peripheral zone has recently been linked by studies identifying so-called proliferative inflammatory atrophy as a possible precursor of prostatic intraepithelial neoplasia and prostate cancer. This paper will discuss the available evidence suggesting that chronic inflammation may be involved in the development and progression of chronic prostatic disease, although a direct causal role for chronic inflammation or infection in prostatic carcinogenesis has yet to be established in humans. Further basic and clinical research in the

  15. Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis.

    Directory of Open Access Journals (Sweden)

    Ferdinando Fusco

    Full Text Available A significant percentage of patients with lower urinary tract symptoms (LUTS secondary to benign prostatic hyperplasia (BPH achieve clinically meaningful improvement when receiving placebo or tadalafil 5mg once daily. However, individual patient characteristics associated with treatment response are unknown.This integrated clinical data mining analysis was designed to identify factors associated with a clinically meaningful response to placebo or tadalafil 5mg once daily in an individual patient with LUTS-BPH. Analyses were performed on pooled data from four randomized, placebo-controlled, double-blind, clinical studies, including about 1,500 patients, from which 107 baseline characteristics were selected and 8 response criteria. The split set evaluation method (1,000 repeats was used to estimate prediction accuracy, with the database randomly split into training and test subsets. Logistic Regression (LR, Decision Tree (DT, Support Vector Machine (SVM and Random Forest (RF models were then generated on the training subset and used to predict response in the test subset. Prediction models were generated for placebo and tadalafil 5mg once daily Receiver Operating Curve (ROC analysis was used to select optimal prediction models lying on the ROC surface.International Prostate Symptom Score (IPSS baseline group (mild/moderate vs. severe for active treatment and placebo achieved the highest combined sensitivity and specificity of 70% and ~50% for all analyses, respectively. This was below the sensitivity and specificity threshold of 80% that would enable reliable allocation of an individual patient to either the responder or non-responder group.This extensive clinical data mining study in LUTS-BPH did not identify baseline clinical or demographic characteristics that were sufficiently predictive of an individual patient response to placebo or once daily tadalafil 5mg. However, the study reaffirms the efficacy of tadalalfil 5mg once daily in the

  16. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study

    Institute of Scientific and Technical Information of China (English)

    YANG Yong; ZHAO Xiao-feng; LI Han-zhong; WANG Wei; ZHANG Yong; XIAO He; ZHANG Xin

    2007-01-01

    Background The primary objectives of the treatment for the lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are to produce rapid, sustained, and safe improvements in the symptoms that affect the quality of life in the majority of men over 50. In this study, we evaluated the efficacy and safety of the combined therapy with terazosin (α1-adrenergic receptor antagonist) and tolterodine (anticholinergic agent) for LUTS associated with BPH.Methods This combination study included 69 patients diagnosed with LUTS associated with BPH based on the International Prostate Symptom Scores (IPSS), urinary flow rate, prostate volume, urinary residual, and their serum prostate-specific antigen levels. Initially, 191 patients were treated with terazosin 2 mg once daily for one week. Those patients with continued LUTS after the initial treatment were allocated randomly into two groups: terazosin group (n=36)in which patients were treated with terazosin 2 mg once daily for six weeks, and combination group (n=33) in which patients were treated with both terazosin 2 mg once daily and tolterodine 2 mg twice daily for 6 weeks.Results The IPSS were significantly improved in both groups after treatment, and the reduction of IPSS in the combination group was significantly greater than that in the terazosin group (P<0.01). A decrease in urgency, frequency and nocturia were the main contributory factors causing the reduction of IPSS in the combination group. The differences about the peak urinary flow rate and the residual urine from the baseline values were noted in both groups after treatment,but were not significant between the two groups. The incidence of adverse effects in the combination group was higher than that in the terazosin group. As expected the most common adverse effect was mouth dryness which was associated with anticholinergic drugs such as tolterodine.Conclusions Patients with LUTS associated BPH appear the improved IPSS after

  17. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia.

    Directory of Open Access Journals (Sweden)

    Shun-Fa Hung

    Full Text Available OBJECTIVE: Chronic inflammation is considered as one of the contributing mechanisms of lower urinary tract symptoms (LUTS. Serum C-reactive protein (CRP level is the widely used biomarker of inflammatory status. This study investigated the association between serum CRP level in men with benign prostatic hyperplasia (BPH and lower urinary tract symptoms (LUTS before and after medical treatment. METHODS: A total of 853 men with BPH and LUTS were enrolled. All patients completed the International Prostate Symptoms Score (IPSS questionnaire and urological examinations. The parameters of uroflowmetry (maximum flow rate, Qmax; voided volume, VV, post-void residual (PVR, total prostate volume (TPV and transition zone index (TZI, serum prostate specific antigen (PSA, and serum CRP levels were obtained. All patients were treated with alpha-blocker or antimuscarinic agent based on the IPSS voiding to storage subscore ratio (IPSS-V/S. Correlation analyses were performed between serum CRP levels with age, IPSS, TPV, TZI, Qmax, PVR, VV, PSA and between baseline and post treatment. RESULTS: The mean age was 66.9 ± 11.6 years old and the mean serum CRP levels were 0.31 ± 0.43 mg/dL. Univariate analyses revealed serum CRP levels were significantly associated with age (p<0.001, PSA levels (p = 0.005 and VV (p = 0.017, but not significantly associated with TPV (p = 0.854 or PVR (p = 0.068. CRP levels were positively associated with urgency (p<0.001 and nocturia (p<0.001 subscore of IPSS, total IPSS (p = 0.008 and storage IPSS (p<0.001 and negatively associated with IPSS- V/S ratio (p = 0.014. Multivariate analyses revealed that serum CRP levels were significantly associated with age (p = 0.004 and storage IPSS subscore p<0.001. Patients with IPSS-V/S<1 and treated with tolterodine for 3 months had significant decrease of CRP levels after treatment. CONCLUSION: Serum CRP levels are associated with storage LUTS and sensory bladder disorders, suggesting chronic

  18. Benign Prostatic Hyperplasia Electrification Surgical Nursing Intervention%前列腺增生症电气化手术的护理干预

    Institute of Scientific and Technical Information of China (English)

    王爱云

    2014-01-01

    Objective: analysis of 47 cases of benign prostatic hyperplasia (BPH) common nursing problems for electrification surgery patients and summarize the nursing points. Methods: a retrospective analysis of 47 patients from January 2006 to 2009 January for electrified operation implementing comprehensive care, assessment and evaluation of patients. Results: in this group, 47 cases in 21 patients with bladder improve symptoms, accounted for 45%; postoperative incontinence in 12 cases, accounting for 26%; erectile dysfunction in 8 cases, accounting for 17%; 6 cases of retrograde ejaculation, accounted for 13%. Except for 2 cases of re operation hemostasis in patients with bleeding, the others were cured. Conclusion: according to the common problems in peri operation period, nursing care plans, implementation of holistic nursing care has important clinical significance to promote the rehabilitation of patients with prostatic hyperplasia after. Carry out holistic nursing care, can reduce the complications of patients, reduce pain, establish the confidence to overcome the disease, so that they soon.%目的:分析47例前列腺增生症(BPH)患者行电气化术常见的护理问题,并总结护理要点。方法回顾性分析2006年1月~2009年1月行电气化手术47例患者实施综合性护理,对患者进行评估和评价。结果本组47例中有21例有膀胱促进症状,占45%;术后失禁12例,占26%;勃起功能障碍8例,占17%;逆行射精6例,占13%。除2例患者术后并发出血再次手术止血外,其余患者均痊愈出院。结论根据患者围手术期常见问题,制定护理计划,实施整体性护理对促进前列腺增生症患者术后康复具有重要临床意义。做好整体护理工作,就能够为患者减少各并发症,减少痛苦,树立战胜疾病的信心,使他们早日康复。

  19. Open suprapubic versus retropubic prostatectomy in the treatment of benign prostatic hyperplasia during resident's learning curve: a randomized controlled trial

    Directory of Open Access Journals (Sweden)

    Arie Carneiro

    2016-04-01

    Full Text Available ABSTRACT Purpose: This study compared the suprapubic (SP versus retropubic (RP prostatectomy for the treatment of large prostates and evaluated perioperative surgical morbidity and improvement of urinary symptoms. Materials and Methods: In this single centre, prospective, randomised study, 65 consecutive patients with LUTS and surgical indication with prostate volume greater than 75g underwent open prostatectomy to compare the RP (32 patients versus SP (33 patients technique. Results: The SP group exhibited a higher incidence of complications (p=0.002. Regarding voiding pattern analysis (IPSS and flowmetry, both were significantly effective compared to pre-treatment baseline. The RP group parameters were significantly better, with higher peak urinary flow (SP: 16.77 versus RP: 23.03mL/s, p=0.008 and a trend of lower IPSS score (SP: 6.67 versus RP 4.14, p=0.06. In a subgroup evaluation of patients with prostate volumes larger than 100g, blood loss was lower in those undergoing SP prostatectomy (p=0.003. Patients with prostates smaller than 100g in the SP group exhibited a higher incidence of low grade late complications (p=0.004. Conclusions: The SP technique was related to a higher incidence of minor complications in the late postoperative period. High volume prostates were associated with increased bleeding when the RP technique was utilized. The RP prostatectomy was associated with higher peak urinary flow and a trend of a lower IPSS Score.

  20. Double-blind randomized placebo-controlled study of bixa orellana in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Luis Zegarra

    2007-08-01

    Full Text Available OBJECTIVE: To determine the efficacy of Bixa Orellana (BO in patients with benign prostatic hyperplasia (BPH presenting moderate lower urinary tract symptoms (LUTS. MATERIALS AND METHODS: It is a prospective double-blind randomized placebo-controlled study. One thousand four hundred and seventy eight patients presenting moderate LUTS associated to BPH were interviewed, from whom we selected 136 to fulfill the criteria of inclusion and exclusion. Assignation was performed at random in blocks of four to receive B0 at a dose of 250 mg 3 times a day or placebo (Pbo for 12 months, 68 patients were assigned to each group. From the patients in the study we obtained data of demographic, epidemiologic, symptom score, uroflowmetry and post void residual urine variables. RESULTS: Basically both groups were compared clinically, demographically and biochemically. Throughout the study variations of symptom score, mean delta symptom score during each visit and the final average delta were similar for both groups (BO - 0.79 ± 1.87 and Pbo - 1.07 ± 1.49 (p = 0.33. Similarly variations of Qmax mean, Qmax average delta and final average delta were similar (BO 0.44 ± 1.07 and Pbo 0.47 ± 1.32 (p = 0.88. Variations of post void residual urine mean, post void residual urine average delta in each visit and the final average delta were similar for both groups (BO 4.24 ± 11.69 and Pbo 9.01 ± 18.66 (p = 0.07. No differences were found in the answers of clinically significant improvement assessed with relative risk and risk differences, even though the proportion of adverse effects was similar for both groups. CONCLUSION: Patients with BPH that present moderate LUTS did not show any benefit receiving BO when compared to placebo.

  1. Advances in Drug Therapy of Benign Prostatic Hyperplasia%良性前列腺增生症的药物治疗进展

    Institute of Scientific and Technical Information of China (English)

    廖倩(综述); 黄伟华(审校)

    2015-01-01

    The prostate is male sexual organ,located below the bladder neck,surrounding the binding site of the opening of bladder and urethra.Benign prostatic hyperplasia(BPH) is a kind of common disease among the old men.Its typical symptom is urination discomfort.The main treatment methods are drug therapy, operation and minimally invasive treatment.Drug therapy is the first choice for early BPH or aged patients for whom operation is unsuitable.The safety and effectiveness of drug therapy has been confirmed.Here is to make a review of the effects and mechanisms of 5-αreductase inhibitor,α1-adrenergic receptor blockers,M receptor blocking agent,medicinal plants,Chinese patent medicine and other drugs in BPH treatment.%前列腺是男性特有的性腺器官,位于膀胱颈的下方,包绕着膀胱口与尿道结合部位。良性前列腺增生症( BPH)是中老年男性最为常见的一种疾病,典型症状为排尿不适,其主要的治疗方法有药物治疗、手术治疗和微创治疗。而对于早期有临床症状或年龄偏大不适合手术的患者主要采用药物治疗。 BPH药物治疗的安全性和有效性已得到证实。该文对5α-还原酶抑制剂、α1肾上腺素能受体阻滞剂、M受体阻滞剂、植物药、中成药等药物治疗BPH的作用机制予以综述。

  2. Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations

    Science.gov (United States)

    Lee, Lulu K; Goren, Amir; Boytsov, Natalie N; Donatucci, Craig F; McVary, Kevin T

    2016-01-01

    Objective Erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) frequently co-occur in men aged ≥40, along with lower urinary tract symptoms (LUTS) secondary to BPH. Given little real-world evidence on treatment use or satisfaction with treatment for concurrent BPH/LUTS and/or ED, this study examined medication regimens and differences in satisfaction and health-related quality of life (HRQoL) across regimens among men with concurrent BPH and ED. Methods A cross-sectional study was conducted using an Internet survey of participants recruited through an online panel. Respondents (N=736) included men (aged ≥40) who self-reported a diagnosis of both ED and BPH with prescription treatment in the past 3 months for both conditions. Treatment satisfaction (eg, convenience and ease of planning) and HRQoL (eg, International Prostate Symptom Score, sleep quality) were self-reported. Generalized linear models examined the association of regimen with treatment satisfaction and HRQoL, adjusting for covariates (eg, age and comorbidities). Results Final analyses included participants (N=507) using: tadalafil once-daily monotherapy (22%), tadalafil for ED with an alternate BPH therapy (36%), or another phosphodiesterase type-5 inhibitor (PDE5-I) combination (41%). These groups represented the major categories of treatment regimens found in the sample, excluded participants with ambiguous regimens, and were aligned with current standard of care for BPH and ED. Overall, patients reported moderate levels of BPH and a moderate-to-severe degree of ED. Tadalafil monotherapy patients had higher treatment satisfaction scores and greater reported ease of treatment planning and convenience than PDE5-I combination patients. No significant intergroup differences were found on HRQoL. Conclusion A majority of patients (59%) took tadalafil alone or in combination for BPH/ED treatment. Tadalafil monotherapy patients reported greater treatment satisfaction than patients taking PDE5

  3. Holmium laser enucleation versus transurethral resection in patients with benign prostate hyperplasia: an updated systematic review with meta-analysis and trial sequential analysis.

    Directory of Open Access Journals (Sweden)

    Sheng Li

    Full Text Available BACKGROUND: Holmium laser enucleation (HoLEP in surgical treatment of benign prostate hyperplasia (BPH potentially offers advantages over transurethral resection of the prostate (TURP. METHODS: Published randomized controlled trials (RCTs were identified from PubMed, EMBASE, Science Citation Index, and the Cochrane Library up to October 10, 2013 (updated on February 5, 2014. After methodological quality assessment and data extraction, meta-analysis was performed using STATA 12.0 and Trial Sequential Analysis (TSA 0.9 software. RESULTS: Fifteen studies including 8 RCTs involving 855 patients met the criteria. The results of meta-analysis showed that: a efficacy indicators: there was no significant difference in quality of life between the two groups (P>0.05, but compared with the TURP group, Qmax was better at 3 months and 12 months, PVR was less at 6, 12 months, and IPSS was lower at 12 months in the HoLEP, b safety indicators: compared with the TURP, HoLEP had less blood transfusion (RR 0.17, 95% CI 0.06 to 0.47, but there was no significant difference in early and late postoperative complications (P>0.05, and c perioperative indicators: HoLEP was associated with longer operation time (WMD 14.19 min, 95% CI 6.30 to 22.08 min, shorter catheterization time (WMD -19.97 h, 95% CI -24.24 to -15.70 h and hospital stay (WMD -25.25 h, 95% CI -29.81 to -20.68 h. CONCLUSIONS: In conventional meta-analyses, there is no clinically relevant difference in early and late postoperative complications between the two techniques, but HoLEP is preferable due to advantage in the curative effect, less blood transfusion rate, shorter catheterization duration time and hospital stay. However, trial sequential analysis does not allow us to draw any solid conclusion in overall clinical benefit comparison between the two approaches. Further large, well-designed, multicentre/international RCTs with long-term data and the comparison between the two approaches remain open.

  4. The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

    Science.gov (United States)

    Lythgoe, Casey; McVary, Kevin T

    2013-12-01

    The relationship between lower urinary tract symptoms secondary to BPH and ED has recently been the subject of significant research due to the prevalence of both conditions concomitantly existing in older men. Many large-scale studies have demonstrated an association between erectile dysfunction and lower urinary tract symptoms. Although the mechanisms underlying the relationship between LUTS and ED are not fully elucidated, several theories are currently proposed in literature: the nitric oxide/cGMP pathway, RhoA/Rho-kinase signaling, pelvic atherosclerosis associated with chronic hypoxia, and autonomic adrenergic hyperactivity. The mechanisms by which these pathways affect the bladder, prostate, pelvic vasculature and spinal cord are also the subject of current research. In this chapter, we examine the randomized, placebo-controlled trials that have evaluated the use of PDE-5Is in LUTS, as well as randomized, controlled trials (RCTs) researching combination PDE-5Is and alpha blockers. PMID:24136683

  5. Microwave Treatment of Prostate Cancer and Hyperplasia

    Science.gov (United States)

    Arndt, G. Dickey; Ngo, Phong; Carl, J. R.; Raffoul, George

    2005-01-01

    Microwave ablation in the form of microwave energy applied to a heart muscle by a coaxial catheter inserted in a vein in the groin area can be used to heat and kill diseased heart cells. A microwave catheter has been developed to provide deep myocardial ablation to treat ventricular tachycardia by restoring appropriate electrical activity within the heart and eliminating irregular heartbeats. The resulting microwave catheter design, which is now being developed for commercial use in treating ventricular tachycardia, can be modified to treat prostate cancer and benign prostatic hyperplasia (BPH). Inasmuch as the occurrence of BPH is increasing currently 350,000 operations per year are performed in the United States alone to treat this condition this microwave catheter has significant commercial potential.

  6. Clinical analysis of the transurethral plasmakinetic resection of prostate in therapy of benign prostatic hyperplasia%经尿道前列腺等离子电切术治疗前列腺增生的临床分析

    Institute of Scientific and Technical Information of China (English)

    张军民; 孙贵财

    2015-01-01

    目的 探讨经尿道前列腺等离子电切术治疗前列腺增生的临床疗效.方法 选取前列腺增生患者80例,随机分为两组,对照组采用经尿道前列腺电切术进行治疗,实验组采用经尿道前列腺等离子电切术进行治疗.观察比较两组患者的临床疗效以及预后情况.结果 实验组术中出血量、留置导管时间、并发症发生率与对照组比较差异有统计学意义(P<0.05);实验组手术时间、住院时间、术后阳痿发生率以及逆行射精发生率与对照组比较差异未见统计学意义(P>0.05).结论 采用经尿道前列腺等离子电切术对前列腺增生患者进行治疗,创伤小、安全性高、临床疗效确切,值得临床普及和应用.%Objective To investigate the clinical curative effect of the transurethal plasmakinetic resection of the prostate on benign prostatic hyporplasia.Methods Eighty patients with hyperplasia of prostate were selected as the objects.The patients were randomly divided into two groups.The urethra prostate electricity cut method were given to the patients of control group.The transurethral plasmakinetic resection of prostate method were given to the patients of experimental group.The clinical curative effect and prognosis of two groups of patients was compared.Results The intraoperatie blood loss in experimental group was significantly less than that in the control group (P < 0.05).The indwelling catheter time in experimental group was significantly shorter than that in the control group (P < 0.05).The operation time and hospital stay were similar with the control group (P > 0.05).The incidence of postoperative impotence and retrograde ejaculation of the experimental group were similar with the control group (P > 0.05).Conclusions The transurethral plasmakinetic resection of prostate to treat patients with benign prostatic hyperplasia is small trauma,high safety and clinical curative effect,so is worthy to be popularized and

  7. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia - the Markov model based on data from Montenegro

    Directory of Open Access Journals (Sweden)

    Dabanović Vera

    2016-01-01

    Full Text Available Background/Aim. Benign prostatic hyperplasia (BPH is one of the most common disease among males aging 50 years and more. The rise of the prevalence of BPH is related to aging, and since duration of life time period has the tendency of rising the prevalence of BPH will rise as costs of BPH treatment will and its influence on health economic budget. Dutasteride is a new drug similar to finasteride, inhibits enzyme testosterone 5-alpha reductase, diminish symptoms of BPH, reduce risk of the complications and increases quality of life in patients with BPH. But, the use of dutasteride is limited by its high costs. The aim of this study was to compare cost effectiveness of dutasteride and finasteride from the perspective of a purchaser of health care service (Republic Institute for Health Insuranse, Montenegro. Меthods. We constructed a Markov model to compare cost effectivenss of dutasteride and finasteride using data from the available pharmacoeconomic literature and data about socioeconomic sphere actual in Montenegro. A time horizon was estimated to be 20 years, with the duration of 1 year per one cycle. The discount rate was 3%. We performed Monte Carlo simulation for virtual cohort of 1,000 patients with BPH. Results. The total costs for one year treatment of BPH with dutasteride were estimated to be 6,458.00 € which was higher comparing with finasteride which were 6,088.56 €. The gain in quality adjusted life years (QALY were higher with dutasteride (11.97 QALY than with finasteride (11.19 QALY. The results of our study indicate that treating BPH with dutasteride comparing to finasteride is a cost effective option since the value of incremental cost-effectiveness ratio (ICER is 1,245.68 €/QALY which is below estimated threshold (1,350.00 € per one gained year of life. Conclusion. Dutasteride is a cost effective option for treating BPH comparing to finasteride. The results of this study provide new information for health care decision

  8. Interstital Laser Thermotherapy for the Treatment of Benign Prostatic Hyperplasia%激光间质内凝固治疗前列腺增生症

    Institute of Scientific and Technical Information of China (English)

    单炽昌; 吴开俊; 郭彬

    2001-01-01

    目的 探讨激光间质内凝固治疗前列腺增生症的效果。 方法 前列腺增生症患者100例,平均年龄68岁。Ⅰ度增生8例,Ⅱ度增生72例,Ⅲ度增生20例。在硬膜外麻醉下行前列腺组织激光间质内凝固治疗。Nd∶YAG激光输出功率50 W,每增生叶穿刺1~6点,每点治疗时间5 min。 结果 随访3~24个月,70%的病人症状和尿流率明显改善,无一例发生尿失禁及严重感染等合并症,23例因故改行其他手术方式治疗。 结论 激光间质内凝固治疗前列腺增生症方法简单、安全,尤其适合于高危病人,治疗效果与手术者的经验和插入前列腺叶的点数有关。%Objective To evaluate the therapeutic effect of interstitial laser thermotherapy for the treatment of benign prostatic hyperplasia(BPH). Methods 100 patients with BPH were treated by interstitial Nd∶YAG laser thermotherapy from Nov 1993 to June 1998. The laser output power was 50 W. 1-6 points in a lobe were inserted and irradiated, 5 min per point. Results The patients were followed up for 3-24 months with satisfactory result. Amelioration of subjective symptoms and improvement of MFR were achieved in 70% of the 100 cases. Conclusions The results show that interstitial Nd∶YAG laser thermotherapy is safe and simple, especially indicated for high risk patients. Efficacy of the procedure is higly related to the experience of the operator and to the number of treatment points.

  9. [Benign prostatic hyperplasia: medical therapy].

    Science.gov (United States)

    Schlenker, B; Gratzke, C; Weidlich, P; Seitz, M; Reich, O; Stief, C G

    2007-08-16

    Primary aims of the medical therapy for BPH are improvement of subjective symptoms and quality of life as well as the prevention of long-term complications such as acute urinary retention and renal failure. Secondary goal is inhibition of disease progression. The medical therapy should be tailored to each patient according to the individual complaints and risk of progression. Plant extracts, alpha-blockers and 5-alpha reductase inhibitors represent the most common prescribed substances. Recent data suggest beneficial effects for the use of antimuscarinic agents and phosphodiesterase type 5 inhibitors. PMID:17912863

  10. 经尿道前列腺切除术对高龄高危前列腺增生症患者生活质量的影响%Transurethral resection of the prostate benign prostatic hyperplasia on elderly quality of life of patients

    Institute of Scientific and Technical Information of China (English)

    刘毅

    2011-01-01

    目的:探讨经尿道前列腺切除术对高龄高危前列腺增生症患者生活质量的影响.方法:将我院2008年1月-2010年6月住院治疗的56例经尿道前列腺电切术治疗的高龄高危前列腺增生症患者IPSS评分、QOLS评分、SAS评分、SDS评分术前术后的比较结果:与术前比较,术后高龄高危前列腺增生症患者IPSS评分、QOLS评分、SAS评分、SDS评分均有显著改善,差异有统计学意义(P<0.05).结论:经尿道前列腺切除术能明显改善高龄高危前列腺增生症患者的生活质量,缓解焦虑、紧张的情绪,提高临床疗效.%Objective:Transurethral resection of benign prostatic hyperplasia on elderly quality of life of patients. Methods: The hospital in January 2008-2010 hospitalized in June of 56 cases of transurethral resection of the elderly patients with benign prostatic hyperplasia IPSS score, QOLS score. SAS score, SDS score comparison of preoperative and postoperative. Results:Compared with the preoperative and postoperative elderly patients with benign prostatic hyperplasia IPSS score, QOLS scores, SAS scores, SDS scores were significantly improved, the difference was statistically significant (P<0.05). Conclusion: The transurethral resection of the prostate can significantly improve elderly patients with benign prostatic hyperplasia the quality of life, relieve anxiety, tension, improve the efficacy.

  11. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia

    DEFF Research Database (Denmark)

    Hansen, B J; Flyger, H; Brasso, K;

    1995-01-01

    To validate the Danish Prostatic Symptom Score (DAN-PSS-1), a self-administered quality-of-life questionnaire comprising 12 questions related to voiding problems and the perceived bother of each individual symptom.......To validate the Danish Prostatic Symptom Score (DAN-PSS-1), a self-administered quality-of-life questionnaire comprising 12 questions related to voiding problems and the perceived bother of each individual symptom....

  12. 前列腺增生术后患者谵妄的影响因素及预见性护理%Analysis of influencing factors and nursing care of postoperative delirium in patients with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    陶菊; 马胜珺; 徐青青

    2013-01-01

    Objective To investigate the influence factors of postoperative delirium in benign prostatic hyperplasia patients,so as to provide the basis for developing predictive assessment and establishing corresponding nursing intervention measures.Methods In this retrospective study,the clinical data of 210 patients with prostate surgery,of which 19 cases complicated with postoperative delirium during January 2010 and June 2012 were analyzed statistically.Results Postoperative delirium in patients with benign prostatic hyperplasia was a common result of multiple factors,the reason mainly were age,operation stress response,hyoxemia and pain,etc.Conclusions Providing predictive and corresponding nursing intervention after prostate operation can significantly reduce the incidence of postoperative delirium and promote the patients' recovery.%目的 探讨前列腺增生手术后患者并发谵妄的影响因素,为护士进行预见性评估、制定相应护理干预措施提供依据.方法 2010年1月至2012年6月行前列腺增生手术患者210例,术后并发谵妄19例,对其临床资料进行回顾性分析.结果 前列腺增生术后并发谵妄是多因素共同作用的结果,高龄、手术应激反应、低氧血症、疼痛等都可引起谵妄的发生.结论 护士正确评估病情,早期给予预见性护理,能减少前列腺增生术后谵妄的发生,促进患者康复.

  13. Angiographic anatomic findings of prostatic arteries in patients with benign prostatic hyperplasia%良性前列腺增生症患者的前列腺动脉解剖特点

    Institute of Scientific and Technical Information of China (English)

    张国栋; 王茂强; 段峰; 袁凯; 李凯; 阎洁羽; 常中飞; 王燕

    2014-01-01

    Objective To describe the prostatic arterial anatomy of patients with benign prostatic hyperplasia(BPH) on arterial angiography.Methods In a retrospective study of selective prostatic artery (PA) DSA for prostatic arterial embolization(PAE),bilateral PA were indicated in 55 patients with BPH.All the patients underwent selective angiography in the internal iliac arteries and PAs.Each internal iliac artery was evaluated regarding the number of PAs and their origins,trajectory,diameters,and anastomoses with adjacent arteries.Results One hundred and ten internal iliac arteries gave rise to a total of 114 PAs.One hundred and six internal iliac arteries(96.4%,106/110) had only a PA,and 4 internal iliac arteries(3.6%,4/110) had two independent PAs.The left and right PA origin were asymmetric in 36 patients(65.5%,36/55) and symmetric in the other 19 patients(34.5%,19/55).In 37 patients(67.3%,37/55),the prostate was dominantly vascularized by unilateral PA.Forty five PAs(39.5%,45/114) originated from the glutealpudendal trunk,37 PAs(32.6%,37/114) originated from the superior vesical artery,and 32 PAs(27.9%,32/114) originated from the internal pudendal artery.Eight two PAs(72.1%,82/114) had a superior origin and 32(27.9%,32/114) had an inferior origin.In 43(39.1%,43/110) internal iliac arteries,PAs had the anastomoses to adjacent arteries.The mean PA diameter was(0.9±0.4) mm(ranged from 0.5 to 1.5 mm).In the 17 of 20 patients with prostate volume more than 100 cm3,the PA was seen with a larger diameter (> 1.2 mm) and a corkscrew pattern of intra-prostate arteriola.Conclusions Angiography of prostatic arteries in patients with benign prostatic hyperplasia showed the prostatic arterial origin,diameter and pattern were variable.PA had abundant anastomoses to adjacent arteries.%目的 探讨良性前列腺增生症(BPH)患者前列腺动脉(PA)血管造影的解剖特点.方法 回顾性分析行经导管超选择性PA DSA和超选择性前列腺动脉

  14. 尿动力学检测在前列腺增生患者中的意义%Urodynamic test in the detection of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    贾利民; 张晨光; 王艳凤

    2014-01-01

    目的:分析前列腺增生症患者的尿动力学参数,为个性化治疗前列腺增生症提供依据。方法:2011年1月至2013年1月我科收治800名前列腺增生症患者,经直肠指诊、泌尿系彩超,膀胱镜等初步诊断为前列腺增生,对所有患者进一步行尿动力学检查。结果:本组800例患者中,无梗阻8例;可疑梗阻89例,其中逼尿肌收缩无力23例,逼尿肌收缩乏力66例;膀胱出口明显梗阻(BOO)703例,患者中伴不稳定膀胱132例,低顺应性膀胱486例,不稳定膀胱合并低顺应性膀胱18例。平均最大尿流率(8.2±1.5〕mL/s,平均残余尿量(82.6±75.6)mL,急迫尿意时膀胱容量(280.6±171.3)mL,与同期体检中心健康者正常值比较有差异(P<0.05)。顺应性(24.4±16.5)mL/cmH2 O,与同期体检中心健康者正常值比较无差异(P>0.05)。结论:尿流动力学检测对前列腺增生症患者具有重要意义。%Objectives:To analyze urodynamic parameters of patients with benign prostatic hyperplasia (BPH)so as to provide the basis for individualized treatment of the disease.Method:800 BPH patients who came to our hospital between January 201 1 and January 2013 were selected.They were preliminarily diagnosed by rectal examination,urinary tract ultrasonography,and cystoscopy as BPH.Urodynamic test was conducted for further diag-nosis.Results:Among the 800 patients,there were 8 cases without obstruction,89 with suspicious obstruction of which 23 with detrusor contraction asthenia and 66 with detrusor contraction fatigue.There were 703 cases with bladder outlet obstruction (BOO),and among 703 cases,132 were complicated with unstable bladder,486 low compliance bladder,18 unstable bladder combined low compliance bladder.The mean maximum urinary flow rate was (8.2 ±1.5)mL/s,the average residual urine volume was (82.6 ±75.6)mL,the urge urinary bladder capacity was (280.6 ±171.3)mL,and these three

  15. Diagnostic Value of 64-slice CT Perfusion Imaging in Prostate Cancer and Benign Prostatic Hyperplasia%64排CT灌注成像对前列腺癌与良性前列腺增生的诊断价值

    Institute of Scientific and Technical Information of China (English)

    常泰; 戴娜

    2011-01-01

    [目的]探讨前列腺64排CT灌注成像的可行性及对前列腺癌与良性前列腺增生(BPH)的诊断价值.[方法]选择经手术或穿刺病理证实的前列腺癌患者28例(A组)和BPH患者35例(B组),所有患者均行前列腺64排CT灌注扫描,比较两组灌注参数:血流量 (BF)、血容量(BV)、峰值(PE)、达峰时间(TTP)、表面通透性(PS).[结果]A组BF、BV、PE分别为(0.492±0.115) mL/(100 g·min),(0.146±0.019) mL/100 g,(33.4±5.1) HU均显著小于BPH组(1.712±0.095) mL/(100 g·min),(0.276±0.031) mL/100 g,(56.7±6.7) HU(P<0.05),TTP、PS分别为(54.2±5.6)S和(54.8±6.9)mL/(100 g·min)均显著大于BPH组(26.4±4.6)S和(20.1±4.8)mL/(100 g·min) (P<0.05).[结论]前列腺64排CT灌注成像方法可行,灌注数据获得简单快捷,能够在一定程度上反映出前列腺血流灌注变化;前列腺64排CT灌注成像能定量地提供前列腺血流信息,可无创性地辅助诊断前列腺癌和BPH.%[Objective] To explore the feasibility and diagnostic value of 64-clice CT perfusion imaging in prostate cancer(PC) and benign prostatic hyperplasia(BPH). [Methods] Twenty-eight PC patients (group A) and thirty-five BPH patients (group B) confirmed by surgery or pathology were selected. All patients were performed by 64-slice CT perfusion of prostate. The perfusion parameters such as blood flow(BF) , blood volume (BV) , peak enhancement (PE) , time to peak (TTP) and permeability surface(PS) were compared between two groups. [Results] BF, BV and PE in group A were 0. 492 ± 0. 115 mL/(100g · min),(0. 146 ± 0. 019) mL/100g and (33. 4 ± 5. 1)HU respectively, which were significantly lower than those in group B[(1. 712 ± 0.095) mL/(100 g · min),(0. 276 ± 0. 031) mL/100 g and (56. 7 ± 6. 7) HU] ( P <0. 05). TTP and PS in group A were 54. 2 ± 5. 6S and 54. 8 ± 6. 9ml/(100g · min) respectively, which were significantly higher than those in group B[(26. 4 ± 4. 6)s and (20. 1 ± 4. 8) mL/(100g · min)]( P <0. 05

  16. Steroid hormone receptors in prostatic hyperplasia and prostatic carcinoma.

    Science.gov (United States)

    Khalid, B A; Nurshireen, A; Rashidah, M; Zainal, B Y; Roslan, B A; Mahamooth, Z

    1990-06-01

    One hundred and six prostatic tissue samples obtained from transurethral resection were analysed for androgen and estrogen receptors. In 62 of these, progesterone and glucocorticoid receptors were also assayed. Steroid receptors were assayed using single saturation dose 3H-labelled ligand assays. Ninety percent of the 97 prostatic hyperplasia tissues and six of the nine prostatic carcinoma tissues were positive for androgen receptors. Estrogen receptors were only present in 19% and 33% respectively. Progesterone receptors were present in 70% of the tissues, but glucocorticoid receptors were present in only 16% of prostatic hyperplasia and none in prostatic carcinoma. PMID:1725553

  17. 前列腺增生合并膀胱癌手术35例临床分析%Clinicalanalysis of 35 patients with benign prostatic hyperplasia consolidate with bladder cancer surgery

    Institute of Scientific and Technical Information of China (English)

    梁浩

    2012-01-01

    Objective To observe the clinical effect of transurelhral eleclrovaporization ablation (TUVP) applied to the patients with benign proslatie hyperplasia consolidated with bladder cancer. Methods To select 35 patients of benign prostatic hyperplasia consolidated with bladder cancer were performed TUVP at the same lime, compare with the preoperalive and th postoperative 6 months of the score of international prostate symptom (1PSS), the score of quality of life (QOL), the maximum urinary flow (Qmax) , residual urine volume (PRV) , and postoperative follow-up 1 ~2 year bladder cancer metastasis and recurrence. Results After six months of observation, 1PSS, QOL and PKV was significantly lower than thai of the preoperative, Qmax is obviously higher than that of the preoperalive, it was significant difference (P<0. 05) ; In the follow-up of 1 ~2 years, all patients were no recurrence and metastasis. Conclusion TUVP is a safe method of treat benign proslate hyperplasia consolidated with bladder cancer patients, il can reduce patients the pain of, it can effectively improve the patients quality of life.%目的 观察前列腺增生合并膀胱癌患者同期行经尿道电汽化切除术的临床效果.方法 选取前列腺增生合并膀胱癌且行同期汽化电切手术治疗患者35例,比较患者术前及术后6个月的国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流量(Qmax)、残余尿量(PRV),并术后随访观察1~2年膀胱癌的转移及复发情况.结果 6个月的术后观察,IPSS、QOL及PRV明显低于术前,Qmax明显高于术前,差异具有统计学意义(P<0.05);术后随访1~2年,所有患者均无膀胱癌复发及转移现象.结论 电切术是前列腺增生合并膀胱癌患者比较安全的治疗方法,可以减轻患者的痛苦,能有效地改善患者的生活质量.

  18. 特拉唑嗪治疗良性前列腺增生疗效的Meta分析%Meta-analysis of Therapeutic Efficacy of Terazosin for Benign Prostatic Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    祝凌飞

    2013-01-01

    OBJECTIVE:To evaluate therapeutic efficacy of terazosin in the treatment of benign prostatic hyperplasia.METH-ODS:Retrieved from Pubmed,Cochrane library,University of Cambridge Press Journals,electronic journals of American Medical Association,electronic journals of Royal Society of Chemistry,Wiley-Blackwell full-text database,ELSEVIER electronic journal full-text database,Karger full-text electronic journal,OVID Medical Journal full-text database,Springer Link master point,Oxford Journal full-text database,CNKI,randomized controlled trials (RCT) about terazosin on benign prostatic hyperplasia were included,and packet system was evaluated using the statistical software for WinBUGS.RESULTS:A total of 10 RCT were included,involving 1 493 patients.Meta-analysis results showed that,compared with control group,terazosin could effectively improve IPSS score [WMD=0.75,95%CI(0.03,1.46),P=0.04] and the peak urinary flow rate [WMD=0.81,95%CI(-0.39,0.85),P=0.03].There was statistical significance.In addition,covariance analysis showed that baseline prostate volume didn't influenced the effect of terazosin.CONCLUSIONS:Terazosin can effectively relieve benign prostatic hyperplasia and improve peak urinary flow rate.The effect of terazosin on symptoms and peak urinary flow rate was independent of the baseline prostate size for the range of prostate volumes reported.%目的:系统评价特拉唑嗪治疗良性前列腺增生的疗效.方法:计算机检索Pubmed、Cochrane图书馆、剑桥大学出版社电子期刊、美国医学会电子期刊、英国皇家化学学会电子期刊、Wiley-Blackwell全文电子期刊库、ELSEVIER电子期刊全文库、Karger全文电子期刊、OVID医学全文期刊数据库、Springer Link主站点、牛津期刊全文数据库、中国期刊全文数据库,纳入特拉唑嗪治疗良性前列腺增生的随机对照研究(RCT),采用WinBUGS统计软件进行系统评价.结果:共纳入10项RCT,合计1 493例患者.Meta分析结果

  19. 经直肠三维超声对良性前列腺增生分度的诊断价值%Value of three-dimensional transrectal ultrasonography in the diagnosis of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    皮永前; 潘永寿; 熊思

    2013-01-01

    目的 探讨经直肠三维超声对良性前列腺增生分度的诊断价值.方法 对104例前列腺增生患者应用经直肠三维超声进行常规扫查前列腺,测量前列腺全腺和内腺的上下径、左右径、前后径及前列腺内腺动脉阻力指数;采用三维体积自动测量技术测量前列腺全腺、内腺体积和重量,计算内外腺宽度之比、内外腺厚度之比及移行带指数.结果 依据前列腺全腺重量将前列腺增生分为Ⅰ、Ⅱ、Ⅲ和Ⅳ四组,前列腺内腺重量、移行带指数、内外腺宽度之比、内外腺厚度之比以及前列腺内腺动脉阻力指数在四组间均为Ⅳ>Ⅲ>Ⅱ>Ⅰ(P<0.01),且与前列腺重量呈正相关(P<0.01),是前列腺增生分度较好的指标.结论 前列腺体积及形态改变是超声诊断前列腺增生的重要依据,经直肠三维超声可以准确测量前列腺全腺及内腺体积,为前列腺增生分度提供最直观的形态学指标,移行带指数、内外腺宽度之比等前列腺参数有助于前列腺增生的分度.%Objective To evaluate the value of three-dimensional transrectal ultrasonography (3D-TRUS) in the graduation of benign prostatic hyperplasia (BPH).Methods A total of 104 patients with BPH were checked by 3D-TRUS.The vertical diameter,transverse diameter,anteroposterior diameter of prostate whole gland and inner gland were measured,as well as artery resistance indexes of inner gland.3D-TRUS was used to measure the volume and weight of prostate whole gland,the inner gland.The ratio of the width of the inside and outside the gland,the ratio of the thickness of the inside and outside the gland,and transition zone index (TZI) were calculated.Results According to the weight of prostate whole gland,prostatic hyperplasia was classified into four levels:Ⅰ,Ⅱ,Ⅲ and Ⅳ BPH.The weight of inner gland,TZI,RI of the inner gland artery,the ratio ofinner and outer gland width and the ratio of inner and outer gland

  20. Associations among benign prostate hypertrophy, atypical adenomatous hyperplasia and latent carcinoma of the prostate%良性前列腺肥大、非典型腺瘤性增生和潜伏性前列腺癌的关联

    Institute of Scientific and Technical Information of China (English)

    Konstantinos Stamatiou; Alevizos Alevizos; Mohamed Natzar; Constantinos Mihas; Anargiros Mariolis; Emmanouel Michalodimitrakis; Fragiskos Sofras

    2007-01-01

    Aim: To investigate the frequency of atypical adenomatous hyperplasia (AAH) and its associations with benign prostate hypertrophy (BPH) and latent histological carcinoma of the prostate (LPC) in autopsy material. Methods:Two hundred and twelve prostate specimens obtained from autopsy material were subjected to whole mount analysis in an attempt to investigate the associations among BPH, AAH and LPC. Results: Most histological carcinomas and AAH lesions were found in enlarged prostates with intense hypertrophy. No statistically significant relation was found between BPH and the main characteristics of LPC, such as tumor volume, histological differentiation and biological behavior. Our data regarding multi-focal tumors showed a tendency for multi-focal carcinomas to develop in larger prostates, and a tendency of AAH lesions to develop in larger prostates. No statistically significant relation was found between AAH and LPC. Conclusion: There seems not any causative aetiopathogenetical or topographical relation between AAH lesions and prostate adenocarcinoma. AAH lesion seems to be a well-defined mimicker of prostatic adenocarcinoma, and the reported association of AAH with prostatic carcinoma could probably be an epiphenomenon.

  1. 两种经尿道前列腺电切术的临床疗效比较%A comparative study of transurethral plasmakinetic resection versus transurethral resection of the prostate for benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    成波; 韩瑞发; 白铁男; 刘春雨; 徐勇; 孙光

    2008-01-01

    Objective To compare the efficacy and safety of transurethral plasmakinetic resection of prostate (PKRP) and transurethral resection of prostate (TURP) for benign prostatic hyperplasia (BPH). Methods The clinical and follow-up data of 186 patients with BPH were analyzed retrospectively. Two groups of BPH patients (90 patients in PKRP group,96 patients in TURP group) were treated by PKRP and TURP,respectively. The clinical date and therapeutic result were measured and compared for both in-tra-and inter-groups. Results In PKRP group,the operative time,intraoperative bleeding,the rates of damage of prostate surgical membranes,secondary hemorrhage (within 1 month),the rates of postoperative temporary urinary incontinence (within 2 months) were (65.3 ± 12.8)min,(213.6 ± 78.2)ml,5.6%(5/90),2.2% (2/90)and 21.1% (19/90),respectively,while in TURP group,these parameters were (83.6 ± 17.5) min,( 397.4 ± 142.7 )ml,17.7%( 17/96 ),11.5% ( 11/96 )and 36.5% ( 35/96 ),respectively. There were signif-icant differences between the 2 groups (P 0.05). Conclusions PKRP and TURP have similar efficacy in the treatment of BPH,but PKRP ap-pears to have an advantage of more safety and easier blood controls with less physical damage and complica-lion than those in TURP. PKRP is a better treatment option for BPH.%目的 比较经尿道前列腺等离子双极电切术(PKRP)与经尿道前列腺电切术(TURP)治疗良性前列腺增生(BPH)的主要优缺点及临床疗效.方法 回顾性分析2004年1月至2007年6月收治并获得随访的186例BPH患者的临床资料.PKRP组90例,TURP组96例,比较两组手术时间、术中出血量、前列腺包膜穿孔、术后国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流率(Qmax)、残余尿量(PVR)及并发症的发生率等指标.结果 PKRP组手术时间、术中出血量、前列腺包膜穿孔发生率、术后1个月内继发性出血发生率、术后2个月内暂时性尿失禁发生率分别为(65.3±12

  2. Evaluation of the tumor angiogenesis in benign prostate hyperplasia and prostatic cancer with MR perfusion-weighted imaging%良恶性前列腺疾病肿瘤血管形成的MR灌注加权成像评价

    Institute of Scientific and Technical Information of China (English)

    Jibin Zhang; Junkang Shen; Jianming Xu

    2008-01-01

    Objective: To explore the application of MR perfusion-weighted imaging (PWI) in the benign and malignant prostate diseases, and evaluate the correlations of PWI features with vascular endothelial growth factor (VEGF) and microvessel density (MVD). Methods: Seventy-four consecutive patients who were diagnosed clinically for the prostate diseases, including forty-four cases with benign prostate hyperplasia and thirty cases with prostatic cancer proved pathologically, were examined by PWI. MVD and VEGF were stained with immunohistochemical methods. Some parameters of PWI, including the steepest slope of signal intensity-time curve (SSmax) and the change in relaxation rate (△R2* peak) at lesions, were analyzed.Correlation analysis was used to determine the relationship between the results of PWI and immunohistochemistry. Results:(1) In the benign prostate hyperplasia (BPH), SSmax and △R2* peak of perfusion curve were 34.2 + 2.9 and 1.49±0.11,respectively; however, in the prostatic cancer (Pca), they were 58.6±4.8 and 3.18 + 0.49 respectively; there were statistical differences (t = 2.16 and 2.31, P < 0.05). (2) The VEGF and MVD expressions of thirty Pca patients were significantly higher than those of forty-four BPH patients (X2 = 28.64, P<0.01; t = 21.2, P<0.01). MVD expressions of Pca and BPH groups showed positive associations with VEGF expressions (P<0.01). On MR perfusion-weighted imaging, SSmax and △R2* peak showed associations with MVD and VEGF expressions (P<0.01). Conclusion: On MR perfusion-weighted imaging, SSmax and △R2* peak can reflect MVD and VEGF expression levels in the benign and malignant prostate diseases and might be implied the tumor angiogenesis so as to distinguish benign from malignant and provide the important information for the surgeon to diagnose and treat the prostatic diseases.

  3. Prostate Enlargement: Benign Prostatic Hyperplasia (BPH)

    Science.gov (United States)

    ... specially trained technician performs the procedure in a health care provider’s office, an outpatient center, or a hospital, and a radiologist—a doctor who specializes in medical imaging—interprets ...

  4. Evaluation on Safety and Efficacy of Finasteride in Treatment of Benign Prostatic Hyperplasia%非那雄胺治疗良性前列腺增生症的安全性及疗效评价

    Institute of Scientific and Technical Information of China (English)

    李晓京; 魏艳红; 沈司京; 张蕾

    2016-01-01

    目的:对我国非那雄胺治疗(benign prostatic hyperplasia,BPH)的临床安全性进行系统评价和Meta分析,并与国外相关研究进行比较分析.方法:检索关于非那雄胺单药或与其他药品联和应用,治疗良性前列腺增生的文献.纳入与非那雄胺的有关的随机对照试验(randomized controlled trials,RCT)或临床对照试验(clinical controlled trials,CCT).评价纳入文献质量并提取资料,进行Meta分析或作定性系统评价.结果:共纳入10篇RCT/CCT.分析发现:非那雄胺疗效确定,不良反应少.非那雄胺组与坦索罗辛组相比,在国际前列腺症状评分(international prostate symptom score,IPSS)、最大尿流率(maximal urinary flow rate,Qmax)和前列腺体积改善方面差异有统计学意义(P0.05).非那雄胺联合特拉唑嗪与非那雄胺相比,在前列腺体积、IPSS、Ru、Qmax改善方面差异有统计学意义(P0.05).结论:应用非那雄胺治疗BPH,能显著缓解症状,缩小前列腺体积,不良反应少,且非那雄胺与坦索罗辛或特拉唑嗪联合用较单用非那雄胺治疗更为有效.%OBJECTIVE:To conduct a systematic review with meta-analysis on the clinical safety of finasteride in treatment of benign prostatic hyperplasia ( BPH) , and to compare and analyze the results with related foreign studies . METHODS:Correlative literature with application of single finasteride or finasteride combined with other drugs in treatment of BPH were retrieved .RCT, CCT that related to finasteride were involved .The quality of literature was evaluated , the data were extracted and meta-analysis or qualitative systematic review were conducted .RESULTS:10 RCT/CCT met the inclusion criteria .According to the analysis: finasteride had a curative efficacy with slight adverse reactions .Compared with tamsulosin group , finasteride group had a grater improvement in IPSS score , Qmax and prostate volume , with significant difference ( P 0.05 ) .Compared with finasteride

  5. 前列腺增生合并膀胱结石34例治疗体会%Approach of therapy and result for benign prostatic hyperplasia combined with bladder calculus:for 34 cases

    Institute of Scientific and Technical Information of China (English)

    王华; 陆兆祥; 黄玉良; 梁法政

    2009-01-01

    目的 探讨前列腺增生合并膀胱结石的处理方法 .方法 根据前列腺大小,膀胱结石大小及数目,采取电切镜钩夹法,经尿道碎石法及耻骨上小切口切开膀胱取石法,同期行经尿道前列腺电切术.结果 1例膀胱穿孔改为开放手术,34例皆无电切综合症,术后皆无结石残留,排尿通畅.结论 对前列腺增生合并膀胱结石,应根据前列腺大小,结石大小及数目,选择不同的术式处理,做到手术安全有效.%Aim To investigate the approach to therapy and result for benign prostatic hyperplasia(BPH) combined with bladder calculus.Methods On the basis of the size of prostates,the magnitudes and numbers of bladder calculus,the resectoscope was adopted to clip or claw,with the per-urethra to gallet or microincisal on the pubic bone to remove bladder caoperation,synchronizationally under transurethral electroresection of prostatas(TURP) operation.Result Due to the cystospasm one case changed into breaking operation.There was no residual of calculusis after operation,all patients urinated easily and smoothly.Conclusions For BPH combined with bladder calculus,different types of operation should be selected according to the size of prostates,the magnitudes and the numbers of bladder calculus to ensure the safety and effectiveness of onerations.

  6. Relationship between diet and benign prostatic hyperplasia Relación entre la dieta y el desarrollo de Hiperplasia Prostática Benigna: ¿Qué nos dice la evidencia científica actual?

    Directory of Open Access Journals (Sweden)

    Jon Kepa Balparda Arias

    2010-02-01

    Full Text Available

    Benign prostatic hyperplasia is very common in the general population, both from the histological and the clinical points of view. The role of different factors in its development has been defined by means of epidemiological studies. One such factor is the composition of the diet, as the regular consumption of certain foods may either protect against benign prostatic hyperplasia or increase the risk of its development. Among foods which may play a protective role are lycopene, phytoestrogens and vegetables. On the other hand, the risk of developing the disease may be increased by a diet rich in fat and calories. In this article the main clinical trials concerning this relationship are reviewed, as a way of informing physicians on the dietetic patterns that may influence the frequency or the symptoms of this disease.

    La hiperplasia prostática benigna es muy común en la población general, tanto desde el punto de vista histológico como del clínico. El papel en ella de diversos factores se ha definido por medio de estudios epidemiológicos. Entre ellos está el consumo regular de algunos alimentos que podría actuar como un factor protector o de riesgo para el posterior desarrollo de la enfermedad. Entre los compuestos demostrados como benéficos para la salud prostática están los licopenos, los fitoestrógenos y las verduras. Por otro lado, entre los que podrían aumentar el riesgo de sufrir la hiperplasia prostática benigna se incluyen las dietas hipercal

  7. Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal Cells

    Directory of Open Access Journals (Sweden)

    Stéphane Terry

    2013-07-01

    Full Text Available Despite the high prevalence of histological Benign Prostatic Hypeplasia (BPH in elderly men, little is known regarding the molecular mechanisms and networks underlying the development and progression of the disease. Here, we explored the effects of a phytotherapeutic agent, Lipidosterolic extract of the dwarf palm plant Serenoa repens (LSESr, on the mRNA gene expression profiles of two representative models of BPH, BPH1 cell line and primary stromal cells derived from BPH. Treatment of these cells with LSESr significantly altered gene expression patterns as assessed by comparative gene expression profiling on gene chip arrays. The expression changes were manifested three hours following in vitro administration of LSESr, suggesting a rapid action for this compound. Among the genes most consistently affected by LSESr treatment, we found numerous genes that were categorized as part of proliferative, apoptotic, and inflammatory pathways. Validation studies using quantitative real-time PCR confirmed the deregulation of genes known to exhibit key roles in these biological processes including IL1B, IL1A, CXCL6, IL1R1, PTGS2, ALOX5, GAS1, PHLDA1, IL6, IL8, NFkBIZ, NFKB1, TFRC, JUN, CDKN1B, and ERBB3. Subsequent analyses also indicated that LSESr treatment can impede the stimulatory effects of certain proinflammatory cytokines such as IL6, IL17, and IL15 in these cells. These results suggest that LSESr may be useful to treat BPH that manifest inflammation characteristics. This also supports a role for inflammation in BPH presumably by mediating the balance between apoptosis and proliferation.

  8. Inhibitory effect of Coffea arabica bean in testosterone induced prostatic hyperplasia in Sprague-Dawley rats

    OpenAIRE

    Kristian Alfonso G. Cueto; Jenn Andrea C. Macalincag; Rhoneelet B. Aseremo; Joanne Florence B. Gutierrez; Sarah Jane R. Mabiog; Carina R. Magbojos; Oliver Shane R. Dumaoal

    2016-01-01

    Benign prostatic hyperplasia (BPH) has been described as the uncontrolled prostate gland growth which leads to difficulty in urination. One of the treatment of BPH is saw palmetto lipid extracts which has been shown to inhibit prostate 5 α-reductase and some of its components (lauric acid, myristic acid and oleic acid) also inhibit the enzyme. Coffee was also rich in fatty acids namely linoleic acid, oleic acid and palmitic acid. The aim of this research is to investigate whether ...

  9. Effects of nursing intervention on quality of life of patient with benign prostatic hyperplasia accepted plasmakinetic resection of prostate%护理干预对等离子经尿道前列腺电切术患者生活质量的影响

    Institute of Scientific and Technical Information of China (English)

    钱彦; 沈敏

    2011-01-01

    目的 评价护理干预对等离子经尿道前列腺电切术患者生活质量的影响.方法 123例良性前列腺增生患者被随机分成两组:非护理干预组和护理干预组.采用国际前列腺症状评分表、生活质量评分和世界卫生组织生存质量测定量表简表在术前和手术后的第3个月对患者进行评测.结果 有109例患者进入最后的分析,非护理干预组和护理干预组的国际前列腺症状评分表、生活质量评分和世界卫生组织生存质量测定量表简表的生活质量评分手术后比手术前有明显改善(P<0.05).PKRP 术后,护理干预组患者的生活质最优于非护理干预组.结论 PKRP术能明显改善患者生活质量,护理干预组优于非护理干预组.%Objective To investigate the effects of nursing intervention on quality of life (QOL) of patient with benign prostatic hyperplasia accepted plasmakinetic resection of prostate. Methods From January in 2007 to December in 2009, a total of 123 consecutive men admitted from a waiting list for surgery for benign prostatic hyperplasia (BPH) were prospectively randomized to either nursing intervention or non -nursing intervention. Peri - and postoperative IPSS, QOL, and WHOQOL- BREF outcome data in the third month were obtained. Results Data analysis was based on 109 patients. The IPSS, QOL, and WHOQOL - BREF in non - nursing intervention and nursing intervention group had been significantly improved at post- operation compared to pre- operation. There was significant difference on WHOQOL BREF scores in two groups at post - operation. Conclusion Nursing intervention can improve the quality of life of patients with benign prostatic hyperplasia accepted plasmakinetic resection of prostate. Improving the nursing after the procedure makes good prognosis.

  10. 磁共振波谱成像对中央腺体前列腺癌与良性增生结节的鉴别诊断%Value of magnetic resonance spectroscopic imaging in differential diagnosis of prostate cancer in central gland and benign prostatic hyperplasia nodus

    Institute of Scientific and Technical Information of China (English)

    钟心; 王宏; 董玉茹; 穆学涛; 董悦

    2010-01-01

    Objective To explore the metabolic characteristic of prostate cancer (PCa) in central gland with magnetic resonance (MR) spectroscopic, and evaluate the value of MRS in the differential diagnosis of benign prostatic hyperplasia nodus. Methods MR images were performed in 38 cases with prostate disease by 3.0T MR, 11 cases with PCa in central gland and 27 cases with benign prostatic hyperplasia nodus. All the cases were scanned by routine, then by the combined MRS. MRS findings were reviewed in 27 cases with benign prostatic hyperplasia (BPH) and 11 cases with PCa (3 in central gland origin, 8 with large tumor invading both peripheral zone and central gland). (Cho+Cr)/Cit ratios of PCa and BPH were retrospectively measured, (Cho+Cr)/Cit of PCa voxels were compared with that of BPH voxels. Results Significantly higher choline levels and lower citrate levels were observed in central gland of PCa compared with BPH. In the glandular BPH region, the amount of Cit was high; while in the stromal region, the Cit and Cho level was much lower. The average (Cho+Cre)/Cit values of PCa and BHP were 1.94±1.43 and 0. 83±0. 28 respectively, the difference in ratio between both was statistically significant (P<0. 01). Conclusions The combined use of MRI and MR spectroscopy is propitious for differentiating prostate cancer in central gland and benign prostatic hyperplasia nodus and for increasing the diagnostic accuracy of prostate cancer.%目的 探讨磁共振波谱成像(MRS)检查中央腺体前列腺癌代谢特点,与良性增生结节的鉴别诊断价值. 方法 应用3.0T MR成像仪对38例前列腺疾病患者进行前列腺MRI成像,中央腺体前列腺癌11例,良性前列腺增生27例.在MRI常规成像基础上行MRS检查,分析良性前列腺增生(BPH)和前列腺癌的MRS表现,11例前列腺癌中3例局限于中央腺体,8例肿块较大同时累及外周带,测量中央腺体内前列腺癌及BPH的胆碱(Cho)+肌酐(Cr)/枸橼酸盐(Cit)比值,并对前

  11. Comparision of postoperative sexual function following TVP and open surgery for benign prostatic hyperplasia%TVP与开放手术治疗前列腺增生症术后性功能比较

    Institute of Scientific and Technical Information of China (English)

    徐慧; 朱凯; 王福利

    2003-01-01

    Objective:To observe the effects of transurethral vaporization for prostate (TVP) and suprapubic prostatectomy (SPP) on sexual function of the patients with benign prostatic hyperplasia (BPH). Methods:Followed up for 12 months, the incidences of postoperative impotence and retrograde ejaculation in 100 cases treated with TVP were compared with those in 100 cases treated with SPP. Results: The incidences of postoperative impotence were 4.35% (3/69) and 10.8% (8/74) in those cases treated with TVP and SPP respectively. And the corresponding incidences of retrograde ejaculation were 44.9 % (31/69) and 41.1% (31/74)respectively. Conclusions:As for avoidance of postoperative sexual dysfunction after surgical treatment of BPH, TVP is superior to SPP (P <0.01). There is no obvious difference between TVP and SPP on the incidence of retrograde ejaculation(P >0.05).%目的比较经尿道前列腺汽化术(TVP)、耻骨上前列腺摘除术(SPP)治疗良性前列腺增生症(BPH)术对性功能的影响.方法对100例TVP及100例SPP术后病人进行12个月追踪观察,总结其术后阳萎及逆行射精发生率.结果TVP与SPP术后阳萎发生率分别是4.35%(3/69)和10.81%(8/74),逆行射精发生率分别是44.9%(31/69)和41.9%(31/74).结论此两种术式治疗BPH产生术后性功能损害TVP优于SPP(P<0.01),逆行射精发生率无显著性差异(P>0.05).

  12. Erectile dysfunction in patients with symptomatic benign prostatic hyperplasia.%前列腺增生症患者勃起功能障碍及其影响因素分析

    Institute of Scientific and Technical Information of China (English)

    隆电熙; 吴莉红; 初铭彦; 王高兴

    2011-01-01

    目的 探讨老年男性在前列腺增生症(BPH)患者病史、年龄、IPSS、前列腺体积、最大尿流率及血清PSA与勃起功能障碍(ED)的相关性.方法 采用SPSS10.0软件总结并分析142例前列腺增生症患者病史、年龄、临床症状参数、前列腺体积、最大尿流率、血清PSA与勃起功能国际评分(ILEF-5)、性欲之间的关系.结果 BPH患者142例,年龄50~75岁.115例有ED(80.99%),72例有性欲低下(50.70%).研究显示年龄与性功能关系密切.IPSS评分在IIEF-5正常组与轻、中、重度ED组间比较,差异均有统计学意义(P<0.05).结论 年龄是性功能障碍的主要因素,BPH患者中ED的发生率较高,ED的程度与下尿路症状(LUTS)的严重程度有相关性.%Objective To explore the relationship between history, age, International Prostate Symptom Score (IPSS), prostate volume, maximum urinary flow rate, serum PSA of benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) in the patients with BPH. Methods Data of 142 patients' history of BPH, age, clinical parameters, prostate volume, maximum urinary flow rate, serum PSA and erectile dysfunction, sexual desire were collected and analyzed with software SPSSI0.0. Results 142 patients with BPH aged from 50 to 75 years. The morbidity of ED was 80.99% in the patients; the low sexual desire was 50.70%. Age was found to be associated with sexual function. There was significant difference in the value of IPSS between erectile function normal group and the other abnormal group. Conclusion Age is the main factor in sexual dysfunction. There were high in cadence rate of ED in the patients with BPH, and the degree of ED was related with sever degree of LUTS.

  13. 他汀类药物对老年良性前列腺增生合并代谢综合征患者的作用%Statins for elderly patients with benign prostatic hyperplasia combined metabolic syndrome

    Institute of Scientific and Technical Information of China (English)

    艾银海; 姚敬

    2016-01-01

    Objectives To explore clinical application value of statin drugs in elderly patients with benign prostate hyperplasia (BPH) and metabolic syndrome.Methods One hundred cases of elderly patients with benign prostate hyperplasia (BPH) and the metabolic syndrome were admitted in some hospital from May 2010 to May 2012,who were divided into control group (50 cases) and study group (50 canse),and approved by our hospital ethics committee and informed consent of patients to adopt isometric random sampling method.The patients in the control group were treated with other therapy,while the patients in the study group were treated with statins (simvastatin),The clinical therapeutic effects of the two groups were compared after 6 months.Results The patients in study group were treated with statins.The triglycerides,total cholesterol,high-density lipoprotein cholesterol,low density lipoprotein cholesterol,hypersensitive c-reactive protein,interleukin-6,prostate volume and international prostate symptom score were compared with the control group,the difference between the groups was statistically significant (P < 0.05);The adverse reaction rate of the study group was 8%,while control group was 20%,and the differences were statistically significant (P <0.05).Conclusions Statins in the treatment of benign prostatic hyperplasia (BPH) and the metabolic syndrome,which can improve the body index by regulating blood lipid,reduce the prostate volume,and stop progression of disease,and no adverse events of statins appear and it is worth popularization because of higher value of clinical application.%目的 探究他汀类药物在老年良性前列腺增生(BPH)合并代谢综合征患者临床治疗中的应用价值.方法 选取本院2010年5月至2012年5月收治的100例老年BPH合并代谢综合征患者为研究对象,经本院伦理委员会批准及患者知情同意下由临床医师采取的等距随机抽样法分为对照组及研究组各50例,对照组采用非

  14. Protective effect of Prostane in experimental prostatic hyperplasia in rats

    Institute of Scientific and Technical Information of China (English)

    S.K.Mitra; R.Sundaram; A.R.Mohan; S.Gopumadhavan; M.V.Venkataranganna; UdupaVenkatesha; S.J.Seshadri; S.D.Anmrlikar

    1999-01-01

    Aim: Prostane, a polyherbal formulation, was evaluated for its efficacy on ,5a-reductase inhibition, a-adrenergie anta-gonistic activity and testosterone-induced prostatic hypeqllasia. Methods: 5a-reductase inhibition was evaluated usingrat prostate hornogeante as an enzyme source. Adrenergic antagonistic" activity was evaluated using isolated rat vas def-erens. Experimental prostatic hyperplasia was induced in rats by" giving testosterone 3 mg/kg sc for 21 days. Re-suits: Prostane dose-dependently inhibited 5a-reductase aetivity and exhibited a-adrenergic antagonistic activity. Treat-ment with Prostane at 250, 500 and 750 mg/kg body wt, po for 21 days significantly reduced the prostatic weight, theepithelial height and the stroinal proliferation in experimental prostatic hypertrophy. Conclusion: Prostane is effectivein the treatment of experimental prostatic hypertrophy in rats and may be passed on to clinical trials on benign prostatichypertrophy after necessary toxicological evaluations. ( Asian J Androl 1999 Dec ; l : 175 - t79 )

  15. Micro and bulk analysis of prostate tissues classified as hyperplasia

    Science.gov (United States)

    Kwiatek, W. M.; Banaś, A.; Banaś, K.; Cinque, G.; Dyduch, G.; Falkenberg, G.; Kisiel, A.; Marcelli, A.; Podgórczyk, M.

    2007-07-01

    BPH (Benign Prostatic Hyperplasia) is the most common benign neoplasm (non cancerous enlargement of the prostate gland), whose prevalence increases with age. The gland, when increased in size, exerts pressure on the urethra, causing obstruction to urine flow. The latter may result in severe urinary tract and kidney conditions. In this work prostate samples from patients diagnosed with BPH were analyzed using synchrotron radiation. Micro-analysis of the hyperplastic samples was carried out on the L-beam line at HASYLAB, DESY (Germany), while bulk analysis on selected samples was performed at the DRX2 beamline at LNF, Frascati (Italy). Microanalysis with a mono-energetic beam 15 μm in diameter confirmed that concentrations of certain elements, such as S, Mn, Cu, Fe and Zn, are good indicators of pathological disorders in prostate tissue that may be considered effective tracers of developing compliant. The concentrations of Mn, Cu, Fe and Zn are higher in hyperplastic tissues, as compared to normal ones, while for sulphur the opposite is observed. Additionally, Fe and S K-edge XANES (X-ray Absorption Near Edge Structure) spectroscopy experiments were carried out in order to determine the chemical speciation of these elements in our samples.

  16. Micro and bulk analysis of prostate tissues classified as hyperplasia

    Energy Technology Data Exchange (ETDEWEB)

    Kwiatek, W.M. [Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, ul. Radzikowskiego 152, 31-342 Cracow (Poland)], E-mail: wojciech.kwiatek@ifj.edu.pl; Banas, A.; Banas, K. [Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, ul. Radzikowskiego 152, 31-342 Cracow (Poland); Cinque, G. [INFN- Laboratori Nazionali di Frascati, Via E. Fermi 40, I-00044 Frascati (Italy); Dyduch, G. [Collegium Medicum, Jagiellonian University, Cracow (Poland); Falkenberg, G. [Hasylab, DESY Notkestraae 85, D-22603 Hamburg (Germany); Kisiel, A. [Institute of Physics, Jagiellonian University, ul.Reymonta 4, 30-059 Cracow (Poland); Marcelli, A. [INFN- Laboratori Nazionali di Frascati, Via E. Fermi 40, I-00044 Frascati (Italy); Podgorczyk, M. [Henryk Niewodniczanski Institute of Nuclear Physics, Polish Academy of Sciences, ul. Radzikowskiego 152, 31-342 Cracow (Poland)

    2007-07-15

    BPH (Benign Prostatic Hyperplasia) is the most common benign neoplasm (non cancerous enlargement of the prostate gland), whose prevalence increases with age. The gland, when increased in size, exerts pressure on the urethra, causing obstruction to urine flow. The latter may result in severe urinary tract and kidney conditions. In this work prostate samples from patients diagnosed with BPH were analyzed using synchrotron radiation. Micro-analysis of the hyperplastic samples was carried out on the L-beam line at HASYLAB, DESY (Germany), while bulk analysis on selected samples was performed at the DRX2 beamline at LNF, Frascati (Italy). Microanalysis with a mono-energetic beam 15 {mu}m in diameter confirmed that concentrations of certain elements, such as S, Mn, Cu, Fe and Zn, are good indicators of pathological disorders in prostate tissue that may be considered effective tracers of developing compliant. The concentrations of Mn, Cu, Fe and Zn are higher in hyperplastic tissues, as compared to normal ones, while for sulphur the opposite is observed. Additionally, Fe and S K-edge XANES (X-ray Absorption Near Edge Structure) spectroscopy experiments were carried out in order to determine the chemical speciation of these elements in our samples.

  17. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

    DEFF Research Database (Denmark)

    Andersen, J T; Ekman, P; Wolf, H;

    1995-01-01

    rate, prostate volume, postvoiding residual urinary volume, and serum concentrations of prostate-specific antigen together with laboratory safety parameters were measured at entry and at months 12 and 24. Interim physical and laboratory examinations were performed when indicated clinically. RESULTS....... In finasteride-treated patients the total symptom score improved throughout the study, with a significant difference between the two groups at 24 months (P .... The maximum urinary flow rate decreased in the placebo group, but improved in the finasteride group, resulting in a between-group difference of 1.8 mL/s at 24 months (P group versus -19% in the finasteride-treated group (P

  18. Value of Diffusion-weighted Imaging in Distinguishing Prostate Cancer from Benign Prostatic Hyperplasia:a Meta-analysis%磁共振扩散加权成像鉴别诊断前列腺癌与良性前列腺增生的Meta分析

    Institute of Scientific and Technical Information of China (English)

    孙丽娜; 李前程; 程凯亮; 张孟超; 刘云霞

    2013-01-01

    Purpose To explore the ADC value in distinguishing prostate cancer (PCa) and benign prostatic hyperplasia (BPH) by reviewing related articles. Materials and Methods The studies about the diffusion-weighted images in distinguishing the prostate cancer and benign prostatic hyperplasia were enrolled from the websites of Elsevier Science, PubMed, Springer-Link, Wiley Online Library, Medline and CNKI from 2000 to 2011, with DWI, prostate, cancer, carcinoma and hyperplasia as search terms. According to the uniform inclusion and exclusion criteria, the correct studies were chosen and the parameters including the mean values and standard deviations of ADC value were extracted. Meta-analysis was done by using Stata 11 software. Results A total of 7 studies met the inclusion criteria, including 4 English articles and 3 Chinese articles. The fixed-effect model was used due to no heterogeneity. The standardized mean difference (SMD) was-1.357 and 95%confidence interval (95%CI) was (-1.604,-1.109, P=0.000). Conclusion DWI can be helpful in distinguishing the prostate cancer from the benign prostatic hyperplasia, and the ADC value of PCa is lower than that of BPH.%目的对磁共振扩散加权成像鉴别诊断前列腺癌和良性前列腺增生的文献进行汇总复习,定量分析前列腺癌与良性前列腺增生的表观扩散系数(ADC)值,为临床决策提供依据。资料与方法以“DWI、prostate、cancer、carcinoma、hyperplasia、扩散加权成像、前列腺癌、前列腺增生”为检索词,检索2000~2011年Elsevier Science、PubMed、SpringerLink、Wiley Online Library、Medline 及 CNKI中收录的相关文献,按照统一的纳入及排除标准筛选文献,提取出相关参数及ADC值的平均值和标准差。采用Stata 11软件进行Meta分析。结果共纳入7篇文献,其中英文4篇,中文3篇。应用χ2检验对结果进行异质性分析发现文献无异质性,采用固定效应模型分析发现前列腺癌患

  19. Clinical Efficacy and Safety of Transurethral Vaporization of the Prostate With 1.9 μm Laser in the Treatment of Elderly Patients With Benign Prostatic Hyperplasia%经尿道1.9μm激光前列腺汽化切除术治疗高龄前列腺增生患者的临床疗效及安全性

    Institute of Scientific and Technical Information of China (English)

    李新伟

    2016-01-01

    Objective To investigate the clinical efficacy and safety of transurethral vaporization of prostate with 1.9 μm laser for the treatment of elderly patients with benign prostatic hyperplasia. Methods To collect 160 cases of elderly patients with benign prostatic hyperplasia in our hospital, and to observe the therapeutic effect and safety of transurethral vaporization resection of prostate with 1.9 μm laser. Results All patients achieved good results, there was no significant bleeding and complications, postoperative prognosis and recovery were good. Conclusion Transurethral vaporization resection of prostate for elderly patients with benign prostatic hyperplasia by 1.9 μm laser can achieve more safe and effective therapeutic effect, and has a high value of application.%目的:探讨经尿道1.9μm 激光前列腺汽化切除术治疗高龄前列腺增生患者的临床疗效及安全性。方法收集我院160例高龄前列腺增生患者,对所有患者均实施经尿道1.9μm 激光前列腺气化切除术治疗,观察治疗效果和安全性。结果所有患者均取得较好效果,术中未出现明显出血和并发症,术后预后情况和恢复情况均较好。结论对高龄前列腺增生患者实施经尿道1.9μm 激光前列腺气化切除术治疗可取得更加安全有效的治疗效果,有着很高应用价值。

  20. Comparative analysis of postoperative gland resection rate of PKERP and PKRP in the treatment of moderate to severe benign prostatic hyperplasia%PKERP与PKRP在治疗中重度BPH时腺体切除率的对比分析

    Institute of Scientific and Technical Information of China (English)

    陈冰; 徐嘉云; 刘聪; 胡振兴; 胡庆新

    2013-01-01

    目的:分析比较经尿道双极等离子腔内前列腺剜除术(PKERP)与经尿道前列腺等离子双极电切术(PKRP)在治疗中重度BPH时的组织切除重量和切除率,评价两种手术方式的组织切除率差别及PKERP的术后临床效果.方法:随机对照研究2011年1~12月采用PKERP及PKRP治疗84例腺体重量超过50 g的BPH患者临床资料,对术前B超所测前列腺体积后的估计重量、实际切除重量及手术腺体切除率进行对比分析.结果:84例患者无死亡发生,PKERP术前前列腺估测重量为50.2~135 g,平均为79.4 g;切除组织重量为43.6~112 g,平均为60.7 g,平均切除比率为76.5%.PKRP术前前列腺估测重量为52.2~130.2 g,平均为77.6 g;切除组织重量为28.7~78.1 g,平均为38.1 g,平均切除比率为54.5%.结果显示切除率与前列腺的估测重量呈正相关.两组患者术前前列腺估测重量比较,差异均无统计学意义(P>0.05);两组患者前列腺切除重量及前列腺组织切除率比较,差异均有统计学意义(P<0.05).结论:PKERP治疗中重度BPH临床效果显著,并发症低,可以完整切除增生腺体,降低了腺体残留引发的继发性出血和再手术率.%To analyze Gland resection rate and tissue resection weight of PKERP in the treatment of moderate to severe benign prostatic hyperplasia,to evaluate difference in gland resection rate and postoperative clinical effects for the two methods.Methods:To collect my hospital clinical material of PKERP and PKRP in the treatment of 84 BPH patients whose Glands weighted more than 50 grams during 2011,to make comparative analysis of expected prostate volume measured by B ultrasound before surgery,actual resection weight and gland resection rate.Results:No deaths occurred in 84 BPH patients.In PKERP method:The estimated preoperative weight of the prostate was 50.2-135 g,and average was 79.4 g; The weight of resected tissue was 43.6-112 g,and average was 77.6 g; Average

  1. 治疗仪联合川参通局部注药治疗前列腺增生症213例报道%Study on Clinical Effect of Method of the Treatment Instrument combined with Partial Injection of Chuanshentong Treatment for Benign Prostatic Hyperplasia Report of 213 Cases

    Institute of Scientific and Technical Information of China (English)

    邢子龙

    2012-01-01

      Objective To Study on clinical effect and drug delivery method of method of the treatment instrument combined with partial injection of chuan shen tong treatment for benign prostatic hyperplasia Methods Method of the treatment instrument massage prostate through rectum combined with partial injection of Chinese Native Medicine in perineum directly with the number 5 needle. Results The prostate volume is reduced, the total efficiency of 94.6%. Conclusion The treatment instrument combined with partial injection of chuan shen tong treatment for benign prostatic hyperplasia is a major breakthrough, worthy of clinical use.%  目的探讨治疗仪联合川参通局部注药治疗前列腺增生症的给药方法及临床疗效.方法治疗仪经肛门直肠按摩联合会阴部直接用5号特制针头注射中药制剂.结果前列腺体积缩小,总有效率94.6%.结论治疗仪联合川参通局部注药是治疗前列腺增生症的重大突破,直得临床推广使用.

  2. Portable {sup 90}SR/{sup 90}Y prostatic hyperplasia applicators

    Energy Technology Data Exchange (ETDEWEB)

    Cai, Shanyu; Tang, Kejian; Zhou, Changling [China Institute of Atomic Energy (China); Li, Zhi [Zhelimumen Hospital (China)

    1998-07-01

    In order to seek a new method of curing the benign prostatic hyperplasia (BPH), two different kinds of {sup 9} {sup 0}Sr/9{sup 0}Y intracavity applicators, including a 'urethra-type' and a 'rectum-type', have been developed in China since 1991. The structural design and radiation characteristics of the {sup 90}Sr/{sup 90}Y prostatic hyperplasia applicator are given in this paper. The hypertrophic prostate gland can be irradiated through the wall of the urethra or rectum by {sup 90}Sr/{sup 90}Y beta rays and small quantity of bremsstrahlung radiation from the applicator. Clinical tests indicate that the {sup 90}Sr/{sup 90}Y prostatic hyperplasia applicators provide a safe, effective, non-invasive and economical therapeutic method for BPH. It is especially applicable for old and high-risk patients. (author)

  3. 锯叶棕提取物治疗BPH伴OAB的疗效观察%Effect study of saw palmetto extract in the treatment of benign prostatic hyperplasia with overactive bladder

    Institute of Scientific and Technical Information of China (English)

    白立刚

    2013-01-01

    目的:探讨锯叶棕提取物治疗BPH伴膀胱过度活动症(OAB)的临床疗效.方法:将2012年7月~2013年3月在我院诊断为BPH伴OAB患者100例随机分为研究组50例及对照组50例,研究组口服锯叶棕提取物(沙芭特)160 mg,每天2次;对照组口服坦索罗辛0.2 mg,每天1次.两组患者均服药8周,对比观察两组开始服药前、服药8周后的IPSS评分、OABSS评分、生活质量评分、最大尿流率(Qm.)、24 h排尿次数、夜尿次数、每次排尿量等指标,观察研究组用药前后的疗效.结果:两组患者OAB较治疗前均有明显好转,治疗前后各项指标差异具有统计学意义(P<0.05);除max外,研究组与对照组其余观察指标治疗前后的变化值比较,差异均有统计学意义(P<0.05).结论:锯叶棕提取物(沙芭特)对于BPH伴OAB有明显的治疗作用,临床疗效较好.%To evaluate the clinical efficacy of saw palmetto extract in the treatment of benign prostatic hyperplasia patients with overactive bladder.Methods:100 case were included and were randomly divided into the trial group (50 cases) and control group(50 cases).Patients in trial group were adminstrated with saw palmetto extract at 160 mg and in control group were with tamsulosin at 0.2mg once daily for 8 weeks.The efficacy of treatment were assessed by changes before and after treatment in IPSS,OABSS,Quality of life score,Qmax aily frequency of micturition,the number of nocturia,voiding volumes.Results:There are significant differences in outcome in trial group between before and after treatment(P<0.05).There are no significant difference in the changes before and after treatment betweem two groups.There are significant differences in changes before and after treatment of subjective and objective outcome measures except for Qmax and voiding volumes(P<0.05).Conclusions:Combination saw palmetto extract in treatment of benign prostatic hyperplasia patients with OAB has efficacy.

  4. 锦州地区男性吸烟、体质量指数与临床良性前列腺增生的危险性研究%Cigarette smoking, body mass index associated with the risks of clinical benign prostatic hyperplasia in male patients from Jinzhou area

    Institute of Scientific and Technical Information of China (English)

    卢智泉; 王立华; 贺振权; 刘玉芳; 张国毅; 李志强; 聂绍发

    2007-01-01

    BACKGROUND: Benign prostatic hyperplasia is a common disease of older males. Although the etiology remains unclear, the factors of life style and habits may have an effect on the disease.OBJECTIVE:To examine the association of cigarette smoking and body mass index with the risk of clinical benign prostatic hyperplasia.DESIGN: A hospital-based case-control study SETTINGS: Department of Epidemiology and Statistics, Public Health School,Tongji Medical College, Huazhong University of Science and Technology; Department of Preventive Medicine, Liaoning Medical College.PARTICIPANTS:Totally 343 males with benign prostatic hyperplasia of 50-82 years old (patient group),who were surgically treated between May 2004 and May 2006,were selected from the Department of Urinary Surgery of the First Affiliated Hospital and Third Affiliated Hospital of Liaoning Medical College (former Jinzhou Railway Central Hospital),Jinzhou Central Hospital and Jinzhou Second People's Hospital.Inclusive criteria:① males above 50 years old;intemational prostatic symptom score(IPSS)>7;②Digital recta examination (DRE) after miction indicated prostate grade Ⅰ(transverse diameter>3 cm); ③prostatic volume≥30 g; ④maximum unnary flow rate<15 mL/s;Meanwhile,361 inpatients with diseases irrelative to the risk factors of benign prostatic hyperplasia,prostatic cancer and prostatitis were selected trom the above hospitals as the control group,they were 50-82 years of age with an average of 65 years old.Informed contents were obtained from all the enrolled subjects.METHODS:All the patients and controls were interviewed using an anonymous questionnaire.All participants were asked to report whether they had smoked 20 packs of cigarettes or more in their lifetimes and,if yes,they were smokers,on the contrary they were non-smokers. Based on usual number of cigarettes reported in the questionnaire, men were categorized as 1-10,11-20,21-30 and >30 cigarettes per day

  5. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.

    Directory of Open Access Journals (Sweden)

    Teng-Fu Hsieh

    Full Text Available This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH using the National Health Insurance Research Database (NHIRD in Taiwan.In total, 1,486 adult patients newly diagnosed with BPH and who used 5-alpha-reductase inhibitors were recruited as the study cohort, along with 9,995 subjects who did not use 5-alpha-reductase inhibitors as a comparison cohort from 2003 to 2008. Each patient was monitored for 5 years, and those who subsequently had cardiovascular diseases were identified. A Cox proportional hazards model was used to compare the risk of cardiovascular diseases between the study and comparison cohorts after adjusting for possible confounding risk factors.The patients who received 5-alpha-reductase inhibitor therapy had a lower cumulative rate of cardiovascular diseases than those who did not receive 5-alpha-reductase inhibitor therapy during the 5-year follow-up period (8.4% vs. 11.2%, P=0.003. In subgroup analysis, the 5-year cardiovascular event hazard ratio (HR was lower among the patients older than 65 years with 91 to 365 cumulative defined daily dose (cDDD 5-alpha-reductase inhibitor use (HR=0.63, 95% confidence interval (CI 0.42 to 0.92; P=0.018, however there was no difference among the patients with 28 to 90 and more than 365 cDDD 5-alpha-reductase inhibitor use (HR=1.14, 95% CI 0.77 to 1.68; P=0.518 and HR=0.83, 95% CI 0.57 to 1.20; P=0.310, respectively.5-alpha-reductase inhibitor therapy did not increase the risk of cardiovascular events in the BPH patients in 5 years of follow-up. Further mechanistic research is needed.

  6. 经尿道前列腺等离子电切治疗80岁及以上前列腺增生患者临床观察%Transurethral plasmakinetic resection of prostate for treating benign prostate hyperplasia in elderly patients

    Institute of Scientific and Technical Information of China (English)

    楼水鑫; 章越龙; 丁青; 任黎刚; 毛祖杰; 张大宏; 肖家全

    2011-01-01

    Objective To study the efficacy and safety of transurethral plasmakinetic resection of prostate (PKRP) in treatment of benign prostate hyperplasia in elderly patients aged 80 years and over. Methods Retrospective clinical analysis of 180 case of high risk of benign prostate hyperplasia treated by PKRP in patients aged 80 years and over. Results All the 180 patients underwent the operation successfully. The average time for operation was (45.5±23.3) min and the resected prostate was in an average of (60.3±23.3) g. Neither of blood transfusion during the operation nor aductor reflex and transurethral resection syndrome occurred. International prostate symptom score,residual urine and quality of life decreased from (29.5±5.3) to (10.2±2.8),from (130.5±45.5) ml to (13.5±7.1)ml and from (7.2±1.1) to (1.0±0.5) respectively. The maximum flow rate elevated from (6.2±1.8) ml/s to (24.5±3.1) ml/s. The differences in the above indicators were statistically significant between pre- and post- operation (P<0.05). Conclusions Transurethral plasmakinetic prostatectomy is a reliable and effective surgical method, especially for the aged patients with benign prostate hyperplasia.%目的 探讨经尿道前列腺等离子双极电切术(PKRP)治疗80岁及以上前列腺增生 (BPH)患者的有效性及安全性.方法 回顾分析PKRP治疗的180例80岁及以上高危BPH患者的临床资料.结果 180例手术顺利,手术操作时间平均(45.5±23.3)min.平均切除前列腺(60.3±23.3)g,无输血病例,术中无闭孔神经反射电切综合征出现.术后国际前列腺症状评分由(29.5±5.3)分降至(10.2±2.8)分;最大尿流率由(6.2±1.8)ml/s上升至(24.5±3.1)ml/s;生活质量评分由术前的(7.2±1.1)分下降至(1.0±0.5)分;残余尿由(130.5±45.5)ml降至(13.5±7.1)ml(均P<0.05).结论 PKRP具有安全性高、并发症少、前列腺切尽率高、疗效确切等优点,适宜高龄BPH患者的手术治疗.

  7. 经导管动脉栓塞治疗良性前列腺增生症一例报道%Transcatheter Arterial Embolization for benign prostatic hyperplasia - case report

    Institute of Scientific and Technical Information of China (English)

    兰春虎

    2009-01-01

    经导管动脉栓塞治疗良性前列腺增生症(benign prostatic hyperplasi,BPH),文献报道较少,省内未见报道。兹报告我院栓塞治疗的良性前列腺增生症1例如下。

  8. Tamsulosin combined with solifenacin for benign prostatic hyperplasia complicated with overactive bladder%索利那新联合坦索罗辛治疗前列腺增生合并膀胱出口梗阻

    Institute of Scientific and Technical Information of China (English)

    刘胜; 余昆; 李风; 余志海; 杨忠新; 夏宗禹

    2013-01-01

    目的:探讨索利那新联合坦索罗辛治疗良性前列腺增生(benign prostatic hyperplasia,BPH)合并膀胱出口梗阻(bladderoutlet obstruction,BOO)的有效性及安全性.方法:选择未经治疗且无严重BOO的BPH患者105例进行为期12周的治疗;随机分成Ⅰ、Ⅱ两组,Ⅰ组(n=50)单用坦索罗辛(0.2 mg,每晚),Ⅱ组(n=55)联合服用坦索罗辛(0.2 mg,每晚)和索利那新(5 mg,1次/d).两组分别在治疗前后以国际前列腺症状评分(international prostate symptoms score,IPSS)、生活质量评估(quality of life,QOL)、膀胱过度活动症评分(overactive bladder sypmtom score,OABSS)、最大尿流率(maximum flow rate,Qmax)以及24 h排尿次数、尿急次数、急迫性尿失禁次数和尿潴留次数为评估指标,观察其有效性及安全性.结果:服药12周后,可评价病例97例;两组治疗前后IPSS、QOL、Qmax及24 h排尿次数均得到显著改善(P<0.05);Ⅱ组治疗后OABSS评分以及储尿期症状(尿急、尿频、急迫性尿失禁)明显优于Ⅰ组[(4.82±1.15 vs.9.27±2.10)、(3.31 ±0.18 vs.6.82±2.15)、(8.02 ±2.15 vs.10.13 ±2.07)、(0.50±0.13 vs.2.03±0.87),P<0.05],而Qmax两组治疗后比较差异无统计学意义(15.81±2.56 vs.16.04±3.26,P>0.05);两组均未发生尿潴留,不良事件发生率Ⅰ组为4.3%、Ⅱ组为8.0%.结论:索利那新联合坦索罗辛能有效并安全地缓解BPH所合并的OAB症状,极大地改善了患者的生活质量.%Objective: To evaluate the efficacy and safety of combined use of solifenacin and tamsulosin in the treatment of benign prostatic hyperplasia (BPH) accompanied by overactive bladder(OAB). Methods: Totally 105 cases of clinically diagnosed BPH without serious obstruction of urinary tract were selected and were randomly assigned to Ⅰ group(n=50) to receive 0.2 mg of tamsulosin once a day and Ⅱ group(n=55) to be treated with 0.2 mg of tamsulosin once a day plus 5 mg of solifenacin once a day at night,both for 12

  9. 中西医联合治疗前列腺增生尿潴留60例%Combination of Traditional Chinese and Western Medicine Treatment of 60 Cases of Benign Prostatic Hyperplasia Urine Retention

    Institute of Scientific and Technical Information of China (English)

    田振涛; 何锦华; 易虎

    2013-01-01

    Objective:To investigate the clinical effect of benign prostatic hyperplasia urine retention with combination of traditional Chinese and Western medicine.Methods:60 BPH urine retention patients were selected to treat by acupuncture,moxibustion,prostate microwave and oral Doxazosin and Finasteride.Catheter was removed after 10 days treatment.After three months,the international prostate symptom score(IPSS),quality of life score (QOL),maximum flow rate (MFR),residual urine volume changes were observed and recorded before and after treatment.Results:After three months,the IPSS score was decreased by an average of 6 points ; QOL score was reduced by an average of 3 points ; The maximal urinary flow rate was at an average of (11.4 ± 2.8)mL/s after treatment.The residual urine volume was (27.1 ± 7.2) mL.The extubation rate was 76.7%.Fourteen patients underwent bladder puncture gastrostomy.Extubation patients were followed up for 3 to 6 months without urinary retention recurrence.Conclusion:Combination of traditional Chinese and Western medicine is a safe and effective treatment of BPH urine retention.This treatment can be used as an option for senior patients with urinary retention who have high risk or can not tolerate surgery of BPH.%目的:观察中西医联合治疗前列腺增生尿潴留的临床效果.方法:选择前列腺增生尿潴留患者60例进行针刺、温灸、前列腺微波联合口服可多华和保列治.治疗10天后拔除尿管,3个月后观察记录治疗前后的拔管率、IPSS评分、QOL评分、最大尿流率及残余尿量的变化.结果:联合治疗后IPSS评分平均下降6分,QOL评分平均下降3分,治疗后最大尿流率平均(11.4±2.8) mL/s,残余尿量为(27.1 ±7.2)mL;尿潴留患者拔管率76.7%,14例行膀胱穿刺造瘘术.拔管者随访3~6个月无尿潴留再发.结论:中西医结合治疗老年前列腺增生尿潴留是一种安全有效的非手术治疗方法,可以作为高龄、高危不能耐受手

  10. 经尿道前列腺钬激光剜除术和前列腺电切术的疗效比较%Comparison of Safety and Efficacy Between Holmium Laser Enucleation of the Prostate (HOLEP) and Transurethral Re-section of Prostate(TURP) for Treatment to Benign Prostate Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    史利华

    2015-01-01

    Objective :To compare the safety and efficacy between holmium laser enucleation of the prostate(HOLEP) and transurethral resection of prostate(TURP)for treatment to benign prostate hyperplasia .Methods :Total 60 BPH pa‐tients with indication for surgery were assigned to receive HOLEP or TURP ,with 30 cases in each group .Preoperative assessments included The International Prostate Symptom Score(IPSS) ,the maximum flow rate of urine(Qmax ) ,post ‐void residual urine volume(PVRU) ,ultrasound hemoglobin ,Perioperative assessments included total operating time ,re‐sected tissue weight ,hemoglobin loss ,presence or absence of blood transfusion ,time of catheter removal and duration of hospital stay .Postoperative evaluations were conducted at 1 ,3 ,6 and 12 months .Results :Patients in the HOLEP group had shorter catheterization time and hospital stay ,but longer operating time .Mean hemoglobin loss was lower in the HOLEP group .The follow‐up results up to 12 months regarding IPSS score ,PRV urine volume and Qmax showed that both groups were comparable .Complications were similar between the two procedures with no significant differ‐ence .Conclusion :HOLEP and TURP are safe and highly effective technique for treatment to BPH .But HOLEP more suitable bigger prostate .%目的:比较经尿道前列腺钬激光剜除术(Holmium laser enucleation of the prostate ,HOLEP)与经尿道前列腺电切术(Transurethral resection of prostate ,TURP)治疗良性前列腺增生(Benign prostate hyperplasia ,BPH)的安全性及疗效。方法:随机选取我院2012年3月-2013年9月良性前列腺增生症手术患者,行 HOLEP 患者30例,行 TURP患者30例,所选取患者术前均进行评估测定,测评项目包括国际前列腺症状评分(International prostate symptom score ,IPSS 评分)、最大尿流率(Qmax )、残余尿量(Post‐void residual urine volume ,PVRU)、前列腺超声检查、前列腺特异抗原

  11. Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil.

    Science.gov (United States)

    Gossell-Williams, M; Davis, A; O'Connor, N

    2006-01-01

    The oil from the pumpkin (Cucurbita pepo) seed is claimed to be useful in the management of benign prostatic hyperplasia. This investigation seeks to examine the effect of pumpkin seed oil on testosterone-induced hyperplasia of the prostate of rats. Hyperplasia was induced by subcutaneous administration of testosterone (0.3 mg/100 g of body weight) for 20 days. Simultaneous oral administration of either pumpkin seed oil (2.0 and 4.0 mg/100 g of body weight) or corn oil (vehicle) was also given for 20 days. The weights of the rats were recorded weekly, and the influence of testosterone and pumpkin seed oil on the weight gain of the rats was examined. On day 21, rats were sacrificed, and the prostate was removed, cleaned, and weighed. The prostate size ratio (prostate weight/rat body weight) was then calculated. Neither testosterone nor pumpkin seed oil had any significant influence on the weight gain of the rats. Testosterone significantly increased prostate size ratio (P pumpkin seed oil at 2.0 mg/100 g of body weight. The protective effect of pumpkin seed oil was significant at the higher pumpkin seed oil dose (P pumpkin seed oil can inhibit testosterone-induced hyperplasia of the prostate and therefore may be beneficial in the management of benign prostatic hyperplasia. PMID:16822218

  12. Current status of diagnosis and treatment for benign prostatic hyperplasia in geriatrics outpatient%老年科良性前列腺增生的诊治现状

    Institute of Scientific and Technical Information of China (English)

    周哲; 祝世法; 王建业; 张祥华; 于普林; 董碧蓉; 蹇在金; 鲁翔; 钱芸娟; 方宁远; 高海青

    2011-01-01

    Objective To evaluate the current status of diagnosis and treatment for benign prostatic hyperplasia (BPH) in geriatrics department,and to promote the standardization of diagnosis and treatment.Methods The BPH patients in geriatrics outpatients from 23 cities were included.General conditions,diagnosis and treatment,and the effect of treatment were recorded in registry questionnaire.Results The analysis of 4001 questionnaires showed that the mean international prostate symptom score (IPSS) was (18.8±5.9),and the percent of the moderate and severe symptom was 53.8% and 42.0%,respectively.The morbidities of coexist diseases were 63.9% (hypertension),40.4 % (coronary disease),32.4 % (diabetes mellitus) and 25.7 % (hyperlipidemia).BPH-related complications were urinary infection (21.0%),urinary stone (8.3%),recurrent hematuria (1.8%),hydronephrosis (1.7%),and hernia (0.6%).In the initial evaluation of BPH,27.2% of doctors didn't finish digital rectal examination,and 89.5% of doctors didn't complete PSA test.Among patients with medical therapy,a-receptor blocker was used in 68.1%,5α-reductase inhibitor in 92.9%,Chinese medicine and plant drugs in 11.8%,and M-receptor blocker in 0.4% of the prescriptions.During the first prescription,monotherapy was recorded in 51.1%,and combination therapy with two drugs was recorded in 46.6 %.In the patients with moderate and severe symptoms,60.6% of patients took the drugs regularly,13.9% of patients withdrew the drugs.The reasons for drug adjustment were poor efficacy (23.4%),serious side effects (5.4%),high cost (3.5%),taking inconveniently (2.9%),etc.Conclusions Most BPH patients in geriatrics department have moderate and severe symptoms.Coexist diseases and BPH-related complications should be considered during treatment of BPH.Doctors should realize the importance of digital rectal examination and PSA test.Combination therapy has more efficacy for improving lower urinary symptoms

  13. Preliminary study of 3.0 T MRS features in prostatic central cancer and benign prostate hyperplasia%前列腺中央腺体癌、增生结节3.0 T磁共振波谱成像的初步研究

    Institute of Scientific and Technical Information of China (English)

    安宏斌; 聂伟; 谢元忠

    2016-01-01

    ObjectiveTo analyze the characteristics of 3.0 T MRS and MRI in prostatic central gland cancer and benign prostate hyperplasia. To evaluate the value of MRS in differential diagnosis of both.Methods 3.0 T MRI and MRS findings were reviewed retrospectively in 11 patients with pathologically-confirmed prostatic central gland cancer and 21 patients with benign prostate hyperplasia. The findings of MRI and the (choline+creatine)/citrate [(Cho+Cre)/Cit] ratio of both were compared. Results Enlargement of central grand was found in MRI of 11 cases with prostatic central gland cancer. In 2 cases, the signal in central grand was uneven and irregular low signal was found; In 8 cases, low-slight high mixed signal nodular lesions were found; In 1 case, diffuse low-equal mixed signal nodule was found invading peripheral zone. Enlargement of prostate gland was found in MRI of 21 cases with benign prostate hyperplasia and clear boundary with peripheral zone. 32 nodules were found in 21 cases. Among them, 25 nodules present the different size of circular, oval with high-low-equal mixed signal; 5 circular nodules mainly with slight high signal was around with low-signal envelope; 2 circular nodules were mainly low signal. The ratio of (Cho+Cre)/Cit and the range in central gland cancer and benign prostate hyperplasia regions were 2.75±1.34, 1.12-5.67 and 0.70±0.28, 0.21-1.16, respectively. The difference in ratio between the two groups was statistically significant (t=0.517,P<0.05).Conclusion3.0 T MRI signal of prostatic central cancer is complicated and has no specificity compared with hyperplastic nodule. It is difficult to diagnose by the routine MRI. The characteristics of 3.0 T MRS of both are obviously different. 3.0 T MRS can provide the metabolic information of central gland cancer, can diagnose more conveniently and more effectively.%目的:分析前列腺中央腺体癌、增生结节3.0 T MRI及磁共振波谱成像(MRS)表现征象,探讨MRS对两者鉴别

  14. Giant prostatic hyperplasia: Case report and literature review

    Directory of Open Access Journals (Sweden)

    Oktay Üçer

    2011-12-01

    Full Text Available The giant hyperplasia of the prostate is an extremely rare pathology of prostate gland. We report the uncomplicated removal of the largest ever prostate from Turkey and the 3rd case exceeding 500 grams in the world literature.

  15. Effect of Boerhaavia diffusa in experimental prostatic hyperplasia in rats

    Directory of Open Access Journals (Sweden)

    Bhavin A Vyas

    2013-01-01

    Conclusion: The results suggested that treatment with B. diffusa may improve symptoms of disease and inhibit the increased prostate size. In vitro study implies that herbal extracts has the machinery to produce beneficial effect on prostatic smooth muscle, which would relieve the urinary symptoms of disease. B. diffusa could be a potential source of new treatment of prostatic hyperplasia.

  16. Survey report of diagnosis and treatment status for benign prostatic hyperplasia in Guangzhou retired workers%广州城镇退休职工良性前列腺增生症诊疗状况调查

    Institute of Scientific and Technical Information of China (English)

    王永忠; 刘建平; 郭文彬; 梁胜军; 赵风进; 高伟; 殷振超

    2015-01-01

    目的 为了解当前广州城镇退休职工良性前列腺增生症发病状况,更好的为治疗宣教作指导.方法 结合国内外文献,用我科自制的良性前列腺增生症知识调查表,对荔湾区城镇退休职工 BPH诊疗状况进行调查.结果 发出调查问卷80份,收回有效问卷73份.前列腺症状评分在0~7分有14人,8~19分39人,20 ~ 35分20人.中到重度的评分患者中只有44.1%接受治疗,且皆有家人经济缓助.受访人群中26人合并高血压,19人合并糖尿病,其中7人同时合并高血压、糖尿病.结论 城镇退休职工良性前列腺增生症发病率高,但就诊率低.可能与BPH的健康宣教落后,政府医保门慢政策未倾斜,患者负担重等因素有关系.因而加强BPH的健康宣教及医疗投入显得尤为重要.%Objective To understand diagnosis and treatment status of benign prostatic hyperplasia (BPH) in Guangzhou urban retired workers.Methods Investigated diagnosis and treatment status of BPH in retired workers from Liwan District with self-designed BPH knowledge questionnaire,analyzed the results combined with literature research.Results We gave out 80 questionnaires,and withdrew 73 valid questionnaires.There were 14 persons whose international prostate symptom score (IPSS) were in 0-7,39 persons in 8-19,20 persons in 20-35.Only 44.1% of patients with moderate to severe IPSS received treatment,with family economic aid.There were 26 cases of hypertension,19 cases of diabetes,7 cases of hypertension combined with diabetes.Conclusions Retired workers have a high morbidity in BPH and a low attendance rate,which may be associated with insufficient BPH health education and government health insurance,heavy economic burden of patients.Therefore,it is particularly important to strengthen health education and health finance on BPH.

  17. Inhibitory effect of Coffea arabica bean in testosterone induced prostatic hyperplasia in Sprague-Dawley rats

    Directory of Open Access Journals (Sweden)

    Kristian Alfonso G. Cueto

    2016-05-01

    Full Text Available Benign prostatic hyperplasia (BPH has been described as the uncontrolled prostate gland growth which leads to difficulty in urination. One of the treatment of BPH is saw palmetto lipid extracts which has been shown to inhibit prostate 5 α-reductase and some of its components (lauric acid, myristic acid and oleic acid also inhibit the enzyme. Coffee was also rich in fatty acids namely linoleic acid, oleic acid and palmitic acid. The aim of this research is to investigate whether coffee is effective in preventing testosterone-induced prostatic hyperplasia in rats using testosterone propionate and estradiol valerate. After and before the induction, the rats were tested for prostate specific antigen (PSA . The condition of the prostate gland of the test animals were correlated with the results of the said test and in the histopathologic results. After 14 days of experimentation, animals in the test group significantly decreased their PSA levels as compared to the BPH group. The histomorphology showed that Coffea arabica bean oil inhibited testosterone propionate while estradiol valerate induced prostatic hyperplasia. These findings indicate that Coffee arabica bean oil effectively inhibited the development of BPH. With the proven safety of coffee oil, these findings strongly support the feasibility of using Coffea arabica bean oil therapeutically in treating BPH.

  18. The classification of benign and malignant human prostate tissue by multivariate analysis of {sup 1}H magnetic resonance spectra

    Energy Technology Data Exchange (ETDEWEB)

    Hahn, P.; Smith, I.; Leboldus, L.; Littman, C.; Somorjai, L.; Bezabeh, T. [Institute for Biodiagnostic, National Research Council, Manitoba (Canada)

    1998-04-01

    {sup 1}H magnetic resonance spectroscopy studies (360 MHz) were performed on specimens of benign (n = 66) and malignant (n = 21) human prostate tissue from 50 patients and the spectral data were subjected to multivariate analysis, specifically linear-discriminant analysis. On the basis of histopathological assessments, an overall classification accuracy of 96.6 % was achieved, with a sensitivity of 100 % and a specificity of 95.5 % in classifying benign prostatic hyperplasia from prostatic cancer. Resonances due to citrate, glutamate, and taurine were among the six spectral subregions identified by our algorithm as having diagnostic potential. Significantly higher levels of citrate were observed in glandular than in stromal benign prostatic hyperplasia (P < 0.05). This method shows excellent promise for the possibility of in vivo assessment of prostate tissue by magnetic resonance. (author)

  19. Correlation between benign prostate hyperplasia and the related indicators of atherosclerosis%良性前列腺增生与动脉粥样硬化相关指标的关系

    Institute of Scientific and Technical Information of China (English)

    张瑞华; 秦明照

    2012-01-01

    目的 探讨良性前列腺增生(BPH)与动脉粥样硬化相关指标的关系及其可能的机制.方法 回顾性分析125例男性患者的年龄、身高、体质量、体质指数(BMI)、血清三酰甘油(TG)、总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、糖化血红蛋白、前列腺特异性抗原(PSA),计算胰岛素抵抗指数(HOMA-IR),测定前列腺体积(PV),并获取双侧的踝臂指数(ABI)及心踝血管指数(CAVI)指标.按照PV分为BPH组75例及非BPH组50例,并进行PV与上述危险因素相关性分析. 结果 BPH组BMI、TG、PSA、HOMA-IR、右-CAVI均高于非BPH组,右-ABI低于非BPH组(t=2.177,2.033,3.060,2.859,3.085,2.557,均P<0.05).BPH组糖尿病及冠心病的发生率分别为52%、36%,高于非BPH组30%、10%(x2值=5.917,10.648,P值=0.015、0.001).Pearson相关分析显示PV与BMI、TG、PSA、右-CAVI、左-CAVI呈正相关(r=0.336、0.216、0.556、0.295、0.389,均P<0.05). 结论 胰岛素抵抗、BPH和动脉粥样硬化之间可能存在密切联系.动脉粥样硬化导致前列腺组织缺血缺氧是BPH的可能机制之一.%Objective To investigate the correlation between benign prostate hyperplasia(BPH) and atherosclerotie related indicators.Methods Totally 125 patients were divided into two groups based on prostate volume(PV):50 cases without BPH (PV≤30 ml) and 75 cases with BPH (PV>30 ml).Age,body mass index (BMI),triglycerides (TG),total cholesterol,low-density lipoprotein cholesterol,high-density lipoprotein cholesterol,glycosylated hemoglobin,prostate specific antigen (PSA),HOMA-IR,bilateral ankle brachial index (ABI) and cardio-ankle vascular index (CAVI) were measured and calculated.All these indicators were compared between two groups.The correlations of these indicators with PV were analyzed.Results BMI,TG,PSA,HOMA-IR and right-CAVI in BPH group were higher than in group without BPH (t=2.177,2.033,3.060,2.859,3.085,all P<0.05),and right ABI was lower in

  20. Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation.

    Science.gov (United States)

    Kitzing, Yu Xuan; Prando, Adilson; Varol, Celi; Karczmar, Gregory S; Maclean, Fiona; Oto, Aytekin

    2016-01-01

    Multiparametric magnetic resonance (MR) imaging combines anatomic and functional imaging techniques for evaluating the prostate and is increasingly being used in diagnosis and management of prostate cancer. A wide spectrum of anatomic and pathologic processes in the prostate may masquerade as prostate cancer, complicating the imaging interpretation. The histopathologic and imaging findings of these potential mimics are reviewed. These entities include the anterior fibromuscular stroma, surgical capsule, central zone, periprostatic vein, periprostatic lymph nodes, benign prostatic hyperplasia (BPH), atrophy, necrosis, calcification, hemorrhage, and prostatitis. An understanding of the prostate zonal anatomy is helpful in distinguishing the anatomic entities from prostate cancer. The anterior fibromuscular stroma, surgical capsule, and central zone are characteristic anatomic features of the prostate with associated low T2 signal intensity due to dense fibromuscular tissue or complex crowded glandular tissue. BPH, atrophy, necrosis, calcification, and hemorrhage all have characteristic features with one or more individual multiparametric MR imaging modalities. Prostatitis constitutes a heterogeneous group of infective and inflammatory conditions including acute and chronic bacterial prostatitis, infective and noninfective granulomatous prostatitis, and malacoplakia. These entities are associated with variable clinical manifestations and are characterized by the histologic hallmark of marked inflammatory cellular infiltration. In some cases, these entities are indistinguishable from prostate cancer at multiparametric MR imaging and may even exhibit extraprostatic extension and lymphadenopathy, mimicking locally advanced prostate cancer. It is important for the radiologists interpreting prostate MR images to be aware of these pitfalls for accurate interpretation. Online supplemental material is available for this article.

  1. 老年前列腺增生患者术后谵妄的发生率比较%Comparing the incidence of postoperative delirium in elderly patients with Benign Prostatic Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    王潇然; 于欣; 王永杰; 王加强; 张玉宏; 刘炳辰

    2014-01-01

    Objective: ① To check the effectiveness of CAM (Conscious state Assessment Method) in monitoring posoperative delirium of the elderly patients.②To understand the risk factors of delirium and prevention and treatment.③To understand the effects of the abnormal psychological state on postoperative morbidity and mortality. ④ To understand the effects of these abnormality on the medical institution economy.⑤To describe the etiology and morbidity of postoperative delirium in elderly patients with urological surgery.Methods: 312 patients with benign prostatic hyperplasia were selected from January 2008 to July 2014.We evaluated and recorded the incidence of delirium using insanity evaluation method (CAM) Results:12.5% (39/312) patients suffered from postoperative delirium,and the incidence increased from 5.52% to 5.52% with the age.Conclusion:Postoperative delirium may be the result of multiple factors,which is not only related to biological age,but also related to other factors,such as aging,medication use,surgical stress,an imbalance in the body biochemical,hemodynamic and electrolyte disorder.%目的:①检查使用CAM(意识状态评估方法)监测老年人术后谵妄的有效性;②理解发生谵妄的危险因素及预防、治疗方案;③理解这种心理状态的异常对术后发病率及死亡率的影响;④认知这些异常对医疗机构的经济影响;⑤描述泌尿外科中老年患者术后谵妄的病因学及发病率。方法:2008年1月-2014年7月我院泌尿外科住院手术患者312例,应用精神错乱评估法(CAM)评价并记录谵妄的发生率。结果:12.5%患者(39/312)出现术后谵妄,发病率随着年龄增长从5.52%升高到22.76%。结论:术后谵妄可能是多因素导致的后果,不仅和生理年龄有关,而且和其他因素如老龄、药物使用、外科手术应激、体内生化失衡、血流动力学及电解质紊乱均有关。

  2. Enlarged prostate - after care

    Science.gov (United States)

    ... self-care; Benign prostatic hypertrophy - self-care; Benign prostatic hyperplasia - self-care ... Kaplan SA. Benign prostatic hyperplasia and prostatis. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine . 25th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap ...

  3. 不同糖耐量良性前列腺增生患者的相关危险因素研究%Associated risk factors in different state of glucose tolerance of patients with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    王兆鹏; 刘敏; 王淼; 黄占强; 周健; 王义围

    2016-01-01

    Objective To explore the risk factors of benign prostatic hyperplasia (BPH) in patients with differ-ent glucose tolerance. Methods Ninety-nine patients with BPH, aged≥50 years old, were divided into impaired glu-cose regulation group (n=53, IGR group) and diabetes mellitus group (n=46, DM group) according to 75 g oral glucose tolerance test (OGTT) results. Twenty subjects of normal glucose tolerance without BPH were selected as control group. The baseline data, biochemical indexes, International Prostate Symptom Score (IPSS), prostate volume (PV) were ana-lyzed. Results The body mass index (BMI), fasting plasma glucose (FPG), 2 h plasma glucose (2 hPG), HbA1c, fast-ing insulin (FINS), 2 h insulin (2 h Ins), homeostasis model assessment of insulin resistance (HOMA-IR) were higher in DM group than IGR group and control group (α'<0.017). In IGR group, the 2 hPG, 2 h INS were significantly higher than those in control group (α'<0.017). The TG were higher in DM group than IGR group (P<0.05). From control group to IGR group, DM group, IPSS and PV showed a trend of increasing gradually, and PV, IPSS were higher in DM group and IGR group than control group (α'<0.017). Multiple linear regression analysis showed that PV was positively correlat-ed with age (r=0.897, P<0.05), BMI (r=1.488, P<0.05), and IPSS was positively correlated with age (r=0.427, P<0.05). Conclusion Blood glucose and lipid metabolic disorder is common in patients with BPH. Age and BMI were identified as significant risk factors for BPH.%目的:探讨不同糖耐量的良性前列腺增生(BPH)患者的危险因素。方法2013年12月至2015年6月选取99例年龄≥50岁的BPH患者,根据口服75 g葡萄糖耐量试验(OGTI)结果分为糖调节受损(IGR)组(n=53)和糖尿病(DM)组(n=46),并选取20例糖耐量正常且无BPH患者为正常对照组。比较各组人群基线资料、生化指标、国际前列腺症状评分(IPSS)、前列腺体积(PV)。结果 DM组的体重指数(BMI)

  4. Pharmacological researches of Syngnathus acus Linnaeus on mouse benign prostatic hyperplasia model induced by fetal urogenital sinus implants%尖海龙对胚胎尿生殖窦致小鼠前列腺增生模型的药理作用

    Institute of Scientific and Technical Information of China (English)

    许东晖; 蒋国津; 梅雪婷; 许实波

    2011-01-01

    目的 研究尖海龙对尿生殖窦致小鼠前列腺增生(benign prostatic hyperplasia,BPH)模型的药理作用,探讨尖海龙应用于治疗良性前列腺增生海洋药物开发的可行性.方法 建立16 d龄胎鼠尿生殖窦组织植入法诱导小鼠BPH模型,连续灌胃给予尖海龙(50,100,200 mg·kg-1)30 d后,评价对BPH小鼠前列腺指数和精囊腺指数、血清酸性磷酸酶(ACP)、前列腺组织形态参数的影响.结果 与模型组相比,尖海龙具有升高精囊腺指数,降低前列腺指数、血清ACP、腺体周长、腺体面积、腺上皮高度的作用.结论 尖海龙具有治疗BPH的作用,同时补肾壮阳,克服治疗前列腺增生药物阳痿少精等副作用,可开发成为治疗BPH的海洋药物.%Objective To study the effects of Syngnathus acus Linnaeus on mouse benign prostatic hyperplasia (BPH) induced by fetal urogenital sinus implants, and to investigate the possibility of applying Syngnathus acus Linnaeus to BPH treatment. Methods Mouse BPH model was established by implanting 16 days old embryo urogenital sinus of mouse. After oral administration of Syngnathus acus Linnaeus (50,100,200 mg · kg-1) for 30 days, the indices of seminal vesicle and prostatic weight, serum acid phosphatase (ACP), prostatic gland perimeter, gland area and gland epithelial height of mice were measured. Results Compared to BPH model group,oral administration of Syngnathus acus Linnaeus reduced the prostatic weight, serum ACP, prostatic gland perimeter, gland area and gland epithelial height, and increased the index of seminal vesicle. Conclusion As a traditional drug for invigorating the kidney and strengthening Yang, increasing number of sperms, Syngnathus acus Linnaeus showed therapeutic effects on BPH, hence could be developed a marine drug for treatment of BPH without side effects such as impotence and oligospermatism.

  5. Extract of plantain seed inhibiting benign prostatic hyperplasia of rat and its effect on 5-alpha reductase%车前子提取物抑制大鼠前列腺增生及对5α-还原酶的影响

    Institute of Scientific and Technical Information of China (English)

    王毓平; 李小林; 刘永青; 杨家大; 胡有生; 梁生林

    2013-01-01

    目的 探讨车前子提取物抗大鼠前列腺增生的效应及其可能机制.方法 用去势雄性SD大鼠皮下注射丙酸睾酮造模,按体重随机分组,用不同浓度的车前子提取物进行灌胃;28 d后处死大鼠,取前列腺组织;用生理盐水替代法测量前列腺体积,电子天平称取前列腺湿重、并分别计算前列腺指数;用HE染色显微观察前列腺组织病理学改变;用酶联免疫法(ELISA)测定前列腺组织双氢睾酮含量.结果 车前子提取物显著降低良性前列腺增生模型的前列腺湿重和前列腺指数(P<0.05或P<0.01),减轻了前列腺组织的增生性改变;车前子提取物还降低了前列腺组织双氢睾酮含量(P<0.05或P<0.01).结论 车前子提取物具有抑制良性前列腺增生的作用,其抑制作用与抑制前列腺组织中的5α-还原酶活性,降低组织中双氢睾酮的含量有关.%Objective To study the inhibiting effects of extract of plantain seeds on prostatic hyperplasia (PH) in rat with benign PH (BPH) and explore its possible mechanisms.Methods Rat models with BPH were made by subcutaneously injecting testosterone propionate for 28 d after being castrated and randomly divided 4 groups by weight:model,finasterid,low and high dose groups of extract of plantain seeds,the other group was normal control.Different doses of extract of plantain seeds were administered respectively by gavage,the rats were put to death and prostatic glands were took after 28 d.Prostatic size was measured with normal saline substitution method.Prostatic weight was taken by electronic balance and prostate index was calculated.Pathology change of prostate tissue was observed with HE staining.The dihydrotestosterone content from the prostate gland was determined by ELISA.Results Extract of plantain seeds significantly reduced prostatic weight and index in rat with BPH (P <0.05 or P <0.01),and alleviated the proliferative changes in prostate.Extract of

  6. Effects of Serenoa Repens, Selenium and Lycopene (Profluss® on chronic inflammation associated with Benign Prostatic Hyperplasia: results of “FLOG” (Flogosis and Profluss in Prostatic and Genital Disease, a multicentre Italian study

    Directory of Open Access Journals (Sweden)

    Giuseppe Morgia

    2013-04-01

    Full Text Available Objective To evaluate the efficacy of Profluss® on prostatic chronic inflammation (PCI. Materials and Methods We prospectively enrolled 168 subjects affected by LUTS due to bladder outlet obstruction submitted to 12 cores prostatic biopsy for suspected prostate cancer + 2 cores collected for PCI valuation. First group consisted of 108 subjects, with histological diagnosis of PCI associated with BPH and high grade PIN and/or ASAP, randomly assigned to 1:1 ratio to daily Profluss® (group I for 6 months or to control group (group Ic. Second group consisted of 60 subjects, with histological diagnosis of BPH, randomly assigned to 1:1 ratio to daily Profluss® + α-blockers treatment (group II for 3 months or to control group (group IIc. After 6 months first group underwent 24 cores prostatic re-biopsy + 2 cores for PCI while after 3 months second group underwent two-cores prostatic for PCI. Specimens were evaluated for changes in inflammation parameters and for density of T-cells (CD3, CD8, B-cells (CD20 and macrophages (CD68. Results At follow-up there were statistical significant reductions of extension and grading of flogosis, mean values of CD20, CD3, CD68 and mean PSA value in group I compared to Ic, while extension and grading of flogosis in group II were inferior to IIc but not statistical significant. A statistically significant reduction in the density of CD20, CD3, CD68, CD8 was demonstrated in group II in respect to control IIc. Conclusions Serenoa repens+Selenium+Lycopene may have an anti-inflammatory activity that could be of interest in the treatment of PCI in BPH and/or PIN/ASAP patients.

  7. Association between hypertension,body mass index and benign prostatic hyperplasia%高血压、体质指数与良性前列腺增生关系

    Institute of Scientific and Technical Information of China (English)

    张黎月; 文娟; 齐建军; 闫佳; 张迪; 孙文慧; 卢智泉

    2011-01-01

    目的 探讨高血压、体质指数(BMI)与临床术后良性前列腺增生(BPH)的关系.方法 采用病例对照研究方法,病例为55~90岁临床诊断为BPH、施行手术治疗、术后病理证实为BPH的患者;对照为同期住院的非前列腺增生患者,年龄与病例相同;病例与对照各380例,以1:1匹配;采用自行设计的调查表对研究对象进行调查,内容包括一般情况、身体测量、生活方式、既往史以及BPH家族史等,采用Logistic回归模型计算OR值及其相应的95%C1.结果 调整年龄因素后,与收缩压正常者(<140 mmHg),(1 mmHg=O.133 3 kPa)相比较,收缩压160-179mmHg者和收缩压≥180 mmHg者发生BPH的危险性明显增加(分别为OR=2.135,95%CI=1.139~4.001和OR=2.704,95%CI=1.475-4.958);高血压病程与BPH呈正相关(x2=8.876,P=0.031),病程≥20年组发生BPH的危险性明显增加(OR=4.984,95%a=2.006-12.203,P=0.001).与非高血压者比较,超重或肥胖者罹患高血压发生BPH的危险性明显地增高(OR=2.548,95%CI=1.397-4.648和OR=2.667,95%CI=1.038-13.212).结论 高血压是BPH发病的危险因素;长期罹患高血压、尤其是高收缩压状态能够促进BPH的发生和发展;超重和肥胖的男性高血压BPH的危险性明显增加.%Objective To investigate the association between hypertension, body mass index(BMI) and clinical benign prostatic hyperplasia(BPH). Methods A hospital-based 1:1 matched case-control study was conducted,including the men (55 - 90 years old) who were surgically treated for BPH between 2007 and 2009 ( n = 380) and the controls who were admitted to the same hospital with different diseases not related to prostatic conditions. All subjects were interviewed during their hospitalization with a structured interviewer-administered questionnaire including information on socio-demographic characteristics, lifestyle, detailed medical history, and family history of BPH in first-degree relatives. Odds ratios(ORs) and corresponding 95

  8. 锯叶棕果实提取物联合坦索洛新治疗良性前列腺增生症的临床研究%Clinical efficacy of saw palmetto extract combined with tamsulosin for the treatment of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    夏洪强

    2013-01-01

    Objective To observe the clinical efficacy of the saw palmetto extract combined with tamsulosin for the treatment of benign prostatic hyperplasia .Methods 87 benign prostatic hyperplasia patients were randomly divided into treatment group (45 ca-ses) and control group (42 cases) .The treatment group were treated with saw palmetto extract 160mg twice a day combined with tamsulosin 20mg once a day for 8 weeks .The control group were treated with tamsulosin 20mg once a day for 8 weeks .We com-pared the residual urine volume (RU) ,maximum urinary flow rates (Qmax) ,International Prostate Symptom Score (IPSS) and vol-ume of the prostate (V) before and after the treatment .Results After 8 weeks medication ,there were significant differences of the RU ,Qmax and IPSS between before and after treatment in the control group (P0 .05) .The RU ,Qmax ,IPSS and the volume of the prostate in the treatment group were significantly changed after treatment(P<0 .05) .Conclusion Saw palmetto extract combined with tamsulosin for the treatment of benign prostatic hyper-plasia could effectively improve the patient′s symptoms ,diminish the prostate gland volume and improve the life quality of the pa-tients .%目的观察锯叶棕果实提取物(SPE)联合坦索洛新治疗良性前列腺增生症(BPH)的疗效。方法将87例BPH患者随机分为治疗组(45例)与对照组(42例)。治疗组口服SPE联合坦索洛新,对照组口服坦索洛新,均连续治疗8周,观察治疗前后残余尿量(RU )、最大尿流率(Qmax )、国际前列腺症状评分(IPSS )以及前列腺体积。结果对照组治疗后 RU、Qmax、IPSS较治疗前均有明显改善,差异有统计学意义(P<0.05);前列腺体积比较差异无统计学意义(P>0.05);治疗组的RU、Qmax、IPSS及前列腺体积较治疗前差异有统计学意义(P<0.05)。结论 SPE联合坦索洛新治疗BPH能有效改善患者症状、缩小前列腺体积、提高患者生活质量。

  9. Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction.

    Science.gov (United States)

    Raja, Adita; Hori, Satoshi; Armitage, James N

    2014-04-01

    Although the etiology of lower urinary tract symptoms (LUTS) is often multifactorial, a significant proportion of men over the age of 50 suffer from benign prostatic obstruction (BPO) secondary to benign prostatic hyperplasia. Prostate, being an androgen responsive organ is dependent on the male sex hormone, testosterone, for growth. Thus, treatment strategies that manipulate the levels of circulating hormones that influence the level of testosterone and/or prostatic growth represent an important potential option for patients suffering with troublesome LUTS due to BPO. Despite this, the only hormonal treatment that is currently used in daily clinical practice is the 5-alpha reductase inhibitor. In this article, we review the current evidence on the use of the 5-alpha reductase inhibitors finasteride and dutasteride. We also discuss new emerging hormonal manipulation strategies for patients with LUTS secondary to BPO. PMID:24744519

  10. 老年良性前列腺增生 635例分类处理与提高患者生存质量的相关性分析%Relative analysis of classified treatments and improvement of quality of life in 635 cases of benign prostate hyperplasia

    Institute of Scientific and Technical Information of China (English)

    余斌; 张更

    2002-01-01

    Objective To investigate the method and significance of the classified treatment on benign prostate hyperplasia(BPH) patients according to the symptoms and clinical status. Method The clinical data of 635 patients were analyzed retrospectively. Patients were divided into five groups according to their symptoms and each group was treated differently. Results The rate of cure and utility of the class I patients was 75.2% and 96% , respectively.The cure rate of both class II and class III patients was 100% .The utility rate of the class IV patients was 100% .The whole cure rate and utility rate of the 635 patients were 88.3% and 99.2% ,respectively.Conclusion We can classify the BPH patients according to their symptom and clinical status and treat them differently in terms of classification. This measure can help doctors select the optimal treatment time and method and relieve patients' pain to the maximum extent, thus improving patients' quality of life.

  11. Two cases study of benign prostatic hyperplasia combined with suppurative prostatitis%合并化脓性炎的良性前列腺增生2例病例分析

    Institute of Scientific and Technical Information of China (English)

    丁小举; 张卫星; 王朝亮; 李锐; 张天标

    2014-01-01

    Objective To analyze the clinical feature and diagnosis of BPH combined with suppurative prostatitis. Methods The clinical data of two cases of BPH combined with suppurative prostatitis were retrospectively analyzed. Results The age of the two patients was less than 60. They came to hospital because of AUR with fever and infection. The tPSA of them were greater than 100ng/mL,the US prompt BPH with calcification,and the MRI/MRS prompt BPH with prostatitis.The post-operation routine pathology both diagnosed BPH with focal suppurative prostatitis. Conclusion When the tPSA of the BPH patients is significantly higher,accompanied with diagnosed infection and prostatitis,the treatment should be anti-infective therapy and dynamic monitoring serum PSA,so as to decrease the misdiagnosis rate.%目的:探讨良性前列腺增生合并前列腺化脓性炎的临床表现及诊断。方法回顾分析良性前列腺增生合并化脓性炎2例临床资料。结果2例患者均<60岁,均以发热、感染并急性尿潴留就诊。2例患者tPSA均>100ng/mL,彩超提示前列腺增生并钙化。前列腺MRI及前列腺波谱分析(MRI/MRS)提示良性前列腺增生、前列腺炎。术后常规病理结果示良性前列腺增生并局灶化脓性炎。结论当前列腺增生患者PSA明显升高,客观检查提示前列腺炎、感染时,应积极控制感染、动态监测PSA,以降低前列腺癌的误诊率。

  12. 经直肠B超引导下经会阴注射A型肉毒毒素治疗老年良性前列腺增生症的疗效观察%The Observation of Injection of the BTX-A from Perineum in Gerontic Benign Prostatic Hyperplasia Guided by the Transrectal Ultrasound

    Institute of Scientific and Technical Information of China (English)

    向川南; 罗黔; 姚健; 王宁

    2014-01-01

    Objective To explore the feasibility of the injection of BTX-A in perineum in the benign prostatic hyperplasia. Methods Retrospectively analysis the 31 cases who are 60 years above, from October 2010 to June 2013, who got the injection of BTX-A from the perineum guided by the transrectal ultrasound, and to evaluate the value . Results No complication happened after the injection;4 cases had no ef icacy;19 cases had the urinary problem again in 6 months. Conclusion The method of the injection of the BTX-A from perineum guided by the transrectal ultrasound is convenient, less complication and high ef icacy.%目的:探讨A型肉毒毒素(Botulinum toxin type A, BTX-A)在老年良性前列腺增生症(Benign Prostatic Hyperplasia ,BPH)中应用的可行性。方法回顾性地分析2010年10月~2013年6月来我院就诊的31例进行经直肠B超引导下经会阴注射BTX-A的60岁以上BPH患者的治疗疗效,评价BTX-A在BPH治疗中的价值。结果0例出现BTX-A术后并发症;4例出现注射后无效;19例出现术后6个月后排尿困难。结论经直肠B超引导下经会阴 A型肉毒毒素注射治疗老年BPH具有操作简便、并发症少、有效率高的特点。

  13. [Referral criteria for benign prostatic hyperplasia in primary care.Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Medicina General, Sociedad Española de Medicina de Familia y Comunitaria, Asociación Española de Urología].

    Science.gov (United States)

    Castiñeiras Fernández, J; Cozar Olmo, J M; Fernández-Pro, A; Martín, J A; Brenes Bermúdez, F J; Naval Pulido, E; Molero, J M; Pérez Morales, D

    2010-01-01

    Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-specific antigen (PSA) measurement are diagnostic tests available for general practitioners that allow setting a correct BPH diagnose. Patients with an IPSS1.5 ng/ ml combined treatment and evaluation at the first and sixth month is recommended. Some clear criteria for referral to urology are established in this document, which help in the management of these patients. Those patients with BPH who do not show any improvement at the third month of treatment with alpha-blockers, or the sixth month with 5alpha-reductase inhibitors, will be referred to urology. Patients will also be referred to urology if they have lower urinary tract symptoms, a pathological finding during rectal examination, IPSS>20, PSA>10 ng/ml or PSA>4 ng/ml and free PSA<20% or if they are <50 years with suspected BHP, or if they have any urological complication.

  14. MRI monitoring before, during, and after interstitial laser-induced thermotheraphy of benign prostatic hyperplasia. First clinical experience; MRT-Monitoring vor, waehrend und nach der interstitiellen laserinduzierten Thermotherapie der benignen Prostatahyperplasie. Erste klinische Erfahrungen

    Energy Technology Data Exchange (ETDEWEB)

    Mueller-Lisse, G.U. [Inst. fuer Radiologische Diagnostik, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany)]|[Klinik und Poliklinik fuer Urologie, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany); Heuck, A. [Inst. fuer Radiologische Diagnostik, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany); Stehling, M.K. [Inst. fuer Radiologische Diagnostik, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany); Frimberger, M. [Inst. fuer Radiologische Diagnostik, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany); Thoma, M. [Inst. fuer Radiologische Diagnostik, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany); Schneede, P. [Klinik und Poliklinik fuer Urologie, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany); Muschter, R. [Klinik und Poliklinik fuer Urologie, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany); Hofstetter, A. [Klinik und Poliklinik fuer Urologie, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany); Reiser, M. [Inst. fuer Radiologische Diagnostik, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Muenchen (Germany)

    1996-09-01

    Ten patients with symptomatic BPH had MRI examinations of the prostate 48 h before and after LITT. Online monitoring with MRI at 1.5 T of interstitial Nd:YAG laser energy deposition in the prostate was performed in two patients, repeating a T1-weighted FLASH sequence (TR 100 ms, TE 5 ms, flip angle 90 ) every 20 s. Follow-up MRI examinations 2-3 weeks, 6-8 weeks, and 6-12 months after LITT were carried out in eight patients, using T2-weighted FSE images and contrast-enhanced T1-weighted SE images. The prostate was well delineated in all patients on T2-weighted FSE images, with a rather homogeneous peripheral gland and an inhomogeneous central gland. Volume measurements yielded reproducibilities of 3.2%-4.7%. Signal intensity in the FLASH sequence decreased during LITT, both in the prostate in vivo and in specimens of bovine prostate and seminal vesicles in vitro, with signal developments running in parallel. Areas of energy deposition and signal alteration were not sharply delineated. The latter margin of the laser-induced lesions could not be predicted from the FLASH images, while the tip of the laser fibre was easily recognized. Contrast-enhanced T1-weighted MR images immediately after LITT clearly demarcated low signal intensity surrounding prostate tissue. Follow-up examinations showed a decrease of 20% of prostate volume over a period of 6-12 monts after LITT. Correlation between prostate volume development and lesion volume alteration was 0.85-0.90 (P=0.002-0.007) at all follow-up times. MRI allows rather precise recognition of intraprostatic alterations after LITT, including volume changes over a period of up to 1 year after therapy that can be predicted immediately after LITT. While laser energy deposition in the prostate can be monitored by MRI with T1-weighted FLASH sequences as a function of temperature alteration, it is not possible to determine the lesion margins immediately from the FLASH images. (orig./VHE) [Deutsch] Die Magnetresonanztomographie

  15. 前列腺增生症患者经尿道前列腺电切术后前列腺症状和生存质量评分的变化%Changes in prostate symptoms and quality of life in patients with symptomatic benign prostate hyperplasia before and after transurethral resection of the prostate

    Institute of Scientific and Technical Information of China (English)

    田惠忠; 武治津; 张小东; 杨勇

    2010-01-01

    目的 探讨经尿道前列腺电切(TURP)对良性前列腺增生症(BPH)患者国际前列腺症状评分(IPSS)和生存质量(QOL)评分的影响.方法 对因BPH导致下尿路症状的47例男性患者(平均72岁)行TURP治疗,比较治疗前后IPSS和QOL评分以及最大尿流率、残余尿量及压力-流率检查等指标的变化,分析影响IPSS及QOL评分的因素.结果 术中均无并发症发生,术后2例前尿道狭窄,1例逆向射精,6例急迫性尿失禁加重,对症处理后症状均缓解.手术前、后IPSS及其刺激、梗阻评分分别为(22.7±4.9)与(10.5±5.8)分,(10.5±5.8)与(6.3±3.5)分,(12.1±3.9)与(4.2±3.3)分,QOL评分为(4.6±0.9)和(2.3±1.3)分,最大尿流率为(5.8±2.9)和(12.4±5.2)ml/s,残余尿量为(99±16)和(34±19)ml,差异均有统计学意义(均P<0.01).术后随访时间、前列腺体积和急迫尿意时膀胱容量与术后IPSS有相关性(r=0.751,P<0.05),术后随访时间和年龄与术后QOL评分有相关性(r=0.470,P<0.05).结论 TURP对存在下尿路症状的BPH患者的IPSS、QOL评分均有显著改善,而影响IPSS和QOL评分的相关因素不尽相同.%Objective To investigate changes in symptoms and quality of life (QOL) score before and after transurethral resection of the prostate ( TURP), and their related factors. Methods Forty-seven elderly male patients of benign prostate hyperplasia (BPH) with lower urinary tract symptoms were enrolled in the study, with an average age of 72 years. They all were undergone with TURP and evaluated with international prostate symptoms score (IPSS), QOL score, maximal urine flow rate (Qmax), residual urine volume, pressure-urine flow rate and prostate size before and after the procedure. Changes in these parameters and their related factors were analyzed. Results No complication was observed during TURP in the 47 patients. After TURP, two patients suffered from distal urethra stricture, one from retrograde ejaculation and six from aggravated urgent

  16. Update on the use of dutasteride in the management of benign prostatic hypertrophy

    Directory of Open Access Journals (Sweden)

    Joe Miller

    2007-04-01

    Full Text Available Joe Miller, Thomas H TarterDivision of Urology, Southern Illinois University School of Medicine, Springfield, IL, USAAbstract: Benign prostatic hyperplasia (BPH is a frequent cause of lower urinary symptoms, with a prevalence of 50% by the sixth decade of life. Hyperplasia of stromal and epithelial prostatic elements that surround the urethra cause lower urinary tract symptoms (LUTS, urinary tract infection, and acute urinary retention. Medical treatments of symptomatic BPH include; 1 the 5α-reductase inhibitors, 2 the α1-adrenergic antagonists, and 3 the combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist. Selective α1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that α1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5α-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. The combination of a 5α-reductase inhibitor and a α1-adrenergic antagonist reduces the clinical progression of BPH over either class of drug alone.Keywords: prostatic hyperplasia, 5α-reductase, dutasteride

  17. Contact laser vaporization of the prostate for benign prostatic hypertrophy

    Science.gov (United States)

    Gomella, Leonard G.; Lotfi, M. A.; Milam, Douglas F.; Albala, David; Reagan, Gary

    1994-05-01

    The contact laser applications for the removal of the enlarged prostate are distinctly different than the majority of non-contact Nd:YAG lasers that rely on coagulation necrosis and delayed sloughing. Contact Nd:YAG laser allows cutting, coagulation and vaporization of tissue with minimal penetration beyond the contact surface. Using the contact laser prostatectomy technique, the contact laser probe directly touches and immediately vaporizes the prostatic tissue under the probe. The net result is the immediate removal of the obstructing tissue, in a manner similar to the standard electrosurgical TURP. This immediate removal of tissue offers the patient treated with the contact laser the potential for decreased catheter time and a more rapid resolution of symptoms. Our initial experience suggests that the contact technique may be better suited for the smaller prostate gland (i.e. less than 30 gm). The contact laser may also be used for a procedure termed the `laser assisted TURP': a standard electrosurgical TURP is performed and the contact laser is used for hemostasis. Several investigators have reported non-randomized results of the contact technique with good outcomes. A prospective randomized trial of the contact laser prostatectomy vrs the electrosurgical TURP is underway. The contact laser vaporization of the prostate holds great promise for the treatment of symptomatic benign prostatic hypertrophy: it is virtually bloodless and allows immediate visualization of the TUR defect.

  18. 经尿道等离子体前列腺剜除术与经尿道等离子体前列腺切除术的对比研究%Comparison of transurethral plasmakinetic enucleation and resection of prostate for the treatment of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    潘铁军; 王涛; 文瀚东; 徐耀鹏

    2011-01-01

    目的 比较经尿道等离子体前列腺剜除术(PKEP)与经尿道等离子体前列腺切除(PKRP)近期疗效.方法 将具有手术指征的120例前列腺增生症(BPH)患者随机分为两组,分别行PKEP和PKRP,监测、记录患者围手术期和术后6个月复查的有关指标,对所测指标进行统计学分析.结果 术前两组一般情况比较,差别无显著性(P>0.05);术中出血量、手术时间、术后平均膀胱冲洗时间、置管时间和住院时间,PKEP组明显少于PKRP组(P<0.05);切除腺体重量,PKEP组[(31.6±11.5)g]明显多于PKRP组[(19.7±10.4)g](P<0.05);术后6个月,两组患者残余尿量、最大尿流率均比术前得到明显改善(P<0.05).结论 PKEP治疗BPH具有与PKRP相近的近期疗效;患者术中并发症发生率、恢复时间PKEP明显少于PKRP,是目前有望替代PKRP的一种新方法.%Objective To compare the clinical effects and safety of transurethral plasmakinetic enucleation of prostate (PKEP) and transurethral plasmakinetic resection of prostate(PKRP) in the treatment of benign prostatic hyperplasia(BPH). Methods 120 patients with BPH who had surgical indications were randomized into two groups: PKEP group and PKRP group, with 60 patients in each. The preoperative international prostate symptom score (IPSS), the quality of life (QOL). Quantity of maximum flow rate(Qmax), postvoid residual urine volume (PVR), the perioperative operation time, bleeding, weight of resected prostate, mean bladder irrigating time, catheterization time, and hospitalization were recorded. Six months after the operation, the complications, PVR and Qmax were observed. All results were statistically analyzed. Results There was no significant difference in preoperative factors between the two groups (P>0.05). The mean operation time, hemorrhage, bladder irrigating time, catheterization time and hospitalization were significantly less in the PKEP group than in the PKRP group(P0. 05). PVR and Qmax were

  19. 经尿道双极等离子电切术对良性前列腺增生的疗效及其对性功能影响的研究%Impact of plasmakinetic resection of prostate on sexual function in patients with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    张菊根; 吴振启; 郭建明

    2012-01-01

    Objective To investigate the efficacy of plasmakinetic resection of the prostate (TKRP) in patients with benign prostatic hyperplasia(BPH), and its impact on sexual function. Methods 130 patients with BPH in our hospital from January 2009 to June 2011 were equally divided into the TKRP group,and the transurethral prostate electric resection (TURP) group. The international prostate symptom score (IPSS),quality of life (QOL) score, maximum urinary flow rate (Qmax), operative time, weight of resected prostate tissue,blood loss, indwelling catheter time, postoperative hospital stay, the incidence of erectile dysfunction (ED) and retrograde ejaculation (RE) were observed. Results The intraoperative blood loss, catheterization time and postoperative hospital stay were decreased significantly in the TKRP group than those in TURP group (P0.05). The levels of postoperative IPSS, QOL and residual urine were significantly decreased. The level of Qmax after surgery was increased significantly in both groups compared with the preoperative (P0.05). The incidence of ED in the TKRP group at 6th and 9th month after the treatment was lower than those in the TURP group (P0.05). Conclusion The advantage of TKRP is little trauma, quicker recovery, and little impact on sexual function.%目的 探讨经尿道双极等离子电切术(TKRP)治疗良性前列腺增生(BPH)的疗效及其对性功能的影响.方法 选取2009年1月至2011年6月于复旦大学附属中山医院青浦分院就诊的BPH患者130例,按照手术方式不同分为TKRP组和经尿道前列腺电切术(TURP)组,两组各65例.观察两组的国际前列腺症状评分(IPSS)、生活质量评分(QOL)和最大尿流率(Qmax),手术时间,切除前列腺组织的重量,术中出血量,留置尿管时间,术后住院时间,阴茎勃起功能障碍(ED)和逆行射精(RE)发生率.结果 TKRP组的术中出血量,置管时间和术后住院时间较TURP组明显降低(P<0.01),而手术时间和切除组织两

  20. Relationship between type 2 diabetes mellitus and benign prostatic hyperplasia in elderly patients%2型糖尿病与高龄老人良性前列腺增生症的关系研究

    Institute of Scientific and Technical Information of China (English)

    谢南姿; 王海峰; 罗帮镇; 刘阳

    2013-01-01

    Objective To investigate the relationship between (BPH) and type 2 diabetes mellitus (T2DM) in elderly patients.Methods A total of 167 elderly BPH patients were recruited,including 64 cases of non-diabetic BPH and 103 cases of diabetic BPH.The blood pressure and international prostate symptoms score (IPSS)were documented; the prostate volume (PV)was examined by ultrasonography.Glycated hemoglobin (HbA1C),FBG,FINS,blood lipid and serum prostate specific antigen (PSA) were measured.Results There were no differences in age,prevalence of hypertension and hyperlipidemia between non-diabetic BPH and diabetic BPH patients (P > 0.05).The serum levels of FINS and PSA,PV and IPSS in diabetic BPH patients were higher than those in non-diabetic BPH patients(P <0.05).There were no differences in IPSS,PV and PSA at the different levels of FBG and 2 h PBG in diabetic BPH patients (P > 0.05).The level of IPSS,PV and serum PSA in diabetic BPH patients with abnormal HbAlc were higher than those in BPH patients with normal HbAlc (P < 0.05).Conclusion T2DM might be a risk factor for the onset and development of BPH in elderly patients.%目的 探讨2型糖尿病(T2DM)与高龄老年人良性前列腺增生症(bengn prostatic hyperplasia,BPH)的关系.方法 回顾性分析167例高龄BPH患者的临床资料,其中单纯BPH患者64例,T2DM合并BPH患者103例.收集血压、空腹血糖(FBG)、餐后2h血糖(2 h PBG)、空腹胰岛素(FINS)、糖化血红蛋白(HbAlc)、血脂、血清前列腺特异性抗原(PSA)、国际前列腺症状评分(IPSS)及经腹部超声测量的前列腺体积(PV)等临床资料.结果 单纯BPH组和T2DM合并BPH组,两组年龄、合并高血压及高脂血症情况比较,差异无统计学意义(P>0.05);与单纯BPH组相比,BPH合并T2DM组患者血清FINS、PSA、PV水平及IPSS评分显著升高(P<0.05).BPH合并T2DM组中,不同水平FBG、2 h PBG患者的IPSS评分、PV与血清PSA,差异无统计学意义(p>0.05);BPH合并T2

  1. [Use of Xanthii spinosi herba in treatment of benign prostate hypertrophia].

    Science.gov (United States)

    Varga, Erzsébet; Marcu, Simona Tünde; Adoryan, Boglarka

    2014-01-01

    The aim of our study was to asses the efficacy of Xanthii spinosi herba in the treatment of rats with benign prostate hypertrophia induced under experimental conditions. Benign prostate hypertrophia (BPH) was induced by per oral (p.o.) administration of testosterone undecanoate (40 mg Undestor capsules) in concentrations of 15 mg/ kg/day and 35 mg/ kg/day. Drug induced BPH was treated with Xanthii spinosi herba as infusion and tincture. Drug induced benign prostate hyperplasia in rats was accompanied by a series of physical changes, like weight increase and shinier fur, and also by behavioral changes (increased appetite, aggression, increased libido). Prostate size was higher in all groups of animals treated with testosterone undecanoate compared to the control group. The morphopathological study of the organs taken from slaughtered animals, showed some microscopic changes in the prostate. In animals treated with Xanthii spinosi herba (infusion and tincture) we observed a decrease in volume of the prostate, while the microscopic changes were absent. PMID:25167701

  2. 经尿道2μm激光前列腺剜除术治疗良性前列腺增生的疗效分析%Transurethral prostate enucleation with 2 μm laser in the treatment of benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    郭和清; 洪泉; 周高标; 刘红明; 孙斌; 潘广新; 穆大为; 严景民; 邢继章; 李迪

    2011-01-01

    Objective To investigate the feasibility and efficacy of transurethral prostate enucleation with 2 μm laser in the treatment of benign prostatic hyperplasia (BPH). Methods One hundred and seven patients with BPH were treated by transurethral prostate enucleation with 2 μm laser under continuous epidural anesthesia or laryngeal mask anesthesia. The patient′s, average age was 67±9 yrs (52 to 85 yrs). Of whom, 10 patients had a history of urinary retention. The mean prostate volume was 72.5±17.6 ml (45 to 158 ml). Two deep trenches were cut at the 5 and 7 o, clock position from the bladder neck to the verumontanum. The incision continued to the urethral mucosa and submucosa along with the verumontanum bilaterally in an arc-shape and ended at the internal arc of urethral sphincter. Then the urethral mucosa at the level of the verumontanum was cut and the surgical capsule plane was identified. A retrograde blunt dissection was made along the surgical capsule plane with the resectoscope sheath front-end, and the sheath was swung from side to side to extend the capsule plane. The significantly enlarged middle lobe was treated with laser vaporization resection. In the same way, a trench was made at the 12 o, clock position, and the lateral lobe were removed by the sheath from the verumontanum level, finally only two cord-like pedicles were kept at the 1 and 11 o, clock position at the bladder neck, so that the removed gland tissue was fixed and hung in the gland fossa. For prostate volume less than 60 ml, the laser vaporization resection was carried out directly. If the prostate volume was greater than 60ml, transurethral resection would be performed instead of laser vaporization resection. With 4% mannitol irrigation, the enucleated prostate tissue was then cut into small pieces and washed out by a Braun plastic bottle through the resectoscope sheath. Intraoperative bleeding, operative time, catheterization time, postoperative voiding status, maximum urinary flow

  3. Optical coherence elastography (OCE) as a method for identifying benign and malignant prostate biopsies

    Science.gov (United States)

    Li, Chunhui; Guan, Guangying; Ling, Yuting; Lang, Stephen; Wang, Ruikang K.; Huang, Zhihong; Nabi, Ghulam

    2015-03-01

    Objectives. Prostate cancer is the most frequently diagnosed malignancy in men. Digital rectal examination (DRE) - a known clinical tool based on alteration in the mechanical properties of tissues due to cancer has traditionally been used for screening prostate cancer. Essentially, DRE estimates relative stiffness of cancerous and normal prostate tissue. Optical coherence elastography (OCE) are new optical imaging techniques capable of providing cross-sectional imaging of tissue microstructure as well as elastogram in vivo and in real time. In this preliminary study, OCE was used in the setting of the human prostate biopsies ex vivo, and the images acquired were compared with those obtained using standard histopathologic methods. Methods. 120 prostate biopsies were obtained by TRUS guided needle biopsy procedures from 9 patients with clinically suspected cancer of the prostate. The biopsies were approximately 0.8mm in diameter and 12mm in length, and prepared in Formalin solution. Quantitative assessment of biopsy samples using OCE was obtained in kilopascals (kPa) before histopathologic evaluation. The results obtained from OCE and standard histopathologic evaluation were compared provided the cross-validation. Sensitivity, specificity, and positive and negative predictive values were calculated for OCE (histopathology was a reference standard). Results. OCE could provide quantitative elasticity properties of prostate biopsies within benign prostate tissue, prostatic intraepithelial neoplasia, atypical hyperplasia and malignant prostate cancer. Data analysed showed that the sensitivity and specificity of OCE for PCa detection were 1 and 0.91, respectively. PCa had significantly higher stiffness values compared to benign tissues, with a trend of increasing in stiffness with increasing of malignancy. Conclusions. Using OCE, microscopic resolution elastogram is promising in diagnosis of human prostatic diseases. Further studies using this technique to improve the

  4. 浙江省长兴县良性前列腺增生患者下尿路症状的特征分析%The characteristics analysis of lower urinary tract symptoms in patients with benign prostatic hyperplasia in Changxing county of Zhejiang province

    Institute of Scientific and Technical Information of China (English)

    俞保柱; 王荣江; 曹莉

    2015-01-01

    目的:对浙江省长兴县良性前列腺增生患者下尿路症状的特征进行研究分析。方法:选择2009年3月至2013年9月良性前列腺增生患者2100例作为研究对象,患者年龄介于47~81岁之间。将47~64岁年龄段患者设为对照组,将64~81岁年龄段患者设为观察组,两组各1050例。通过 IPSS(国际前列腺症状)评分量表对两组评分,并观察两组患者 LUTS(下尿路症状)的严重程度,同时观察 LUTS 的严重程度和 IPSS 评分、患者年龄、最大尿流率以及前列腺体积之间的联系,并分析与 LUTS 严重程度的相关因素。患者均通过口服西药坦索洛新胶囊与中药汤剂进行治疗,疗程结束后观察治疗效果。结果:两组年龄及 IPSS评分比较,差异均有统计学意义(P <0.05)。观察组患者的 LUTS 中重度比例76.4%大于对照组患者的LUTS 中重度比例42.0%,差异均有统计学意义(P <0.01)。中重度 LUTS 患者在 IPSS 评分高、患者年龄、前列腺体积方面均高于轻度 LUTS 患者,差异均有统计学意义(P <0.01~0.05)。中重度 LUTS 患者最大尿流率低于轻度 LUTS 患者,差异均有统计学意义(P <0.01)。患者经过中西结合治疗,IPSS 评分显著降低、最大尿流率加快、前列腺体积缩小以及 QOL 评分降低,差异显著(P <0.05)。结论:良性前列腺增生患者普遍存在下尿路症状,患者病情的严重程度与年龄、不良习惯存在紧密的联系,因此老年良性前列腺增生患者需要养成良好的生活习惯防止疾病的恶化。患者经中西医结合治疗后症状得到显著改善、生活质量得到明显的提高。%Objectives:To analyze the characteristics of lower urinary tract symptoms in patients with be-nign prostatic hyperplasia in Changxing county of Zhejiang province.Methods:2100 patients with benign prostatic hyperplasia from March 2009 to September

  5. 单极电切镜经尿道前列腺剜除术与经尿道前列腺切除术治疗前列腺增生症的临床对比研究%Clinical comparison of transurethral enucleation and resection of prostate for treatment of benign prostatic hyperplasia with monopolar resectoscope

    Institute of Scientific and Technical Information of China (English)

    潘东亮; 晋连超; 杨冰; 张祥华

    2013-01-01

    Objectives To compare the clinical viability and safety of transurethral enucleation of prostate (M-TUEP) and transurethral resection of prostate(M-TURP) for treatment of benign prostatic hyperplasia(BPH)with monopolar reseetoscope.Methods 60 patients with BPH who had surgical indications and whose volume of prostate was 50ml-75ml were randomized into M-TUEP group and M-TURP group,with 30 patients in each.The preoperative international prostate symptom score(IPSS),the quality of life(QOL),Quantity of maximum flow rate(Qmax),postvoid residual urine volume(PVR),the perioperative operation time,bleeding,weight of resected prostate,mean bladder irrigating time,catheterization time,and hospitalization were recorded.Three months after the operation,the correlative complications,PVR,Qmax and IPSS were observed.All results were statistically analyzed.Results There was no statistically significant difference in preoperative factors between the two groups (P> 0.05).The mean operation time,hemorrhage,bladder irrigating time,catheterization time,hospitalization and perioperativelly correlative complications were significantly less in the M-TUEP group than in the M-TURP group (P < 0.05).The mean weight of resected prostate was more heavy in the M-TUEP group than in the M-TURP group(P <0.05).There were no significant differences in urinary incontinence,urethral stricture,and retrograde ejaculation between the two groups(P >0.05),PVR,IPSS and Qmax were significantly improved(P <0.05) at three months postoperatively.Conclusions M-TUEP has the same short-term efficacy as M-TURP for the treatment of symptomatic BPH.The advantages of TUEP is higher safty and efficiency of resection and less complications than M-TURP.And M-TUEP is easy to be mastered for urological surgeons and more fit to be popularized in China than enucleation of prostate with lasers.%目的 临床比较单极电切镜经尿道前列腺剜除术(M-TUEP)与经尿道前列腺切除

  6. Analysis of the risk factors for incidental carcinoma of the prostate in patients with benign prostatic hyperplasia Análise dos fatores de risco para o diagnóstico do carcinoma incidental da próstata em pacientes com hiperplasia prostática benigna

    Directory of Open Access Journals (Sweden)

    Alberto Azoubel Antunes

    2006-01-01

    Full Text Available PURPOSE: To determine the occurence of incidental carcinoma of the prostate, its characteristics, and the risk factors for this diagnosis in a group of patients surgically treated for benign prostatic hyperplasia. METHODS: The study comprised a retrospective analysis of 218 patients. After surgical treatment, patients with the finding of incidental carcinoma of the prostate were compared to those without this finding. The preoperative variables analyzed were patient age, digital rectal examination, PSA, PSA density, prostate volume, and preoperative prostate biopsy. We also determined the sensitivity, specificity, positive predictive value, and negative predictive value of digital rectal examination and PSA for the finding of incidental carcinoma of the prostate at surgical specimen analysis. RESULTS: Thirteen (6.2% out of the 218 patients presented incidental carcinoma of the prostate. Eight (61.5% of these tumors were classified as T1a and 5 (38.5% as T1b. Only advanced age (P = 0.003 and the presence of a suspect digital rectal examination (P = 0. 016 were statistically related to the findings of the surgical specimen analysis. The sensitivity, specificity, positive predictive value, and negative predictive value for the diagnosis of incidental carcinoma were 23.0%, 96.6%, 30.0%, and 95.2% for a suspect digital rectal examination and 85.0%, 34.1%, 7.5%, and 97.2% for a PSA greater than 4.0 ng/mL. The accuracy for these methods was 92.2% and 37.1%, respectively. CONCLUSIONS: Advanced age and the presence of a suspect digital rectal examination represent the most important risk factors for the diagnosis of an incidental carcinoma of the prostate. However, the low positive predictive values reflect the weak correlations among these variables.OBJETIVO: Determinar a ocorrência do carcinoma incidental da próstata, suas características e fatores de risco para o diagnóstico em um grupo de pacientes tratados cirurgicamente para hiperplasia prost

  7. 锯叶棕果实提取物治疗BPH引起的下尿路症状疗效观察%Clinical efficacy of saw palmetto extract in the treatment of benign prostatic hyperplasia patients with lower urinary tract symptoms

    Institute of Scientific and Technical Information of China (English)

    杨栋; 吴晓飞; 朱朝晖; 杨雄

    2012-01-01

    Objective:To evaluate the clinical efficacy of saw palmetto extract in the treatment of benign prostatic hyperplasia(BFH) patients with lower urinary tract symptoms(LUTS). Methods: 30 BPH patients with LUTS were treated with saw palmetto extract 160mg twice a day for 8 weeks. We compared the maximum urinary flow rates(Qmax), Volume of the prostate(V) , International Prostate Symptom Scores(IPSS), Quality of Life indexes (QOL) and post-void residual urine(PVR) before and after the treatment. Results: After 8 weeks medication, the Qmax, IPSS, QOL and PVR of the patients have significantly difference compared to which before the treatment. No patients experienced the adverse event. Conclusions: Saw palmetto extract is effective and safe in the treatment of BPH patients with LUTS.%目的:探讨锯叶棕果实提取物治疗BPH引起的下尿路症状的疗效.方法:采用锯叶棕果实提取物单药治疗30例前列腺增生伴下尿路症状患者8周,分别比较患者治疗前后的最大尿流率、前列腺体积、剩余尿量、IPSS评分及QOL评分的变化情况.结果:治疗8周后,患者的最大尿流率、剩余尿量、IPSS评分及QOL评分均有明显改善,前列腺体积则无明显变化.所有患者均无明显不良反应.结论:锯叶棕果实提取物能有效改善BPH患者的下尿路症状.

  8. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue

    DEFF Research Database (Denmark)

    Usher, Pernille Autzen; Thomsen, Ole Frøkjær; Iversen, Peter;

    2005-01-01

    RNAs was predominantly seen in cells identified as macrophages, which in most of the carcinomas (approximately 90%) were located in the interstitial tissue between the tumor cell islands, while in most of the benign hyperplasias they were located in the lumen of the glands and were in only a few cases (approximately 30......RNA and immunoreactivity in 16 prostate adenocarcinomas and 9 benign prostate hyperplasias. uPA mRNA and uPAR mRNA expression were found in 9 and 8 of the adenocarcinomas, respectively, and in 7 and 6 of the benign hyperplasias, respectively. In both malignant and benign lesions, expression of these 2 m......%) found in the interstitial tissue. uPAR immunoreactivity correlated with the mRNA expression and was, in addition, found in neutrophils. PAI-1 mRNA was detected in 13 of the 16 carcinomas and in 8 of the 9 benign hyperplasias, located in scattered fibroblast-like cells in both groups, in some vascular...

  9. Hiperplasia Prostática Benigna e PSA: o efeito dominó Benign prostatic hyperplasia and PSA: the domino effect Hiperplasia benigna de prostata y PSA: el efecto dominó

    Directory of Open Access Journals (Sweden)

    José Agostinho Santos

    2012-12-01

    Full Text Available

    Após a publicação de uma recomendação contra o rastreio câncer prostático pela U.S. Preventive Services Task Force, a comunidade médica não poderá desvincular-se das particularidades relacionadas com o antígeno prostático específico (PSA. O enfoque dado às guidelines da Hiperplasia Prostática surge pela possível partilha, a determinado ponto da sua abordagem, de um trilho que cursa também com a solicitação do PSA. Os resultados de dois grandes ensaios clínicos constituem o maior corpo da evidência actual e deles sobressai que o número de homens que evitaram a morte por câncer prostático após submetidos ao rastreio foi reduzido. Há evidência de que 100-200 em 1000 homens rastreados terão um falso-positivo, a maioria dos quais será biopsada, com possíveis danos psicológicos e orgânicos. O Médico de Família deverá relembrar que não é recomendado que se ofereça esta análise, sem que primeiro discuta, juntamente com o paciente, as questões inerentes ao PSA.

    After U.S. Preventive Services Task Force published a recommendation against prostate cancer screening, the medical community cannot extricate itself from all specific features associated with the prostate-specific antigen (PSA. The focus given to the guidelines of the Prostatic Hyperplasia happens for the possible sharing of a certain point of its approach with the prostatic cancer case-finding, that is the PSA test. The results of two large clinical trials represent the largest body of evidence and they say the number of men who avoided prostate cancer death after subjected to screening was reduced. There is evidence that 100-200 in 1000 screened men will have a false-positive, most of which will have a biopsy with possible psychological damage and organic. The GP should remember that it is not recommended to provide this test, without first discussing together with

  10. Hi-tech of the prostate: interstitial laser coagulation of benign prostatic hypertrophy

    Science.gov (United States)

    Muschter, Rolf; Hofstetter, Alfons G.; Hessel, Stefan F. F.; Keiditsch, Ernst; Rothenberger, Karl-Heinz; Schneede, Peter; Frank, Klaus H.

    1992-06-01

    We report on the new technique of interstitial laser coagulation of the prostate (ILCP) in the treatment of benign prostatic hyperplasia (BPH). Basic experiments by use of a Nd:YAG laser in combination with a newly designed fiber tip homogeneously distributing the laser irradiation have been performed in potato, muscle, liver, and surgically removed human BPH-tissue to determine the volume of coagulation. The coagulation zone surrounding the probe was well defined and homogeneous. The size was dependent on laser power and irradiation time. Carbonization was never present except in darker tissues irradiated with high energy. Volume and time resolved measurements correlated well with the size of coagulation. 10 W and 5 minutes, for example, resulted in a coagulation zone of 17 X 15 mm. Comparable results have been seen in in-vivo experiments in surgically exposed canine prostates. Specimen for macroscopic and microscopic examination were taken immediately after treatment and after 5 and 35 days. The well demarked coagulation necrosis of the early stage resulted in cystic degeneration and fibrosis in the later stages. This was combined with shrinkage and reduction in volume. The urothelium of the urethra, the external sphincter and the rectum showed no damage. Until now, 15 patients suffering from obstructive symptoms due to BPH have been treated with interstitial laser coagulation. The probes were inserted from the perineum into the center of each lateral lobe of the prostate by transrectal ultrasound guidance, while the median lobe was treated by urethroscopic guidance, while the median lobe was treated by urethroscopic control. Dependent on the size of the prostate irradiation, time was 5 to 10 minutes per lobe at a power setting of 5 to 10 W.

  11. Estudo exploratório da utilização de saw palmetto no tratamento da hiperplasia benigna da próstata por urologistas de Porto Alegre Investigation study concerning the saw palmetto use for the benign prostatic hyperplasia treatment by urologists in Porto Alegre

    Directory of Open Access Journals (Sweden)

    Gabriela Ferreira

    2008-06-01

    Full Text Available O objetivo deste trabalho foi avaliar a utilização de fitoterápicos a base de saw palmetto na terapia sintomática da hiperplasia benigna da próstata (HBP por médicos urologistas da cidade de Porto Alegre. Consistiu em um estudo transversal, exploratório, por meio de entrevista semi-estruturada aplicada a urologistas de Porto Alegre. A amostra foi obtida utilizando catálogo do plano de saúde UNIMED- Porto Alegre. A randomização foi realizada através de sistemática aleatória, sendo sorteados trinta e cinco médicos, dos quais 21 foram selecionados para realização da pesquisa através de questionário. Todos os urologistas entrevistados avaliam e tratam pacientes com hiperplasia benigna da próstata. O saw palmetto não foi citado como terapia medicamentosa de 1ª ou 2ª escolhas no tratamento da HBP. O grupo farmacológico mais freqüentemente utilizado para o tratamento da HBP foi ∝-bloqueadores. Mais da metade dos médicos entrevistados relata ter conhecimento sobre a utilização do saw palmetto, principalmente através de artigos científicos. Os resultados indicam que o saw palmetto não é prescrito pelos urologistas em Porto Alegre, todavia a maior parte destes profissionais tem conhecimento sobre sua utilização.The aim of this work was to assess the prescription of saw palmetto phytomedicines for improving symptoms of benign prostatic hyperplasia (BPH by urologists in Porto Alegre (Brazil. The study was transversal and exploratory consisting of a semi-structured interview with urologists. The sample was obtained from the UNIMED Catalog - Porto Alegre (Brazil. The randomization was made by chance, being selected thirty-five physicians. The first twenty-one who accepted to participate were interviewed. All the interviewed urologists treat patients with benign prostatic hyperplasia. The saw palmetto was not mentioned as the first or second choice for treating BPH. The α-blockers were the most mentioned pharmacological

  12. Bipolar Plasma Kinetic Prostatectomy Combined with Holmium Laser Percutaneous Nephrolithotomy for Senior High Risk Patients with Benign Prostate Hyperplasia and Complicated Bladder Stone%双极等离子电切联合经皮膀胱通道钬激光碎石治疗高龄高危前列腺增生合并膀胱结石

    Institute of Scientific and Technical Information of China (English)

    吴序立; 郑培奎; 黄伟雄

    2015-01-01

    目的:探讨经尿道前列腺双极等离子电切术( transurethral plasmakinetic resection of the prostate ,TUPKRP)联合经皮膀胱穿刺造瘘钬激光碎石术治疗高龄高危良性前列腺增生( benign prostate hyperplasia , BPH )合并膀胱结石的效果。方法回顾性分析2009年1月~2014年5月采用该方法治疗BPH合并膀胱结石73例患者的临床资料,年龄70~95岁,平均85.6岁,均伴有1种或以上心脑血管等并发症,术前B超测量前列腺35~105 g,其中58例提示中叶明显突入膀胱,膀胱结石直径1.5~4.5 cm。结果73例均一次手术成功,碎石时间15~50 min,平均24 min;前列腺电切时间40~135 min,平均70 min。术中术后无大出血、电切综合征、膀胱穿孔、结石残留、严重感染等并发症发生。术后3~5天拔除尿管,无尿漏、排尿困难、尿失禁,病理检查均为BPH。术后住院时间5~10 d,平均6 d。术后3个月国际前列腺症状评分(IPSS)由(23.5±5.1)分降至(7.5±1.6)分,生活质量评分(QOL)由(5.1±0.5)分降至(2.2±0.8)分,最大尿流率(Qmax)由(6.2±2.4)ml/s上升至(17.9±4.2)ml/s,残余尿量由(185.6±29.7)ml降至(30.0±21.2)ml(P均<0.05)。结论 TUPKRP联合经皮膀胱穿刺造瘘钬激光碎激光碎石术是治疗高龄高危BPH合并膀胱结石的安全有效的方法。%Objective To evaluated the role of transurethral plasmakinetic resection of the prostate ( TUPKRP ) in combination with percutaneous bladder channel lithotripsy with holmium laser in the treatment of benign prostate hyperplasia ( BPH) and bladder stone in senior patients . Methods Seventy-three patients treated during January 2009 to May 2014 were retrospectively reviewed.The patients aged 70-95 years old (mean, 85.6 years old).All of the patients were complicated with one or more diseases of the cardiovascular

  13. 高龄高危患者经尿道前列腺气化电切术疗效分析%The efficiency of transurethral vaporization of the prostate in advanced age and high risk patients with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    赵军; 张宁; 胡岚亭; 汪清

    2012-01-01

    目的 探讨高龄高危前列腺增生患者经尿道前列腺气化电切术的临床疗效.方法 应用经尿道前列腺气化电切术治疗高龄高危前列腺增生患者36例,观察手术时间、术中出血量、手术并发症,记录并分析手术前后国际前列腺症状评分(IPSS)、生活质量评分(QOL)、残余尿量(PVR)及最大尿流率(Qmax)等指标的变化.结果 全部患者均安全度过围手术期,平均手术时间30 ~ 120min,失血量50~ 200 mL;术后随访6~12个月排尿通畅,疗效满意.IPSS由术前(26.5±2.8)分降至术后(8.4±1.3)分,QOL由术前(7.3±1.2)分降至术后(2.8±0.3)分,PVR由术前70 ~ 430 mL降至术后14 ~ 28 mL,Qmax由术前0~10 mL/s升至术后(15.2±2.6)mL/s;4项指标与术前比较,差异均有显著性(P <0.01).结论 重视并加强个体化围手术期的处理;对高龄高危前列腺增生患者行经尿道前列腺气化电切术,手术安全有效.%[ Objective ] To study the clinical efficiency of transurethral vaporization resection of the prostate (TURP) in advanced age and high risk patients with benign prostatic hyperplasia (BPH). [Methods] 36 advanced age and high risk patients with BPH were treated with TURP. The operation time, blood loss and surgical complications were observed. Before and after surgery, the international prostate symptom score (IPSS), quality of life score (QOL), residual urine volume (PVR), maximum urinary flow rate (Qmax) and other indicators of changes were recorded and analyzed at the same time. [ Results ] All patients were safe during the perioperative period, the average operation time was 30-120 menthe blood loss was 50~200mL. Patients were followed up for 6 to 12 months, all of whom had fluent urination and the effect was satisfied. Before and after operation, the IPSS decreased from (26.5± 2.8) to (8.4±1.3J ,QOL decreased from (7.3±1.2) to (2.8±0.3) min, PVR decreased from 70-430 mL to 14-28 mL and Qmax improved from 0~10 mL/s to (15

  14. 经尿道前列腺等离子腔内剜除术对良性前列腺增生患者术后性功能的影响%Influence of transurethral enucleative resection of prostate on postoperative sexual function of patients ;with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    黄欢; 卢书雄; 刘晖; 曾海平

    2015-01-01

    目的:对比研究经尿道前列腺等离子腔内剜除术(TUERP)与经尿道前列腺电切术(TURP)对术前保留性功能的良性前列腺增生患者术后性功能的影响。方法100例术前保留性功能的良性前列腺增生患者按照手术方式分为TUERP组(TUERP手术治疗)和TURP组(TURP手术治疗),每组50例,观察患者术前以及术后6、12个月的国际前列腺症状评分表(IPSS)评分和国际勃起功能指数评分简表(IIEF-5)评分,同时评价患者术后12个月阴茎勃起功能障碍、精量增加、精量减少、射精疼痛及逆行射精的发生情况。结果两组患者在IPSS评分以及精量增加、精量减少、射精疼痛及逆行射精的发生率方面比较差异无统计学意义(P>0.05);但TUERP组患者术后6个月及12个月的IIEF-5评分均较TURP组高(P0.05). TUERP group had higher IIEF-5 scores in 6 and 12 months after operation than the TURP group (P<0.05), and its incidence of erectile dysfunction was lower than the TURP group (P<0.05). Conclusion Compared with TURP, TUERP can reduce incidence of erectile dysfunction in benign prostatic hyperplasia patients with preoperative reserved sexual function, and this method has little influence on postoperative sexual function.

  15. Premalignant lesions of prostate and their association with nodular hyperplasia and carcinoma prostate

    Directory of Open Access Journals (Sweden)

    Rekhi Bharat

    2004-01-01

    Full Text Available BACKGROUND : A relatively new development in the arena of prostatic histopathological study is the premalignant proliferative changes in the glandular epithelium, possibly relating to carcinoma. Two major categories have come up, namely prostatic intraepithelial neoplasia (PIN and atypical adenomatous hyperplasia (AAH. AIMS : The aims of present study were to identify foci of the two putative premalignant conditions viz. PIN and AAH in ducto-acinar lining epithelia of 200 prostatectomy specimens and their association with nodular hyperplasia and adenocarcinoma prostate. MATERIAL AND METHODS : Micro sections from 200 prostatectomy specimens, received in the Department of Pathology, PGIMS, Rohtak, were extensively studied for the presence and association of premalignant conditions. Significant values were obtained by employing Chi-square (x2 test, with P value < 0.05 as significant. RESULTS : Out of 177 cases of nodular hyperplasia, 53 (29.9% showed PIN and 38 (20.3% showed presence of AAH. All 6 cases (100% of pure carcinoma revealed foci of PIN. Out of the remaining 23 cases of carcinoma with nodular hyperplasia, foci of PIN were observed in 16 cases (94.1% and AAH in 2 cases (11.7%. High-grade PIN was observed in 20 cases (86.9% of the total 23 cases of carcinoma, with/without nodular hyperplasia and 20 cases (11.2% of nodular hyperplasia. Low-grade PIN was observed in 33 cases (18.6% of nodular hyperplasia and in only 1 case (5.8% of carcinoma prostate with nodular hyperplasia. CONCLUSION : PIN, especially high-grade type was the most commonly observed premalignant lesion, in cases of adenocarcinoma, thereby suggesting it to be the likely precursor of carcinoma prostate. AAH showed a weaker association with carcinoma.

  16. Maternal Obesity, Cage Density, and Age Contribute to Prostate Hyperplasia in Mice.

    Science.gov (United States)

    Benesh, Emily C; Gill, Jeff; Lamb, Laura E; Moley, Kelle H

    2016-02-01

    Identification of modifiable risk factors is gravely needed to prevent adverse prostate health outcomes. We previously developed a murine precancer model in which exposure to maternal obesity stimulated prostate hyperplasia in offspring. Here, we used generalized linear modeling to evaluate the influence of additional environmental covariates on prostate hyperplasia. As expected from our previous work, the model revealed that aging and maternal diet-induced obesity (DIO) each correlated with prostate hyperplasia. However, prostate hyperplasia was not correlated with the length of maternal DIO. Cage density positively associated with both prostate hyperplasia and offspring body weight. Expression of the glucocorticoid receptor in prostates also positively correlated with cage density and negatively correlated with age of the animal. Together, these findings suggest that prostate tissue was adversely patterned during early life by maternal overnutrition and was susceptible to alteration by environmental factors such as cage density. Additionally, prostate hyperplasia may be acutely influenced by exposure to DIO, rather than occurring as a response to worsening obesity and comorbidities experienced by the mother. Finally, cage density correlated with both corticosteroid receptor abundance and prostate hyperplasia, suggesting that overcrowding influenced offspring prostate hyperplasia. These results emphasize the need for multivariate regression models to evaluate the influence of coordinated variables in complicated animal systems. PMID:26243546

  17. Expression of hypoxia-inducible factor 1α in human normal, benign, and malignant prostate tissue

    Institute of Scientific and Technical Information of China (English)

    都镇先; 藤山千里; 陈永昕; 真崎善二郎

    2003-01-01

    Objective To investigate hypoxia-inducible factor 1α (HIF-1α) protein expression in normal prostates (NP), benign prostatic glandular hyperplasia (BPH), and prostate adenocarcinoma (Pca).Methods HIF-1α protein expression was determined by immunohistochemistry in formalin-fixed and paraffin-embedded specimens obtained from 13 cases of NP, 28 cases of BPH, and 34 cases of Pca. In cases of Pca, the relationship between HIF-1α protein expression and certain clinicopathological factors, such as clinicopathologic stage and Gleason score, was evaluated.Results NP manifested no immunoreactivity, whereas Pca and BPH showed significantly increased HIF-1α protein expression. A significantly higher expression was observed in Pca specimens compared with BPH samples. In Pca, no significant relationship between HIF-1α protein expression and clinicopathological factors was found.Conclusion Our findings of increased HIF-1α protein expression in BPH and Pca specimens suggests the potential role of this protein in BPH and Pca.

  18. Exosomal lncRNAs may to Help Distinguish Prostate Cancer from Benign Disease

    Directory of Open Access Journals (Sweden)

    Mustafa eIsin

    2015-05-01

    Full Text Available Exosomes are membranous vesicles containing various biomolecules including lncRNAs which are involved in cellular communication and are secreted from many cells including cancer cells. In our study, investigated the exosomal GAS5 and lincRNA-p21 lncRNA levels in urine samples from 30 patients with prostate cancer (PCa and 49 patients with benign prostatic hyperplasia. Quantification of lncRNA molecules was performed by real-time PCR. We observed a significant difference in the exosomal lincRNA-p21 levels between PCa and BPH patients whereas the GAS5 levels did not reveal a difference. Our data suggest that the discriminative potential of exosomal lincRNA-p21 levels may help to improve the diagnostic prediction of the malignant state for patients with prostate cancer.

  19. Can Metabolic Disorders in Aging Men Contribute to Prostatic Hyperplasia Eligible for Transurethral Resection of the Prostate (TURP?

    Directory of Open Access Journals (Sweden)

    Aleksandra Rył

    2015-03-01

    Full Text Available Purpose: The aim of this study was to evaluate the incidence and severity of metabolic disorders occurring in the metabolic syndrome in patients with benign prostatic hyperplasia eligible for surgical treatment. Methods: The study group consisted men with diagnosed benign prostatic hyperplasia. The control group consisted patients recruited from basic health care units. Abdominal circumference, body weight and blood serum metabolic parameters were determined in the experimental and control groups. The concentrations of glucose were determined, as well as total cholesterol (ChT, low-density lipoprotein (LDL, high density lipoprotein (HDL and triglycerides (TAG, by spectrophotometric method using reagent kits. Results: In the study group 91 (60.3% cases of metabolic syndrome (MetS were diagnosed, while in the control group 71 (46.1% men met the diagnostic criteria for this syndrome (p = 0.018. The analysis shows a relationship between MetS in patients with BPH and concentration glucose, ChT, LDL, HDL, systolic blood pressure and diastolic blood pressure. We found no significant statistical relationship between body weight, abdominal circumference and concentration TAG, hypertension in patients and controls. Conclusions: in the study presented in this article, statistically significant relationships between BPH and the diagnostic parameters of the metabolic syndrome were demonstrated. These results indicate to the necessity of the modification of the lifestyle, taking preventive measures in diabetes, and evaluation of lipid metabolism disorders. It is recommended to assess symptoms that may suggest BPH (as a manifestation of LUTS in men over 50 years of age with diagnoses of metabolic disorders (including MetS, and provide them with specialist urological care in order to prevent surgical treatment of the prostate.

  20. Efficacy of four-step method transurethral plasmakinetic enucleation of prostate with preservation of the bladder neck in the treatment of benign prostatic hyperplasia%“四步法”保留膀胱颈等离子前列腺剜除术治疗良性前列腺增生的疗效研究

    Institute of Scientific and Technical Information of China (English)

    李功成; 潘铁军; 文瀚东; 沈国球; 涂忠; 杨家荣

    2015-01-01

    Objective:To explore the safety and efficiency of four-step method transurethral plasmakinetic enu-cleation of prostate with preservation of the bladder neck (FSMPKEP)for benign prostatic hyperplasia (BPH ). Methods:200 patients with BPH were divided into FSMPKEP group (n =80)and transurethral plasmakinetie resec-tion of prostate (PKRP)group (n =120).The clinical indicators of perioperative and 3-month postoperative period were analyzed.Results:There was no significant difference in preoperative factors between the two groups (P >0.05).The mean operative time,bladder irrigating time,catheterization time and hospital stay were shortened in the FSMPKEP group as compared with those in the PKRP group (P 0.05 ).Maximum urinary flow (Qmax )in FSMPKEP group (1 9.50 ± 2.32 mL/s)was increased as compared with PKRP group (18.60 ± 2.58 mL/s)(P <0.05).The incidence rate of retrograde ejaculation in FSMPKEP group (22.50%,18/80)was signifi-cantly lower than in PKRP group (68.33%,82/120)(P <0.05).Conclusions:FSMPKEP is as effective as PKRP for the treatment of BPH,which has the characteristic of short postoperative recovery time,more removal of the prostate tissue and low incidence rate of retrograde ejaculation at the same time.FSMPKEP is safe,effective and ide-al minimally invasive treatment procedure for BPH.%目的::探讨“四步法”保留膀胱颈等离子前列腺剜除术(FSMPKEP)治疗前列腺增生症(BPH)的安全性和有效性.方法:200例BPH 患者根据手术方法分为2组,行 FSMPKEP 术80例与经尿道双极等离子前列腺切除术(PKRP)120例,记录患者围手术期和术后6个月有关指标并进行统计学分析.结果:术前两组一般情况比较差异无统计学意义(P >0.05).手术时间、术后平均冲洗时间、留置尿管时间和住院时间, FSMPKEP 组少于 PKRP 组,前者切除腺体率多于 PKRP 组(P <0.05).术后6个月两组在国际前列腺症状评分(IPSS)、生活质量(QOL)评分、剩余

  1. 经尿道RevoLix2μm激光前列腺切除术对患者性功能的影响%The Impact of Transurethral RevoLix 2 Micron Continuous wave Laser Vaporesection of Prostate on Sexual Functions of the Patients with Benign Prostatic Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    贾永中; 贺兵; 庞栋; 罗敏; 李玉柱; 肖序仁

    2011-01-01

    目的:探讨采用RevoLix 2 μm激光手术系统治疗BPH对患者性功能的影响.方法:对120例BPH患者进行了RevoLix 2μm激光手术治疗,全部病例均行IPSS评分.利用国际勃起功能障碍问卷-5(IIEF-5)和自制统一的射精障碍调查表,分别于术前、术后半年了解患者阴茎勃起功能情况、性欲、射精情况及对性生活满意程度进行调查.结果:全部手术均成功,IPSS有明显改善,从(25.12±3.21)分下降为(6.26±2.12)分,(P<0.05).术后患者均保留性功能.IIEF-5术前评分为(23.50±3.12)分,术后半年为(22.40±4.62)分;术前有性欲者占81.67%,术后半年占85.00%,手术前后比较差异无统计学意义(P>0.05).术前射精异常者占23.33%,术后半年射精异常者占71.67%,术后射精功能较术前明显下降(P<0.05).术前对性生活满意者占65.00%,术后占70.00%,手术前后比较差异无统计学意义(P>0.05).结论:RevoLix 2μm激光手术系统治疗BPH有效安全,术中、术后并发症少,对患者阴茎勃起功能、对性生活满意程度及性欲无明显影响,其影响主要为射精障碍.术中操作仔细,防止损伤影响阴茎勃起的神经血管束,术后处理得当,可减少或避免对患者的性功能影响.%Objective:To evaluate the impact of transurethral RevoLix 2 micron continuous wave laser vapore-section of prostate on sexual functions of the patients with benign prostatic hyperplasia(BPH). Methods: A total of 120 aged patients with BPH who reported normal sexual relation before operation were followed up for 6 months in this study, the International Prostate Symptom Score (IPSS),the International erectile dysfunction questionnaire (IIEF-5) and a self-designed ejaculatory questionnaire were used before operation and 6 months later after operation. The incidence of erectile dysfunction, index of sexual activation including sexual interest, pleasure in sex, sexual climax, satisfaction for sexual intercourse were

  2. The value of 3 . 0 T magnetic resonance spectroscopy with T2 WI in the dif-ferential diagnosis between prostate cancer and benign prostatic hyperplasia%3.0 T磁共振波谱成像结合T2 WI对前列腺癌与前列腺增生的鉴别诊断价值

    Institute of Scientific and Technical Information of China (English)

    刘兴华; 曾文兵; 汪明全; 温云; 王怀武

    2014-01-01

    目的:探讨3.0T磁共振波谱成像(magnetic resonance spectroscopy,MRS)结合T2WI对前列腺癌与前列腺增生的鉴别诊断价值。方法:回顾性分析49例经直肠超声引导下穿刺活检证实的前列腺病变患者的MRI资料,其中前列腺增生27例,前列腺癌22例,所有患者均行常规T2 WI及MRS检查。 T2 WI分析前列腺的大小、形态、病变位置、信号特点和病变累及的范围等。 MRS根据穿刺病理结果选择体素,测量相应体素的枸橼酸盐( Citrate,Cit)、胆碱( Choline,Cho)、肌酸( Creatine,Cre)的峰值、( Cho+Cre)/Cit的比值。数据经K-S检验证实为正态分布后,采用独立样本t检验进行比较。结果:22例前列腺癌病例中T2 WI序列18例有典型的肿瘤征象,其中4例膀胱受累,12例精囊腺受累,4例直肠受累,盆腔淋巴结转移8例,骨盆转移11例。余4例未见明显前列腺癌征象。所有前列腺增生病例T2 WI序列均具有典型的增生征象。前列腺癌病例共选取136个体素,MRS主要表现为Cit峰明显降低甚至消失,Cho峰显著升高,两者波峰可呈现倒置。前列腺增生病例共选取132个体素,MRS主要表现为Cit峰高耸,Cho峰及Cre峰较低。前列腺癌组(Cho+Cre)/Cit平均值为2.05±0.61,前列腺增生组为0.53±0.19,两组数据符合正态分布特点,差异具有统计学意义(t=-27.241,P<0.05)。结论: MRS结合T2WI对前列腺癌与前列腺增生的诊断和鉴别诊断,均具有较高的临床应用价值。%Objective:To investigate the value of 3. 0T magnetic resonance spectroscopy with T2 WI in the differential diagnosis be-tween prostate cancer(PCa)and benign prostatic hyperplasia(BPH). Methods:Retrospectively analyses MRI data of 49 patients with prostate diseases confirmed by transrectal ultrasound-guided needle biopsy. 27 patients were PCa and 22 patients were BPH. All patients were performed traditional MRI(T2WI)and magnetic resonance spectroscopy(MRS). T2WI sequence

  3. Clinical significance of simultaneous transurethral resection of a bladder tumor and the prostate in the treatment of non-muscle invasive bladder cancer with benign prostatic hyperplasia%非肌层浸润性膀胱癌合并良性前列腺增生患者同期行经尿道电切手术的疗效和安全性分析

    Institute of Scientific and Technical Information of China (English)

    陈海昕; 张冠; 方自林; 王翔; 刘乃波

    2011-01-01

    Objective To evaluate the clinical significance of simultaneous transurethral resection (TUR) of a bladder tumor and the prostate in the treatment of non-muscle invasive bladder cancer with benign prostatic hyperplasia (BPH).Methods Patients were divided into two groups.Group A contained 46 male patients who accepted TUR for the treatment of both bladder cancer and benign prostatic hyperplasia.Group B contained 69 male patients who accepted TURBt only.Clinical data were retrospectively collected and analyzed to compare clinical outcomes and safety in these two groups.Results The bladder cancer recurrence rates in group A and B were 50.0% and 50.7%,the average recurrence free time was 20 and 18 months,and the progression rates were 6.5% and 7.2%,respectively.There were no significant differences between the two groups for either average recurrence free time or progression rates (P > 0.05).Recurrences in the prostatic urethra were found in two cases in group A and one case in group B and all three cases were in T1 G3.Conclusions Simultaneous TUR for bladder tumor and the prostate can be safely and effectively performed in terms of oncologica] control in patients who have non-muscle invasive and low grade bladder tumors ( T1G1 - G2 ) with lower urinary tract obstruction caused by BPH.But this procedure should be cautiously performed on patients with T1 G3 bladder tumors.%目的 探讨合并BPH的非肌层浸润性膀胱癌患者同期行经尿道电切(TUR)手术的疗效和安全性.方法 合并BPH的非肌层浸润性膀胱癌患者46例(A组)同期行TURBt和TURP治疗,非肌层浸润性膀胱癌仅行TURBt的男性患者69例(B组)作为对照组.A组年龄54~80岁,平均69岁;肿瘤单发37例、多发9例,肿瘤直径0.5 ~3.5 cm,平均2.8 cm.B组55~82岁,平均70岁;肿瘤单发54例、多发15例;肿瘤直径0.5~24.0 cm,平均2.9 cm;2组比较差异无统计学意义(P>0.05).结果 2组均顺利完成手术.随访24 - 96个月,平均44

  4. 机关事业单位职工良性前列腺增生患病情况及相关因素分析%Analysis of the status of benign prostatic hyperplasia and related factors in health examination among cadres

    Institute of Scientific and Technical Information of China (English)

    孙赞; 陈正荣; 滕秋艳; 廉娜

    2013-01-01

    Objective To investigate the status of benign prostatic hyperplasia(BPH) and to explore the related factors of benign prostatic hyperplasia in cadres. Methods: 847 cases of male officials between 40 and 60 years old, who came to take part in the healthy examination, received the measurement of the level of blood pressure, blood lipids, glucose, uric acid , creatinine and routine blood count, and the examination of prostate and liver with type B ultrasonic diagnostic apparatus. Results: The ratio of BPH among the officials is about 28.8%, in which the low-grade BPH is 7.1%, the middle-grade BPH is 21.7%, and high-grade BPH case has not been found in this investigation. While the age groups were getting older, the prevalence of BPH became higher (χ2 =22.4, P0.05), the prevalence of hepatic steatosis in the middle-grade group was higher than it in the low-grade BPH group (χ2 =4.01, P0.05). Conclusions: BPH is associated with age and hypertension, and NBPH group in along with hepatic steatosis may accelerate the development of BPH.%目的分析机关事业单位男性职工群体中良性前列腺增生(BPH)的患病情况,探讨其发病的相关因素.方法对参加健康体检的40岁-60岁847名机关事业单位职工,进行血压、血糖、总胆固醇、甘油三酯、转氨酶、转肽酶、总蛋白、球蛋白、血尿酸、肌酐值、血常规的各项指标检查,同时做腹部B超检查前列腺和肝脏.结果 BPH的患病率为28.8%,其中轻度BPH为7.1%,中度BPH为21.7%,本次体检未发现重度BPH.BPH患病率随年龄组的递增而升高(χ2=22.4,P 0.05),但中度BPH组中并发脂肪肝的比例明显高于轻度BPH组(χ2=4.01,P<0.05).结论该人群BPH的患病率较高,高血压、超重或肥胖是其主要影响因素,脂肪肝的并存可能加快BPH病情的发展.

  5. Transurethral electric cutting jointing laparoscopic sleeve needle treatment for benign prostatic hyperplasia complicated with bladder stones%经尿道电切联合经腹腔镜套管针取石治疗BPH并发膀胱结石

    Institute of Scientific and Technical Information of China (English)

    于满; 李俊鹏; 王凤阁; 王庚; 王泽民; 宋殿宾; 周晓松

    2014-01-01

    目的:探讨良性前列腺增生合并膀胱结石的治疗方法。方法采用经尿道前列腺电切术(TURP)联合经腹腔镜套管针(Trocar)取出结石治疗BPH并发膀胱结石32例。结果32例中单发结石23例,2块结石4例,多发结石5例。结石大小为1.5cm~3.0cm。除4例因结石太多(分别为3~183块),反复进出Trocar使膀胱造瘘通道迷失而失败外,其余28例均成功。未出现膀胱穿刺通道漏尿、延迟愈合、感染等并发症。结论前列腺增生并发膀胱结石的患者,采用经尿道前列腺电切联合Trocar膀胱穿刺取石是一种可行的操作,达到微创治疗的目的。%Objective To evaluate treatment methods for benign prostatic hyperplasia ( BPH) combined with bladder stones. Methods A total of 32 BPH patients with bladder calculi underwent transurethral resection of the prostate combining with laparoscopic Trocar suprapubic lithotomy. Results Twenty-three of 32 patients had single calculi,4 patients had 2 piece of stone and 5 patients multiple stones. Stone size ranged from 1.5 cm to 3.0 cm. The treatment for 4 cases with much more stone was faliure due to bladder colostomy channel failure and the other 28 cases were successful. Bladder puncture channel leakage, delayed union, complication such as infection did not occur. Conclusion For BPH patients with bladder stones, transurethral resection of prostate combining with laparoscopic Trocar therapy is a feasible operation, and it realize the purpose of intracavitary treatment completely.

  6. Ananlysis of the effect and safety of transurethral vaporization of the prostate in the treatment of advanced age and high risk patients with benign prostatic hyperplasia%经尿道前列腺气化电切术治疗高龄、高危良性前列腺增生疗效分析

    Institute of Scientific and Technical Information of China (English)

    张春山

    2014-01-01

    目的:观察经尿道前列腺气化电切( TUVP)治疗高龄、高危良性前列腺增生( BPH)患者的疗效及安全性。方法回顾性分析47例在经尿道汽化电切治疗的高龄、高危BPH患者临床资料,分析围手术期并发症发生率,比较手术前、后前列腺症状评分(IPSS)、残余尿量(RUV)、最大尿流率(Qmax)及生活质量评分(QOL)。结果47例患者手术时间57~214 min,平均(95.2±36.7)min,切除前列腺腺体重量31~69 g,平均(39.8±10.3)g,术中未出现闭孔反射或电切综合征。3例患者出现尿路感染,无真性尿失禁发生。术后3个月与术前比较,患者最大尿流率[(26.5±2.8)mL/s与(8.4±1.3)mL/s,t=11.32,P<0.01]得到显著改善,残余尿量降低[(7.3±1.2)mL与(2.8±0.3)mL,t=4.36,P<0.05],IPSS[(170.9±121.5)分与(25.5±10.0)分,t=18.29,P<0.01]、QOL评分[(8.1±2.5)分与(15.2±2.6)分,t=8.54,P<0.05]增加。结论高龄BPH患者可耐受经尿道前列腺气化电切术,围手术期无严重并发症发生,术后BPH症状获得显著改善。%Objective To observe the effect and safety of transurethral vaporization of the prostate( TURP) in the treatment of advanced age and high risk patients with benign prostatic hyperplasia( BPH) .Methods Clinical data of 47 advanced age and high risk patients with BPH which were treated with TURP were retrospectively analyzed. The operation time, blood loss and surgical complications were observed.Before and after surgery, the international prostate symptom score( IPSS) ,quality of life score( QOL) ,residual urine volume( PVR) ,maximum urinary flow rate ( Qmax) were recorded and analyzed at the same time.Results 47 patients operation time was 57~214 min,mean time was (95.2 ±36.7) min.There was none obturator nerve reflex or TURP syndrome happened.And 3 patients had

  7. Effect of self-care theory on self-efficacy and self-care ability of benign prostatic hyperplasia patients%自护理论对前列腺增生患者自我效能感及自护能力的影响

    Institute of Scientific and Technical Information of China (English)

    杨桂芹

    2014-01-01

    Objective To explore the effect of self -care theory in the operation period on benign prostatic hyperplasia pa-tients.Methods A total of 100 cases of plasmakinetic resection patients in our hospital from 2012 December to 2013 November were ran-domly divided into the observation group and the control group , 50 cases in each group , the control group was received routine nursing care , the observation group was used self -care theory in perioperative operation nursing , nursing effects were compared between two groups.Results Self-efficacy scores , positive coping scores in the observation group were significantly higher than those in the control group, negative coping scores were significantly lower than those in the control group , the complications were significantly less than that in the control group , the hospitalization time was significantly shorter than that in the control group , nursing satisfaction was significantly higher than the control group with statistical significance ( P<0.05 ) .Self care ability score in health knowledge level , self concept , self responsi-bility in the observation group were higher than those in the control group with statistical significance ( P<0.05 ) .Conclusions The self-care theory in the nursing of benign prostatic hyperplasia operation patients can improve the sense of self efficiency , strengthen the ability of self nursing and reduce the complications.%目的:探讨自护理论在前列腺增生患者围术期中的应用效果。方法选取我院2012年8月至2013年11月收治的100例前列腺等离子切除术的患者为研究对象,随机分为观察组和对照组,每组50例,对照组采用常规护理,观察组将自护理论应用到围术期护理中,比较两组患者的护理效果。结果观察组的自我效能感评分、积极应对评分显著高于对照组,消极应对评分显著低于对照组,并发症显著少于对照组,住院时间显著短于对照组,护理满意度

  8. 2μm 激光治疗长期口服抗凝药物良性前列腺增生临床观察%2 μm laser in treating benign prostatic hyperplasia with long-term anticoagulative therapy

    Institute of Scientific and Technical Information of China (English)

    汪中兴; 李学德; 江志勇; 何庆鑫; 樊胜海; 贲晶华

    2015-01-01

    目的:探讨2μm 激光治疗长期口服抗凝药物良性前列腺增生患者的安全性及有效性。方法:对28例长期服用抗凝药物良性前列腺增生患者行经尿道前列腺2μm 激光“刀削面”式汽化切除术。结果:手术时间为30~70min,平均时间(45±13)min;术后持续膀胱冲洗1~3d;留置尿管2~6d,膀胱造瘘管于拔出尿管后次日拔出;术后住院时间4~7d。术后随访3~6个月,术前与术后6个月平均 IPSS 分别为:(22.7±4.5)分、(6.8±3.5)分;QOL 分别为:(5.2±0.4)分、(2.2±1.2)分;Qmax 分别为:(6.4±1.5)mL/s、(18.8±3.2)mL/s,上述三项指标与术前比较,均有明显改善(P <0.01)。结论:经过严格术前评估与恰当处理,2μm 激光治疗长期口服抗凝药物良性前列腺增生患者安全有效。%Objectives:To analyze the technical properties and safety of 2μm laser in the management of benign prostatic hyperplasia with long -term anticoagulative therapy.Methods:28 patients with obstructive BPH and long -term anticoagulative therapy were treated transurethrally by the ‘sliced noodles -vaporesection’tech-nique using the Revolix70 W 2μm continuous laser.Results:The mean operation time was (45 ±1 3)(30 -70) min;mean continuous bladder irrigation time was 1 ~3d;mean catheter time was 2 ~6d;mean hospitalization time was 4 -7d.All patients were followed up for 3 to 6 months,and IPSS and QOL -Score improved from (22.7 ± 4.5)and (5.2 ±0.4)to (6.8 ±3.5)and (2.2 ±1 .2)respectively at six months after operation (P <0.05). Mean Qmax increased from (6.4 ±1 .5)mL/s preoperatively to (1 8.2 ±3.2)mL/s 6 months postoperatively (P <0.05).Conclusion:With strict preoperative evaluation and management,2μm continuous laser is safe and effec-tive in treating benign prostatic hyperplasia with long -term anticoagulative therapy.

  9. Cross-sectional and longitudinal studies on interaction between bladder compliance and outflow obstruction in men with benign Prostatic hyperplasia%前列腺增生男性膀胱顺应性与流出道梗阻间相互关系的横截面与纵向研究

    Institute of Scientific and Technical Information of China (English)

    L.M.Liao; W.Schaefer

    2007-01-01

    Aim:To explore the interaction between bladder compliance (BC) and bladder outflow obstruction (BOO) in men with benign prostatic hyperplasia (BPH) using cross-sectional and longitudinal studies. Methods: A total of 181 men with BPH were recruited, and 100 of them were followed for one year. Cystometry was performed in a standing or a sitting position with 30 mL/min infusion. BC was manually corrected and defined. Obstruction coefficient (OCO), linear passive urethral resistance relation and international continence society (ICS) nomogram were used to diagnose BOO. The obstructed parameters were compared between the reduced BC group and the non-reduced group. BC was compared between the first investigation at the beginning of study and the second investigation at the end of study during the one-year follow-up period. Results: The group with reduced BC had increased OCO and linear passive urethral resistance relation. BC was significantly lower in the obstructed group (55.7 mL/cm water) than that in unobstructed and equivocal one (74.9 mL/cm water, P < 0.01). BC gradually reduced with the increased obstructed grade. There was a significantly weak negative correlation between BC and OCO (r = - 0.132, P<0.01).Over the one-year follow-up period in the longitudinal study, BC for all men changed from 54.4 to 48.8 mL/cm water (P > 0.05), and BC for the group with BOO fell from 58.4 ± 70.1 to 46.5 ± 38.7 mL/cm water (P > 0.05). Conclusion:In men with BPH, a significant systematic decrease occurred in BC in the obstructed group and a significant systematic increase with urethral resistance occurred in the low BC group. A longitudinal study of the tendency of BC reduction in a group with BOO is necessary in the future.

  10. UV-spectrophotometric screening of 5α-reductase inhibitors for benign prostatic hyperplasia treatment%应用紫外分光光度法筛选5α-还原酶抑制剂治疗前列腺增生

    Institute of Scientific and Technical Information of China (English)

    许东晖; 王朝禾; 王丽红; 梅雪婷; 许实波

    2007-01-01

    AIM: Tranditional methods of screening drugs for benign prostatic hyperplasia(BPH)requires senile male animals such as dogs or rats.It consumes a long time to get the results. Over-expression of type Ⅱ5α-reductase in prastate induces BPH.A fast and efficient screening model of type Ⅱ5α-reductase inhibitors for BPH was set up in this paper.METHODS:Microsomes were extracted from male Sprague-Dawley rat livers by gradient centrifugation.Type Ⅱ5α-reductase enzyme-catalyzed reaction was assayed by UV-spectrophotometry using testosterone as a substrate and NADPH as hydrogen donor.The change of enzymatic activity was recorded with a NADPH wavelength of 340 nm by subtracted descending velocity of the control(without 5α-reductase).Effects at different conditions(temperatures,pH,enzyme and testosterone concentrations)on 5α-reductase were assayed.RESULTS:The suitable condition of type Ⅱ5α-reductase reaction Was defined as concentration of 109.05 mg protein/L enzyme(pH 6.00)with 2 μmol/L testosterone at 37℃.Michaelis'constant of type Ⅱ5α-reductase was 0.6μmol/L.Finasteride,a new drug for BPH,significantly inhibited activity of type Ⅱ 5α-reductase.IC50 of finasteride Was 64.1 nmol/L.As solvent of drugs,concentration of ethanol below 1.1% did not inhibite enzymatic activity(P>0.05).Concentration of ethanol above 1.6%could obviouslv suppress enzymatic activity(P<0.01).Daytime difference within five days had no significant difference(P>0.05).CONCLUSION:A handy and fast screening method for type Ⅱ 5α-reductase inhibitors has been set up using UV-spectrophotometry.It may be used to screening drugs for BPH treatment.

  11. Distinguishing prostate cancer from benign confounders via a cascaded classifier on multi-parametric MRI

    Science.gov (United States)

    Litjens, G. J. S.; Elliott, R.; Shih, N.; Feldman, M.; Barentsz, J. O.; Hulsbergen-van de Kaa, C. A.; Kovacs, I.; Huisman, H. J.; Madabhushi, A.

    2014-03-01

    Learning how to separate benign confounders from prostate cancer is important because the imaging characteristics of these confounders are poorly understood. Furthermore, the typical representations of the MRI parameters might not be enough to allow discrimination. The diagnostic uncertainty this causes leads to a lower diagnostic accuracy. In this paper a new cascaded classifier is introduced to separate prostate cancer and benign confounders on MRI in conjunction with specific computer-extracted features to distinguish each of the benign classes (benign prostatic hyperplasia (BPH), inflammation, atrophy or prostatic intra-epithelial neoplasia (PIN). In this study we tried to (1) calculate different mathematical representations of the MRI parameters which more clearly express subtle differences between different classes, (2) learn which of the MRI image features will allow to distinguish specific benign confounders from prostate cancer, and (2) find the combination of computer-extracted MRI features to best discriminate cancer from the confounding classes using a cascaded classifier. One of the most important requirements for identifying MRI signatures for adenocarcinoma, BPH, atrophy, inflammation, and PIN is accurate mapping of the location and spatial extent of the confounder and cancer categories from ex vivo histopathology to MRI. Towards this end we employed an annotated prostatectomy data set of 31 patients, all of whom underwent a multi-parametric 3 Tesla MRI prior to radical prostatectomy. The prostatectomy slides were carefully co-registered to the corresponding MRI slices using an elastic registration technique. We extracted texture features from the T2-weighted imaging, pharmacokinetic features from the dynamic contrast enhanced imaging and diffusion features from the diffusion-weighted imaging for each of the confounder classes and prostate cancer. These features were selected because they form the mainstay of clinical diagnosis. Relevant features for

  12. Transurethral bipolar plasmakinetic resection combined with 2 μm laser vaporization in the treatment of larger-volumed benign prostate hyperplasia%经尿道等离子双极电切联合2μm激光汽化治疗大体积良性前列腺增生

    Institute of Scientific and Technical Information of China (English)

    廖乃凯; 俞建军; 徐月敏; 乔勇; 陈忠; 胡晓勇; 宋鲁杰; 李超

    2012-01-01

    目的 探讨经尿道等离子双极电切(Bipolar plasmakinetic resection of the prostate,PKRP)联合2 μm激光汽化治疗大体积前列腺增生的安全性和有效性.方法 分别用PKRP及PKRP联合2 μm激光汽化治疗80 g以上BPH患者各148例和136例, 比较两组的手术时间、切除组织量、术后血红蛋白变化、膀胱冲洗时间、留置尿管时间、住院时间及手术并发症发生率和疗效.结果PKRP联合2μm激光汽化组手术前后血红蛋白变化较PKRP组小,手术时间、术后膀胱冲洗、留置尿管及住院时间明显缩短,术后继发性出血、输血及尿路刺激症状发生率降低,两者差异具有统计学意义(P<0.05).两组术中切除组织量、术后尿道狭窄、暂时性尿失禁及逆行射精发生率比较差异均无统计学意义(P>0.05).术后随访半年,两组患者术后残余尿量、IPSS评分、生活质量评分及最大尿流率术后均较术前明显改善,差异具有统计学意义(P<0.05),但两组间的改善程度差异无显著意义(P>0.05).结论采用经尿道等离子双极电切联合2μm激光汽化术治疗良性前列腺增生,充分发挥了PKRP和2μm激光汽化的优势,出血更少,速度更快,效果较好,是大体积良性前列腺增生较为理想的微创治疗选择.%Objective To investigate the effectiveness and safety of transurethral bipolar pla'smakinetic resection of the prostate (PKRP), or combined with 2 urn laser vaporization in the treatment of larger-volumed benign prostate hyperplasia. Methods A total of 284 patients with the prostate heavier than 80g were included in this study. Out of them, 136 patients were treated by PKRP combined with 2 nm laser vaporization and the other 148 by PKRP. All the patients were followed up to compare the duration of operation, resected weight, hemoglobin change, duration of irrigation, catheterization, and hospitalization, complications and clinic effectiveness of the two groups. Results

  13. Impact of minimally invasive surgery on the sexual function of patients with benign prostatic hyperplasia%经尿道前列腺电切术与双极等离子前列腺切除术对良性前列腺增生患者性功能影响的对比研究

    Institute of Scientific and Technical Information of China (English)

    杨玉恺; 李飞; 陆鲲; 周德雄; 胡东亮; 胡万里

    2015-01-01

    目的:评价经尿道前列腺电切术(TURP)与经尿道双极等离子前列腺切除术(PKRP)治疗良性前列腺增生对患者术后性功能的影响。方法:采用随机分组法将2011年6月至2013年9月我院收治的良性前列腺增生患者156例分成两组,各78例,分别给与不同手术方式。记录患者术后国际前列腺症状评分表(IPSS)及国际勃起功能指数评分表(IIEF -5)的评分,同时观察术后患者阴茎勃起功能障碍、精液量减少及逆行射精的发生情况。结果:术后6、9个月两组患者 IPSS 评分较术前均有所下降,差异有统计学意义(P <0.05);但组间 IPSS 评分均无明显差异(P >0.05)。术后6、9个月,PKRP 组 IIEF -5评分均高于 TURP组(P <0.05),PKRP 组患者的 ED 发生率(7.69%)显著低于 TURP 组(24.36%)(P <0.05%)。结论:与经尿道前列腺电切术相比,经尿道双极等离子前列腺切除术较经尿道电切术能够降低术后阴茎勃起功能障碍的发生率,对患者的性功能影响较小。%Objectives:To evaluate the postoperative sexual function of patients having received transure-thral resection of the transurethral resection (TURP)and bipolar plasma kinetic resection of the prostate (PKRP) for benign prostatic hyperplasia (BPH).Methods:156 BPH patients who were treated in four hospitals from June 2011 to September 2013 were selected and divided into two groups randomly.Each group had 78 cases,and was given different surgical methods.The International Prostate Symptom Score (IPSS),the International Index of Erec-tile Function score (IIEF -5),the incidence of erectile dysfunction,retrograde ejaculation and ejaculation reduce were observed.Results:Compared with those preoperative,the IPSS score 6 months and 9 months after operation of the two groups decreased,with statistically significant difference (P 0.05).The IIEF -5 scores 6 months and 9

  14. A phytosterol enriched refined extract of Brassica campestris L. pollen significantly improves benign prostatic hyperplasia (BPH) in a rat model as compared to the classical TCM pollen preparation Qianlie Kang Pule'an Tablets.

    Science.gov (United States)

    Wang, Ruwei; Kobayashi, Yuta; Lin, Yu; Rauwald, Hans Wilhelm; Fang, Ling; Qiao, Hongxiang; Kuchta, Kenny

    2015-01-15

    In Qinghai Province, the Brassica campestris L. pollen preparation Qianlie Kang Pule'an Tablet (QKPT) is traditionally used for BPH therapy. However, in QKPT the content of supposedly active phytosterols is relatively low at 2.59%, necessitating high doses for successful therapy. Therefore, a phytosterol enriched (4.54%) refined extract of B. campestris pollen (PE) was developed and compared with QKPT in a BPH rat model. Six groups of rats (n=8 each), namely sham-operated distilled water control, castrated distilled water control, castrated QKPT 2.0g/kg, castrated PE 0.1g/kg, castrated PE 0.2g/kg, and castrated PE 0.4g/kg, were intragastrically treated with the respective daily doses. Testosterone propionate (0.3mg/day) was administered to all castrated rats, while the sham-operated group received placebo injections. After 30 days, the animals were sacrificed and prostates as well as seminal vesicles excised and weighted in order to calculate prostate volume index (PVI) as well as prostate index (PI) and seminal vesicle index (SVI), defined as organ weight in g per 100g body weight. Compared with sham-operated controls, PI (p<0.01), PVI (p<0.01), and SVI (p<0.01) were all significantly increased in all castrated, testosterone treated rats. After treatment with PE at 0.4 and 0.2g/kg or QKPT at 2.0g/kg per day, both indices were significantly reduced (p<0.01) as compared to the castrated distilled water control. For PE at 0.1g/kg per day only PI was significantly reduced (p<0.05). At the highest PE concentration of 0.4g/kg per day both PI and SVI were also significantly reduced when compared to the QKPT group (p<0.05). Both PE and QKPT demonstrated curative effects against BPH in the applied animal model. In its highest dose at 0.4g/kg per day, PE was clearly superior to QKPT.

  15. Diagnosis of prostate cancer by quantitative analysis of 3DMRSI data: A new model

    Institute of Scientific and Technical Information of China (English)

    QUAN Hong; WANG Xiaoying; BAO Shanglian; WANG Huiliang; LI Feiyu; HUANG Rong

    2005-01-01

    Three-dimensional magnetic resonance spectroscopic imaging (3DMRSI) is helpful to identify prostate cancer (PC)from benign prostate hyperplasia (BPH) and to show the distribution of tumor infiltration. Combined with the (Cho + Cre)/Cit ratio, the z-score model can effectively discriminate prostate cancer from stromal benign prostate hyperplasia (sBPH) and detect small malignant lesions (SML).

  16. Clinical efficacy and safety analysis of long-term use of finasteride in benign prostatic hyperplasia%长期应用非那雄胺治疗良性前列腺增生临床疗效及安全性

    Institute of Scientific and Technical Information of China (English)

    万奔; 朱刚; 王建龙; 王建业; 许进

    2009-01-01

    目的 观察服用非那雄胺14年治疗良性前列腺增生(BPH)的临床疗效及安全性.方法 对1994年12月至2009年2月连续服用非那雄胺(5 mg/d)治疗BPH的41例患者进行临床观察,记录治疗前后患者夜尿次数、前列腺体积、血肌酐、丙氨酸氦基转移酶(ALT)、血白细胞、血清前列腺特异抗原(PSA)变化;同时记录治疗期间发生急性尿潴留、接受外科治疗及药物特殊不良作用(如乳腺癌和前列腺癌等)临床资料. 结果 本组41例患者观察终止时平均年龄(87.9±5.4)岁,平均治疗时间(141.1±27.1)个月.治疗前后,患者夜尿次数分别为(1.8±1.5)次和(3.2±1.3)次,差异有统计学意义(t=-4.52,P0.05).分层研究发现,治疗前前列腺体积0.05);治疗前体积25~40 ml者,治疗后体积缩小17.2%(t=2.59,P40 ml者,治疗前后体积缩小1.1%(t=0.07,P>0.05).治疗前后患者血肌酐分别为(96.8±18.6)μmol/L和(86.4±32.3)μmol/L(t=1.79,P>0.05),血白细胞计数分别为(6.4±1.5)×109>/L和(6.0±1.7)× 109/L(t=1.13,P>0.05),PSA分别为(1.2±2.0)μg/L和(1.4±1.7)μg/L(t=-0.49,P>0.05).本组3例(7.3%)发生急性尿潴留,经导尿后好转;无确诊前列腺癌和乳腺癌病例. 结论 BPH患者长期服用非那雄胺可以有效控制BPH的临床进展,无严重并发症.%Objective To evaluate the safety and clinical efficacy of finasteride in treating patients with benign prostatic hyperplasia (BPH) during a 14-year period in a hospital.Methods Forty-one patients with BPH receiving finasteride 5 mg daily for the treatment from December 1994 to Febrary 2009 were included in the study. The base line and the end of study data of nocturia, prostate volume, serum creatine, complete blood count and serum prostatic specific antigen (PSA) were recorded. The acute urinary retention, surgical treatment and drug adverse reaction (prostate cancer or breast cancer) during the observation periods were recorded as well. Results All the 41 cases took

  17. 非那雄胺对慢性心力衰竭合并良性前列腺增生老年男性患者的疗效%Effects of finasteride for elderly male patients with chronic congestive heart failure combined with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    廖伟光; 苏海龙; 陈协生; 李锦萍; 廖淑莲

    2012-01-01

    目的 探讨非那雄胺对慢性心力衰竭(chronic heart failure,CHF)合并良性前列腺增生(benign prostatic hyperplasia,BPH)的老年男性患者的疗效.方法 95例CHF合并BPH老年男性按数字表法随机分为治疗组及对照组,两组均根据患者的心功能情况规范使用抗心力衰竭治疗.治疗组使用非那雄胺,对照组使用安慰剂治疗2年.观察两组前列腺体积、国际前列腺症状评分表(IPSS)评分、BPH患者生活质量(QOL)评分、肌酐、血尿素氮、N末端脑钠肽前体、肌钙蛋白、左心室射血分数(LVEF)、急性尿潴留、需手术干预、心血管事件、心力衰竭再住院率、心功能的变化及主要副作用等指标,并进行比较.结果 治疗组心血管事件发生率[23.25%( 10/43) vs.47.61%(20/42),P<0.05]、心力衰竭再住院率[25.58%(11/43)vs.50.00%(21/42),P<0.05]、急性尿潴留率[ 13.95% (6/43) vs.42.85% (18/42),P<0.05]、需手术干预率[16.27% (7/43)vs.52.38% (22/42),P<0.05],明显低于对照组,差异有统计学意义.治疗组前列腺体积、国际前列腺症状评分表评分及肌酐、N末端脑钠肽前体浓度低于对照组,差异有统计学意义(P<0.05).两组治疗2年后在勃起功能障碍、性欲减退、乳腺增大、乳腺疼痛的发生率比较,差异无统计学意义(P>0.05).结论 对于CHF合并BPH的患者在规范的治疗心力衰竭的基础上应尽早长期使用非那雄胺,可显著降低患者的主要心血管事件发生率、心力衰竭再次住院率、急性尿潴留率、需手术干预率,缩小前列腺体积,改善下尿道症状及患者生活质量,而无明显增加副作用.%Objectives To observe the effects of finasteride for elderly male patients with chronic congestive heart failure (CHF) combined with benign prostatic hyperplasia (BPH). Methods A total of 95 BPH combined with CHF elderly male patients were randomly divided into treatment group and control group

  18. Correlation between serum cystatin C content and renal function in aged patients with benign prostatic hyperplasia%血清胱抑素C含量与老年良性前列腺增生症患者肾功能的相关性

    Institute of Scientific and Technical Information of China (English)

    沈丹; 曹萍; 李睿; 钟亚

    2015-01-01

    目的:探讨老年良性前列腺增生症(BPH)患者血清胱抑素 C(Cys C)的变化,及其与肾功能的相关性。方法:回顾性分析237例老年 BPH 患者的临床资料,按照国际前列腺症状评分(IPSS),分为轻度25例、中度67例、重度145例;纳入同期非前列腺增生患者110例作为正常对照组。检测各组血清 Cys C、血尿素氮(BUN)、肌酐(Scr)、空腹血糖(FBG)、血脂和前列腺特异性抗原(PSA)水平,计算前列腺体积(PV)。结果:与正常对照组比较,BPH 患者的 PV显著增大[(18.94±4.62)ml 比(40.09±12.72)ml],最大尿流率(Qmax )显著降低[(18.67±4.60)ml/s 比(9.93±3.54)ml/s],血清 Cys C 水平显著升高[(1.03±0.23)mg/L 比(1.53±0.61)mg/L],P 均<0.01。亚组分析显示,在轻、中、重度 BPH 组血清 Cys C 水平[(1.32±0.45)mg/L,(1.42±0.32)mg/L,(1.61±0.64)mg/L]均显著高于正常对照组(P 均<0.01);且重度组显著高于轻、中度组(P <0.01或 P <0.05)。Pearson 相关分析显示,血清 Cys C与 BPH 患者的年龄、收缩压、舒张压、FBG、BUN、Scr、PV、IPSS 评分均呈显著正相关(r=0.179~0.580,P <0.05或<0.01),与 Qmax 呈显著负相关(r=-0.243,P <0.05)。结论:血清 Cys C 水平在老年 BPH 患者显著升高,且与前列腺增生程度有关,与肾功能相关,可用于预测老年 BPH 患者的肾功能。%Objective:To explore the correlation between serum cystatin C (Cys C)content and renal function in aged patients with benign prostatic hyperplasia (BPH).Methods:Clinical data of 237 aged BPH patients were retro-spectively analyzed.According to international prostate symptom score (IPSS),they were divided into mild group (n=25),moderate group (n=67)and severe group (n= 145);another 110 patients without prostatic hyperplasia were enrolled as normal control group in the

  19. The effectiveness of Saw Palmetto and Sanmiaosan on benign prostatic hyperplasia in Chinese patients: a randomized double-blinded placebo-controlled clinical study%舒尿宝(棕榈子加三妙散)胶囊治疗前列腺增生随机双盲安慰剂对照临床研究

    Institute of Scientific and Technical Information of China (English)

    吴志辉; 郑景辉; 梁秉中

    2013-01-01

    Objective To investigate the effects of Saw palmetto and Sanmiaosan on BPH among Chinese males in Hong Kong. Methods The study was designed as a double-blinded placebo-controlled trial. Forty subjects aged 50~80 were randomly divided into two groups, and treated with herbal medicine or placebo for 6 months. Eligible subjects were evaluated by means of International Prostate Symptom Score (IPSS), quality of life (QOL), prostate volume, urinary flow rate (Qmax) and post-void residual volume. Results IPSS total score of herbal drug group showed a significant improvement compared with the placebo group; however, the difference did not attain statistical significance (P = 0.120). IPSS irritative score in herbal drug group showed a significant improvement (P = 0.053), and nocturia also remarkably decreased (P=0.083). Urinary flow rate (Qmax) of herbal drug group after treatment was significantly increased (P=0. 061). The overall effective rate of herbal drug group and placebo group was 70% and 36. 8%, respectively, with a significant difference between the two groups (P = 0. 038). Conclusion Herbal drug was beneficial in improving the lower urinary tract symptoms in patients with benign prosta-tic hyperplasia.%目的 观察三妙散加味治疗良性前列腺增生症的临床疗效.方法 随机双盲安慰剂对照试验,40名年龄50~80岁患者,随机分为对照(安慰剂)组和三妙散加味(舒尿宝)组.观察治疗前后患者的国际前列腺症状评分(IPSS)、生活质量指数(QOL)、前列腺体积(PV)、最大尿流率(Qmax)和膀胱残余尿量(PVR)的变化.结果 IPSS总分虽然舒尿宝组改善较安慰剂组明显,但无统计学意义(P=0.120);IPSS刺激症状在舒尿宝组有明显改善(P=0.053),夜尿也明显减少(P=0.083).最大尿流率Qmax在舒尿宝组治疗后有明显增加(P=0.061).治疗后舒尿宝组的有效率达70%,安慰剂组为36.8%,两组间有显著性差别(P=0.038).结论 舒尿宝有助于改善前列腺增生患者下尿道症状.

  20. Application of Transurethral Enucleation Plus Gland Extraction from Small Incision in the Hypogastrium for Large benign Prostatic Hyperplasia Surgery%经尿道腔内剜除加下腹小切口腺体取出术在大体积前列腺增生症手术中的应用

    Institute of Scientific and Technical Information of China (English)

    谢小平; 关刚强; 王鹏; 何燊; 谢玥

    2011-01-01

    Objective:To investigate the feasibility, effectiveness and practicality of transurethral enucleation plus gland extraction from small incision in the hypogastrium for large benign prostatic hyperplasia surgery. Methods:45 patients received transurethral enucleation plus gland extraction from small incision in the hypogastrium. In the operation, we divided the gland into 2- 3 pieces with transurethral plasma electrocautery at first, then stripped them from the prostate capsule and pushed them into the bladder, coagulated the wound surface, later we had a 2-3 em incision in the middle of hypogastrium to remove the pieces of the gland. After surgery, we had observed the operation time, intraoperative blood loss and the Occurrence of various complications. Results: All 45 patients successfully received transurethral enucleation plus gland extraction from small incision in the hypogastrium,and the operative time ranged from 48 to 72 minutes(an average of 57 minutes), blood loss ranged from 50-160 ml(an average of 89ml), transurethral resection syndrome(TURS) has occurred in none of them. Among the 45 patients, 8 had mild urinary incontinence, which had been cured within 2-5 days through pelvic floor muscle exercise; 5 cases had mild signs of bladder stimulation, which had been relieved by spasmolysis and odynolysis therapy; infection of incision had occurred in none of them. Followed up had been taken in 37 cases from 2 to 18 months, no urethral stenosis and other complications observed. Conclusions:We have concluded that the superiority of transurethral enucleation plus gland extraction from small incision in the hypogastrium is that the hyperplastic gland has been stripped intra-cavity by minimally invasive method which leads to less trauma, bleeding and residual gland, as well as the stripped gland has been removed rapidly by combination of open surgery. Thus the gland can be removed more thoroughly, safely, rapidly and effectively. In a word, transurethral

  1. Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate.

    Science.gov (United States)

    Maund, Sophia Lisette; Nolley, Rosalie; Peehl, Donna Mae

    2014-02-01

    Few preclinical models accurately depict normal human prostate tissue or primary prostate cancer (PCa). In vitro systems typically lack complex cellular interactions among structured prostatic epithelia and a stromal microenvironment, and genetic and molecular fidelity are concerns in both in vitro and in vivo models. 'Tissue slice cultures' (TSCs) provide realistic preclinical models of diverse tissues and organs, but have not been fully developed or widely utilized for prostate studies. Problems encountered include degeneration of differentiated secretory cells, basal cell hyperplasia, and poor survival of PCa. Here, we optimized, characterized, and applied a TSC model of primary human PCa and benign prostate tissue that overcomes many deficiencies of current in vitro models. Tissue cores from fresh prostatectomy specimens were precision-cut at 300 μm and incubated in a rotary culture apparatus. The ability of varied culture conditions to faithfully maintain benign and cancer cell and tissue structure and function over time was evaluated by immunohistological and biochemical assays. After optimization of the culture system, molecular and cellular responses to androgen ablation and to piperlongumine (PL), purported to specifically reduce androgen signaling in PCa, were investigated. Optimized culture conditions successfully maintained the structural and functional fidelity of both benign and PCa TSCs for 5 days. TSCs exhibited androgen dependence, appropriately undergoing ductal degeneration, reduced proliferation, and decreased prostate-specific antigen expression upon androgen ablation. Further, TSCs revealed cancer-specific reduction of androgen receptor and increased apoptosis upon treatment with PL, validating data from cell lines. We demonstrate a TSC model that authentically recapitulates the structural, cellular, and genetic characteristics of the benign and malignant human prostate, androgen dependence of the native tissue, and cancer-specific response

  2. Biological effect of human serum collected before and after oral intake of Pygeum africanum on various benign prostate cell cultures

    Institute of Scientific and Technical Information of China (English)

    Stéphane Larré; Philippe Camparo; Eva Comperat; Delphine Boulbés; Mohammed Haddoum; Sylvain Baulande; Pascal Soularue; Pierre Costa; Olivier Cussenot

    2012-01-01

    Pygeum africanum (Tadenan) is a popular phytotherapeutic agent used in the treatment of symptomatic benign prostatic hyperplasia.The active compounds of the drug have not been identified,and determining the plasma concentration of the drug is,therefore,not possible.Because there are conflicting results on the efficacy of this drug,we aimed to investigate its effect on prostate cell growth in vitro using human serum collected before and after Pygeum africanum intake.We used primary and organotypic cultures of human prostatic stromal myofibroblast cell line WPMY and prostatic epithelial cell line PNT2.We also used fresh benign prostatic tissue.The serum of a treated man induced decreases in the proliferation of primary cells,organotypic cells and WPMY cells but not PNT2 cells.We also analysed the effect of treated serum on the gene expression profile of WPMY cells.The transcriptome analysis revealed an upregulation of genes involved in multiple tumour suppression pathways and a downregulation of genes involved in inflammation and oxidative-stress pathways.The oral intake of Pygeum africanum resulted in serum levels of active substances that were sufficient to inhibit the proliferation of cultured myofibroblasts prostatic cells.This inhibition was associated with changes in the transcriptome.

  3. Gleason Score 6 - Prostate Cancer or Benign Variant?

    Science.gov (United States)

    Knüchel, Ruth

    2015-01-01

    The leading motivation behind wanting to call a 'malignant' prostate lesion 'benign' is the evidence of indolent prostate cancer that is not associated with a fatal outcome and in part makes therapeutic measures such as surgery and radiotherapy appear like overtreatment for some or possibly the majority of such patients. The present article reviews the definitions of 'precancerous lesion' and 'cancer' from a histopathologic point of view as the basis and gold standard for diagnosis. It is clear that with the 2 modifications implemented since its first publication, the Gleason score as the grading system for prostate cancer has shifted towards a low malignant subgroup diagnosed as Gleason 6. The recommendation of the International Society of Urological Pathology to change the Gleason score to a 5-tiered system, starting with grade group 1, is presented here, and may help doctor-patient communication especially in the active surveillance setting. PMID:26633167

  4. 良性前列腺增生症患者经耻骨上膀胱造瘘与经尿道置管两种方法行排尿期压力-流率测定的结果比较%Pressure-flow studies in patients with benign prostatic hyperplasia: a study comparing suprapubic and transurethral methods

    Institute of Scientific and Technical Information of China (English)

    S. C. Zhao; S. B. Zheng; W. L. Tan; P. Zhang; H. Qi

    2006-01-01

    目的:对良性前列腺增生症患者应用经耻骨上膀胱造瘘与经尿道置管两种方法行排尿期压力-流率测定,对结果进行比较.方法:对23例良性前列腺增生症患者同时以经耻骨上膀胱造瘘与经尿道置管两种方法行排尿期压力-流率测定,记录标准的尿流动力学参数,并以尿道阻力因子、AG数以及Sch(a)fer列线图三种方法对梗阻程度进行分级.结果:经耻骨上膀胱造瘘与经尿道置管相比,最大尿流率显著提高(P<0.05),最大尿流率时的逼尿肌压力显著降低(P<0.05),尿道阻力因子显著降低(P<0.01),AG数显著减小(P<0.01),最大膀胱容量显著增加(P<0.01).在Sch(a)fer列线图中,有10人(43.5%)分级未变,12人(52.2%)减少1级,1人(4.3%)减少2级;在AG数分区比较中,有18人(78.3%)分区未变,4人(17.4%)从梗阻区变为可疑区,1人(4.3%)从可疑区变为非梗阻区.结论:行排尿期压力-流率测定时,经耻骨上膀胱造瘘与经尿道置管两种方法可能产生不同的检测结果;后者如果选用8 F经尿道测压管会增加膀胱出口梗阻的诊断.%Aim: To compare the use of the suprapubic puncture method versus the transurethral method in pressure-flow studies in patients with benign prostatic hyperplasia. Methods: Twenty-three men with benign prostatic hyperplasia underwent both suprapubic and transurethral pressure-flow studies during a single session. Standard pressure-flow variables were recorded in all patients with both methods, enabling calculation of obstruction using commonly used grading systems, such as the urethral resistance algorithm, the Abrams-Griffith (AG) number and the Sch(a)fer linear nomogram. Results: There were statistically significant differences between the methods in the mean values of maximum flow rate (P<0.05), detrusor pressure at the maximum flow (P < 0.01), urethral resistance algorithm (P<0.01), AG number (P<0.01) and maximum cystic capacity (P<0.01). Of the men

  5. Critical review of lasers in benign prostatic hyperplasia (BPH)

    NARCIS (Netherlands)

    S. Gravas; A. Bachmann; O. Reich; C.G. Roehrborn; P.J. Gilling; J. de la Rosette

    2011-01-01

    Laser technology has been applied to treat LUTS secondary to BPH for > 15 years. Some of the early approaches failed to fulfil our expectations and have been abandoned, but technological advancements and growing clinical experience have produced more refined techniques and devices with clinical outc

  6. Protective effect of preserving bladder neck integrity on erectile function in patients undergoing plasmakinetic vaporization for benign prostatic hyperplasia%保存膀胱颈完整性在经尿道前列腺等离子电切术中对低龄患者勃起功能的影响

    Institute of Scientific and Technical Information of China (English)

    徐战平; 刘久敏; 郑祥光; 蒲小勇

    2014-01-01

    Objective To explore the clinical value of preserving the integrity of the bladder neck in plasmakinetic vaporization of the prostate (PKVP) in protecting the erectile function and improving the quality of life of patients with benign prostatic hyperplasia (BPH) below 60 years of age. Methods Thirty-two patients with BPH, with a mean age of 55.4 years (range 50-60 years), were enrolled the study to undergo PKVP with Gyrus bipolar systems, in which the transverse fiber muscle area of the bladder neck were carefully preserved. The erectile function and the quality of life of the patients were evaluated with the International Index of Erectile Function (IIEF)-5 and Quality of Life (QoL) before and after the operation. Retrograde ejaculation was also observed after the operation. Results In the 6-month follow-up, only 1 (3.13%) patient was found to have erectile dysfunction. Five patients (15.6%) reported retrograde ejaculation 3 months after the surgery, and only 3 patients (9.4%) had retrograde ejaculation at 6 months. Conclusion Preserving the bladder neck in PKVP may protect the erectile function with BPH below 60 years of age.%目的:探讨经尿道前列腺等离子电切术(PKVP)中保留膀胱颈完整性对低龄前列腺增生患者性功能及其生活质量的影响。方法32例低龄前列腺增生症患者,平均55.4岁(50~60岁)。采用Gyrus等离子系统行前列腺电切,术中注意保留膀胱颈横行纤维肌肉区。术前和术后采用勃起功能国际问卷(IIEF-5)和生活质量评分表(QoL)评价患者勃起功能和生活质量,同时观察随访患者有无逆行射精等。结果所有患者随访均超过6月,随访期间只有1例患者(3.13%)术后勃起功能异常;术后3个月5例患者(15.6%)出现逆行射精,术后6个月有3例(9.4%)仍有逆行射精。结论 PKVP术中注意保留膀胱颈,对低龄前列腺增生症患者术后勃起功能有保护作用。

  7. 进入不同治疗方案良性前列腺增生患者客观指标的数据分析%Data analysis of the objective observation parameters of benign prostatic hyperplasia patients accepting different treatment regimens

    Institute of Scientific and Technical Information of China (English)

    张耀光; 曾平; 王建业; 刘明; 万奔; 魏东; 邓庶民; 许进; 伍建业; 褚欣

    2008-01-01

    目的 了解进入观察等待、药物治疗和手术治疗3种治疗方案的良性前列腺增生患者的主要客观指标的具体数据,分析其对治疗方案选择的影响.方法 按照试验规定的纳入和排除标准,选择初诊的良性前列腺增生患者329例,按目前泌尿外科的实际诊疗状况,将患者列入观察等待(61例)、药物治疗(179例)和手术治疗(89例)3种治疗方案组,对入组患者的前列腺体积、血清前列腺特异性抗原(PSA)、最大尿流率、平均尿流率,排尿量、残余尿指数等进行观察.结果 观察等待、药物治疗和手术治疗3种治疗方案组患者的前列腺体积(ml)均数为33.0、40.1、65.5;最大尿流率(ml/s)均数为17.1、12.4、9.1;平均尿流率(ml/s)均数为9.9、7.3、4.2;排尿量(ml)均数为332、247、188.以上指标组间差异具有统计学意义.血清前列腺特异性抗原(ng/ml)均数为1.53、1.99、5.44;残余尿量(ml)均数为21、45、208.这2种指标手术治疗组与其他2组间差异具有统计学意义,而在药物治疗和观察等待组间差异无统计学意义.结论 前列腺体积、血清前列腺特异性抗原(PSA)、最大尿流率、平均尿流率、排尿量、残余尿是良性前列腺增生症患者选择治疗方案的重要影响因素.%Objective To observe different objective observation parameters of the benign prostatic hyperplasia(BPH)patients accepting different treatment strategies,and to further analyze the relationship of these factors with the treatment option.Methods Three hundred and twenty-nine BPH patients,aged 50-80,were assigned into 3 groups jointly decided by the physicians and patients based on the individual conditions and the patients'willingness:watchful waiting group(n=61),aged(63±8),drug treatment group(n=179),aged(68±7),and operation group(n=89),aged(71±6).The data of prostate volume,prostate specific antigen(PSA),maximum flow rate(Qmax),average flow rate,urinating volume

  8. Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer human prostate

    Directory of Open Access Journals (Sweden)

    Olmedilla Gabriel

    2010-01-01

    Full Text Available Abstract Background In this study was investigate IAPs in normal human prostate (NP, benign prostatic hyperplasia (BPH, prostatic intraepithelial neoplasia (PIN and prostatic carcinoma (PC, and their involvement in apoptosis/proliferation via NF-kB (TNF-α, IL-1 stimulation. Methods Immunohistochemical and Western blot analyses were performed in 10 samples of normal prostates, 35 samples of BPH, 27 samples diagnosis of PIN (with low-grade PIN or high-grade PIN and 95 samples of PC (with low, medium or high Gleason grades. Results In NP, cytoplasm of epithelial cells were positive to c-IAP1/2 (80% of samples, c-IAP-2 (60%, ILP (20%, XIAP (20%; negative to NAIP and survivin. In BPH, epithelial cells were immunostained to c-IAP1/2 (57.57%, c-IAP-2 (57.57%, ILP (66.6%, NAIP (60.6%, XIAP (27.27%, survivin (9.1%. Whereas low-grade PIN showed intermediate results between NP and BPH; results in high-grade PIN were similar to those found in PC. In PC, epithelial cells were immunostained to c-IAP1/2, c-IAP-2, ILP, NAIP, XIAP (no Gleason variation and survivin (increasing with Gleason. Conclusions IAPs could be involved in prostate disorder (BPH, PIN and PC development since might be provoke inhibition of apoptosis and subsequently cell proliferation. At the same time, different transduction pathway such as IL-1/NIK/NF-kB or TNF/NF-kB (NIK or p38 also promotes proliferation. Inhibitions of IAPs, IL-1α and TNFα might be a possible target for PC treatment since IAPs are the proteins that inhibited apoptosis (favour proliferation and IL-1α and TNFα would affect all the transduction pathway involucrate in the activation of transcription factors related to survival or proliferation (NF-kB, Elk-1 or ATF-2.

  9. Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate

    International Nuclear Information System (INIS)

    In this study was investigate IAPs in normal human prostate (NP), benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN) and prostatic carcinoma (PC), and their involvement in apoptosis/proliferation via NF-kB (TNF-α, IL-1) stimulation. Immunohistochemical and Western blot analyses were performed in 10 samples of normal prostates, 35 samples of BPH, 27 samples diagnosis of PIN (with low-grade PIN or high-grade PIN) and 95 samples of PC (with low, medium or high Gleason grades). In NP, cytoplasm of epithelial cells were positive to c-IAP1/2 (80% of samples), c-IAP-2 (60%), ILP (20%), XIAP (20%); negative to NAIP and survivin. In BPH, epithelial cells were immunostained to c-IAP1/2 (57.57%), c-IAP-2 (57.57%), ILP (66.6%), NAIP (60.6%), XIAP (27.27%), survivin (9.1%). Whereas low-grade PIN showed intermediate results between NP and BPH; results in high-grade PIN were similar to those found in PC. In PC, epithelial cells were immunostained to c-IAP1/2, c-IAP-2, ILP, NAIP, XIAP (no Gleason variation) and survivin (increasing with Gleason). IAPs could be involved in prostate disorder (BPH, PIN and PC) development since might be provoke inhibition of apoptosis and subsequently cell proliferation. At the same time, different transduction pathway such as IL-1/NIK/NF-kB or TNF/NF-kB (NIK or p38) also promotes proliferation. Inhibitions of IAPs, IL-1α and TNFα might be a possible target for PC treatment since IAPs are the proteins that inhibited apoptosis (favour proliferation) and IL-1α and TNFα would affect all the transduction pathway involucrate in the activation of transcription factors related to survival or proliferation (NF-kB, Elk-1 or ATF-2)

  10. Transurethral dividing vaporesection using the RevoLix 2 micron continuous wave laser for the treatment of benign prostatic hyperplasia%经尿道2 μm激光分割式汽化切除术治疗良性前列腺增生

    Institute of Scientific and Technical Information of China (English)

    杨勇; 孙东种; 张旭; 魏志涛; 许勇; 洪宝发

    2009-01-01

    Objective To report the method of transurethral"dividing vaporesection"of pros- tate in the management of benign prostatic hyperplasia using the RevoI.ix 70 W 2 micron continuous laser,and evaluate its safety and clinical effects. Methods From August 2007 to August 2008,1 1 0 patients with obstructive BPH were treated transurethraly under epidural or sacral anesthesia using the "dividing vaporesection"technique.by which the whole prostatic gland was divided into several leaves longitudaly,then resected transversely blocks by blocks.Mean prostatic volume was(59.9±22.8) ml.Pre- and postoperative data were evaluated in operating time,blood loss.collected prostatic speci- mens,catheter-time,hospitalization time,PSA,post voiding residual volume(PVR),urinary flow rate(Qmax),international prostatic symptom scores(IPSS),and quality of life(QOL).SPSS 15.0 software was used for data analysis. Results A1l cases were treated under epidural or sacral anes- thesia.Mean operation time was(46.6±16.8)rain.Mean blood loss was(38士8)ml during the oper- ation.Mean collected prostatic specimens were(1 1.0±3.5)g and could be easily flashed out of the bladder.Mean catheter time was(2.3±1.3)d.Mean hospitalization time was(4.2±1.6)d.All cases were followed up for 6 to 12 months.Mean PSA and PVR dropped from(3.8±0.9)ng/ml to(2.65±1.3)ng/ml and from(1 15.3±35.2)ml to(41.6±12.7)ml,respectively.Mean Qmax increased from (4.3±1.8)ml/s preoperatively to(14.5±3.6)ml/s postoperatively.IPSS and QOL-Score improved from 27.9±6.5 and 5.2±0.5 to 9.6±2.3 and 2.5±0.6,respectively(P<0.05).There were 2 ca- ses with secondary bleeding and recovered under conservative managements.Two cases of external u- retbral strictures were met and treated with urethral dilatation successfully.0nly 1 case of urinary in- continence was observed and recovered 6 months later. Conclusion The method of'dividing vapore- section'of the prostate using the 2 micron laser system is a rapid,effective and safe

  11. Acute colonic obstruction due to benign prostatic hypertrophy.

    LENUS (Irish Health Repository)

    Mac Giobuin, S

    2012-02-01

    A seventy two year old man presented to the Emergency Department with clinical features of colonic obstruction. Subsequent radiological investigations confirmed this impression and revealed the aetiology to be compression of the sigmoid colon against the sacrum by a massively distended urinary bladder. Chronic urinary retention due to benign prostatic hypertrophy is an extremely unusual cause of large bowel obstruction. Little in this patient\\'s clinical findings suggested this aetiology. We reviewed the literature in this area and highlight the benefits of CT scanning over contrast studies.

  12. 非那雄胺联合M受体拮抗剂治疗前列腺增生合并膀胱过度活动症的疗效%Effect of non finasteride combined with M receptor antagonists in the treatment of benign prostatic hyperplasia with overactive bladder

    Institute of Scientific and Technical Information of China (English)

    翁文锋; 范杨轶; 徐伟全

    2014-01-01

    目的:探讨和分析对前列腺增生合并膀胱过度活动症采取非那雄胺联合M受体拮抗剂治疗的临床疗效及价值。方法选取2012年1月~2013年6月接受治疗的前列腺增生合并膀胱过度活动症患者70例为研究对象,均给予非那雄胺联合M受体拮抗剂治疗,观察和对比患者治疗前后IPSS(国际前列腺症状评分)、OABSS(膀胱过度活动症评分)及尿急次数等变化情况。结果治疗后,患者的IPSS评分、OABSS评分均较治疗前明显降低,尿急次数、残余尿量、前列腺体积均较治疗前明显减少;治疗前后各项指标对比差异均有统计学意义(P<0.05)。结论临床上对前列腺增生合并膀胱过度活动症患者给予非那雄胺联合M受体拮抗剂治疗,能明显改善患者前列腺症状,减轻膀胱过度活动症,改善患者前列腺功能及提升生活质量。%Objective To investigate and analyze the hyperplasia of prostate and bladder hyperactive disorder take finasteride combined the clinical curative effect and value of M receptor antagonist treatment.Methods from January 2012 to June 2012 treated 70 cases of hyperplasia of prostate and bladder hyperactive disorder patients as the research object, all give finasteride combined M receptor antagonist treatment, observation and comparison before and after treatment in patients with IPSS(international prostate symptom score), OABSS bladder hyperactive disorder(score) and urgency number changes. ResultsAfter treatment, the patients of IPSS score, OABSS score was significantly decreased, the number of urgency, residual urine volume, prostate volume was significantly reduced the; Each index contrast differences before and after the treatment are statistically significant.Conclusion Clinical patients with hyperplasia of prostate and bladder hyperactive disorder give finasteride combined M receptor antagonist treatment, can significantly improve symptoms of prostate

  13. Negative control of epithelial cell proliferation by prostatic stroma

    NARCIS (Netherlands)

    A. Kooistra (Anko)

    1995-01-01

    textabstractProstatic diseases are rather frequently occurring disorders in the male population. Prostatic adenoma -better known as benign prostatic hyperplasia (BPH)- is the most common benign neoplasm in men. Prostate cancer is the most commonly diagnosed malignancy in men and second leading cause

  14. Alternative treatment of prostatic urethral obstruction secondary to benign prostatic hypertrophy

    International Nuclear Information System (INIS)

    Benign prostatic hypertrophy (BPH) produces symptoms that currently can only be treated surgically either by open or endoscopic prostatectomy. We have undertaken animal (1) and human studies to determine if invasive radiologic techniques utilizing balloon catheters could be applied to the treatment of this common ailment. We report a series of twelve patients treated by retrograde transurethral balloon catheter prostatic dilatation. The procedure is performed using topical anesthesia with a specially designed balloon catheter (Medi-Tech, Inc.). The procedure is done on an outpatient basis and is completed within approximately 15 minutes. Relatively long-term results have resulted in persistent relief of symptoms. No complications have been encountered. We anticipate that balloon dilatation of the prostatic urethra will have a major impact on the treatment of BPH based on the promising preliminary results. Transurethral resection of the prostate (TURP) is associated with moderate morbidity and significant cost which can be reduced by the proposed procedure. (orig.)

  15. 双倍剂量坦索罗辛对良性前列腺增生引起的下尿路症状的临床研究%Clinical study of double dose of Tamsulosin for lower urinary tract symp-toms caused by benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    徐海亮

    2015-01-01

    Objective To investigate the efficacy of double dose of Tamsulosin in the treatment of lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). Methods 64 patients associated with BPH caused by LUTS from June 2010 to June 2012 in Zhumadian Central Hospital were randomly divided into double-dose group (Tamsulosin 0.4 mg) and recommended dose group (Tamsulosin 0.2 mg) accoding to 1:1 ratio, with 32 cases in each group, entered 8 weeks of double-blind drug treatment. The efficacy and the clinical symptoms, international prostate symptom score (IPSS), quality of life (QOL), storage symptom scores (SSS), maximum flow rate (Qmax), residual volume (RV) and prostate volume changes were compared between the two groups after treatment for 8 weeks. Results The im-provement rate of clinical symptoms of the double-dose group was significantly higher than the recommended dose group, the difference was significant (87.5% v s 68.8%, P0.05). Conclusion Double dose of Tamsulosin can significantly improve subjective symptoms and Qmax of patients with BPH compared with the recommended dose, but it still needs large prospective randomized controlled trials to prove the safety and effectiveness of double dose of Tamsulosin for a long-term medication.%目的:探讨双倍剂量坦索罗辛对良性前列腺增生引起的下尿路症状的疗效。方法将2010年6月~2012年6月河南省驻马店市中心医院确诊的64例良性前列腺增生(BPH)伴下尿路症状(LUTS)患者按1:1的比例完全随机分配到双倍剂量组(坦索罗辛0.4 mg)和推荐剂量组(坦索罗辛0.2 mg)各32例,进入8周的双盲药物治疗期。比较两组治疗8周后临床症状的疗效以及两组治疗前后国际前列腺症状评分(IPSS)、生命质量评分(QOL)、储尿期症状评分(SSS)、最大尿流率(Qmax)、残余尿量(RV)及前列腺体积的变化情况。结果双倍剂量组的临床症状改善率明显高于推荐剂量组(87.5%比68.8%)(P<0

  16. Effects of Botulinum Toxin Type A on Cell Apoptosis in Rat Benign Prostatic Hyperplasia Model%A型肉毒毒素注射引起大鼠前列腺增生模型细胞凋亡的研究

    Institute of Scientific and Technical Information of China (English)

    杨雄; 杨栋; 侯腾; 马彦; 汪隆旺; 韩晓敏; 李兵; 陈朝晖

    2011-01-01

    目的:探讨A型肉毒毒素注射后前列腺的组织形态学变化.方法:建立SD大鼠前列腺增生模型,模型大鼠前列腺内分别注射不同剂量的A型肉毒毒素后,TUNEL检测前列腺细胞的凋亡,免疫组织化学技术检测对照组与10 U肉毒毒素注射组Bcl-2、Fas及Caspase-3的表达差异.结果:随着注射剂量的加大,大鼠前列腺体积及湿重出现明显下降,细胞凋亡增加.相比对照组,10U肉毒毒素注射组Bcl-2的表达下调而Fas及Caspase-3的表达上调.结论:A型肉毒毒素能有效的缩小前列腺体积,引起前列腺细胞的凋亡.%Objective:To investigate the morphological changes of rat prostate after the injection of Botulinum toxin type A. Methods: We established prostatic hyperplasia model of SD rats and injected different doses of botulinum toxin type A into the prostates of BPH rat model. Prostatic cells apoptosis was detected by TUNEL assay.The expression of Bcl-2、Fas, and Caspase-3 were evaluated as well. Results:In the botulinum toxin type A injection group, it was observed that the volume and wet weight of rat prostates were decreased, that cell apoptosis was increased. The expressions of Bcl-2, Fas, and Caspase-3 in 10U botulinum toxin injection group were different compared to the control group. Conclusions: Botulinum toxin type A can diminish the volume and wet weight of rat prostate and induce apoptosis of prostatic cells.

  17. Ultrasonographic Findings of the Prostatic Disease : Comparative Analysis of the Benign and Malignant Nodules

    Energy Technology Data Exchange (ETDEWEB)

    Song, Yun Gyu; Kim, Ji Yang; Lee, Su Han; Kong, Su Jin; Sung, Young Soon; Kwon, Jae Soo [Masan Samsung General Hospital, Masan (Korea, Republic of)

    1996-06-15

    We evaluated the characteristics of the benign and malignant nodules on transrectal ultrasound in diagnosis of prostatic disease. Histologic examination of the trans perineal prostatic biopsy of the total 47 cases resulted in 19 cases of BPH, 8 cases of prostatic cancer, and 20 cases of normal prostatic tissue group. The hypoechoic mass in peripheral zone on TRUS had high possibility of prostatic carcinoma and the isoechoic or mixed echogenic mass in central gland had high possibility of benign lesion. Hypoechoic haloes around nodules and cysts were noted in BPH and normal prostatic tissue group, that were compatible with benign lesion. The mean value of PSA was 12.0 ng/ ml in BPH, 8.5 ng / ml in normal prostatic tissue group, and 65.6 ng / ml in prostatic cancer, which was very high in prostatic cancer. Between BPH and normal prostatic tissue group, there was no demonstrable difference in location of nodule, pattern of calcification, and echogenicity of the nodules on TRUS. The size of prostatic gland was relatively smaller and mean value of PSA was lower in normal prostatic tissue group, compared with in BPH. In conclusion, the location of the nodules and PSA value are considered to be important in differentiation of the benign and malignant prostatic nodules

  18. Efficacy and safety of tamsulosin on treating benign prostatic hyperplasia:a systematic review and updated meta -analysis%盐酸坦索罗辛治疗前列腺增生症的系统回顾及更新荟萃分析

    Institute of Scientific and Technical Information of China (English)

    安琪; 刘德忠; 陈一然; Russell Smith; 刘昂; 邹练

    2015-01-01

    目的:利用 Meta 分析系统观察盐酸坦索罗辛治疗前列腺增生症的疗效。方法:检索 Co-chrane 图书馆,Embase 数据库,Pubmed 数据库,中国生物医学文献数据库,CNKI 数据库,VIP 数据库,万方数据库,纳入盐酸坦索罗辛治疗前列腺增生症的随机对照治疗(RCT),并进行方法学质量评价,采用 Rev-Man5.2软件进行统计分析,并发表偏倚评估和敏感性分析。结果:最终有10篇 RCT 文献纳入本项研究, Meta 分析结果显示盐酸坦索罗辛在 IPSS /Boyarsky symptom score,Qmax /MFR 以及 QoL score[SMD =-0.34,P <0.00001;WMD =1.10,P <0.00001;WMD =-0.39,P =0.0007]效果方面明显优于安慰剂组(P<0.01),但该药的某些副作用较安慰剂相比亦有显著差别(RR =1.12,P <0.0001)。结论:盐酸坦索罗辛在治疗前列腺增生症中疗效确切,是治疗前列腺增生症的有效方法,但需注意其潜在的副作用。%To systematically update and review the efficacy and safety of different dosages of tamsulosin treatments on lower urinary tract symptoms (LUTS)in male benign prostatic hyperplasia (BPH)patients to provide more reliable evidence for the use of tamsulosin.Methods:Relevant paper in PubMed (1 966 - May 201 4),Em-base (1 974 - May 201 4),the Cochrane Library Database (201 4,Issue 5)and China National Knowledge Infra-structure (CNKI)(1 995 -201 4)were reviewed.The assessed outcome measures included international Prostate Symptom Score (IPSS)/Boyarsky symptom score,quality of life (QOL)score,maximum flow rate (MFR/Qmax ) and AEs (adverse events).Two authors independently assessed the study quality and extracted data.All data were analyzed through RevMan 5.2.The meta -analysis included ten randomized controlled trials and the study durations ranged from 4 weeks to 1 2 weeks.Results:The pooled results showed that the change in the tamsulosin group was

  19. 北京地区46家医院2008-2010年抗良性前列腺增生药利用分析%Analysis of the Utilization of Drugs against Benign Prostatic Hyperplasia in 46 Hospitals of Beijing Area from 2008 to 2010

    Institute of Scientific and Technical Information of China (English)

    任伟; 白利; 张石革; 甄健存

    2012-01-01

    OBJECTIVE: To evaluate the utilization of the drugs against benign prostatic hyperplasia (BPH) in hospitals of Beijing area. METHODS: By retrospective study, the utilization of the drugs against BPH in 46 hospitals of Beijing area during the period of 2008 -2010 was analyzed statistically in respect of DDDs, DDC, the rank of consumption sum (B) and the rank of DDDs (A), etc. RESULTS: The average annual growth rate of consumption sum of the drags against BPH in hospitals at this area was about 13.82%. Finasteride, tamsulosin, doxazosin, terazosin, prostate took the first five places on the lists of consumption sum and DDDs of the drugs against BPH over past three years, with an average annual growth rate of consumption sum of 17.45%, 17.35%, 9.69%, 9.43%, 16.90%, respectively. The total market share for the drugs ranking of six to ten decreased from 11.12% in 2008 to 9.04% in 2010. Amount and DDDs of anti-androgenic hormone drugs and a, receptor blocking reached 98.97% and 97.14% in 2010. DDC changed little in three years, and the top two drags in the list of market share were finasteride and tamsulosin with B/A of 1. CONCLUSIONS: The consumption sum of the drags against BPH in Beijing area shows an obvious increase trend. Anti-androgenic hormone drugs and ai receptor blocking were mainly used in the clinic, and the combination of above two drugs could make synergis-tic action with the increase of treatment cost. Herbal medicines have good therapeutic effect and relatively low price without significant adverse reactions. More research efforts should be made to further promote the clinical application of herbal medicines.%目的:评价北京地区医院抗良性前列腺增生(BPH)药的利用情况.方法:采用回顾性方法,对北京地区46家医院2008-2010年抗BPH药的用药频度(DDDs)、日均费用(DDC)及药品销售金额排序(B)/DDDs排序(A)值等进行统计、分析.结果:该地区医院抗BPH药销售金额年均增长率约为13.82%;单药

  20. Prostate resection - minimally invasive - discharge

    Science.gov (United States)

    ... a burning sensation when you urinate, fever, or chills). Your urine stream is not as strong, or ... pubmed/23234640 . Roehrborn CG. Benign prostatic hyperplasia: Etiology, pathophysiology, epidemiology, and natural history. In: Wein AJ, Kavoussi ...

  1. Effects of retrospective quality control on pressure-flow data with computer-based urodynamic systems from men with benign prostatic hyperplasia%对良性前列腺增生患者计算机化尿动力仪获取的压力-流率测定数据的回顾性质量控制及效果

    Institute of Scientific and Technical Information of China (English)

    L. M. Liao; W. Schaefer

    2007-01-01

    Aim: To evaluate the effects of retrospective quality control on pressure-flow data with computer-based urodynamic systems from men with benign prostatic hyperplasia (BPH). Methods: A total of 582 traces of pressure-flow study from 181 men with BPH was included in the study. For each trace, maximum urinary flow rate (Qmax) and detrusor pressure at Qmax (pdet.Qmax) were, respectively, read from manually smoothed and corrected uroflow and detrusor pressure curves from the computer print-outs. Obstruction coefficient, International Continence Society (ICS) and Schaefer nomograms were used to detect urethral resistance and to diagnose obstruction. The results obtained by manual reading were compared with those from computer-based systems. Results: After manual correction,Qmax underwent a consistently significant decrease by 1.2 mL/s on average (P < 0.001), and had a change range of 0.5-10.4 mL/s. However, pdet. Qmax underwent inconsistently intra-individual changes after correction. The obstruction coefficient increased significantly, by an average of 0.07 (P < 0.05). Using the ICS nomogram, the percentage of obstruction increased from 69.8% to 73.9%, and of the non-obstruction decreased from 8.8% to 5.3% (P < 0.05).There were 11% of traces that changed the classifications using the ICS nomogram, and 28.9% that changed the grades for the Schaefer nomogram. Conclusion: Systematically significant differences in parameters from pressure-flow study between manual readings and computer recordings were demonstrated. Manual correction resulted in a consistently lower Qmax, a higher urethral resistance, and an aggravating obstruction. Manual readings can correct considerable false diagnoses for obstruction. Retrospective quality control of pressure-flow data with computer-based systems is necessary.%目的:评估良性前列腺增生(BPH)患者计算机化尿动力仪压力-流率测定数据的回顾性质量控制效果.方法:来自181例BPH患者的582次压力-流

  2. 以Orem自理理论为框架的护理干预对前列腺增生患者自护能力的影响%Effect of Orem self-care theory application on the self-care agency of patients with benign prostatic hyperplasia

    Institute of Scientific and Technical Information of China (English)

    张金华; 李素青; 刘丽

    2012-01-01

    Objective To explore the effect of the nursing intervention based on Orem self-care theory on the self-care ability of perioperative patients with benign prostatic hyperplasia (BPH).Methods Convenient sampling method was used.Totals of 128 cases of BPH patients were recruited and randomly divided into control group and experimental group.The control group received routine nursing and health education,while the experimental group received the nursing intervention that based on Orem self-care theory.The Exercise of Self-Care Agency Scale was used to measure the self-care ability of patients,and the incidence of bladder spasm of two group was observed in post operation.Results There was significantly difference between experimental group and control group in the score of the dimension of self-concept [(131.62±15.73) vs ( 109.21±19.89)],the sense of self responsibility [ (28.31±5.14) vs (21.53 ±7.18)],self-management skills [ (35.15 ±2.89) vs (26.19 ±5.36) ] and health knowledge level [ (45.27 ± 3.15) vs (38.17 ± 4.10) ] (t =4.316,-7.241,-8.676,-9.140,respectively; P < 0.05 or P < 0.001).The incidence of bladder spasm of experimental group (9.4% ) was significantly lower than that of control group 23.4% ( x2 =4.743,P <0.05 ).Conclusions The nursing intervention based on Orem self-care theory improve the self-care agency of patients with BPH,reduce the incidence of bladder spasm,improve their subjective euphoria and promote their recovery.%目的 探讨以Orem自理理论为框架的护理干预对前列腺增生(BPH)患者围手术期自护能力的影响.方法 采用方便取样方法选取BPH患者128例,随机分为对照组和观察组各64例.对照组患者接受常规护理和健康教育,观察组在常规护理的基础上接受以Orem自理理论为框架的护理干预.采用自我护理能力测定量表(ESCA)评价患者的自护能力并比较两组患者术后膀胱痉挛的发生率.结果 观察组患者自我护理能力、自护

  3. Holmium laser enucleation of the prostate hyperplasia: technical aspects

    Directory of Open Access Journals (Sweden)

    P. V. Glybochko

    2015-01-01

    Full Text Available Holmium laser enucleation of the prostate (HoLEP was first described by doctor P.J. Gilling et al. from New Zealand in 1996. The operation involves anatomical dissection of the prostatic tissue off the surgical capsule using a high-powered holmium laser followed by intravesical morsellation. The objective of this article is to explain the techniques for HoLEP.

  4. Molecular markers for prostate cancer.

    NARCIS (Netherlands)

    Reynolds, M.A.; Kastury, K.; Groskopf, J.; Schalken, J.A.; Rittenhouse, H.G.

    2007-01-01

    Serum PSA testing has been used for over 20 years as an aid in the diagnosis and management of prostate cancer. Although highly sensitive, it suffers from a lack of specificity, showing elevated serum levels in a variety of other conditions including prostatitis, benign prostate hyperplasia, and non

  5. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia

    OpenAIRE

    Sakata Koichi; Morita Tatsuo

    2012-01-01

    Abstract Background To assess the ejaculatory disorder caused by silodosin in the prostatic hyperplasia patients who carry out sexual actions (sexual intercourse, masturbation). Method The subjects of this study were 91 patients who had been clinically diagnosed to have LUTS/BPH at this hospital, who were administered silodosin at 4 mg twice a day, and who gave response to a questionnaire survey related to ejaculatory disorder. Sexual intercourse and masturbation were regarded as sexual actio...

  6. 钬激光前列腺剜除术治疗良性前列腺增生的自学学习曲线%Analysis of Self-taught Learning Curve of Holmium Laser Enucleation of Prostate for Benign Prostatic Hyperplasia

    Institute of Scientific and Technical Information of China (English)

    刘可; 肖春雷; 马潞林

    2016-01-01

    目的:探讨钬激光前列腺剜除术( holmium laser enucleation of prostate,HoLEP)的手术效率、安全性及学习曲线。方法回顾性分析2014年6月~2015年6月一位具有500例以上经尿道前列腺电切术( transurethral resection of prostate, TURP)等腔内手术经验的泌尿外科医师采用钬激光前列腺剜除术治疗的第1~45例良性前列腺增生患者临床资料。按时间顺序分为A、B、C三组,每组15例。3组年龄、前列腺体积、前列腺特异抗原( prostate specific antigen,PSA)差异无显著性( P>0.05)。比较3组手术时间、术后第1天血红蛋白下降值及留置尿管时间。用前列腺体积除以手术时间计算剜除效率。结果3组手术剜除效率分别为(0.34±0.14)、(0.36±0.16)、(0.49±0.18)ml/min,组间比较有显著差异(F=4.025,P=0.025),C组较A组及B组剜除效率明显提高(P=0.013、0.028)。3组手术时间、血红蛋白下降值、保留尿管时间、术中输血例数、并发症例数差异无显著性(P>0.05)。手术并发症包括中转TURP 2例,术后发热超过38℃5例,术后压力性尿失禁4例,膀胱损伤1例,尿道狭窄1例,术后活动性出血1例。 HoLEP自学学习曲线为30例。结论对于有腔内手术经验的泌尿外科医师,自学HoLEP需经过30例手术实践,可使剜除效率显著提高。在学习曲线早期阶段应选取前列腺体积0. 05). Clinical data including operative time, hemoglobin decrease, and catheterization duration were compared among the 3 groups. The efficiency for enucleation was calculated as prostatic volume divided by operation time. Results The average enucleation efficiency of 3 groups was 0. 34 ± 0. 14, 0. 36 ± 0. 16, and 0. 49 ± 0. 18 ml/min, respectively, with a significant difference among the 3 groups (F =4. 025, P =0. 025). The group C obtained significantly improved efficiency as comparing with the group A and group B (P=0. 013 and 0. 028, respectively). No significant difference was

  7. Partial association of restriction polymorphism of the ligand binding domain of human androgen receptor in prostate cancer

    Directory of Open Access Journals (Sweden)

    Mohamed Hessien

    2016-04-01

    Conclusion: Our results indicate that the loss of the restriction integrity in the C-terminal part (exons: 7 and 8 of the LBD is associated with the progression of benign prostatic hyperplasia to prostate cancer.

  8. Prepubertal exposure to bisphenol-A induces ERα upregulation and hyperplasia in adult gerbil female prostate.

    Science.gov (United States)

    Campos, Mônica S; Galvão, André L V; Rodríguez, Daniel A O; Biancardi, Manoel F; Marques, Mara R; Vilamaior, Patrícia S L; Santos, Fernanda C A; Taboga, Sebastião R

    2015-06-01

    Prostate physiology is highly dependent on oestrogenic and androgenic homeostasis. Interferences in this equilibrium, especially in early periods of life, may disrupt the prostate and increase the susceptibility to the development of diseases with ageing. Taking this into account, and considering the increase of environmental chemicals with endocrine-disrupting potential such as bisphenol-A (BPA), this study aimed to evaluate the prostates of adult female gerbils exposed to BPA and BPA plus testosterone from pubertal to adult periods. Morphological, stereological and chemical analyses revealed that long-term BPA exposure, even in environmental dosages, increases the proliferative status of the prostate, increases the number of ERα-positive stromal cells and elicits the development of prostatic hyperplasia in adult female gerbils. Moreover, we also observed that the association with testosterone did not increase the proliferative status of the gland, which shows that low levels of BPA are enough to cause an oestrogenic disruption of the prostate in young adults. This evidence suggests that this oestrogenic endocrine disruptor may increase the susceptibility to prostatic disorders with ageing. PMID:26098999

  9. Transurethral resection of the prostate - discharge

    Science.gov (United States)

    ... infection (burning sensation when you urinate, fever, or chills) Your urine stream is not as strong, or ... chap 93. Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. In: Wein AJ, Kavoussi ...

  10. 中国泌尿外科医师管理良性前列腺增生患者实际操作模式的调查研究%Survey of the management of benign prostatic hyperplasia by Chinese urologists

    Institute of Scientific and Technical Information of China (English)

    王少刚; 叶章群; 许克新; 毕建斌; 许传亮

    2015-01-01

    Objective The aim of this study was to investigate the understanding and application of the Chinese Urological Association (CUA) guidelines of Benign Prostatic Hyperplasia (BPH) (2011 edition) in Chinese urologists.Methods The survey was conducted between September,2012 and November,2012.Questionnaires designed by the CUA were used to investigate the understanding and management of BPH in CUA-registered urologists,who work in clinic for at least 20 hours per week.Data,including general characteristics of the urologists,understanding of BPH,BPH diagnosing in suspected patients,BPH treatment,and follow up,were collected.7500 questionnaires were distributed.A total of 4 897 participants responded (response rate 70.0%).86 questionnaires with incomplete information and 37 duplicate questionnaires were excluded.And 4 774 validate questionnaires were included for the analysis,finally.The mean age of those investigated urologists was (39.9±9.2) years old.Among them,3 802 (81.0%) urologists work in the tertiary hospital,878 (18.7%) urologists work in the secondary hospital and 12 (0.3%) urologists work in the other hospital.The district distribution in those urologists included 455 (9.6%) in northeast china,812 (17.1%) in north china,1 696 (35.6%) in east china,869 (18.2%) in south china,634 (13.3%) in southwest china,295 (6.2%) in northwest china.1 835 (43.8%) urologists have less than ten years working experience.1 505 (35.9%) urologists have 11 to 20 years working experience.The 21 to 20 years working experience was reported in 705 (16.8%) urologist.And the other 149 (3.5%) urologists have working experience more than 31 years.The educational background in this study included doctor degree in 732 (15.8%) urologists,master degree in 1 729 (37.4%) urologists,bachelor degree in 2 067 (44.7%)urologists and college degree in 101 (2.1%) urologists.The position composition included 834 (18.2) directors,1 371 (30.0%) deputy directors,1 605

  11. Circulating Prostate Cells Found in Men with Benign Prostate Disease Are P504S Negative: Clinical Implications

    Directory of Open Access Journals (Sweden)

    Nigel P. Murray

    2013-01-01

    Full Text Available Introduction. Developments in immunological and quantitative real-time PCR-based analysis have enabled the detection, enumeration, and characterization of circulating tumor cells (CTCs. It is assumed that the detection of CTCs is associated with cancer, based on the finding that CTCs can be detected in all major cancer and not in healthy subjects or those with benign disease. Methods and Patients. Consecutive men, with suspicion of prostate cancer, had blood samples taken before prostate biopsy; mononuclear cells were obtained using differential gel centrifugation and CPCs detecting using anti-PSA immunocytochemistry. Positive samples underwent further classification with anti-P504S. Results. 329 men underwent prostate biopsy; of these men 83 underwent a second biopsy and 44 a third one. Of those with a biopsy negative for cancer, 19/226 (8.4% had CPCs PSA (+ P504S (− detected at first biopsy, 6/74 (8.1% at second biopsy, and 5/33 (15.2% at third biopsy. Men with cancer-positive biopsies did not have PSA (+ P504S (− CPCs detected. These benign cells were associated with chronic prostatitis. Conclusions. Patients with chronic prostatitis may have circulating prostate cells detected in blood, which do not express the enzyme P504S and should be thought of as benign in nature.

  12. Prostatic hyperplasia and congenital bladder diverticulum. A case report

    Directory of Open Access Journals (Sweden)

    Ciro Esteban Delgado Cantero

    2011-04-01

    Full Text Available Congenital diverticula in adults are typically associated with bladder outlet obstruction and their manifestation is most commonly by urinary sepsis. The case of a 69 years old male patient who attended consultation because of nocturia, thin urine stream, pushing, urgent urination and sense of incomplete emptying is presented. Through rectal examination grade I prostate with discrete grade I asymmetry consistent with right nodular lobe that did not rise to the surface was detected. During the physical examination tumor mass was palpated in the lower abdomen region. It was painless. Ultrasound and cystography showed giant bladder diverticulum with a narrow neck into the right lateral wall of the bladder. Cystoscopy confirmed the diagnosis and the patient was treated trough surgery. Histology revealed mucosal layers and muscle and adventitia in the wall, thus confirming congenital origin. Recovering after surgery was satisfactor.

  13. Benign or Malignant? Two Case Reports of Gigantic Prostatic Cyst

    Directory of Open Access Journals (Sweden)

    Jiang Yu

    2016-09-01

    Full Text Available A 60-year-old male with a huge prostate cyst presented with obstruction symptom of urethra and intestinal tract. Complete excision of the cystic prostate failed as a result of the strong adherence and twice operations history, but we confirmed prostate adenocarcinoma and relieved his obstruction symptom. Case 2 was a 77-year-old male with an 8 cm cyst of which biopsy showed prostate cancer in local hospital. He was admitted 18 months later because of intestinal obstruction. Radical resection had a satisfied result of obstruction symptom and PSA. Here we summarized malignant characteristics of cystic lesions in prostate or surrounding structures and management.

  14. Prooxidant-antioxidant balance in the prostate and blood of rats with sulpyride[corrected]-induced prostatic hyperplasia corrected with prostatilen.

    Science.gov (United States)

    Belostotskaya, L I; Gomon, O N; Nikitchenko, Yu V; Chaika, L A; Bondar, V V; Dzyuba, V N

    2005-03-01

    We studied the effects of 30-day injections of sulpyride and treatment with Prostatilen on the development of prostatic hyperplasia and LPO in rats. Sulpyride induced proliferation of lateral lobes, increased the content of lipid hydroperoxides and glutathione peroxidase activity in the gland; in the blood this preparation increased lipid hydroperoxide concentration and decreased glutathione peroxidase and total antioxidant activity. Prostatilen prevented the development of hyperplasia and normalized the prooxidant-antioxidant balance in tissues, except total antioxidant activity of the blood.

  15. TRANSURETHRAL RADIOFREQUENCY HEATING OR THERMOTHERAPY FOR BENIGN PROSTATIC HYPERTROPHY - A PROSPECTIVE TRIAL ON 65 CONSECUTIVE CASES

    NARCIS (Netherlands)

    MEIER, AHP; WEIL, EHJ; VANDOORN, ESCV; VERHAEGH, GTCM; JANKNEGT, RA

    1992-01-01

    65 consecutive cases with symptomatic benign prostate hypertrophy were treated with transurethral radiowave thermotherapy (TURF) using the Thermex-II at a temperature of 44.5-degrees-C. We report uroflowmetry and symptom scores after a follow-up of 6 months. The mean age was 63 years, the mean maxim

  16. Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate.

    Science.gov (United States)

    Dueregger, Andrea; Schöpf, Bernd; Eder, Theresa; Höfer, Julia; Gnaiger, Erich; Aufinger, Astrid; Kenner, Lukas; Perktold, Bernhard; Ramoner, Reinhold; Klocker, Helmut; Eder, Iris E

    2015-01-01

    Tumor cells adapt via metabolic reprogramming to meet elevated energy demands due to continuous proliferation, for example by switching to alternative energy sources. Nutrients such as glucose, fatty acids, ketone bodies and amino acids may be utilized as preferred substrates to fulfill increased energy requirements. In this study we investigated the metabolic characteristics of benign and cancer cells of the prostate with respect to their utilization of medium chain (MCTs) and long chain triglycerides (LCTs) under standard and glucose-starved culture conditions by assessing cell viability, glycolytic activity, mitochondrial respiration, the expression of genes encoding key metabolic enzymes as well as mitochondrial mass and mtDNA content. We report that BE prostate cells (RWPE-1) have a higher competence to utilize fatty acids as energy source than PCa cells (LNCaP, ABL, PC3) as shown not only by increased cell viability upon fatty acid supplementation but also by an increased ß-oxidation of fatty acids, although the base-line respiration was 2-fold higher in prostate cancer cells. Moreover, BE RWPE-1 cells were found to compensate for glucose starvation in the presence of fatty acids. Of notice, these findings were confirmed in vivo by showing that PCa tissue has a lower capacity in oxidizing fatty acids than benign prostate. Collectively, these metabolic differences between benign and prostate cancer cells and especially their differential utilization of fatty acids could be exploited to establish novel diagnostic and therapeutic strategies. PMID:26285134

  17. Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate.

    Directory of Open Access Journals (Sweden)

    Andrea Dueregger

    Full Text Available Tumor cells adapt via metabolic reprogramming to meet elevated energy demands due to continuous proliferation, for example by switching to alternative energy sources. Nutrients such as glucose, fatty acids, ketone bodies and amino acids may be utilized as preferred substrates to fulfill increased energy requirements. In this study we investigated the metabolic characteristics of benign and cancer cells of the prostate with respect to their utilization of medium chain (MCTs and long chain triglycerides (LCTs under standard and glucose-starved culture conditions by assessing cell viability, glycolytic activity, mitochondrial respiration, the expression of genes encoding key metabolic enzymes as well as mitochondrial mass and mtDNA content. We report that BE prostate cells (RWPE-1 have a higher competence to utilize fatty acids as energy source than PCa cells (LNCaP, ABL, PC3 as shown not only by increased cell viability upon fatty acid supplementation but also by an increased ß-oxidation of fatty acids, although the base-line respiration was 2-fold higher in prostate cancer cells. Moreover, BE RWPE-1 cells were found to compensate for glucose starvation in the presence of fatty acids. Of notice, these findings were confirmed in vivo by showing that PCa tissue has a lower capacity in oxidizing fatty acids than benign prostate. Collectively, these metabolic differences between benign and prostate cancer cells and especially their differential utilization of fatty acids could be exploited to establish novel diagnostic and therapeutic strategies.

  18. Potassium channels in prostate and colonic cancer

    OpenAIRE

    Ousingsawat, Jiraporn

    2007-01-01

    Large conductance Ca2+-activated K+ channels in human prostate cancer The KCNMA1 gene encoding the alpha-subunit of BK channels is amplified and BK channel expression is enhanced in late-stage, metastatic and hormone-refractory human prostate cancer tissues, whereas benign prostate tissues show only a weak expression of BK channels. PC-3 hormone-insensitive prostate cancer cells, but not hormone-sensitive prostate cancer cells (LNCaP) and benign prostate hyperplasia cells (BPH-1), show an ...

  19. Detection of Xenotropic Murine Leukemia Virus-Related Virus in Prostate Biopsy Samples

    International Nuclear Information System (INIS)

    Objective: To determine the association of Xenotropic murine leukemia virus related virus (XMRV) infection with prostate cancer and compare it with benign prostate hyperplasia. Study Design: Case control study. Place and Duration of Study: Department of Histopathology and Molecular Pathology, Dow University of Health Sciences, Karachi, from January 2009 to December 2012. Methodology: XMRV was screened in 50 prostate cancer and 50 benign prostatic hyperplasia biopsies using conventional end-point PCR. Other studied variables were family history of prostate cancer, patients age and Gleason score. Results: XMRV was detected in 4 (8%) of the 50 prostate cancer biopsy specimens compared to none in biopsies with benign prostatic hyperplasia. However, there was no significant statistical association of XMRV infection with the other variables. Conclusion: A low frequency of XMRV infection was found in this case-control study. Men, who harbor XMRV infection, may be at increased risk of prostate cancer but this needs to be investigated further at a larger scale. (author)

  20. Hepatic Focal Nodular Hyperplasia: A Benign Incidentaloma or a Marker of Serious Hepatic Disease?

    OpenAIRE

    G. Muguti; Tait, N; Richardson, A; Little, J. M.

    1992-01-01

    Amongst 17 patients with hepatic focal nodular hyperplasia (FNH) encountered at Westmead Hospital between 1981 and 1990, FNH was found in association with hepatocellular carcinoma (HCC) in three (3/ 17), one male and two females, one of whom also had peliosis and an hepatic adenoma. FNH was also found in association with other conditions which may affect hepatic function, structure or circulation, including chronic obstructive airways disease (2), congestive cardiomyopathy (1), ch...

  1. 前列腺增生症术后排尿困难的原因及预防%Causes and prevention of dysuria after hyperplasia of prostate operation

    Institute of Scientific and Technical Information of China (English)

    周小川; 刘亮; 潘丽娜

    2002-01-01

    Objective To investigate cause and prevention of dysuria after hyperplasia of prostate operation. Methods To analyze 66 cases of dysuria after hyperplasia of prostate operation retrospectively. Result The most common reasons to dysuria are orderly stenosis of bladder neck; inflammatory edema of bladder neck; urethral stricture; rehyperplasia of remained prostate tissue; neruogenic bladder; prominence of ureteral crest; clot obstruction. Conclusion Prevention of dysuria after hyperplasia of prostate operation consists in preoperative satisfied diagnosis and correct treatment in operation and after operation.

  2. Extensive prostatic calculi in alkaptonuria: An unusual manifestation of rare disease

    Directory of Open Access Journals (Sweden)

    Gaurav Sali

    2015-07-01

    Full Text Available Extensive prostatic calculi in a young man should always elicit the suspicion of alkaptonuria. Although prostatic calculi are seen in chronic prostatitis, chronic pelvic pain syndrome and benign prostate hyperplasia, none of these have prostatic calculi or calcification as extensive as in alkaptonuria. A 36 years young man who had severed obstructive lower urinary tract symptoms with extensive prostatic calculi was found to be alkaptonuric on further evaluation.

  3. Extensive prostatic calculi in alkaptonuria: An unusual manifestation of rare disease

    OpenAIRE

    Gaurav Sali; Appu Thomas; Ginil Kumar; Balagopalan Nair; Kalvampara Sanjeevan; Georgie Mathew; Kannan Nair

    2015-01-01

    Extensive prostatic calculi in a young man should always elicit the suspicion of alkaptonuria. Although prostatic calculi are seen in chronic prostatitis, chronic pelvic pain syndrome and benign prostate hyperplasia, none of these have prostatic calculi or calcification as extensive as in alkaptonuria. A 36 years young man who had severed obstructive lower urinary tract symptoms with extensive prostatic calculi was found to be alkaptonuric on further evaluation.

  4. Prazolin as a treatment for benign prostatic hypertrophy: a study in a tertiary care centre

    OpenAIRE

    Donepudi Pavan Kumar; K. Ravishankar

    2016-01-01

    Background: Benign prostatic hypertrophy (BPH) is one of the most common disorders effecting elderly men resulting in lower urinary tract symptoms (LUTS), including urinary frequency, retention, nocturia, intermittent force of the urinary stream, sensation of incomplete bladder emptying etc. The medical treatment preferred of late is with alpha-1 blockers or 5-alpha-reductase inhibitors or anti androgens. Prazosin, an older alpha-1 adrenergic blocker is considered a very useful drug in the tr...

  5. 经尿道前列腺等离子腔内剜除术对良性前列腺增生患者性功能影响的前瞻性研究%Transurethral enucleation of plasma chamber of benign prostatic hyperplasia on sexual function in patients with prospective study

    Institute of Scientific and Technical Information of China (English)

    何国伟; 刘春晓; 尹杰; 麦能斌; 陈向新; 林靖波; 麦源

    2010-01-01

    Objective To compare transurethral enucleation of plasma chamber(TUERP)plasma and tran-surethral resection of the prostate(PKRP) treatment efficacy,security and the impact on sexual function.Methods 80 cases of BPH patients were randomly divided into two groups,TUERP and PKRP.Follow-up for 12 months,compared two groups maximum urinary flow rate(Qmax),residual urine volume(PVR),serum prostate-specific antigen(PSA) level,prostate volume(PV),international prostate symptom score(IPSS),quality of life score(QOL),the bladder prostate prominent(IPP)and other indicators and erectile dysfunction and retrograde ejaculation changing circum-stances were compared.Results In the weight of prostate surgery there were significant differences,in which removal of the weight of TUERP group significantly higher than PKRP group.After 12 months,32 cases of TUERP patients and 31 patients of PKRP group completed follow-up.After 1,3,6,12 months,Qmax,PVR,IPSS,QOL improved than that before surgery.Two groups were compared after a month,and there were significant differences in prostate volume,which TU/ERP group was significantly smaller than PKRP group.After3 months in the prostate volume and residual U-rine volume there were significant differences,both TUERP group Was significantly smaller than PKRP group.After 6 months and 12 months in the prostate volume,residual urine volume and there were significant differences in PSA,both TUERP group was significantly smaller than PKRP group.ED,and retrograde ejaculation occured after the rate of two between the two groups was no significant difference.Conclusion Transurethral enueleation of plasma chamber on sexual function in patients,but through the appropriate personalized treatment,sexual function in some patients was recoverable.%目的 比较经尿道前列腺等离子腔内剜除术(TUERP)与经尿道前列腺等离子切除术(PKRP)治疗良性前列腺增生(BPH)的疗效、安全性以及对性功能的影响.方法 80例BPH患者随机

  6. Ultrasonographic and cytopathologic aspects of prostate disease in 52 dogs

    Directory of Open Access Journals (Sweden)

    Antonio Carlos Cunha Lacreta Junior

    2012-03-01

    Full Text Available This study evaluated 52 dogs, which were male, intact, varied in age, of pure or mixed breed, with clinical signs suggestive of prostatic disease. Each individual underwent an ultrasound examination and fine-needle aspiration biopsy of the prostate gland for cytological evaluation. Benign prostatic hyperplasia (BPH was the most frequent prostatic disease, followed by cystic benign prostatic hyperplasia, bacterial prostatitis, abscesses, cysts, adenocarcinoma, nonbacterial prostatitis and paraprostatic cysts. The highest frequencies of prostate disorder were found in mixed breeds, followed by poodles and German shepherds. Ultrasound examination allowed the determination of prostate size, as well as the visualization of the diseases affecting the gland, and was effective in guiding aspiration biopsy. The cytological evaluation of the gland, especially when associated with changes in ultrasound images, revealed the presumptive diagnosis of the condition.

  7. EVALUATION OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN RATIO IN THE DIAGNOSIS OF PROSTATE CANCER

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    @@ It's reported that free to total prostate specific antigen ration (f/tPSA) can provide more benefit than the single use of prostate specific antigen (PSA) in the diagnosis of prostate cancer (PCa). We measured serum PSA and fPSA levels in 62 cases of benign prostatic hyperplasia (BPH) and 40 cases of PCa using radioimmunoassay, with patients' age range 59y~ 89y.

  8. 老年前列腺增生症与代谢综合征相关性分析%Correlation between prostatic hyperplasia and metabolic syndrome

    Institute of Scientific and Technical Information of China (English)

    张汝; 王建; 李改丽; 王晓湘; 胡健; 陶金; 全燕; 肖兴荣; 孙梅芹

    2011-01-01

    目的 探讨老年良性前列腺增生症(benign prostatic hyperplasia,BPH)与代谢综合征(metabolic syndrome,MS)的关系.方法 回顾我院1601例军队离退休干部体检资料,均为男性,根据有无BPH分为BPH组1230例和对照Ⅰ组371例;又根据有无MS分为MS组 516例和对照Ⅱ组1085例,分别对2组进行比较.结果 与对照Ⅰ 组比较,BPH组体重指数、空腹血糖、舒张压明显升高,差异有统计学意义.(P<0.05).多因素logistic回归分析,体重指数、空腹血糖、舒张压升高是BPH的独立危险因素.与对照Ⅱ组比较,MS组体重指数、前列腺体积、下尿路症状评分明显升高,差异有统计学意义(P<0.05,P < 0.01).结论 体重指数、高血糖和高血压是BPH的危险因素,MS是加重BPH患者下尿路症状的原因之一.%Objective To investigate the relationship between metabolic syndrome(MS) and benign prostatic hyperplasia(BPH). Methods Medical information of 1061 military retired men in our hospital was reviewed retrospectively. According to presence or absence of BPH,they were divided into BPH group(1230) and control group Ⅰ (371);also according to presence or absence of MS,they were divided into MS group (516) and control group Ⅱ (1085). The two groups were compared respectively. Results Body mass index,fasting blood sugar and diastolic blood pressure were significantly higher in BPH group than in control Ⅰ group. Multivariate regression analysis showed that increase in body mass index, fasting blood sugar and diastolic blood pressure were the independent risk factors for BPH. The body mass index, prostate volume and lower urinary tract symptom scores were significantly higher in MS group than in control Ⅱ group. Conclusions Body mass index,hyperglycemia and hypertension are the risk factors for BPH. MS is one of the causes of aggravating lower urinary tract symptoms in BPH patients.

  9. A Rare Prostatic Diagnosis of an Old Man: A Pure Prostatic Leiomyoma

    Directory of Open Access Journals (Sweden)

    W. M. van Ulden-Bleumink

    2013-01-01

    Full Text Available A pure leiomyoma of the prostate is a rare benign tumor. An 82-year-old man was referred to our urology department with gross hematuria and complete urinary retention. Examination revealed a benign prostatic hyperplasia. Transrectal ultrasound showed a prostate of 125 mL. Serum PSA was 1.9 µg/L. A simple retropubic prostatectomy was performed. Histopathological examination showed a pure leiomyoma of the prostate, without the presence of glandular prostate tissue. The diagnosis, characteristics, and treatment of this tumor are described.

  10. [Effect of biologically active substances of animal and plant origin on prooxidant-antioxidant balance in rats with experimental prostatic hyperplasia].

    Science.gov (United States)

    Belostotskaia, L I; Nikitchenko, Iu V; Gomon, O N; Chaĭka, L A; Bondar', V V; Dziuba, V N

    2006-01-01

    The effect of biologically active complexes of animal (prostatilen) and plant (permixon) origin on physiological indices of prostate and prooxidant-antioxidant balance in prostate and blood was studied in rats with the hyperprolactinemia-induced prostatic hyperplasia. It was shown that both prostatilen (1 mg of the total peptides per kg) and permixon (100 mg of Serenoa repens extract per kg) prevent increase in the prostate mass and volume, in the content of lipid hydroperoxides, and in the glutathione peroxidase activity in prostate. Prostatilen, in contrast to permixon, normalized the content of lipid hydroperoxides (increased under hyperplazia conditions) and increases glutathione peroxidase activity (reduced under hyperplazia conditions).

  11. Susceptibility weighted imaging: a new tool in the diagnosis of prostate cancer and detection of prostatic calcification.

    Directory of Open Access Journals (Sweden)

    Yan Bai

    Full Text Available BACKGROUND: Susceptibility weighted imaging (SWI is a new MRI technique which has been proved very useful in the diagnosis of brain diseases, but few study was performed on its value in prostatic diseases. The aim of the present study was to investigate the value of SWI in distinguishing prostate cancer from benign prostatic hyperplasia and detecting prostatic calcification. METHODOLOGY/PRINCIPAL FINDINGS: 23 patients with prostate cancer and 53 patients with benign prostatic hyperplasia proved by prostate biopsy were scanned on a 3.0T MR and a 16-row CT scanner. High-resolution SWI, conventional MRI and CT were performed on all patients. The MRI and CT findings, especially SWI, were analyzed and compared. The analyses revealed that 19 out of 23 patients with prostate cancer presented hemorrhage within tumor area on SWI. However, in 53 patients with benign prostatic hyperplasia, hemorrhage was detected only in 1 patient in prostate by SWI. When comparing SWI, conventional MRI and CT in detecting prostate cancer hemorrhage, out of the 19 patients with prostate cancer who had prostatic hemorrhage detected by SWI, the prostatic hemorrhage was detected in only 7 patients by using conventional MRI, and none was detected by CT. In addition, CT demonstrated calcifications in 22 patients which were all detected by SWI whereas only 3 were detected by conventional MRI. Compared to CT, SWI showed 100% in the diagnostic sensitivity, specificity, accuracy, positive predictive value(PPV and negative predictive value(NPV in detecting calcifications in prostate but conventional MRI demonstrated 13.6% in sensitivity, 100% in specificity, 75% in accuracy, 100% in PPV and 74% in NPV. CONCLUSIONS: More apparent prostate hemorrhages were detected on SWI than on conventional MRI or CT. SWI may provide valuable information for the differential diagnosis between prostate cancer and prostatic hyperplasia. Filtered phase images can identify prostatic calcifications as

  12. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia

    Directory of Open Access Journals (Sweden)

    Sakata Koichi

    2012-10-01

    Full Text Available Abstract Background To assess the ejaculatory disorder caused by silodosin in the prostatic hyperplasia patients who carry out sexual actions (sexual intercourse, masturbation. Method The subjects of this study were 91 patients who had been clinically diagnosed to have LUTS/BPH at this hospital, who were administered silodosin at 4 mg twice a day, and who gave response to a questionnaire survey related to ejaculatory disorder. Sexual intercourse and masturbation were regarded as sexual actions in this study. Results Ejaculatory disorder occurred in 38 (42% of the 91 silodosin administration cases. Forty (44% of the 91 patients answered that they carried out sexual actions after oral intake of silodosin. When the investigation was conducted only in those who exercised sexual actions, ejaculatory disorder was observed in 38 (95% of these 40 patients, indicating a high incidence. When asked if disturbed by the ejaculatory disorder, 29 (76% of the 38 patients who had ejaculatory disorder answered yes. Oral silodosin was discontinued due to the ejaculatory disorder in 2 (5% of these patients. On the whole, the discontinuation rate of oral silodosin was 2% (2/91 patients. Conclusion It was demonstrated that the administration of silodosin induced ejaculatory disorder at a high incidence. Since it is possible that the high frequency of ejaculatory disorder by silodosin may reduce QOL, it is considered necessary to provide sufficient information related to ejaculatory disorder at the time of treatment with silodosin.

  13. Telomerase activity in needle biopsies from prostate cancer and benign prostates

    NARCIS (Netherlands)

    Wymenga, LFA; Wisman, GBA; Ruiters, MHJ; Mensink, HJA; Veenstra, R.

    2000-01-01

    Background Telomerase activation is thought to be essential for the immortality of cancer cells. It may be a prognostic factor in small volume well differentiated prostate cancers and hence a guide for the aggressiveness of the approach. The length of the chromosome tips (telomeres) are maintained b

  14. Use of high-intensity focused ultrasound in the treatment of both benign and malignant prostatic disease

    Science.gov (United States)

    Kernen, Kenneth M.; Miles, Brian J.

    2000-05-01

    , investigators found rectal injuries in up to 15%, anastomotic strictures in 27% and urinary incontinence in approximately 58%, as well as an overall higher estimated blood loss, transfusions, and hospital stay greater than that of a standard radical retropubic prostatectomy. Cryotherapy also has a significant complication rate with incontinence (73%), impotence (72%), and prolonged dysuria in 67%. In this report, biopsies were negative in 77% but biochemical failure occurred in 58% of patients. High intensity focused ultrasound (HIFU) therapy is a relatively new treatment modality and is being applied transrectally for the treatment of both benign prostatic hyperplasia and adenocarcinoma of the prostate. The therapy is also under evaluation at multiple centers in the United States for the treatment of radiorecurrent prostate cancer. In Europe, it not only being evaluated as treatment for radiorecurrent prostate cancer, but is also being evaluated and offered as a minimally invasive primary therapy for prostate cancers localized to the gland. The technique of HIFU generation has been previously described in detail. The ablation device is comprised of a patient treatment table, main computer, an oscillator, power amplifier, power measurement system, probe movement system, endorectal probe with built-in ultrasound scanner and treatment transducer, and reprography equipment. The patient is administered either a spinal or general anesthesia, positioned on the treatment table on his side with the legs flexed, the endorectal probe is then inserted. The ultrasound imaging is used to detect the contours of the prostate and the target volume to be treated is then calculated. Under computer control, the HIFU device position and then successively repositions the endorectal probe, delivering the high intensity focused ultrasound according to the treatment blocks defined by the surgeon. This sequence then repeats until all sectors of the prostate have been treated. HIFU is generated by high

  15. The experience of using sonoelastography of prostate in prostatic diseases

    Directory of Open Access Journals (Sweden)

    P. S. Zubeev

    2014-11-01

    Full Text Available Objective. To assess sonoelastography opportunities in differential diagnosis of prostatic diseases; to place sonoelastography in general algorithm of prostatic diseases diagnostics.Materials and methods. 91 patients under examination were divided into three groups. The first group included 21 patients (23.1 % with suspected prostate carcinoma, later they underwent puncture multifocal biopsy of prostate with morphological verification of prostate carcinoma. The second group consisted of 51 patients (56.0 % with benign prostatic hyperplasia, and in the third group there were 19 patients (20.9 % with acute and chronic prostatitis.Results. 91 patients with different prostatic diseases were examined. There were defined PSA (prostate specific antigen level, and performed TRUS (transrectal ultrasound, biopsy and sonoelastography of prostate. In 72 patients SEG (sonoelastography-picture of prostate was compared to morphological diagnosis. According to SEG findings, 43 (81.1 % patients were revealed to have the areas of reduced compliance due to what malignancy in prostate gland (PG was excluded. Morphological diagnosis of prostate carcinoma was confirmed in 21 patients. In 51 patients SEG-picture corresponded to benign process confirmed by histology.Conclusion. Sonoelastography is a modern diagnostic technique of prostatic diseases, seminal vesicles, paraprostatic space. The distinguished mapping types enable to make differential diagnosis of different prostatic pathological processes. Sonoelastography improves prostate carcinoma diagnostics and staging, and also has economic significance value when compared to MRP (magnetic resonance tomography with bolus contrast.

  16. Prostatic Cancer: Diagnosis and Differentiation by Dynamic Contrast-Enhanced MRI

    Institute of Scientific and Technical Information of China (English)

    SHIHao; DINGHongyu; ZHANGGuangying; YANGZhenzhen

    2005-01-01

    Objective: To assess the role of dynamic contrast-enhanced MRI (DCE-MRI) in the diagnosis and differentiation of prostatic cancer (PC). Methods: Five volunteers, 36 patients with benign prostatic hyperplasia (BPH) and 13 patients with biopsy-proven prostate cancer underwent conventional MRI, DCE-MR1 and delayed enhancement MRI. The value of the signal intensity in DCE-MRI was measured and calculated to draw the time-signal intensity curve of the normal peripheral zone (PZ), the prostate cancer and the benign prostatic hyperplasia. Results: In DCE-MRI, the normal peripheral zone was enhanced mildly and slowly and the peak value was located in late phase. The enhancement of the lesions in 36 patients with the benign prostatic hyperplasia was obvious in early phase and strengthened gradually, and then turned to decrease in late phase after peak value. The lesions in 9 of 13 cases with prostate cancer were enhanced obviously in early phase and washed out rapidly, and the peak value was located in early phase, but the peak value was in mediate and late phase in the other 4 cases with diffuse lesion in the prostate on T2WI. Conclusion: In DCE-MRI, the enhancement patterns of the normal peripheral zone,the prostate cancer and the benign prostatic hyperplasia were significantly different. DCE-MRI was very useful in the diagnosis and differentiation of prostate cancer.